Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.5 - thrombin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abetalipoproteinemia
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Abnormalities, Multiple
Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity.
Abortion, Habitual
Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study.
Increased thrombin generation in women with recurrent miscarriage.
Abortion, Spontaneous
Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study.
Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe).
Increased thrombin generation measured in the presence of thrombomodulin in women with early pregnancy loss.
Platelet function in patients with a history of unexplained recurrent miscarriage who subsequently miscarry again.
Abruptio Placentae
Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells.
Mechanisms of thrombin-Induced myometrial contractions: Potential targets of progesterone.
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes.
Abscess
Complications of modern diagnostic cerebral angiography in an academic medical center.
Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution.
Acidosis
Acidosis induced by carbon dioxide insufflation decreases heparin potency: a risk factor for thrombus formation.
Acidosis, magnesium and acetylsalicylic acid: effects on thrombin.
Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis.
Capacitative calcium influx and intracellular pH cross-talk in human platelets.
Coagulation Changes to Systemic Acidosis and Bicarbonate Correction in Swine.
Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability.
Coagulopathy induced by acidosis, hypothermia and hypocalcaemia in severe bleeding.
Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro.
Effects of acidosis on fetal and maternal blood coagulation: a fetal lamb model.
Effects of emergency treatment mode of damage-control orthopedics in pelvic fracture complicated with multiple fractures.
Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs.
Independent contributions of hypothermia and acidosis to coagulopathy in swine.
Influence of hypercapnia and hypoxia on rabbit platelet aggregation.
Mechanistic Modeling of the Effects of Acidosis on Thrombin Generation.
Preconditioning Effect of Remifentanil Versus Fentanyl in Prevalence of Early Graft Dysfunction in Patients After Liver Transplant: A Randomized Clinical Trial.
[Trauma-induced coagulopathy--mechanisms and state of the art treatment].
Acidosis, Lactic
Use of clinical pathology in evaluation of horses with colic.
Acquired Immunodeficiency Syndrome
A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
Clinical use of topical thrombin as a surgical hemostat.
Looking at the proteases from a simple perspective.
Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS.
Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes.
Sepsis and disseminated intravascular coagulation.
The action of thrombin on modified fibrinogen.
The use of new procoagulants in blunt and penetrating trauma.
Thrombin induces apoptosis in human tumor cells.
Thrombin use in surgery: an evidence-based review of its clinical use.
Acromegaly
The haemostatic system in acromegaly: a single-centre case-control study.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Acquired resistance to activated protein C in breast cancer patients.
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
APC resistance during the normal menstrual cycle.
Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives.
Changes of hemostatic variables during oral contraceptive use.
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Development of a calibrated automated thrombography based thrombin generation test in mouse plasma.
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Effect of blood loss during caesarean section on coagulation parameters.
Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay.
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Effects of hormone replacement on hemostasis in spontaneous menopause.
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Exercise-induced activation of coagulation in subjects with activated protein C resistance.
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Factor V Leiden.
Hematologic risk factors for stroke in Saudi children.
Hemostasis during normal pregnancy and puerperium.
Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism.
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.
Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis.
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a?2GPI and aPS/PT antibodies.
Lemierre syndrome variant: Staphylococcus aureus associated with thrombosis of both the right internal jugular vein and the splenic vein after the exploration of a river cave.
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance.
Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
Proteolysis of protein C in pooled normal plasma and purified protein C by activated protein C (APC).
Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Screening for thrombophilia: a laboratory perspective.
Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.
The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature.
The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index.
The effects of transport temperature and time on routine and specialized coagulation assays.
The use of direct oral anticoagulants in inherited thrombophilia.
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Thrombotic disease in the myeloproliferative neoplasms.
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.
Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
Acute Coronary Syndrome
A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes.
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Acute coronary syndromes: a focus on thrombin.
Acute myocardial ischemia and infarction: making the right decisions in antithrombotic and reperfusion therapies.
Advances in antiplatelet therapy for ACS and PCI.
Anticoagulants in acute coronary syndromes.
Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes.
Antiplatelet and antithrombin therapies in the acute coronary syndromes.
Antithrombins and the importance of good control.
Antithrombotic therapy in acute coronary syndromes.
Antithrombotic therapy in patients with acute coronary syndromes.
Antithrombotic treatment in acute coronary syndromes.
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Bivalirudin during primary PCI in acute myocardial infarction.
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery.
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Clinical outcomes of bivalirudin for ischemic heart disease.
Clinical results with direct thrombin inhibitors.
Clinician update: direct thrombin inhibitors in acute coronary syndromes.
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Coagulation activation and long-term outcome in acute coronary syndromes.
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator.
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in High-Risk Patients Undergoing Percutaneous Coronary Intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin Study).
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Current Update on Glycoprotein IIb-IIIa and Direct Thrombin Inhibition in Percutaneous Coronary Intervention for Non-ST Elevation Acute Coronary Syndromes: Balancing Bleeding Risk and Antiplatelet Efficacy.
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion.
Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET.
Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.
Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
Direct thrombin inhibitor-bivalirudin functionalized plasma polymerized allylamine coating for improved biocompatibility of vascular devices.
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions.
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients?
Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group.
Direct thrombin inhibitors in acute coronary syndromes.
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention.
Direct thrombin inhibitors in acute coronary syndromes: present and future.
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct thrombin inhibitors.
Direct Thrombin Inhibitors.
Direct thrombin inhibitors: pharmacology and clinical relevance.
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation.
Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy.
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial.
Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion.
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention.
Emerging oral antiplatelet therapies for acute coronary syndromes.
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events.
Failure of thrombin generation markers to triage patients presenting with chest pain.
Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction.
Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET.
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense.
Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.
ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.
In the Bivalirudin Era, are we still Looking for a Potent Antiplatelet Agent?
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease.
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates.
Low molecular weight heparins in the treatment of unstable angina.
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.
Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?
Mental stress and physical exercise increase platelet-dependent thrombin generation.
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
New strategies in the management of acute coronary syndromes.
New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
Novel anticoagulant therapy: principle and practice.
Novel inhibitors of factor X for use in cardiovascular diseases.
Novel oral anticoagulants for acute coronary syndrome.
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Novel oral anticoagulants in the management of coronary artery disease.
Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 inhibition and Thrombin Receptor Antagonists.
Oral antiplatelet therapy in acute coronary syndromes: recent developments.
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Pathobiology of thrombin in acute coronary syndromes.
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Plasma tissue factor in coronary artery disease: further step to the understanding of the basic mechanisms of coronary artery thrombosis.
Platelet Activation Determined by Flow Cytometry Persists Despite Antithrombotic Therapy in Patients with Unstable Angina and Non-Q-Wave Myocardial Infarction.
Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery.
Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
Prevention of cardiovascular events after acute coronary syndrome.
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response.
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.
Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase.
Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes.
Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Role of oral anticoagulants in patients after an acute coronary syndrome.
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Safety of bivalirudin in patients with coronary artery disease.
Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.
Systematic Review of Hirudin in Acute Coronary Syndromes and Percutaneous Coronary Intervention.
TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1.
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
The biology of thrombin in acute coronary syndromes.
The clinical and economic impact of bivalirudin for percutaneous coronary intervention.
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
The GUSTO 2b and related studies. Global Use of Strategies to Open Occluded Coronary Arteries.
The Spectrum of Thrombin in Acute Coronary Syndromes.
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis"
Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.
Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients.
Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition.
Thrombin in arterial thrombosis.
Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion.
Thrombin induces cyclooxygenase-2 expression and prostaglandin E(2) release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages.
Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Treatment of arterial thromboembolic disease.
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Use of direct thrombin inhibitors in acute coronary syndrome.
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Vasoflux, a new anticoagulant with a novel mechanism of action.
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Will oral antithrombin agents replace warfarin?
Ximelagatran (AstraZeneca).
Ximelagatran.
[Coronary thrombosis--pathogenic basis of acute coronary syndromes]
[New oral anticoagulants: recommendations, precautions and perspectives for use].
[Persistent activation and/or reactivation in the subacute phase of unstable angina. Reasons for prolonged antithrombotic treatment]
[Prehospital treatment with bivalirudin in acute myocardial infarction referred for primary angioplasty. About 152 consecutive patients study.]
Acute Kidney Injury
Argatroban for anticoagulation in continuous renal replacement therapy.
Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane.
Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.
Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury.
Thrombin down-regulates the TGF-beta-mediated synthesis of collagen and fibronectin by human proximal tubule epithelial cells through the EPCR-dependent activation of PAR-1.
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
[New findings on the physiopathology of acute hemolytic transfusion reactions]
Acute Lung Injury
Anticoagulant therapy for acute lung injury or pneumonia.
Antithrombin III deficiency in neonatal respiratory distress syndrome.
Coagulation and inflammation in acute lung injury.
Crosstalk between thrombosis and inflammation in lung reperfusion injury.
Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs.
Heparin improves gas exchange during experimental acute lung injury in newborn piglets.
Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.
Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury.
Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells.
Platelet Activation and Aggregation Promote Lung Inflammation and Influenza Virus Pathogenesis.
Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor.
Thrombin inhibitors reduce intrapulmonary accumulation of fibrinogen and procoagulant activity of bronchoalveolar lavage fluid during acute lung injury induced by pulmonary overdistention in newborn piglets.
Tissue factor-dependent coagulation protease signaling in acute lung injury.
Adenocarcinoma
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.
Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.
Adenocarcinoma of Lung
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.
Adenomyosis
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Adrenocortical Hyperfunction
Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism.
Afibrinogenemia
A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice.
Chronic subdural hematoma in a patient with congenital afibrinogenemia successfully treated with fibrinogen replacement.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Hemostatic and thrombotic issues in cardiac surgery.
Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution.
Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion.
Stimulation of fibrinogen synthesis by thrombin in rabbits with ancrod-induced afibrinogenemia.
Techniques for evaluating the cause of bleeding in the ICU. Diagnostic clues and keys to interpreting hemostatic tests.
Thrombin clotting time.
Thromboelastography and thrombin generation assay in inherited afibrinogenemia.
Treatment of afibrinogenemia in a chihuahua.
[Analysis of gene mutation spectrum and pharmacokinetics of fibrinogen infusion in 146 cases of congenital fibrinogen disorders].
[Congenital afibrinogenemia. II. Studies on thrombin formation and inactivation (silent coagulation)]
[Defibrination syndrome after snake bites]
[Inherited Afibrinogenemia Caused by Compound Heterozygous Mutations in the Beta beta-Chain of Fibrinogen.]
[The importance of the enzyme preparation ancistron-N in the diagnosis of disseminated intravascular coagulation]
Albuminuria
Low but sustained coagulation activation ameliorates glucose induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy.
Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.
Procoagulant activity in patients with combined type 2 diabetes and coronary artery disease: No effects of long-term exercise training.
Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients.
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease.
Alkalosis
Capacitative calcium influx and intracellular pH cross-talk in human platelets.
Thrombin stimulation of Cl-/HCO3- exchange in human platelets.
Altitude Sickness
Hypobaric Hypoxia Causes Elevated Thrombin Generation Mediated by FVIII that is Balanced by Decreased Platelet Activation.
Alveolar Bone Loss
Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol.
Alzheimer Disease
Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease.
Control of hippocampal pKr-2 expression reduces neurotoxic symptoms in 5XFAD mice.
Cyclin D1, cdk4, and Bim are involved in thrombin-induced apoptosis in cultured cortical neurons.
Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.
Femtomolar Detection of Thrombin in Serum and Cerebrospinal Fluid via Direct Electrocatalysis of Oxygen Reduction by the Covalent G4-Hemin-Aptamer Complex.
First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease.
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.
Injured brain endothelial cells release neurotoxic thrombin.
Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect.
Mechanism of thrombin clearance by human astrocytoma cells.
Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease.
Non-age related differences in thrombin responses by platelets from male patients with advanced Alzheimer's disease.
Protease nexin-1, a potent thrombin inhibitor, is reduced around cerebral blood vessels in Alzheimer's disease.
Proteolysis of non-phosphorylated and phosphorylated tau by thrombin.
Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases.
Role of p38 and p44/42 mitogen-activated protein kinases in microglia.
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Serine proteases and their serpin inhibitors in Alzheimer's disease.
Short-term treatment with dabigatran alters protein expression patterns in a late-stage tau-based Alzheimer's disease mouse model.
Targeting thrombin: an inflammatory neurotoxin in Alzheimer's disease.
The Alzheimer's disease peptide ?-amyloid promotes thrombin generation through activation of coagulation factor XII: comment.
The Alzheimer's disease peptide ?-amyloid promotes thrombin generation through activation of coagulation factor XII: reply.
The Alzheimer's disease peptide A? promotes thrombin generation through activation of coagulation factor XII.
Thrombin accumulation in brains of patients with Alzheimer's disease.
Thrombin and antithrombotics.
Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis.
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain.
Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities.
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Thrombin, a mediator of neurotoxicity and memory impairment.
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase.
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase.
[Changes in the blood clotting system of patients with atherosclerotic and senile dementias]
Amnesia
Recovery from trauma induced amnesia correlates with normalization of thrombin activity in the mouse hippocampus.
Reversal of Trauma-Induced Amnesia in Mice by a Thrombin Receptor Antagonist.
Amyloidosis
A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia.
Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality.
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Amyotrophic Lateral Sclerosis
Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders.
Anaphylaxis
A Case of Intraoperative Anaphylaxis Caused by Bovine-Derived Thrombin.
Anaphylactic reaction to bovine thrombin in ultrasound-guided treatment of femoral pseudoaneurysm.
Anaphylactic reaction to topical bovine thrombin.
Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention.
Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population.
Autologous thrombin for treatment of pseudoaneurysms.
Evidence of fibrinogen degradation in rat anaphylaxis.
THE COAGULATION OF BLOOD BY SNAKE VENOMS AND ITS PHYSIOLOGIC SIGNIFICANCE.
[Anaphylactic shock following topical use of thrombin for irrigation of urinary bladder]
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
[Treatment of postcatheterization femoral false aneurysms]
Anemia
A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm.
Acute kidney injury in high-risk cardiac surgery patients: roles of inflammation and coagulation.
Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.
Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia.
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
Renal involvement in sepsis: a prospective single-center study of 136 cases.
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Tissue factor and thrombin in sickle cell anemia.
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
[Coagulopathy and anemia caused by anticonvulsants]
[The diagnostic difficulties in a case of a hemorrhagic syndrome in an infant]
Anemia, Aplastic
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Anemia, Refractory
The human thrombin receptor gene and the 5q-syndrome.
Anemia, Sickle Cell
Decreased thrombin activity by a Congolese herbal medicine used in sickle cell anemia.
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis.
Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation.
Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation.
Enhanced thrombin generation in children with sickle cell disease.
Excess of heme induces tissue factor-dependent activation of coagulation in mice.
Hypercoagulability in sickle cell disease: a curious paradox.
Hypercoagulability in sickle cell disease: new approaches to an old problem.
Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception.
Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state.
Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.
Red blood cells and thrombin generation in sickle cell disease.
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells.
The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease.
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Thrombin Generation in Children with Sickle Cell Disease: Relationship with Age, Hemolysis, Transcranial Doppler Velocity and Hydroxyurea Treatment.
Thrombin generation in vivo and ex vivo in sickle cell disease patients.
Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children.
Tissue factor and thrombin in sickle cell anemia.
Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis.
Aneurysm
A case of gastroduodenal artery aneurysm in a HIV-positive patient treated by combined percutaneous thrombin injection and endovascular coil embolization.
A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm.
A ruptured aneurysm after stent graft puncture during computed tomography-guided thrombin injection.
Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate?
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Branch ligatures and blood aspiration for post-traumatic superficial temporal artery pseudoaneurysm: surgical technique.
Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair.
Coagulation of aneurysms by direct percutaneous thrombin injection.
Colonic necrosis subsequent to catheter-directed thrombin embolization of the inferior mesenteric artery via the superior mesenteric artery: a complication in the management of a type II endoleak.
Combined Endovascular Exclusion with Percutaneous Sac Aspiration and Thrombin Injection in the Management of Popliteal Artery Aneurysm.
Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion.
CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair.
Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection.
Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm.
Embolization of a Giant Hepatic Venous Aneurysm by Complementary Use of Coils, Vascular Plug, and Thrombin.
Embolization of a subclavian artery aneurysm with steel coils and thrombin.
Embolization of an Internal Iliac Artery Aneurysm after Image-Guided Direct Puncture.
Endoscopic ultrasound-guided thrombin injection in a large splenic artery aneurysm: first report in a patient with tropical chronic pancreatitis.
Endovascular management of a rare complication of an aortic coarctation.
Endovascular management of an infected superficial femoral artery pseudoaneurysm.
Endovascular Solution to Endoleak Phenomenon After Open Repair of Abdominal Aortic Aneurysm.
Endovascular therapy of arteriovenous malformation in a male patient with severe post-coital pelvic pain.
Endovascular treatment of pseudoaneurysms in pancreatitis.
EVAR: critical applied aortic morphology relevant to type-II endoleaks following device enhancement in patients with abdominal aortic aneurysms.
Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery.
Iliac artery pseudoaneurysm presenting as a paravertebral collection: a potentially fatal mimic.
Innominate artery aneurysm with hemoptysis and airway compression in a patient with bovine aortic arch.
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report.
Interventional therapy for stenosis and aneurysm in renal graft artery: report of 9 cases.
Intraoperative thrombin occlusion of a visceral artery aneurysm.
Intraprocedural and postprocedural perigraft arterial sac embolization (PASE) for endoleak treatment.
Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass?
Ischemic colitis following translumbar thrombin injection for treatment of endoleak.
Laser-assisted transprosthesial coil embolization combined with thrombin injection for treatment of an endoleak type II after endovascular aneurysm repair.
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Microsurgical and Endovascular Management of Congenital Iliac Aneurysms in the Neonatal Period: Two Cases and a Literature Review.
Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution.
Percutaneous Cyanoacrylate Glue Injection into the Renal Pseudoaneurysm to Control Intractable Hematuria After Percutaneous Nephrolithotomy.
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Percutaneous injection therapy for a peripheral pulmonary artery pseudoaneurysm after failed transcatheter coil embolization.
Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin.
Percutaneous puncture and embolisation for pancreatitis-related pseudoaneurysm: the feasibility of thrombin injection even in collection of fluid surrounding the pseudoaneurysm.
Percutaneous thrombin embolization of a pancreatico-duodenal artery pseudoaneurysm after failing of the endovascular treatment.
Percutaneous Thrombin Injection for Treatment of a Splenic Artery Aneurysm.
Percutaneous thrombin injection of carotid artery pseudoaneurysm.
Percutaneous thrombin injection of splanchnic artery aneurysms: two case reports.
Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement.
Percutaneous treatment of a ruptured superior mesenteric artery aneurysm in a child.
Posttraumatic Lingual Artery Pseudoaneurysm Treated with Ultrasound-Guided Percutaneous Thrombin Injection.
Prophylactic Aneurysm Embolization during EVAR Is Safe, Improves Sac Regression and Decreases the Incidence of Type II Endoleak.
Pseudoaneurysm of the radial artery diagnosed by bedside ultrasound.
Radial Artery Pseudoaneurysms Treated by Ultrasound-Guided Differential Compression: An Effective and Simple Method.
Reducing duplex examinations in patients with iatrogenic pseudoaneurysms.
Reperfusion of splanchnic artery aneurysm following transcatheter embolization: treatment with percutaneous thrombin injection.
Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice.
Ruptured left gastric artery aneurysm successfully treated by thrombin injection: case report and literature review.
Saccular Aneurysm of Superior Vena Cava Treated with Percutaneous, Transcatheter Thrombin Injection.
Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms.
Sonographically guided thrombin injection for the treatment of femoral artery pseudoaneurysm.
Spontaneous pseudo-aneurysm of the deep femoral artery treated by a covered stent.
Strategies of endoleak management following endoluminal treatment of abdominal aortic aneurysms in 95 patients: how, when and why.
Strategies to Reduce the Rate of Type II Endoleaks: Routine Intraoperative Embolization of the Inferior Mesenteric Artery and Thrombin Injection Into the Aneurysm Sac.
Temporary aneurysm neck balloon occlusion during percutaneous thrombin embolization of a superficial femoral artery pseudoaneurysm.
The dermatan sulfate-dependent anticoagulant pathway is mostly preserved in aneurysm and in severe atherosclerotic lesions while the heparan sulfate pathway is disrupted.
The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm.
The use of thrombin in the radiology department.
Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm.
Thrombin injection for the treatment of mycotic gluteal aneurysm.
Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients.
Thrombin injection versus compression of femoral artery pseudoaneurysms.
Thrombin obliteration of subclavian artery aneurysm with intravascular balloon protection.
Transcatheter thrombin embolization of a giant visceral artery aneurysm.
Transcatheter thrombosis of a leaking saccular aneurysm of the main renal artery with preservation of renal blood flow.
Transcaval embolization as an alternative technique for the treatment of type II endoleak after endovascular aortic aneurysm repair.
Transluminal coil embolization of an inferior gluteal artery aneurysm by ultrasound-guided direct puncture of the target vessel.
Transluminal thrombin injection and exclusion of a paramesenteric abdominal aortic aneurysm.
Traumatic Inferior Gluteal Artery Aneurysm Managed with Emergency Transcatheter Thrombin Injection.
Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin.
Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection.
Treatment of type II endoleak with a transcatheter transcaval approach: results at 1-year follow-up.
Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac.
Treatment protocol of traumatic pseudoaneurysm of the superficial temporal artery.
Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience.
Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience.
Upper gastrointestinal bleeding due to hepatic artery aneurysm: Case report and literature review.
Use of FloSeal in the endovascular treatment of voluminous aneurysm of a lower gluteus artery.
[Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm]
[Iatrogenic aneurysm of the hepatic artery. Treatment by percutaneous injection of thrombin and selective arterial embolization]
[Minimally invasive percutaneous contrast-ultrasound guided thrombin occlusion of iatrogenic pseudoaneurysm]
[The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection]
Aneurysm, Dissecting
Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product.
Aneurysm, False
A Bail Out Solution for an Urgent Situation: Endovascular Exclusion and Embolization of an Infected Femoral Pseudoaneurysm.
A cost effective endovascular approach for management of post-catheterization profunda femoris artery pseudoaneurysm using thrombin.
A hybrid approach for vascular control and repair of an expanding iatrogenic femoral artery pseudoaneurysm.
A novel approach to the management of carotid blowout syndrome: the use of thrombin in a case of failed covered stenting.
A novel approach to treating a post-sternotomy internal mammary artery pseudoaneurysm.
A novel interventional method for treating femoral pseudoaneurysms: results from a monocentric experience.
A novel minimally invasive method of successful tissue glue injection in patients with iatrogenic pseudoaneurysm.
A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection.
A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation.
A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication.
A prospective study on ultrasound-guided compression therapy or thrombin injection for treatment of iatrogenic false aneurysms in patients receiving full-dose anti-platelet therapy.
A prospective study on ultrasound-guided percutaneous thrombin injection for treatment of iatrogenic post-catheterisation femoral pseudoaneurysms.
A Pseudoaneurysm of the Deep Palmar Arch After Penetrating Trauma to the Hand: Successful Exclusion by Ultrasound Guided Percutaneous Thrombin Injection.
A Pulsatile Mass in the Right Buttock.
A Rare Case of Axillary Artery Pseudoaneurysm Due to Shoulder Dislocation Treated With Percutaneous Thrombin Injection.
A Rare Case of Iatrogenic Pseudoaneurysm of the Left Brachiocephalic Vein After Central Venous Catheterization Treated With Thrombin Injection.
A review of the therapeutic uses of thrombin.
A visceral pseudoaneurysm: management by EUS-guided thrombin injection.
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck.
Anaphylactic reaction to bovine thrombin in ultrasound-guided treatment of femoral pseudoaneurysm.
Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention.
Anastomotic Pseudoaneurysm Formation After Bypass Grafting to Porcelainized Peroneal Artery: Successful Treatment by Percutaneous Thrombin Injection.
Angiography-guided percutaneous thrombin injection for haemostasis of active bleeding complicated by femoral access: a case report.
Arterial complications associated with cardiac catheterization in pediatric patients with a previous history of kawasaki disease.
Autologous thrombin for treatment of pseudoaneurysms.
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula.
Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique.
Brachial pseudoaneurysm of the neonate with partial response to thrombin injections and late spontaneous thrombosis and regression during expectant management.
Cannulated screw for proximal tibial fracture complicated by iatrogenic popliteal pseudoaneurysm: definitive treatment by ultrasound-guided thrombin injection.
Cardiologist operated ultrasound guided thrombin injection as a safe and efficacious first line treatment for iatrogenic femoral artery pseudoaneurysms.
Catheter-directed endovascular application of thrombin: Report of 3 cases and review of the literature.
Choosing a treatment method for post-catheterization pseudoaneurysms guided by the late to early velocity index.
Coil embolization of inferior epigastric artery pseudoaneurysm after percutaneous thrombin injection failure: a case report.
Combined endovascular intervention and percutaneous thrombin injection in the treatment of iatrogenic pseudoaneurysm. Case report.
Combined percutaneous thrombin injection and endovascular treatment of gastroduodenal artery pseudoaneurysm (PAGD): case report.
Combined thrombin-collagen injection for the management of an iatrogenic pseudoanuerysm in the popliteal region.
Combining Percutaneous Ultrasound-Guided Hematoma Aspiration and Compression Repair to Treat Femoral Artery Pseudoaneurysm after Cardiac Catheterization.
Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.
Comparison of the Efficacy and Safety of Two Dosing Protocols for Ultrasound Guided Thrombin Injection in Patients with Iatrogenic Femoral Pseudoaneurysms.
Comparison of ultrasound-guided thrombin injection of iatrogenic pseudoaneurysms based on neck dimension.
Complete percutaneous decannulation from femoral venoarterial extracorporeal membrane oxygenation.
Complex subclavian artery pseudoaneurysm causing failure of endovascular stent repair with salvage by percutaneous thrombin injection.
Complications of modern diagnostic cerebral angiography in an academic medical center.
Complications of percutaneous thrombin injection in patients with postcatheterization femoral pseudoaneurysm.
Compression repair versus low-dose thrombin injection for the treatment of iatrogenic femoral pseudoaneurysm: a retrospective case-control study.
Contrast-enhanced ultrasound-guided thrombin injection in the management of iatrogenic pseudoaneurysm (PSA): A case report and review of literatures.
Correction of procedural arterial pseudoaneurysms: established and novel procedures.
Crural artery traumatic injuries: treatment with embolization.
CT-guided percutaneous thrombin injection for treatment of an inferior pancreaticoduodenal artery pseudoaneurysm.
CT-Guided Thrombin Injection to Control Rapid Expansion of Ascending Aortic False Aneurysm 15 Months After Bentall-Bono Operation.
Current treatment methods for postcatheterization pseudoaneurysms.
Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection.
Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European Study.
Deep Pelvic Postprostatectomy Pseudoaneurysm Treated by Transrectal Ultrasound-Guided Thrombin Injection.
Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm.
Development of nonobstructive intraarterial thrombi after injection of thrombin into pseudoaneurysms.
Diagnosis and management of pseudoaneurysms.
Diagnosis and treatment of iatrogenic femoral artery pseudoaneurysms.
Dissecting pseudoaneurysm of the proper hepatic artery repaired by primary anastomosis: a case report.
Distal radial pseudoaneurysm after chronic total occlusion percutaneous coronary intervention resolved by percutaneous thrombin injection.
Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Duplex-directed thrombin injection as a method to treat femoral artery pseudoaneurysms.
Duplex-guided thrombin injection for iatrogenic femoral artery pseudoaneurysm is effective even in anticoagulated patients.
Duplex-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Effective treatment of iatrogenic femoral pseudoaneurysms by combined endovascular balloon inflation and percutaneous thrombin injection.
Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial.
Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device.
Embolization of traumatic pseudoaneurysms after total knee arthroplasty.
Embolotherapy of a high-flow false aneurysm by using an occlusion balloon, thrombin, steel coils, and a detachable balloon.
Endoscopic and percutaneous ultrasound-guided thrombin and glue injection in a pseudoaneurysm of the right hepatic artery.
Endoscopic ultrasound guided thrombin injection of angiographically occult pancreatitis associated visceral artery pseudoaneurysms: Case series.
Endoscopic ultrasound-guided coil embolization and thrombin injection of a bleeding gastroduodenal artery pseudoaneurysm.
Endoscopic ultrasound-guided injection therapy for hepatobiliary disease.
Endoscopic ultrasound-guided thrombin injection for management of visceral artery pseudoaneurysm: A novel approach.
Endoscopic ultrasound-guided thrombin injection for the treatment of pancreatic pseudoaneurysm.
Endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms.
Endovascular coil embolization for large femoral false aneurysms: two case reports.
Endovascular management of an infected superficial femoral artery pseudoaneurysm.
Endovascular management of femoral access-site and access-related vascular complications following percutaneous coronary interventions (PCI).
Endovascular repair of a large post-traumatic calf pseudoaneurysm and arteriovenous fistula.
Endovascular retrograde recanalization in Asian critical limb ischaemia patients.
Endovascular Treatment of a Giant Aorto-Ostial Renal Artery Pseudoaneurysm.
Endovascular Treatment of Complications of Femoral Arterial Access.
Endovascular treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde Angio-Seal deployment.
Erratum to: Deep Pelvic Postprostatectomy Pseudoaneurysm Treated by Transrectal Ultrasound-Guided Thrombin Injection.
EUS-guided thrombin injection of cystic artery pseudoaneurysm leading to Mirizzi's syndrome and hemobilia.
Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization.
Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms.
Expect the unexpected: acute and subacute coronary stent thrombosis following percutaneous thrombin injection for treatment of femoral pseudoaneurysm.
External carotid artery pseudoaneurysm following microvascular free flap reconstruction. The role of endovascular thrombin injection in embolization: a case report and review.
Extravasating uterine pseudoaneurysm: A rare cause of postpartum haemorrhage.
Factors associated with pseudoaneurysm development and necessity for reintervention: a single centre study.
Fascial suture technique versus open femoral access for thoracic endovascular aortic repair.
Fatal Complication after Thrombin Injection for Post-Catheterization Femoral Pseudoaneurysm.
Feasibility and Safety of Vascular Closure Devices in an Antegrade Approach to Either the Common Femoral Artery or the Superficial Femoral Artery.
Femoral Arterial Haemostasis Using an Anchored Collagen Plug after Percutaneous EVAR with an Ultra-Low Profile Device: Prospective Audit of an Evolving "Post-Close" Technique.
Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm.
Femoral artery thrombosis following percutaneous treatment with thrombin injection of a femoral artery pseudoaneurysm: a case report.
Femoral pseudoaneurysms requiring surgical treatment.
Femoral pseudoaneurysms: management with percutaneous thrombin injections--success rates and effects on systemic coagulation.
Flow reduction aided thrombin injection for complex femoral pseudoaneurysms: Case series and review of the literature.
Hepatic artery pseudoaneurysm after liver transplantation: treatment with percutaneous thrombin injection.
How to perform ultrasound-assisted thrombin injection for closure of iatrogenic femoral pseudoaneurysm.
Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.
Human thrombin injection for the percutaneous treatment of iatrogenic pseudoaneurysms.
Iatrogenic Femoral Artery Pseudoaneurysm.
Iatrogenic Femoral Pseudoaneurysm and Secondary Ipsilateral Deep Vein Thrombosis: An Indication for Early Surgical Exploration.
Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes.
Iatrogenic femoral pseudoaneurysms: thrombin injection after failed US-guided compression.
Iatrogenic pseudoaneurysms: comparison of treatment modalities, including duplex-guided thrombin injection.
Iatrogenic subclavian artery pseudoaneurysm causing airway compromise: treatment with percutaneous thrombin injection.
Iatrogenic thyroid pseudoaneurysm following thyroid nodule radiofrequency ablation.
Iatrogenic venous pseudoaneurysm: case report and review of the literature.
Image-guided Percutaneous Splenic Interventions.
Imaging-guided percutaneous thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms.
Impact of thrombin injection in femoral artery pseudoaneurysms with AV-fistula.
Incidence of infectious complications after an ultrasound-guided intervention.
Inferior epigastric artery pseudoaneurysm: ultrasound diagnosis and treatment with percutaneous thrombin.
Intercostal artery pseudoaneurysm after ultrasound-guided liver biopsy: a case report and review of the literature.
Intercostal artery pseudoaneurysm: a rare complication of transaortic transcatheter aortic valve implantation.
Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report.
Interventional treatment of arterial injury during blind central venous catheterisation in the upper thorax: experience from two centres.
Interventional treatment of bleeding complications due to percutaneous cannulation for peripheral extracorporeal membrane oxygenation.
Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab.
Ipsilateral femoral vein compression: a contraindication to thrombin injection of femoral pseudoaneurysms.
Large femoral aneurysm as a late complication after vessel closure device application.
Large iatrogenic pseudoaneurysm of the posterior tibial artery treated with sonographically guided thrombin injection.
Late to early velocity index as a predictor of iatrogenic femoral artery pseudoaneurysm recurrence in patients treated with ultrasound-guided thrombin injection.
Letter to 'Novel approach to uterine artery pseudoaneurysm embolization for delayed post-partum hemorrhage': Thrombin really necessary?
Low-dose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms.
Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm.
Lumbar artery pseudoaneurysm following renal biopsy: treatment with ultrasound-guided thrombin injection.
Management of an Iatrogenic Pseudoaneurysm of the Superior Gluteal Artery by Percutaneous Ultrasound-Guided Thrombin Injection: A Case Report.
Management of complex, two chamber false aneurysm by thrombin injections.
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Managing coronary artery vein bypass graft stump pseudoaneurysm: a novel approach.
Medial plantar artery pseudoaneurysm following percutaneous pinning for lisfranc fracture-dislocation.
Midterm Results of the Treatment of Penetrating Abdominal Aortic or Iliac Artery Ulcer with the BeGraft Balloon-Expandable Covered Stent-A Single-Center Experience.
Minimally invasive application of thrombin in the treatment of pseudoaneurysms following open aortic surgery.
Minimally invasive intervention of radial artery pseudoaneurysm using percutaneous thrombin injection.
Minimally Invasive Repair of a Left Ventricular Pseudoaneurysm After Surgical Patch Reconstruction of an Infarct-Related Free Posterior Wall Rupture: CT-Guided Intervention.
Minimally invasive therapy of pseudoaneurysms of the trunk: application of thrombin.
Non Surgical Management of Pseudoaneurysms.
Non-invasive repair of an iatrogenic tibial artery branch pseudoaneurysm after intramedullary nailing.
Nonsurgical Repair of a Pseudoaneurysm in a Cynomolgus Macaque (Macaca fascicularis).
Novel approach to uterine artery pseudoaneurysm embolization for delayed post-partum hemorrhage: Thrombin really necessary? Reply.
Obliteration of femoral artery pseudoaneurysm by thrombin injection.
Occlusion of a giant splenic artery pseudoaneurysm with percutaneous thrombin-collagen injection.
Occlusion of iatrogenic pseudoaneurysms with percutaneous ultrasound guided thrombin injection.
Occlusion of postcatheterisation femoral pseudoaneurysms with percutaneous thrombin injection under ultrasound guidance.
Occlusion of pseudoaneurysms using human or bovine thrombin using contrast-enhanced ultrasound guidance.
Outcomes of Ultrasound-Guided Thrombin Injection of Nongroin Arterial Pseudoaneurysms.
Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection.
Paravertebral pseudoaneurysm thrombosed after percutaneous thrombin injection.
Pathological fracture of the clavicle causing subclavian pseudoaneurysm formation.
Pelvic arterial pseudoaneurysm-a rare complication of Cesarean section: diagnosis and novel treatment.
Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution.
Percutaneous Decannulation Instead of Surgical Removal for Weaning After Venoarterial Extracorporeal Membrane Oxygenation-A Crossed Perclose ProGlide Closure Device Technique Using a Hemostasis Valve Y Connector.
Percutaneous duplex-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms.
Percutaneous embolization of post traumatic splenic pseudoaneurysm.
Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization.
Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up.
Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression.
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Percutaneous occlusion of posttraumatic aortic arch pseudoaneurysm by catheter-based delivery of thrombin.
Percutaneous puncture and embolisation for pancreatitis-related pseudoaneurysm: the feasibility of thrombin injection even in collection of fluid surrounding the pseudoaneurysm.
Percutaneous repair of abdominal aortic pseudoaneurysm by catheter-based delivery of thrombin.
Percutaneous repair of radial artery pseudoaneurysm in a hemodialysis patient using sonographically guided thrombin injection.
Percutaneous suture technique with ProGlide to manage vascular access pseudoaneurysm after percutaneous coronary intervention procedure: A case report.
Percutaneous thrombin embolisation of an iatrogenic pseudoaneurysm of the subclavian artery with neuroprotection in a critically ill patient.
Percutaneous thrombin embolization of a pancreatico-duodenal artery pseudoaneurysm after failing of the endovascular treatment.
Percutaneous thrombin embolization of a post-traumatic superficial temporal artery pseudoaneurysm.
Percutaneous thrombin embolization of a ruptured peripancreatic pseudoaneurysm.
Percutaneous Thrombin Injection Based on Computational Fluid Dynamics of Femoral Artery Pseudoaneurysms.
Percutaneous thrombin injection for pseudoaneurysm repair.
Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm of the gastroduodenal artery.
Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm.
Percutaneous Thrombin Injection for Treatment of a Hepatic Arterial Pseudoaneurysm after the Placement of a Transjugular Intrahepatic Portosystemic Shunt.
Percutaneous thrombin injection for treatment of an intrarenal pseudoaneurysm.
Percutaneous thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms: a case for caution.
Percutaneous thrombin injection in an infant to treat hepatic artery pseudoaneurysm after failed embolization.
Percutaneous thrombin injection of a femoral artery pseudoaneurysm with simultaneous venous balloon occlusion of a communicating arteriovenous fistula.
Percutaneous thrombin injection of a pulmonary artery pseudoaneurysm refractory to coil embolization.
Percutaneous thrombin injection of carotid artery pseudoaneurysm.
Percutaneous Thrombin Injection of Common Carotid Artery Pseudoaneurysm without Cerebral Protection.
Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement.
Percutaneous thrombin injection to treat a post-traumatic hepatic pseudoaneurysm.
Percutaneous thrombin injection treatment of a femoral artery pseudoaneurysm with simultaneous arterial balloon occlusion: Case report and review of the literature.
Percutaneous thrombin injection treatment of a gluteal pseudoaneurysm following radiofrequency ablation of a hip osteoid osteoma in a 6-year-old boy.
Percutaneous thrombin injection treatment of a profunda femoris pseudoaneurysm after femoral neck fracture.
Percutaneous thrombin injection under sonographic guidance for exclusion of non-catheterizable post-pancreatitis pseudoaneurysm of the superior mesenteric artery: a minimally invasive and expeditious treatment option.
Percutaneous thrombin injection with a distal embolic protection device for treatment of a common carotid artery pseudoaneurysm.
Percutaneous transthoracic embolisation for massive haemoptysis secondary to peripheral pulmonary artery pseudoaneurysms.
Percutaneous treatment of a splenic artery pseudoaneurysm by thrombin injection.
Percutaneous Treatment of Iatrogenic Pseudoaneurysms by Cyanoacrylate-Based Wall-Gluing.
Percutaneous ultrasonographically guided thrombin injection of iatrogenic pseudoaneurysms in unusual sites.
Percutaneous ultrasound guided thrombin injection for axillary artery pseudoaneurysm following stenting of the arterial duct in two infants: Case report with review of literature.
Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms.
Percutaneous ultrasound-guided thrombin injection as first-line treatment of pancreatic pseudoaneurysm.
Percutaneous ultrasound-guided thrombin injection for coagulation of post-traumatic pseudoaneurysms.
Percutaneous ultrasound-guided thrombin injection for the treatment of iatrogenic femoral artery pseudoaneurysms.
Percutaneous ultrasound-guided thrombin injection for the treatment of pseudoaneurysms.
Percutaneous ultrasound-guided thrombin injection is effective even in infants with external iliac artery pseudoaneurysms.
Percutaneous ultrasound-guided thrombin injection of a post-traumatic pancreatic pseudoaneurysm in a pediatric patient.
Peripheral artery aneurysm.
Personal experiences in direct ultrasound-guided injection of thrombin into the lumen of pseudoaneurysm as a method of treatment in case of iatrogenic femoral artery damage.
Post-catheterization pseudoaneurysm in a one-year-old child treated by ultrasound-guided human thrombin injection.
Post-procedural pseudoaneurysms: Single-center experience.
Post-sternotomy intercostal artery pseudoaneurysm. Sonographic diagnosis and thrombosis by ultrasound-guided percutaneous thrombin injection.
Post-traumatic hepatic artery pseudoaneurysm treated with endovascular embolization and thrombin injection.
Post-traumatic pseudoaneurysm of the medial plantar artery with arteriovenous fistula treated by coil embolization of the main feeding artery and percutaneous thrombin injection.
Post-traumatic pseudoaneurysm of the thyrocervical trunk.
Postcatheterization femoral artery pseudoaneurysms: therapeutic options. A case-controlled study.
Postcatheterization pseudoaneurysm: results of US-guided percutaneous thrombin injection in 240 patients.
Postcatheterization pseudoaneurysms: new developments in the diagnosis and treatment with ultrasound.
Postpyelolithotomy renal artery pseudoaneurysm management with percutaneous thrombin injection: a case report.
Posttraumatic Lingual Artery Pseudoaneurysm Treated with Ultrasound-Guided Percutaneous Thrombin Injection.
Posttraumatic pseudoaneurysm of the hepatic artery: treatment with ultrasound-guided percutaneous transhepatic thrombin injection.
Predictors of Groin Access Pseudoaneurysm Complication: A 10-Year Institutional Experience.
Procedural outcomes with use of the flash ostial system in aorto-coronary ostial lesions.
Prolonged generalized urticarial reaction after percutaneous thrombin injection for treatment of a femoral artery pseudoaneurysm.
Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms.
Protected carotid stenting: safety and efficacy of the MedNova NeuroShield filter.
Pseudoaneurysm after pertrochanteric femur fracture: a case report.
Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection.
Pseudoaneurysm after vacuum-assisted breast biopsy treated with percutaneous thrombin injection.
Pseudoaneurysm following vertebral biopsy and treatment with percutaneous thrombin injection.
Pseudoaneurysm in a patient with haemophilia A: thrombin injection plugs the hole.
Pseudoaneurysm in association with a knee endoprothesis operation in an inhibitor-positive haemophilia A patient - treatment with local thrombin.
Pseudoaneurysm in the iliac fossa after renal transplantation--treatment with ultrasound-guided thrombin injection.
Pseudoaneurysm of the breast related to 18-gauge core biopsy: successful repair using sonographically guided thrombin injection.
Pseudoaneurysm of the inferior epigastric artery: a rare complication of laparoscopic ventral hernia repair.
Pseudoaneurysm of the radial artery diagnosed by bedside ultrasound.
Pseudoaneurysm of the superior lateral genicular artery following anterior cruciate ligament repair.
Pseudoaneurysm of ulnar artery after endoscopic carpal tunnel release.
Pseudoaneurysms of the extremity without fracture: treatment with percutaneous ultrasound-guided thrombin injection.
Pseudoaneurysms.
Radial artery pseudoaneurysm: a maneuver to decrease the risk of thrombin therapy.
Radial Artery Pseudoaneurysms Treated by Ultrasound-Guided Differential Compression: An Effective and Simple Method.
Re: Internal mammary artery pseudoaneurysm complicating central venous line placement: treatment with percutaneous thrombin injection.
Recurrence of dialysis shunt pseudoaneurysm following percutaneous thrombin embolization.
Recurrence of Thrombin-Injected Pseudoaneurysms Under Ultrasound Guidance: A 10-Year Retrospective Analysis.
Reducing duplex examinations in patients with iatrogenic pseudoaneurysms.
Regarding "A prospective study of ultrasound-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication".
Regarding "Bovine thrombin injection for the treatment of iatrogenic arterial pseudoaneurysms: is it too good to be true?".
Renal artery pseudoaneurysm following renal transplantation and treatment by percutaneous thrombin injection.
Response to article on endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms.
Response to letter on endoscopic ultrasound-guided thrombin injection a management approach for visceral artery pseudoaneurysm: case series.
Results of a new human recombinant thrombin for the treatment of arterial pseudoaneurysm.
Safety and Effectiveness of Percutaneous Low-Dose Thrombin Injection for Femoral Puncture Site Pseudoaneurysms in Neurointervention: Single-Center Experience.
Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort.
Safety and efficacy of the StarClose vascular closure system using 7-F and 8-F sheath sizes: a consecutive single-center analysis.
Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms.
Salvage of autogenous dialysis access with balloon-assisted thrombin injection.
Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms.
Secondary Femoral Access Hemostasis During Transcatheter Aortic Valve Replacement: Impact of Vascular Closure Devices.
Severe allergic reaction: A rare complication of ultrasound-guided injection of thrombin in a femoral pseudoaneurysm.
Short-term results with transcatheter aortic valve replacement for treatment of left ventricular assist device patients with symptomatic aortic insufficiency.
Sonographically guided percutaneous thrombin injection for treatment of a vein graft pseudoaneurysm.
Sonographically guided percutaneous thrombin injection versus sonographically guided compression for femoral artery pseudoaneurysms.
Sonographically guided thrombin injection for the treatment of femoral artery pseudoaneurysm.
Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution.
Splenic artery pseudoaneurysm treated with thrombin injection guided by endoscopic ultrasound.
Spontaneous external jugular vein pseudoaneurysm treated by thrombin injection: Case report and literature review.
Stent graft exclusion of pseudo-aneurysm arising from PTFE hemodialysis graft after recurrence following ultrasound guided thrombin injection.
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Successful balloon assisted percutaneous thrombin injection of right subclavian artery pseudoaneurysm.
Successful direct thrombin injection of a femoral artery pseudoaneurysm in an anticoagulated patient with a mechanical mitral valve.
Successful endovascular treatment of a hemodialysis graft pseudoaneurysm by covered stent and direct percutaneous thrombin injection.
Successful percutaneous thrombin injection of a brachial artery pseudoaneurysm in a neonate.
Successful Percutaneous Transcatheter Closure of a Common Femoral Artery Pseudoaneurysm With Use of MicroVascular Plug Despite Continued Catheter-Directed Thrombolysis.
Successful Post-Pancreatitis Pseudoaneurysm Coagulation by Percutaneous Computed Tomography (CT)-Guided Thrombin Injection.
Successful sonographically guided thrombin injection in an infant with a femoral artery pseudoaneurysm.
Successful Treatment of a Common Femoral Arterial Pseudoaneurysm with US-Guided Thrombin Injection: A Case Report.
Successful treatment of a femoral artery pseudoaneurysm mimicking a deep venous thrombosis following cardiac catheterization.
Successful treatment of a femoral pseudoaneurysm by ultrasonographically-guided application of a suture-mediated closure device.
Successful treatment of a mycotic pseudoaneurysm of the brachial artery with percutaneous ultrasound-guided thrombin injection and antibiotics.
Successful treatment of a two centimeter breast pseudoaneurysm with thrombin injection.
Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection.
Successful Treatment of Iatrogenic Subclavian Artery Pseudoaneurysm by Ultrasound-Guided Thrombin Injection.
Successful treatment of uterine artery pseudoaneurysm with laparoscopic temporary clamping of bilateral uterine arteries, followed by hysteroscopic surgery.
Superior mesenteric artery pseudoaneurysm following pancreaticoduodenectomy: management by endovascular stent-graft placement and transluminal thrombin injection.
Surgery versus non-surgical treatment for femoral pseudoaneurysms.
Surgical Treatment of an Extrarenal Pseudoaneurysm After Kidney Transplantation.
Temporary aneurysm neck balloon occlusion during percutaneous thrombin embolization of a superficial femoral artery pseudoaneurysm.
The recurrence of iatrogenic femoral artery pseudoaneurysm after occlusion by ultrasound guided percutaneous thrombin injection.
The Use of ExoSeal Vascular Closure Device for Direct Antegrade Superficial Femoral Artery Puncture Site Hemostasis.
The Use of the Starclose Device for Obtaining Femoral Artery Hemostasis.
Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience.
Thrombin injection and compression with removable guidewire in the treatment of postcatheterization femoral pseudoaneurysm.
Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child.
Thrombin injection for failed stent graft repair of perforated atherosclerotic aortic ulcer.
Thrombin injection for pseudoaneurysm occlusion: technical considerations.
Thrombin injection for repair of pseudoaneurysms: a case for caution.
Thrombin injection for the repair of brachial artery pseudoaneurysms.
Thrombin injection for treating a subclavian artery pseudoaneurysm.
Thrombin injection for treatment of brachial artery pseudoaneurysm at the site of a hemodialysis fistula: report of two patients.
Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy.
Thrombin injection of a pancreaticoduodenal artery pseudoaneurysm after failed attempts at transcatheter embolization.
Thrombin injection to treat a scalp pseudoaneurysm.
Thrombin Injection to Treat an Iatrogenic Internal Mammary Artery Pseudoaneurysm.
Thrombin injection to treat pseudoaneurysm of internal mammary artery bypass graft: a case report.
Thrombin injection versus compression of femoral artery pseudoaneurysms.
Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis.
Thrombosis of a proximal aortic false aneurysm following AAA repair by endovascular thrombin injection.
Transarterial Thrombin Injection Secured with an Embolic Protection Device as a Treatment for a Superior Mesenteric Artery Pseudoaneurysm.
Transcatheter occlusion of a profunda femoral artery pseudoaneurysm using thrombin.
Translumbar thrombin embolization of an aortic pseudoaneurysm complicating lumbar disk surgery.
Transluminal occlusion of a pseudoaneurysm arising from a thoracic aortic graft patch using catheter delivery of thrombin.
Transvaginal ultrasound-guided direct thrombin injection for the treatment of intramyometrial pseudoaneurysm in a young female with uterine hemorrhage after failed uterine artery embolization.
Traumatic Aorto-Cisterna Chlyi Fistula with Treatment of Aortic Pseudoaneurysm with CT-Guided Thrombin Injection.
Traumatic axillary artery pseudoaneurysm treated with intravascular balloon occlusion and percutaneous thrombin injection.
Traumatic Inferior Gluteal Artery Aneurysm Managed with Emergency Transcatheter Thrombin Injection.
Traumatic pseudoaneurysm following ankle trauma.
Traumatic Pseudoaneurysm of Anterior Tibial Artery Treated by Thrombin Injection.
Traumatic pseudoaneurysm of the anterior tibial artery treated with ultrasound-guided thrombin injection in a pediatric patient.
Traumatic pseudoaneurysm of the ulnar artery treated with ultrasound guided thrombin injection.
Treatment for femoral pseudoaneurysms.
Treatment of a radial artery pseudoaneurysm with ultrasound-guided percutaneous thrombin injection in a patient with Behçet's syndrome.
Treatment of a splenic artery pseudoaneurysm by endoscopic ultrasound-guided thrombin injection.
Treatment of an extracapsular post-renal biopsy pseudoaneurysm with ultrasound-guided thrombin injection.
Treatment of an iatrogenic femoral artery pseudoaneurysm with concomitant arteriovenous fistula with percutaneous implantation of an amplatzer vascular plug.
Treatment of an iatrogenic femoral artery pseudoaneurysm with percutaneous duplex-guided injection of thrombin.
Treatment of arterial pseudoaneurysms with percutaneous ultrasound-guided thrombin injection.
Treatment of Common Femoral Artery Pseudoaneurysm: A Novel Approach Utilizing a VASCADE Percutaneous Closure Device.
Treatment of femoral artery pseudoaneurysm with percutaneous thrombin injection.
Treatment of femoral artery pseudoaneurysms using percutaneous thrombin injection under ultrasound guidance alone-proceed with caution.
Treatment of femoral artery pseudoaneurysms using ultrasound-guided thrombin injection.
Treatment of femoral artery pseudoaneurysms with percutaneous thrombin injection.
Treatment of femoral pseudoaneurysms. Percutaneous US-guided thrombin injection versus US-guided compression.
Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair.
Treatment of iatrogenic femoral artery false aneurysms with ultrasound-guided thrombin injection.
Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection.
Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin.
Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection.
Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients.
Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review.
Treatment of Iatrogenic Pseudoaneurysms Using Ultrasound-Guided Thrombin Injection over a 5-Year Period.
Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection.
Treatment of post-catheterization femoral artery pseudo-aneurysm with para-aneurysmal saline injection.
Treatment of postcatheterisation false aneurysms: ultrasound-guided compression vs ultrasound-guided thrombin injection.
Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection.
Treatment of radial and ulnar artery pseudoaneurysms using percutaneous thrombin injection.
Treatment of spontaneous lumbar artery pseudoaneurysm by computed tomography--guided thrombin injection.
Treatment of subclavian artery pseudoaneurysm with use of US-guided percutaneous thrombin injection.
Treatment of temporal artery pseudoaneurysms.
Treatment options for traumatic pseudoaneurysms of the paravisceral abdominal aorta.
Treatment protocol of traumatic pseudoaneurysm of the superficial temporal artery.
Treatment strategies for bleeding from gastroduodenal artery pseudoaneurysms complicating the course of chronic pancreatitis-A case series of 10 patients.
True and false aneurysms of the femoral artery.
Two Rare Cases of Posttraumatic Peripheral Artery Pseudoaneurysm.
Ulnar pseudoaneurysm after transulnar coronary angiogram treated with percutaneous ultrasound-guided thrombin injection.
Ultrasonic-guided percutaneous injection of pancreatic pseudoaneurysm with thrombin.
Ultrasonography-guided percutaneous thrombin injection of postcatheterization pseudoaneurysms.
Ultrasound Guided Compression Versus Ultrasound Guided Thrombin Injection for the Treatment of Post-Catheterization Femoral Pseudoaneurysms: Systematic Review and Meta-Analysis of Comparative Studies.
Ultrasound Guided Local Endovascular Coiling of an Iatrogenic Superficial Temporal Artery Pseudoaneurysm.
Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms.
Ultrasound guided percutaneous thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Ultrasound guided percutaneous thrombin injection for the treatment of post-catheterisation femoral pseudoaneurysm.
Ultrasound guided percutaneous thrombin injection in a radial artery pseudoaneurysm following percutaneous coronary intervention.
Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention.
Ultrasound guided thrombin injection of pseudoaneurysm of the radial artery after percutaneous coronary intervention.
Ultrasound guided thrombin injection to treat a pseudoaneurysm secondary to chronic pancreatitis.
Ultrasound-guided percutaneous thrombin for the management of superior mesenteric artery pseudoaneurysm.
Ultrasound-guided percutaneous thrombin injection for femoral artery pseudoaneurysms.
Ultrasound-guided percutaneous thrombin injection for post-catheterization pseudoaneurysm.
Ultrasound-guided percutaneous thrombin injection for treatment of extrarenal pseudoaneurysm after renal transplantation.
Ultrasound-guided percutaneous thrombin injection for treatment of femoral pseudoaneurysms: technical note.
Ultrasound-guided percutaneous thrombin injection of iatrogenic upper extremity pseudoaneurysms.
Ultrasound-Guided Thrombin Injection for Iliopsoas Pseudoaneurysm.
Ultrasound-guided thrombin injection for pseudoaneurysms: a case series at a local hospital.
Ultrasound-guided thrombin injection for the treatment of an iatrogenic hepatic artery pseudoaneurysm: a case report.
Ultrasound-Guided Thrombin Injection for the Treatment of Femoral Pseudoaneurysm in Pediatric Patients.
Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery.
Ultrasound-guided thrombin injection for the treatment of postcatheterization pseudoaneurysms.
Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience.
Ultrasound-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms compared with open surgery: first experiences from a single institution.
Ultrasound-guided thrombin injection for treatment of superficial traumatic pseudoaneurysms and associated expanding hematomas: experience in five patients.
Ultrasound-guided thrombin injection in the management of pseudoaneurysm after percutaneous arterial access.
Ultrasound-guided thrombin injection in the treatment of iatrogenic arterial pseudoaneurysms: Single-center experience.
Ultrasound-guided thrombin injection is a safe and durable treatment for femoral pseudoaneurysms.
Ultrasound-Guided Thrombin Injection Is a Safe and Effective Treatment for Femoral Artery Pseudoaneurysm in the Morbidly Obese.
Ultrasound-guided thrombin injection is the treatment of choice for femoral pseudoaneurysms.
Ultrasound-guided thrombin injection of femoral artery pseudoaneurysms.
Ultrasound-guided thrombin injection of genicular artery pseudoaneurysm.
Ultrasound-guided thrombin injection of iatrogenic femoral pseudoaneurysms: a prospective analysis.
Ultrasound-guided thrombin injection of iatrogenic groin pseudoaneurysm: Doppler features and technical tips.
Ultrasound-guided thrombin injection of iatrogenic pseudoaneurysm at a community hospital.
Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience.
Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience.
Ultrasound-guided thrombin injection: an alternative treatment for femoral artery pseudoaneurysm with better efficiency and safety.
Ultrasound-guided thrombin injections for arterial pseudoaneurysms: a 14-year study conducted at King Khalid University Hospital Vascular Lab.
Ultrasound-guided transvaginal thrombin injection of uterine arteries pseudoaneurysms.
US-guided percutaneous thrombin injection: a new method of repair of superficial temporal artery pseudoaneurysm.
Use of an endovascular stent graft and percutaneous thrombin injection to treat an iatrogenic hepatic artery pseudoaneurysm.
Use of the 8-f angio-seal vascular closure device in large-caliber arteriotomies.
Usefulness of ultrasonography in diagnosis, percutaneous management and follow up of post-traumatic scalp pseudoaneurysms.
Utility of percutaneous thrombin injection for treating visceral pseudoaneurysms.
Varied percutaneous and endovascular management of large iatrogenic Profunda Femoris artery pseudoaneurysm.
Vascular and interventional case of the day. Pancreatic head pseudoaneurysm treated with percutaneous thrombin injection.
[Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm]
[Application of the percutaneuos thrombin injection in treatment of iatrogenic femoral pseudoaneurysms]
[Comment to article Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.]
[Complex supraclavicular false aneurysm. Case report.]
[Embolotherapy: principles and indications.]
[Feasibility, efficacy and safety of transbrachial access for interventional therapy on paravalvular leak post surgical valve replacement].
[Femoral artery pseudoaneurysms: treatment with ultrasound guided thrombin injection in 28 patients]
[Femoral pseudoaneurysms - ultrasound-guided thrombin injection as a method of treatment]
[Minimally invasive percutaneous contrast-ultrasound guided thrombin occlusion of iatrogenic pseudoaneurysm]
[Non-surgical therapy of iatrogenic false aneurysms]
[Percutaneous thrombin injection for closure of femoral pseudoaneurysms: preliminary experience]
[Puncture treatment of pseudoaneurysms of femoral arteries with the use of human thrombin].
[The treatment of iatrogenic spurious aneurysm of the femoral artery by direct thrombin injection]
[Traumatic pseudoaneurysm of the superficial temporal artery].
[Treatment of iatrogenic femoral artery pseudoaneurysms].
[Treatment of iatrogenic femoral pseudoaneurysms by ultrasound-guided percutaneous thrombin injection: effectiveness and complications]
[Treatment of iatrogenic femoral pseudoaneurysms with thrombin injection--results in 54 patients]
[Treatment of post-catheterization pseudoaneurysms by ultrasound-guided thrombin injection: A single-center experience and practical guideline].
[Treatment of postcatheterization femoral false aneurysms]
[Treatment of pseudoaneurysms after vascular interventions]
[Treatment of pseudoaneurysms by thrombin injection].
[Treatment of pseudoaneurysms with injection of thrombin]
[Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.]
[Ultrasound guided percutaneous thrombin injection for treatment of a pseudoaneurysm after inguinal or brachial catheterization; good results in 14 patients]
[Ultrasound-guided intraluminal thrombin injection for false aneurysm: report of one case]
[Ultrasound-guided percutaneous thrombin injection therapy for the treatment of iatrogenic brachial pseudoaneurysms].
[Ultrasound-guided thrombin injection for the treatment of femoral artery pseudoaneurysms--report of three cases]
[US-guided percutaneous management of femoral artery pseudoaneurysms by thrombin injection: personal experience and review of the literature]
[Usefulness of sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms]
Aneurysm, Infected
Mycotic Aneurysm of the Hepatic Artery: A Case Report and its Management.
Percutaneous thrombin embolization of a hepatic artery mycotic aneurysm.
The use of thrombin in the radiology department.
Aneurysm, Ruptured
A ruptured aneurysm after stent graft puncture during computed tomography-guided thrombin injection.
The use of thrombin in the radiology department.
Angina Pectoris
Fibrin generation and digestion in patients with angina pectoris.
Functional and antigenic antithrombin III in angina pectoris and acute myocardial infarction patients.
Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
[The effect of plasmasorption on the content of natural antibodies to thrombin and alpha 2-macroglobulin in stenocardia patients]
[The prognostic significance of changes in the level of natural antibodies to thrombin in stenocardia patients]
[Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease]
Angina, Stable
Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
Bivalirudin during primary PCI in acute myocardial infarction.
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients.
Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction.
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Markers of hemostatic activation in affected coronary arteries during angioplasty.
Platelet release reaction and prostaglandin pathway activation in angina patients during exercise: effect of indobufen.
Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet' Response to Clopidogrel in Patients with Stable Angina.
The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention.
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]
Angina, Unstable
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris.
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Advances in antithrombotic therapy: novel agents.
Anti-thrombotic and anticoagulant treatment in interventional cardiology.
Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization.
Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Antithrombotic effects of hirulog in a rat carotid endarterectomy model.
Bivalirudin: a direct thrombin inhibitor.
Coagulation activation and long-term outcome in acute coronary syndromes.
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Coronary angioplasty for unstable angina.
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy).
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy).
Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris.
Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction.
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study.
Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina patients.
G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Heparin and antiaggregating therapy in unstable angina.
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense.
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
Increased number of thromboxane A2-prostaglandin H2 platelet receptors in active unstable angina and causative role of enhanced thrombin formation.
Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of thrombosis, fibrinolysis and atherosclerotic burden.
Lack of Correlation Between Activation of Hemostatic Mechanism and Inflammation in Unstable Angina Pectoris.
Low molecular weight heparin in acute stroke.
Newer antithrombin agents in acute coronary syndromes.
Platelet-dependent thrombin generation in patients with unstable angina pectoris.
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina.
Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Synthetic direct thrombin inhibitors in unstable angina - more questions than answers.
Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina.
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.
The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis"
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Thrombin activity and early outcome in unstable angina pectoris.
Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest.
Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
Thrombin inhibitors as anticoagulant agents.
Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal?
Thrombomodulin--endothelial thrombin receptor in blood of patients with unstable angina pectoris.
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Transient intermittent lymphocyte activation is responsible for the instability of angina.
Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty.
Wall passivation for unstable angina.
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
[Blood coagulation and fibrinolysis in arteriosclerosis]
[Clinical presentation of unstable angina may influence the formation of thrombin during spontaneous episodes of ischemia]
[Pathophysiology of acute coronary syndromes]
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins]
[Unstable angina pectoris: coagulation disorder and its therapy]
Angioedema
Coagulation and Skin Autoimmunity.
Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency.
In vitro interaction of C1-inhibitor with thrombin.
Inflammation and Coagulation in Urticaria and Angioedema.
Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency.
Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant.
Angioedemas, Hereditary
Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.
Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency.
Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 P.Thr309Lys Variant.
Angiomyolipoma
Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection.
Anthrax
Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Antiphospholipid Syndrome
A catastrophic antiphospholipid syndrome complicated with heparin-induced thrombocytopaenia, successfully managed with double filtration plasmapheresis, steroids and a direct thrombin inhibitor.
A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms.
Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events.
Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency.
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin.
Identification of thrombin antibodies in patients with antiphospholipid syndrome.
Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome.
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
Thrombin Generation in a patient with Triple Positive Antiphospholipid Syndrome Treated with Three Different Anticoagulants.
Thrombin generation in antiphospholipid syndrome.
Thrombin inhibition profiles in healthy individuals and thrombophilic patients.
Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.
Treatment Algorithms in Systemic Lupus Erythematosus.
Antithrombin III Deficiency
A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor.
Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.
Prophylactic antithrombin III administration during pregnancy immediately reduces the thrombin hyperactivity of congenital antithrombin III deficiency by forming thrombin-antithrombin III complexes.
The transient increase of plasma thrombin-antithrombin III (TAT) complex levels in patients with congenital antithrombin III deficiency during antithrombin III administration is due to extraction of thrombin from fibrin.
Thrombin generation and formation of thrombin-antithrombin III complexes in congenital antithrombin III deficiency.
Aortic Aneurysm
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice.
Aortic Aneurysm, Abdominal
A case of hybrid repair of ruptured abdominal aortic aneurysm with use of thrombin for acute treatment of type II endoleak.
Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate?
Changes in circulating markers of coagulation and fibrinolysis after EVAR.
Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair.
Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm.
CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair.
Effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis.
Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping.
Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair.
Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass?
Ischaemia and reperfusion during open abdominal aortic aneurysm surgery induce extensive thrombin generation and activity.
Markers of proteolysis, fibrinolysis, and coagulation in relation to size and growth rate of abdominal aortic aneurysms.
Percutaneous direct thrombin injection with hydrodissection to manage type II endoleak after endovascular abdominal aortic aneurysm repair.
Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery.
Successful treatment of a type-II endoleak with percutaneous CT-guided thrombin injection in a patient after endovascular abdominal aortic aneurysm repair.
The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm.
Transluminal thrombin injection and exclusion of a paramesenteric abdominal aortic aneurysm.
Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac.
Vascular surgical society of great britain and ireland: inhibition of systemic fibrinolysis is associated with myocardial injury in patients operated on for ruptured abdominal aortic aneurysm
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.]
Aortic Aneurysm, Thoracic
Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice.
Aortic Coarctation
Endovascular management of a rare complication of an aortic coarctation.
Platelet-derived microparticles promote endothelial cell proliferation in hypertension via miR-142-3p.
Aortic Valve Stenosis
Activated factor XI and tissue factor in aortic stenosis: links with thrombin generation.
Ambivalent effect of aortic stenosis on von Willebrand factor and thrombin generation. Is transvalvular gradient the guilty party?
Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration.
Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis.
Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties.
Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.
Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis.
Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis.
Oral Anticoagulation Therapy and Progression of Calcific Aortic Valve Stenosis: Factor Xa versus Factor IIa Inhibition?
Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin.
Appendicitis
[The role of thyroid and thymic hormones in regulation of fibrinolytic and pro-coagulant activity of leukocytes in patients with acute destructive appendicitis]
Arenaviridae Infections
Haemostatic derangements associated with arenavirus infection in the guinea-pig: radioimmunoassay of fibrinopeptide A to assess thrombin action in infected animals.
Arrhythmias, Cardiac
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Platelet reactivity and mean platelet volume as risk markers of thrombogenesis in atrial fibrillation.
Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes: implications for ischemic sodium loading.
Arterial Occlusive Diseases
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban.
Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin.
Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with ASA in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class.
Thrombin-antithrombin complex and the prothrombin fragment in arterial and venous blood of patients with peripheral arterial disease.
Arteriosclerosis
Fibrin formation and degradation in patients with arteriosclerotic disease.
Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds.
[Effect of alimentary lipemia on thrombin generation in the plasma of healthy persons and in arteriosclerosis]
[Pathogenesis of arteriosclerosis. Thrombin, factor XIII and fibronectin as regulators of fibroblast proliferation, endothelial cells and smooth muscle cells]
[The thrombin generation test and heparin overloading in normal subjects and patients with arteriosclerosis]
Arteriovenous Fistula
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula.
Endovascular repair of a large post-traumatic calf pseudoaneurysm and arteriovenous fistula.
Endovascular Treatment of Complications of Femoral Arterial Access.
Femoral pseudoaneurysm thrombinjection.
Interventional treatment of arterial injury during blind central venous catheterisation in the upper thorax: experience from two centres.
Percutaneous thrombin injection of a femoral artery pseudoaneurysm with simultaneous venous balloon occlusion of a communicating arteriovenous fistula.
Post-traumatic pseudoaneurysm of the medial plantar artery with arteriovenous fistula treated by coil embolization of the main feeding artery and percutaneous thrombin injection.
Ultrasound-guided thrombin injection in the management of pseudoaneurysm after percutaneous arterial access.
Arteriovenous Malformations
Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Nonsurgical treatment of scalp arteriovenous malformation using a combination of ultrasound-guided thrombin injection and transarterial coil embolization.
Arthritis
Amelioration of collagen-induced arthritis by thrombin inhibition.
Autoantibody-mediated arthritis in the absence of C3 and activating Fc? receptors: C5 is activated by the coagulation cascade.
Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis.
Leech thrombin inhibitors.
Prothrombin gene expression in articular cartilage with a putative role in cartilage degeneration secondary to joint immobility.
Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.
Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody.
Thrombin promotes matrix metalloproteinase-13 expression through the PKC? c-Src/EGFR/PI3K/Akt/AP-1 signaling pathway in human chondrocytes.
Treatment Algorithms in Systemic Lupus Erythematosus.
Arthritis, Experimental
Amelioration of collagen-induced arthritis by thrombin inhibition.
Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Arthritis, Rheumatoid
A hirudin-sensitive, growth-related proteinase from human fibroblasts.
Alterations of the thrombin generation profile in rheumatoid arthritis.
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Assessment of hemostatic disturbances in women with established rheumatoid arthritis.
Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro.
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis.
Nanostructured bioluminescent sensor for rapidly detecting thrombin.
Osteopontin is dispensable for protection against high load systemic fungal infection.
Relationship between cathepsin B and thrombin in rheumatoid arthritis.
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.
Thrombin generation in rheumatoid arthritis.
Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition.
Thrombin in inflammation and healing: relevance to rheumatoid arthritis.
Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor.
Thrombin inhibits the anti-myeloperoxidase and ferroxidase functions of ceruloplasmin: relevance in rheumatoid arthritis.
Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue.
Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis.
Thrombin stimulates cell proliferation in human fibroblast-like synoviocytes in nuclear factor-kappaB activation and protein kinase C mediated pathway.
Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts.
Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis.
Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1.
Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin.
Arthus Reaction
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Asthma
A functional polymorphism (-603A --> G) in the tissue factor gene promoter is associated with adult-onset asthma.
Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation.
alpha-Thrombin increases cytosolic calcium and induces human airway smooth muscle cell proliferation.
alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors.
Asthma is associated with enhanced thrombin formation and impaired fibrinolysis.
Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein.
Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Dose-dependent differential effects of thrombin in allergic bronchial asthma.
Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice.
Effect of thrombin on permeability of human epithelial cell monolayers.
Impaired fibrinolysis and lower levels of plasma ?2-macroglobulin are associated with an increased risk of severe asthma exacerbations.
Increased thrombin activity after allergen challenge: a potential link to airway remodeling?
Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells.
Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF?, in Peripheral Blood.
Prothrombotic state in patients with severe and prednisolone-dependent asthma.
Role of the coagulation system in allergic inflammation in the upper airways.
Role of the extracellular signal-regulated kinase 1/2 signaling pathway in the process of thrombin-promoting airway remodeling in ovalbumin-allergic rats.
The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.
Thrombin in the airways of asthmatic patients.
Thrombin lag time is increased in children with mild asthma.
Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways.
[Coagulation activity in the airways of asthmatic patients]
[Potential mechanisms of airway remodeling initiated by activated thrombin in asthma]
Astrocytoma
A requirement for Ras protein function in thrombin-stimulated mitogenesis in astrocytoma cells.
A rho exchange factor mediates thrombin and Galpha(12)-induced cytoskeletal responses.
Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced morphological changes in 1321N1 human astrocytoma cells.
Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes.
Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells.
G12 requirement for thrombin-stimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells.
Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma.
Mechanism of thrombin clearance by human astrocytoma cells.
Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation.
Quantification of extracellular UDP-galactose.
Regulated release of nucleotides and UDP sugars from astrocytoma cells.
Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis.
Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2.
Subnanomolar concentrations of thrombin enhance the volume-sensitive efflux of taurine from human 1321N1 astrocytoma cells.
The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain.
The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells.
Thrombin and trypsin act at the same site to stimulate phosphoinositide hydrolysis and calcium mobilization.
Thrombin produces phosphorylation of cytosolic phospholipase A2 by a mitogen-activated protein kinase kinase-independent mechanism in the human astrocytoma cell line 1321N1.
Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61.
Thrombin receptors modulate insulin-stimulated phosphatidylinositol 3,4,5-trisphosphate accumulation in 1321N1 astrocytoma cells.
Atherosclerosis
A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice.
A Heparin based dual ratiometric sensor for Thrombin.
A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production.
A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation.
Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms.
Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation.
Acute and persistent platelet and coagulant activities in atherothrombosis.
Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB.
Alterations of vascular reactivity in atherosclerosis.
American Heart Association scientific sessions.
An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion.
Anti-hypertensive effect of the Dongchunghacho, Isaria sinclairii, in the spontaneously hypertensive rats.
Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys.
Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.
Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN.
Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation.
Association of aortic valve sclerosis with thrombin generation in hypertensive patients.
Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E.
Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates.
Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice.
Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin.
Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate.
Baicalin Protects against Thrombin-Induced Cell Injury in Human Umbilical Vein Endothelial Cells.
Bi-cell surface plasmon resonance detection of aptamer mediated thrombin capture in serum.
Blood coagulation and the risk of atherothrombosis: a complex relationship.
cAMP response element-binding protein mediates thrombin-induced proliferation of vascular smooth muscle cells.
Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study.
Comparative beneficial effects on platelet functions and atherosclerosis of dietary linoleic and gamma-linolenic acids in the rabbit.
Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin.
Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism.
Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation.
Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits.
Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE-/--LDLR-/- Double-Knockout Mice.
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells.
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation.
Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.
Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells.
Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.
Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.
Human cytomegalovirus infection and atherothrombosis.
Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.
Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system.
Impaired platelet prostacyclin receptor activity: a monozygotic twin study discordant for spinal cord injury.
In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity.
Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes.
Induction of synthesis of a large heparan sulfate proteoglycan, perlecan, by thrombin in cultured human coronary smooth muscle cells.
Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis.
Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction.
Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation.
Is thrombin a key player in the 'coagulation-atherogenesis' maze?
Loss of Biglycan Enhances Thrombin Generation in ApoE-Deficient Mice Implications for Inflammation and Atherosclerosis.
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
Low dose of alcohol attenuates pro-atherosclerotic activity of thrombin.
Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy.
Mechanisms of sex steroids. Future developments.
Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis.
Mitochondrial protein CMPK2 regulates IFN alpha-enhanced foam cell formation, potentially contributing to premature atherosclerosis in SLE.
Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients.
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis.
New insights into modulation of thrombin formation.
New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
Non-conventional hemostatic risk factors for coronary heart disease in individuals with spinal cord injury.
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.
Pharmacologic agents in stroke prevention, acute stroke therapy, and interventional procedures.
Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions.
Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis.
Place of drug therapy in the treatment of carotid stenosis.
Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors.
Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis.
Platelet-dependent thrombin generation in patients with hyperlipidemia.
Platelet-Derived Exosomal MicroRNA-25-3p Inhibits Coronary Vascular Endothelial Cell Inflammation Through Adam10 via the NF-?B Signaling Pathway in ApoE-/- Mice.
Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis.
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Potent non-peptide thrombin receptor antagonists.
Potential non-glycoprotein IIb/IIIa effects of abciximab.
Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats.
Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice.
Protein Kinase C? Via Activating Transcription Factor 2-Mediated CD36 Expression and Foam Cell Formation of Ly6Chi Cells Contributes to Atherosclerosis.
Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease.
Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase.
Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells.
Regenerated Endothelium and Its Senescent Response to Aggregating Platelets.
Relationship between thrombin generation and carotid intima-media thickness.
Release of plasminogen activator from isolated perfused dog heart.
Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis.
Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty.
Role of the thrombin receptor in restenosis and atherosclerosis.
Role of thrombin in the pathogenesis of atherosclerosis.
Role of thrombogenic factors in the development of atherosclerosis.
Role of thrombosis in atherosclerosis and its complications.
Short-term venous stasis induces fibrinolytic activation but not thrombin formation.
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.
Suppressing thrombin generation is compatible with the development of atherosclerosis in mice.
Targeting factor Xa and thrombin: impact on coagulation and beyond.
The Beneficial Effects of a Direct Thrombin Inhibitor, Dabigatran Etexilate, on the Development and Stability of Atherosclerotic Lesions in Apolipoprotein E-deficient Mice : Dabigatran etexilate and atherosclerosis.
The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.
The effect of thrombin on low-density lipoprotein permeability and uptake by an arterial endothelial smooth muscle cell bilayer.
The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in Apolipoprotein E-deficient mice.
The hemostatic system as a regulator of inflammation in atherosclerosis.
The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein.
The isoelectric point of thrombin and its behaviour compared to prothrombin at some solid surfaces.
Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: role of thrombin in atherosclerosis and restenosis.
Thrombin and antithrombotics.
Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process.
Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis.
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.
Thrombin as a regulator of inflammation and reparative processes in tissues.
Thrombin contraction of vascular smooth muscle: implications for vasospasm.
Thrombin generation and atherosclerosis.
Thrombin generation in the Glasgow Myocardial Infarction Study.
Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
Thrombin generation's role in predicting coronary disease severity.
Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells.
Thrombin induces interleukin-6 expression through the cAMP response element in vascular smooth muscle cells.
Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-?B signaling pathway activation in vascular endothelial cells.
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
Thrombin receptor antagonists as novel therapeutic targets.
Thrombin receptor expression in normal and atherosclerotic human arteries.
Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells.
Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways.
Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2.
Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism.
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro.
Thrombin-induced glucose transport via Src-p38 MAPK pathway in vascular smooth muscle cells.
Thrombin.
Thrombomodulin domains attenuate atherosclerosis by inhibiting thrombin-induced endothelial cell activation.
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Tissue factor-driven thrombin generation and inflammation in atherosclerosis.
Transcriptional regulation of platelet-derived growth factor-B chain by thrombin in endothelial cells: involvement of Egr-1 and CREB-binding protein.
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor.
Vascular thrombin receptor regulation in hypertensive rats.
Vorapaxar in the secondary prevention of atherothrombosis.
[Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?]
[Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages]
[Regulation of the endothelial function by thrombomodulin and/or thrombin receptor]
Atrial Fibrillation
?T -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
A case of dabigatran-associated acute renal failure.
A Case of Liver Failure Due to Dabigatran Treated with Venovenous He-modiafiltration and Idarucizumab.
A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor.
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses.
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time.
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
A review of the clinical uses of ximelagatran in thrombosis syndromes.
Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin.
Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation.
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.
Acute management of bleeding in patients on novel oral anticoagulants.
Acute myocardial infarction after switching from warfarin to dabigatran.
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation.
American Heart Association scientific sessions.
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
An overview of anticoagulants, antiplatelet agents, and the combination in patients with mechanical heart valves.
Analysis of the influence of dabigatran on coagulation factors and inhibitors.
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Anticoagulation for atrial fibrillation in the elderly.
Anticoagulation in atrial fibrillation.
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
Anticoagulation-related intracranial hemorrhages.
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden.
Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease.
Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran.
Atrial fibrillation in the elderly.
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Cardiology.
Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran.
Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy.
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series.
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Clopidogrel hydrogen sulphate for atrial fibrillation.
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.
Coagulation derangement and risk factors for valve thrombosis following transcatheter aortic valve implantation.
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease.
Comparative effectiveness of oral anticoagulants in everyday practice.
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation.
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.
Cutting through the statistical fog: understanding and evaluating non-inferiority trials.
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study.
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment.
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: reply.
Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation.
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Dabigatran for left ventricular thrombus.
Dabigatran for stroke prevention in atrial fibrillation.
Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.
Dabigatran in clinical practice.
Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.
Dabigatran overdose secondary to acute kidney injury and amiodarone use.
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.
Dabigatran Use in the Real World A Multihospital System Experience.
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study.
Dabigatran versus warfarin in patients with mechanical heart valves.
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study).
Dabigatran, a Cause of Hematologic Emergency.
Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Dabigatran: Experience in standard clinical practice.
Dabigatran: patient management in specific clinical settings.
Dabigatran: ready for prime time?
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Defining nonvalvular atrial fibrillation: A quest for clarification.
Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Dental management considerations for a patient taking dabigatran etexilate: a case report.
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Direct thrombin inhibition to prevent stroke in atrial fibrillation.
Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation.
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Direct thrombin inhibitors in atrial fibrillation reloaded.
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Direct thrombin inhibitors versus warfarin in nonvalvular atrial fibrillation.
Direct Thrombin Inhibitors.
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.
Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Effect of hypertension on anticoagulated patients with atrial fibrillation.
Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation.
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Effects of aspirin on status of thrombin generation in atrial fibrillation.
Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.
Emerging role of direct thrombin inhibitors in nonvalvular atrial fibrillation: potential and peril.
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
Evaluating and assessing dabigatran drug interactions.
Ex Vivo Thrombin Generation in Patients With Venous Thromboembolic Disease or Atrial Fibrillation on Long-Term Oral Anticoagulation.
Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Gastrointestinal disorders and dabigatran.
Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran.
Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice.
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Hemorrhagic complications associated with dabigatran use.
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.
Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Imaging of Hemorrhagic Stroke.
Impact of dabigatran on platelet function and fibrinolysis.
Impaired renal function and bleeding in elderly treated with dabigatran.
Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice.
In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke.
Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment.
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran.
Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.
Insights into atrial fibrillation.
Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran.
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect.
Left atrial appendage thrombus on full-dose dabigatran treatment: a case report.
Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation.
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report.
Management of dabigatran-induced bleeding with continuous venovenous hemodialysis.
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
Monitoring and reversal strategies for new oral anticoagulants.
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
Monitoring the roles of prothrombin activation fragment 1 and 2 (F1?+?2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
New anticoagulants.
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
New oral anticoagulants: will they replace warfarin?
New possibilities in anticoagulant management of atrial fibrillation.
New therapeutic option for thromboembolism--dabigatran etexilate.
New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery.
Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Novel anticoagulant therapy: principle and practice.
Novel therapies for the prevention of stroke.
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran.
Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment.
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal.
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal.
Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
Positive Outcome After Intentional Overdose of Dabigatran.
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Pradaxa-induced esophageal ulcer.
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Preventing stroke in atrial fibrillation: the SPORTIF programme.
Prevention of stroke in patients with atrial fibrillation.
Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke.
Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels.
Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Removal of dabigatran by hemodialysis.
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration.
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
SPORTIF III and SPORTIF V: Stroke Prevention Using the Direct Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation.
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack.
Statins and the risk of bleeding in patients taking dabigatran.
Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Stroke prevention using an oral thrombin inhibitor in atrial fibrillation.
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. Pooled Analysis from the SPORTIF III and V Studies.
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Stroke prevention: managing modifiable risk factors.
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation.
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation.
The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs.
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation.
The immediate future for the medical treatment of atrial fibrillation.
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
The Pharmacology and Therapeutic Use of Dabigatran Etexilate.
The pharmacology and therapeutic use of dabigatran etexilate.
The pharmacology of novel oral anticoagulants.
The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.
The role of oral direct thrombin inhibitors in atrial fibrillation.
The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran.
The use of dabigatran in elderly patients.
Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban.
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects.
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
Thrombus formation in left atrium on dabigatran therapy.
Transitions of care in anticoagulated patients.
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Trials and tribulations of non-inferiority: the ximelagatran experience.
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Use of Extracorporeal Techniques in the Removal of Dabigatran.
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.
Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.
Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
Vitamin K antagonists. Ready to be replaced?
What did we learn from new oral anticoagulant treatment?
Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation.
Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Will oral antithrombin agents replace warfarin?
Will this be the end of the anticoagulation clinic for patients with atrial fibrillation?
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Ximelagatran for stroke prevention in atrial fibrillation.
Ximelagatran--recent comparisons with warfarin.
Ximelagatran.
Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
[Anticoagulation with atrial fibrillation]
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
[Dabigatran: a new therapeutic alternative in the prevention of stroke].
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
[Direct oral thrombin inhibitor, "dabigatran"].
[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
[Evidence of novel oral anticoagulants (NOAC)].
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
[Hemodialysis to remove anticoagulant dabigatran during emergencies].
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013.]
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
[Modern Approaches to Prevention of Thromboembolic Complications in Patients With Nonvalvular Atrial Fibrillation With a Direct Thrombin Inhibitor Dabigatran].
[Monitoring of Oral Thrombin Inhibitor].
[New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring].
[New antithrombotics for atrial fibrillation.]
[New oral anticoagulants : Better than vitamin K antagonists?]
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
[New oral anticoagulants: recommendations, precautions and perspectives for use].
[Non-valvular atrial fibrillation: direct thrombin inhibitors versus VKA].
[Novel oral anticoagulants (NOAC)].
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
[Perioperative management and therapy of bleeding complications].
[Pharmacology of the new oral anticoagulants].
[Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
[The effects of continuous renal replacement therapy (CRRT) and intermittent haemodialysis (IHD) in the treatment of dabigatran overdose. Case report].
[Waiting for the new oral anticoagulants: questions and answers about dabigatran].
[Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status]
Autoimmune Diseases
Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease.
Effects of calorie restriction and ?-3 dietary fat on aging in short-and long-lived rodents.
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
Osteopontin: another piece in the systemic lupus erythematosus immunopathology puzzle.
Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study.
The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.
Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases.
[Acquired factor V deficiency: A rare bleeding disorder with variable clinical presentations.]
Azotemia
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Use of clinical pathology in evaluation of horses with colic.
Bacteremia
An outbreak of pseudobacteremia caused by Enterobacter cloacae from a phlebotomist's vial of thrombin.
Complete antithrombin replacement for anticoagulation for cardiopulmonary bypass to repair severe infective mitral valve endocarditis.
Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study.
Bacterial Infections
Disseminated intravascular coagulation and bacterial infections in the elderly.
Fibrinogenolytic and anticoagulant activities in the tissue covering the stingers of marine stingrays Dasyatis sephen and Aetobatis narinari.
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
[A case of thrombocytopenia due to heparin therapy for a progressing ischemic stroke]
Bernard-Soulier Syndrome
Binding of thrombin to functionally defective platelets: a hypothesis on the nature of the thrombin receptor.
Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation.
Contrasting effects of thrombin and the thrombin receptor peptide, SFLLRN, on aggregation and release of 14C-serotonin by human platelets pretreated with chymotrypsin or serratia marcescens protease.
Defective thrombin-induced calcium changes and aggregation of Bernard-Soulier platelets are not associated with deficient moderate-affinity receptors.
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome.
Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin.
Molecular abnormalities in Glanzmann's thrombasthenia, Bernard-Soulier syndrome, and platelet-type von Willebrand's disease.
Molecular characterization of two mutations in platelet glycoprotein (GP) Ib alpha in two Finnish Bernard-Soulier syndrome families.
Novel genetic abnormalities in Bernard-Soulier syndrome in India.
Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of Bothrops jararaca.
[Genetic markers and thrombin reaction in a family of Bernard-Soulier syndrome]
beta-Thalassemia
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
Protein C levels in beta-thalassemia major patients in the east Nile delta of Egypt.
Bicuspid Aortic Valve Disease
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Bile Duct Diseases
[Plasma antithrombin and thrombin inhibitor in liver parenchymal and bile duct disease.]
Biliary Fistula
How to improve bilio-stasis in liver surgery.
Biliary Tract Diseases
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
[STUDIES ON THE THROMBIN TEST IN LIVER AND BILIARY TRACT DISEASES.]
Biliary Tract Neoplasms
Experimental and clinical studies on liver regeneration following transcatheter portal embolization.
Blister
Activation of blood coagulation in autoimmune skin disorders.
Effect of spontaneous pathology and thrombin on leukocyte adhesion to rat aortic endothelium.
Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases.
Rapid preparation of small-volume autologous fibrinogen concentrate and its same day use in bleb leaks after glaucoma filtration surgery.
Skin autoimmunity and blood coagulation.
The procoagulant effect of thrombin on fibrin(ogen)-bound platelets.
The use of autologous fibrinogen concentrate in treating ocular hypotony after glaucoma filtration surgery.
[Coagulation factors in human born blisters (author's transl)]
Blood Coagulation Disorders
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
[On the diagnosis of blood coagulation disorders in obstetrics by means of the thrombin time determination]
Blood Platelet Disorders
Failure to mobilize intracellular calcium in response to thrombin in a patient with familial thrombocytopathy characterized by macrothrombocytopenia and abnormal platelet membrane complexes.
Thrombin generation in patients with cirrhosis: the role of platelets.
Bone Diseases, Metabolic
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.
Bone Resorption
Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro.
Cyclosporine A inhibits bone resorption in cultured neonatal mouse calvaria.
Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption.
Effect of auranofin on resorption, prostaglandin synthesis and ultrastructure of bone cells in cultured mouse calvaria.
Experimental considerations on the measurement of prostaglandins during long-time incubations of neonatal mouse calvaria.
Expression of the thrombin receptor in developing bone and associated tissues.
Prostaglandin-related bone resorption in cultured neonatal mouse calvaria: evaluation of biopotency of nonsteroidal anti-inflammatory drugs.
RANKL induces components of the extrinsic coagulation pathway in osteoclasts.
Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria.
Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants.
Role of bacterial proteinases in matrix destruction and modulation of host responses.
Second messengers in thrombin-stimulated bone resorption.
Suramin is a potent inhibitor of calcemic hormone- and growth factor-induced bone resorption in vitro.
Thrombin effects on osteoblastic cells. II. Structure-function relationships.
Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism.
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Thrombin, a stimulator of bone resorption.
Bradycardia
Pulmonary Arterial Hypertension and Endothelial Dysfunction Is Linked to NADPH Oxidase-Derived Superoxide Formation in Venous Thrombosis and Pulmonary Embolism in Mice.
Brain Concussion
Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
Brain Diseases
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Thrombin in inflammatory brain diseases.
Brain Edema
A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats.
A novel aspect of thrombin in the tissue reaction following central nervous system injury.
A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model.
Activation of p44/42 mitogen activated protein kinases in thrombin-induced brain tolerance.
Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning.
Blood-brain barrier breakdown and repair by Src after thrombin-induced injury.
Brain edema from intracerebral hemorrhage.
Brain pericytes are the most thrombin-sensitive matrix metalloproteinase-9-releasing cell type constituting the blood-brain barrier in vitro.
Complement inhibition attenuates brain edema and neurological deficits induced by thrombin.
Cytopathological alterations and therapeutic approaches in Binswanger's disease.
Effect of thrombin on blood brain barrier permeability and its mechanism.
Effects of brain hypothermia on brain edema formation after intracerebral hemorrhage in rats.
Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats.
Effects of hypothermia on thrombin-induced brain edema formation.
Expression of matrix metalloproteinse-9 in thrombin-induced brain edema formation in rats.
Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation.
Holo-transferrin and thrombin can interact to cause brain damage.
Hyperbaric oxygen for experimental intracerebral hemorrhage.
Induction of colligin may attenuate brain edema following intracerebral hemorrhage.
Intracerebral hemorrhage induces edema and oxidative stress and alters N-methyl-D-aspartate receptor subunits expression.
Intracerebral infusion of thrombin as a cause of brain edema.
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.
Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages.
Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin.
Plasminogen activators potentiate thrombin-induced brain injury.
Protease activated receptor-1 and brain edema formation in glioma models.
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Short period of early reperfusion aggravates blood-brain barrier dysfunction during permanent focal ischemia in rats.
Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment.
Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models.
Testing the effect of PAR1 inhibitors on Plasmodium falciparum-induced loss of endothelial cell barrier function.
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage.
The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
The role of thrombin in gliomas.
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Thrombin and brain recovery after intracerebral hemorrhage.
Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1.
Thrombin enhances glioma growth.
Thrombin exacerbates brain edema in focal cerebral ischemia.
Thrombin hemostatic matrix leading to acute cerebral edema and sterile fluid collection formation post-tumor resection: two cases.
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Thrombin inhibits aquaporin 4 expression through protein kinase C-dependent pathway in cultured astrocytes.
Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron.
Thrombin Preconditioning in Surgical Brain Injury in Rats.
Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy.
Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells.
Thrombin preconditioning, heat shock proteins and thrombin-induced brain edema.
Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway.
Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1.
Thrombin-receptor activation and thrombin-induced brain tolerance.
Thrombin-soaked gelatin sponge and brain edema in rats.
Time course of upregulation of inflammatory mediators in the hemorrhagic brain in rats: correlation with brain edema.
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Up-regulation of brain ceruloplasmin in thrombin preconditioning.
[Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin]
Brain Infarction
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy.
Brain Injuries
Acetazolamide Attenuates Thrombin-Induced Hydrocephalus.
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Acute subdural hematoma: new model delineation and effects of coagulation inhibitors.
Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-?B Signaling.
Brain injury after intracerebral hemorrhage: the role of thrombin and iron.
Chronic thrombin exposure results in an increase in apolipoprotein-E levels.
Complement inhibition attenuates brain edema and neurological deficits induced by thrombin.
Concomitant intracerebral infusion of tissue plasminogen activator and thrombin leads to brain injury.
Disturbances of the coagulatory system in patients with severe cerebral trauma. I.
Effect of minimally invasive surgery for cerebral hematoma evacuation in different stages on motor evoked potential and thrombin in dog model of intracranial hemorrhage.
Effects of alpha-thrombin on superoxide dismutase levels in human cerebral microvascular endothelial cells.
Effects of thrombin on neurogenesis after intracerebral hemorrhage.
Effects of Thrombin on the Neurovascular Unit in Cerebral Ischemia.
Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in organotypic slice culture.
Holo-transferrin and thrombin can interact to cause brain damage.
Hydrocephalus after intraventricular hemorrhage: the role of thrombin.
In models of intracerebral hemorrhage, rivaroxaban is superior to warfarin to limit blood brain barrier disruption and hematoma expansion.
Increase in brain thrombin activity after experimental intracerebral hemorrhage.
Inhibition of prostaglandin E2 receptor EP3 mitigates thrombin-induced brain injury.
Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow.
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury.
Long-time course of protease-activated receptor-1 expression after intracerebral hemorrhage in rats.
Microglial activation and brain injury after intracerebral hemorrhage.
Minocycline reduces intracerebral hemorrhage-induced brain injury.
Mouse model of in situ thromboembolic stroke and reperfusion.
Nestin expression after experimental intracerebral hemorrhage.
Oral anticoagulant-associated intracerebral hemorrhage.
PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats.
Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation.
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Plasminogen activators potentiate thrombin-induced brain injury.
Prothrombin overexpressed in post-natal neurones requires blood factors for activation in the mouse brain.
Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases.
Regulation of neurons and astrocytes by thrombin and protease nexin-1. Relationship to brain injury.
Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors.
Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice.
Role of Lipocalin-2 in Thrombin-Induced Brain Injury.
Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage.
ROS/TXNIP pathway contributes to thrombin induced NLRP3 inflammasome activation and cell apoptosis in microglia.
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat.
Src Family Kinases in Brain Edema After Acute Brain Injury.
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKC?/PKC? signaling.
The deleterious or beneficial effects of different agents in intracerebral hemorrhage: think big, think small, or is hematoma size important?
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention.
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Thrombin inhibitor ameliorates secondary damage in rat brain injury: suppression of inflammatory cells and vimentin-positive astrocytes.
Thrombin is a potent mitogen for rat astroblasts but not for oligodendroblasts and neuroblasts in primary culture.
Thrombin preconditioning attenuates iron-induced neuronal death.
Thrombin Preconditioning in Surgical Brain Injury in Rats.
Thrombin-induced autophagy: a potential role in intracerebral hemorrhage.
Transient receptor potential canonical 3 (TRPC3) mediates thrombin-induced astrocyte activation and upregulates its own expression in cortical astrocytes.
Transient receptor potential canonical 3 inhibitor Pyr3 improves outcomes and attenuates astrogliosis after intracerebral hemorrhage in mice.
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
[Secondary blood coagulation disturbances after severe head injuries (author's transl)]
[Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin]
Brain Injuries, Traumatic
Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-?B Signaling.
Depression following traumatic brain injury in mice is associated with down-regulation of hippocampal astrocyte glutamate transporters by thrombin.
Early posttraumatic changes in coagulation and fibrinolysis systems in isolated severe traumatic brain injury patients and its influence on immediate outcome.
Role of Thrombin in Central Nervous System Injury and Disease.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Thrombin and its precursor in human cerebrospinal fluid.
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Thrombin Hemostatic Matrix Reduces Heterotopic Ossification in Acetabular Fractures fixed via the Kocher-Langenbeck Approach.
Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes.
Thrombin preferentially induces autophagy in glia cells in the rat central nervous system.
Thrombin, a mediator of neurotoxicity and memory impairment.
Brain Ischemia
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.
Activation of p44/42 mitogen activated protein kinases in thrombin-induced brain tolerance.
Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity.
Argatroban in thrombotic stroke.
Coagulation factor Xa activates thrombin in ischemic neural tissue.
Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons.
Dabigatran abrogates brain endothelial cell permeability in response to thrombin.
Effects and mechanisms of triacetylshikimic acid on platelet adhesion to neutrophils induced by thrombin and reperfusion after focal cerebral ischemia in rats.
Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Effects of Thrombin on the Neurovascular Unit in Cerebral Ischemia.
Endogenous Protease Nexin-1 Protects against Cerebral Ischemia.
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors.
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition.
New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).
Preconditioning with thrombin can be protective or worsen damage after endothelin-1-induced focal ischemia in rats.
Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia.
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
The involvement of thrombin in the pathogenesis of glioblastoma.
The prevalence of protein C, protein S, and antithrombin III deficiency in non-APS/SLE Chinese adults with noncardiac cerebral ischemia.
The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Thrombin exacerbates brain edema in focal cerebral ischemia.
Thrombin in ischemic neuronal death.
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Thrombin potently enhances swelling-sensitive glutamate efflux from cultured astrocytes.
Thrombin preconditioning attenuates iron-induced neuronal death.
Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway.
Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1.
Thrombin-receptor activation and thrombin-induced brain tolerance.
Transient focal ischemia in rat brain differentially regulates mRNA expression of protease-activated receptors 1 to 4.
Brain Neoplasms
Brain Tumors Enhance Plasmatic Coagulation: The Role of Hemeoxygenase-1.
Efficacy of a topical gelatin-thrombin hemostatic matrix, FLOSEAL®, in intracranial tumor resection.
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors.
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
The involvement of thrombin in the pathogenesis of glioblastoma.
The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells.
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Breast Diseases
The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.
Breast Neoplasms
Acquired resistance to activated protein C in breast cancer patients.
Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.
Alteration in platelet function in patients with early breast cancer.
Breast Cancer Chemotherapy Induces the Release of Cell Free DNA, a Novel Procoagulant Stimulus.
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Comparison of breast carcinoma prognostic/predictive biomarkers on cell blocks obtained by various methods: Cellient, formalin and thrombin.
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
Determination of HER2/neu Status: A Pilot Study Comparing HER2/neu Dual In Situ Hybridization DNA Probe Cocktail Assay Performed on Cell Blocks to Immunohistochemisty and Fluorescence In Situ Hybridization Performed on Histologic Specimens.
Effects of thrombin/thrombosis in angiogenesis and tumour progression.
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer.
Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients.
Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells.
Lysophospholipids activate ovarian and breast cancer cells.
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion.
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-Kinase in breast cancer.
Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer.
PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation.
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.
Protease-Triggered, Integrin-Targeted Cellular Uptake of Recombinant Protein Micelles.
Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Role of platelet aggregation in metastatic breast cancer patients.
Role of thrombin as a tumor growth factor.
Role of thrombin receptor in breast cancer invasiveness.
Role of tissue factor expression in thrombin generation by canine tumor cells.
Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin.
TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.
The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer.
The elevated homocysteine stimulates changes of haemostatic function of plasma isolated from breast cancer patients.
The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Thrombin generation predicts early recurrence in breast cancer patients.
Thrombin receptor overexpression in malignant and physiological invasion processes.
Tissue factor in cancer progression and angiogenesis.
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.
Use of dabigatran etexilate to reduce breast cancer progression.
Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence.
[Interest of a thrombin and fibrinogen combipatch in preventing breast cancer seroma after lymph node dissection].
Bronchial Hyperreactivity
Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells.
Bronchiolitis Obliterans
alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors.
Bronchitis, Chronic
[Coagulation activity in the airways of asthmatic patients]
Budd-Chiari Syndrome
Budd-Chiari syndrome in a young female with factor V Leiden mutation: successful treatment with lepirudin, a direct thrombin inhibitor.
Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment.
Burkitt Lymphoma
Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production.
Calciphylaxis
Direct oral anticoagulant medications in calciphylaxis.
Candidiasis, Oral
[Molecular pathogenesis of oral candidiasis (candidosis)]
Carcinogenesis
A new type of thrombin inhibitor, noncytotoxic phospholipase A(2), from the Naja haje cobra venom.
Blood coagulation factors as inflammatory mediators.
Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer.
Expression of protease-activated receptors and tissue factor in human liver.
Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1.
Mechanisms coupling thrombin to metastasis and tumorigenesis.
Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages.
Ovarian cancer, the coagulation pathway, and inflammation.
Platelets contribute to the initiation of colitis-associated cancer by promoting immunosuppression.
Protease-activated receptors in cancer: A systematic review.
The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development.
The pivotal role of thrombin in cancer biology and tumorigenesis.
Thrombin drives tumorigenesis in colitis-associated colon cancer.
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Thrombomodulin enhances the invasive activity of mouse mammary tumor cells.
Transcriptomic profiles of tumor-associated neutrophils reveal prominent roles in enhancing angiogenesis in liver tumorigenesis in zebrafish.
[Future potential indications for an oral thrombin inhibitor]
Carcinoma
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Alcoholism and carcinoma change the intracellular pH and activate platelet Na+/H+-exchange in men.
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome.
Circulating vascular endothelial growth factor correlates with systemic thrombin generation in patients with pancreatic carcinoma.
Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection.
Clinical trials with anticoagulant and antiplatelet therapies.
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model.
Effect of thrombin receptor expression on microvessel endothelial cells, and survival by coagulation state in oesophageal squamous cell carcinoma.
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Elevated plasma D-dimer as a predictor of postoperative complications after radical cystectomy.
Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues.
Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells.
Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors.
Microarray studies of factor VIIa-activated cancer cells.
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells.
PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism.
Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.
Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.
Sphingolipid receptor signaling and function in human bladder carcinoma cells: inhibition of LPA- but enhancement of thrombin-stimulated cell motility.
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Stimulation of protease activated receptors on RT4 cells mediates arachidonic acid release via Ca2+ independent phospholipase A2.
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
The enigma PAI-2. Gene expression, evolutionary and functional aspects.
Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Thrombin stimulates arachidonate metabolism in murine tumor cells.
Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.
Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data.
Transient increase in thrombin generation during radiotherapy of uterine carcinoma: A preliminary study using thrombin-antithrombin III complex measurements.
Trousseau's syndrome: multiple definitions and multiple mechanisms.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines.
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
Carcinoma, Bronchogenic
Treatment of malignant tracheobronchial stenosis by Dacron mesh-covered Z-stents.
Carcinoma, Embryonal
Cyclic AMP-mediated augmentation of thrombomodulin gene expression: cell type-dependent usage of control regions.
Carcinoma, Hepatocellular
alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.
Demonstration of the presence of protease-cutting site in the spacer of hepatitis B viral Pol protein.
Experimental and clinical studies on liver regeneration following transcatheter portal embolization.
Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin.
Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Inhibitor against coagulation factor V after liver transplantation.
Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells.
Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues.
Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma.
Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
[High expression of thrombin receptor PAR1 in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma in early stage].
Carcinoma, Intraductal, Noninfiltrating
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion.
PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion.
Carcinoma, Non-Small-Cell Lung
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.
Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition.
Carcinoma, Renal Cell
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors.
PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells.
PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration.
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism.
Thrombin: implications for intratumor therapy against metastasis.
Tumour infarction after pre-operative embolisation of renal carcinoma.
[Occlusion of the renal artery by intra-arterial injection of thrombin in a case of inoperable renal tumour (author's transl)]
[The embolization of inoperable hypernephromas with autogenous fibrin and thrombin]
Carcinoma, Small Cell
Clinical trials with anticoagulant and antiplatelet therapies.
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.
Carcinoma, Squamous Cell
Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.
The enigma PAI-2. Gene expression, evolutionary and functional aspects.
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Carcinosarcoma
Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Cardiac Tamponade
Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture.
Cardiomegaly
c-Src/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction.
Cardiomyopathies
Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.
[Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease]
Cardiomyopathy, Dilated
Activation of coagulation system in dilated cardiomyopathy: comparison of patients with and without left ventricular thrombus.
Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy.
Cardiomyopathy, Hypertrophic
Acute myocardial infarction with diminutive right coronary artery and obstructive hypertrophic cardiomyopathy without significant coronary stenoses.
Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy.
Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation.
Cardiovascular Diseases
A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.
A review of global coagulation assays - Is there a role in thrombosis risk prediction?
Aluminum Metasurface with Hybrid Multipolar Plasmons for 1000-Fold Broadband Visible Fluorescence Enhancement and Multiplexed Biosensing.
Anti inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes.
Antiplatelet aggregation effects of phenanthrenes from Calanthe arisanensis.
Aptamers as Therapeutics in Cardiovascular Diseases.
Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity.
Associations Between Thrombin Generation and the Risk of Cardiovascular Disease in Elderly Patients: Results From the PROSPER Study.
Blood-based omic profiling supports female susceptibility to tobacco smoke-induced cardiovascular diseases.
Clinical Determinants of Thrombin Generation Measured in Presence and Absence of Platelets-Results from the Gutenberg Health Study.
Coagulation and non-coagulation effects of thrombin.
Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.
Computational modelling of inhibitor binding to human thrombin.
Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease.
Daily variations of functional parameters and density distribution in human blood platelets.
Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases.
Direct thrombin inhibitors in cardiovascular disease.
Does Lipid Profile Affect Thrombin Generation During Ramadan Fasting in Patients With Cardiovascular Risks?
Fibrinogen plasma levels as a marker of thrombin activation in diabetes.
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection.
High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
Highly sensitive host-guest mode homogenous electrochemical thrombin signal amplification aptasensor based on tetraferrocene label.
Hirudin: clinical potential of a thrombin inhibitor.
Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies.
Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting.
In silico Prediction of Inhibitory Constant of Thrombin Inhibitors Using Machine Learning.
Inverse association of the endogenous thrombin potential (ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.
Is thrombin a key player in the 'coagulation-atherogenesis' maze?
Leech thrombin inhibitors.
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
New thrombin inhibitors in cardiovascular disease.
PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.
Pathophysiologic roles of the fibrinogen gamma chain.
Platelet regulation of thrombin generation in cardiovascular disease.
Popular naturally occurring antioxidants as potential anticoagulant drugs.
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Proximity Binding and Metal Ion-Dependent DNAzyme Cyclic Amplification-Integrated Aptasensor for Label-Free and Sensitive Electrochemical Detection of Thrombin.
Real-time measurement of thrombin generation using continuous droplet microfluidics.
Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol.
Role of thrombin in the pathogenesis of atherosclerosis.
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Screening of direct thrombin inhibitors from Radix Salviae Miltiorrhizae by a peak fractionation approach.
Structure of a novel thrombin inhibitor with an uncharged D-amino acid as P1 residue.
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
The discovery and characterization of a novel nucleotide-based thrombin inhibitor.
The Effect of Omega-3 Polyunsaturated Fatty Acids on Fibrin and Thrombin Generation in Healthy Subjects and Subjects with Cardiovascular Disease.
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Thrombin generation assay: interactions between chronic inflammation and haemostasis in patients with autoimmune diseases.
Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study.
Thrombin receptor function and cardiovascular disease.
Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase.
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective.
Tissue factor in thrombosis and hemorrhage.
Unchecked thrombin is bad news for troubled arteries.
Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician.
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
[Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia]
Carotid Artery Injuries
Factor V Leiden improves in vivo hemostasis in murine hemophilia models.
Glybenclamide: an antidiabetic with in vivo antithrombotic activity.
Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child.
Carotid Artery Thrombosis
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice.
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis.
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
Carotid Stenosis
Coagulation activation and ultrasound characteristics in patients with carotid artery disease.
Increased thrombin generation in persons with echogenic carotid plaques.
Increased thrombin generation potential in symptomatic versus asymptomatic moderate or severe carotid stenosis and relationship with cerebral microemboli.
Place of drug therapy in the treatment of carotid stenosis.
Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection.
Thrombocyte activation increases with the degree of carotid artery stenosis.
Cataract
Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: role of recombinant hirudin variant III.
Use of fibrin glue in ocular surgery.
Celiac Disease
Onset of Thrombin Generation Occurs More Rapidly in Pediatric Patients With Celiac Disease.
Central Nervous System Diseases
The involvement of thrombin in the pathogenesis of glioblastoma.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Central Nervous System Infections
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Central Nervous System Neoplasms
Role of Thrombin in Central Nervous System Injury and Disease.
Cerebral Amyloid Angiopathy
Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.
Cerebral Hemorrhage
3CB2, a marker of radial glia, expression after experimental intracerebral hemorrhage: role of thrombin.
A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats.
Analysis of thrombin-antithrombin complex contents in plasma and hematoma fluid of hypertensive intracerebral hemorrhage patients after clot removal.
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.
Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning.
Blood-brain barrier breakdown and repair by Src after thrombin-induced injury.
Brain injury after intracerebral hemorrhage: the role of thrombin and iron.
Coated-platelet levels are elevated in patients with transient ischemic attack.
Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice.
Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons.
Controversies of anticoagulation reversal in life-threatening bleeds.
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
Dabigatran abrogates brain endothelial cell permeability in response to thrombin.
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Edema from intracerebral hemorrhage: the role of thrombin.
Effect of delayed argatroban treatment on intracerebral hemorrhage-induced edema in the rat.
Effect of Iron Chelators on Methemoglobin and Thrombin Preconditioning.
Effect of thrombin on blood brain barrier permeability and its mechanism.
Effect of thrombin preconditioning on migration of subventricular zone-derived cells after intracerebral hemorrhage in rats.
Effects of Aerobic Capacity on Thrombin-Induced Hydrocephalus and White Matter Injury.
Effects of hypothermia on thrombin-induced brain edema formation.
Effects of thrombin on neurogenesis after intracerebral hemorrhage.
Effects of thrombin on the secondary cerebral injury of perihematomal tissues of rats after intracerebral hemorrhage.
Excitatory and Mitogenic Signaling in Cell Death, Blood-brain Barrier Breakdown, and BBB Repair after Intracerebral Hemorrhage.
Experimental study on the PAR-1 expression around hemotoma following intracerebral hemorrhage in rats.
Expression of matrix metalloproteinse-9 in thrombin-induced brain edema formation in rats.
Expression of thrombin and its associated protein in cerebellum of human and rat after intracerebral hemorrhage.
Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.
Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in organotypic slice culture.
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
High CSF thrombin concentration and activity is associated with an unfavorable outcome in patients with intracerebral hemorrhage.
HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats.
Hydrocephalus after intraventricular hemorrhage: the role of thrombin.
Impaired adult hippocampal neurogenesis and cognitive ability in a mouse model of intrastriatal hemorrhage.
Increase in brain thrombin activity after experimental intracerebral hemorrhage.
Interactions between rat cortico-striatal slice cultures and neutrophil-like HL60 cells under thrombin challenge: Toward elucidation of pathological events in intracerebral hemorrhage.
Intracerebral hemorrhage induces edema and oxidative stress and alters N-methyl-D-aspartate receptor subunits expression.
Intracerebral hemorrhage injury mechanisms: glutamate neurotoxicity, thrombin, and Src.
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury.
Letter by Moll regarding article, "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran".
Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage.
Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.
Long-term treatment with nicotine suppresses neurotoxicity of, and microglial activation by, thrombin in cortico-striatal slice cultures.
Long-time course of protease-activated receptor-1 expression after intracerebral hemorrhage in rats.
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.
Microglial activation and brain injury after intracerebral hemorrhage.
Minocycline reduces intracerebral hemorrhage-induced brain injury.
Nestin expression after experimental intracerebral hemorrhage.
Novel therapies for intracerebral hemorrhage.
Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin.
Pathophysiological significance of canonical transient receptor potential (TRPC) subfamily in astrocyte activation.
PDGFR-? inhibition preserves blood-brain barrier after intracerebral hemorrhage.
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Plasminogen activators potentiate thrombin-induced brain injury.
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats.
Potentiation of NMDA receptor function by the serine protease thrombin.
Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo.
Relative Importance of Proteinase-Activated Receptor-1 Versus Matrix Metalloproteinases in Intracerebral Hemorrhage-Mediated Neurotoxicity in Mice.
Role of Thrombin in Central Nervous System Injury and Disease.
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Serine protease inhibitor attenuates intracerebral hemorrhage-induced brain injury and edema formation in rat.
Sesamin suppresses activation of microglia and p44/42 MAPK pathway, which confers neuroprotection in rat intracerebral hemorrhage.
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage.
Systemic administration of argatroban inhibits protease-activated receptor-1 expression in perihematomal tissue in rats with intracerebral hemorrhage.
Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment.
The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKC?/PKC? signaling.
The Cerebral Thrombin System Is Activated after Intracerebral Hemorrhage and Contributes to Secondary Lesion Growth and Poor Neurological Outcome in C57Bl/6 Mice.
The deleterious or beneficial effects of different agents in intracerebral hemorrhage: think big, think small, or is hematoma size important?
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Thrombin and brain recovery after intracerebral hemorrhage.
Thrombin exacerbates brain edema in focal cerebral ischemia.
Thrombin preconditioning attenuates iron-induced neuronal death.
Thrombin preconditioning reduces iron-induced brain swelling and brain atrophy.
Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells.
Thrombin promotes pericyte coverage by Tie2 activation in a rat model of intracerebral hemorrhage.
Thrombin promotes the expression of thrombospondin-1 and -2 in a rat model of intracerebral hemorrhage.
Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115).
Thrombin-induced apoptosis in neurons through activation of c-Jun-N-terminal kinase.
Thrombin-induced autophagy: a potential role in intracerebral hemorrhage.
Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1.
Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures.
Thrombin-receptor activation and thrombin-induced brain tolerance.
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Up-regulation of brain ceruloplasmin in thrombin preconditioning.
[Dynamic and long-lasting expression of thrombin receptor-1 after intracerebral hemorrhage in rats].
[Expression of intercellular adhesion molecule-1 and neutrophil infiltration induced by injection of thrombin in rats]
Cerebral Infarction
A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction.
Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.
Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Hematologic abnormalities occur in both cortical and lacunar infarction.
Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction.
Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats.
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats.
The role of thrombin in central nervous system activity and stroke.
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Treatment of intractable arterial hemorrhage during stereotactic brain biopsy with thrombin. Report of three patients.
[Antithrombotic therapy in cerebral infarction]
Cerebrospinal Fluid Leak
Effective Repair of Dural Tear Using Bioabsorbable Sheet with Fibrin Glue.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Cerebrovascular Disorders
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis.
Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke.
Chagas Disease
Absence of myocardial calcium-independent phospholipase A2? results in impaired PGE2 production and decreased survival in mice with acute Trypanosoma cruzi infection.
Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor.
Looking at the proteases from a simple perspective.
Chickenpox
Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation.
Cholangiocarcinoma
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor.
Cholangitis
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Choledocholithiasis
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Cholera
Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.
Colloidal gold: a pluripotent receptor probe.
Determination of the conformations of bound peptides using NMR-transferred nOe techniques.
Effect of cholera toxin on histamine release from bone marrow-derived mouse mast cells.
Electrogenerated trisbipyridyl Ru(II)-/nitrilotriacetic-polypyrene copolymer for the easy fabrication of label-free photoelectrochemical immunosensor and aptasensor: application to the determination of thrombin and anti-cholera toxin antibody.
Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor.
Mechanisms of cholera toxin prevention of thrombin- and PMA-induced endothelial cell barrier dysfunction.
Possible involvement of a GTP-binding protein, the substrate of islet-activating protein, in receptor-mediated signaling responsible for cell proliferation.
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Regulation of thrombin-induced endothelial cell activation by bacterial toxins.
Thrombin exerts a dual effect on stimulated adenylate cyclase in hamster fibroblasts, an inhibition via a GTP-binding protein and a potentiation via activation of protein kinase C.
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Cholestasis
The Coagulation System Contributes to {alpha}V{beta}6 Integrin Expression and Liver Fibrosis Induced by Cholestasis.
Cholesteatoma
A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug.
Chondrosarcoma
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Choroidal Effusions
Recurrent hemorrhagic choroidal detachment associated with disseminated intravascular coagulation.
Chronic Limb-Threatening Ischemia
A direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable critical limb ischemia.
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Altered coagulation profile in peripheral artery disease patients.
Chronic Urticaria
Activation of the Blood Coagulation System in Patients with Chronic Spontaneous Urticaria.
Activation of the Intrinsic Coagulation Pathway in Patients With Chronic Urticaria.
Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.
Emerging drugs for chronic urticaria.
Increase of coagulation potential in chronic spontaneous urticaria.
Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test.
Increased thrombin generation potential in patients with chronic spontaneous urticaria.
Mast cells are critical for the limitation of thrombin-induced skin inflammation.
Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum.
Severe chronic urticaria is associated with elevated plasma levels of D-dimer.
Classical Swine Fever
Isothermal Self-Primer EXPonential Amplification Reaction (SPEXPAR) for Highly Sensitive Detection of Single-Stranded Nucleic Acids and Proteins.
coagulation factor ixa deficiency
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
coagulation factor viia deficiency
Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography.
Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation.
Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice.
Congenital combined defects of factor VII: a critical review.
Generation of genetically-altered mice producing very low levels of coagulation factorVII.
Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII: 30 years of research and innovation.
Recombinant activated factor VII: mechanisms of action and current indications.
The Story of Serum Prothrombin Conversion Accelerator, Proconvertin, Stable Factor, Cothromboplastin, Prothrombin Accelerator or Autoprothrombin I, and Their Subsequent Merging into Factor VII.
Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency.
coagulation factor xa deficiency
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
coagulation factor xia deficiency
Anesthetic management using peripheral nerve block in patients with factor XI deficiency: a case report.
Factor XI deficiency in Kerry Blue Terriers.
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency.
Thrombin generation in patients with factor XI deficiency and clinical bleeding risk.
[Thrombocyte dysfunction in children with albinism]
coagulation factor xiia deficiency
Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins.
Coinfection
A cost effective endovascular approach for management of post-catheterization profunda femoris artery pseudoaneurysm using thrombin.
Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways.
Colic
Hemostatic abnormalities in equine colic.
The coagulation system in horses with colic.
Colitis
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.
Thrombin drives tumorigenesis in colitis-associated colon cancer.
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study.
Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.
Colitis, Ischemic
Ischemic colitis following translumbar thrombin injection for treatment of endoleak.
Colitis, Ulcerative
Acquired inhibitor of thrombin associated with an ulcerative colitis.
Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.
Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
Colitis-Associated Neoplasms
Thrombin drives tumorigenesis in colitis-associated colon cancer.
Colonic Neoplasms
Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.
Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase.
Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
Cellular localization of activated factor X by Xa-specific probes.
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.
Solid tumor cells express functional "tethered ligand" thrombin receptor.
The role of coagulation and platelets in colon cancer-associated thrombosis.
Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin.
Thrombin-dependent modulation of ?1-integrin-mediated signaling up-regulates prolidase and HIF-1? through p-FAK in colorectal cancer cells.
Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.
[Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors]
Colorectal Neoplasms
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer.
Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells.
Coma
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Communicable Diseases
A new fibrin sealant from Crotalus durissus terrificus venom: applications in medicine.
Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants.
The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC.
Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: a systematic review.
Confusion
A reunification of the US ("NIH") and International Unit into a single standard for Thrombin.
From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia.
Congenital Abnormalities
Hemophilia A in cardiac operations: a model of reduced thrombin generation.
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
[Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia]
Congenital Disorders of Glycosylation
Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Congenital disorders of glycosylation as an unusual cause of antithrombin deficiency and elevated thrombin generation.
Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies.
Conjunctivitis
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
Contracture
Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current.
Effects of microtubules and microfilaments on [Ca(2+)](i) and contractility in a reconstituted fibroblast fiber.
Effects of monocrotaline pyrrole and thrombin on pulmonary endothelial cell junction and matrix adhesion proteins.
Coronary Artery Disease
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis.
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction.
Advances in antithrombotic therapy: novel agents.
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.
Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia.
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation.
Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions.
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries.
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment.
Coagulation activity and clinical outcome in unstable coronary artery disease.
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Correlations between platelet-derived microvesicles and thrombin generation in patients with coronary artery disease.
Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.
Expression of Junctional Adhesion Molecule-C on the Surface of Platelets Supports Adhesion, but not Differentiation, of Human CD34 Cells in Vitro.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation.
Haemostatic function in coronary artery disease (CAD).
Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.
Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Identification of new single-nucleotide polymorphisms in the thrombin receptor gene and their effects on coronary artery diseases in Koreans.
IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease.
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Increased plasma thrombin potential is associated with stable coronary artery disease: An angiographically-controlled study.
Increased platelet reactivity and platelet-leukocyte aggregation after elective coronary bypass surgery.
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease.
Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: the role of thrombosis, fibrinolysis and atherosclerotic burden.
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease.
Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis.
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
New thrombin inhibiting strategies for coronary artery disease.
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.
Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease.
Plasma Markers of Procoagulant Activity Among Individuals with Coronary Artery Disease.
Platelet aggregation, coronary artery disease progression and future coronary events.
Platelet function and inhibition in ischemic heart disease.
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis.
Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Relevance of hemostasis on restenosis in clinically stable patients undergoing elective PTCA.
Remote ischemic preconditioning inhibits platelet ?IIb ?3 activation in coronary artery disease patients receiving dual antiplatelet therapy: A randomized trial.
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.
The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis.
Thrombin and plasmin activity in coronary artery disease.
Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun.
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition.
Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention.
Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease.
Thrombin inhibitors in acute coronary artery disease.
Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease.
Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.
Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery.
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group.
[Chronic ischemic cardiopathy: antiplatelet agents and anticoagulants, new protocols for prevention and treatment]
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]
[The role of thrombin activatable fibrinolysis inhibitors (TAFI) in coronary artery disease]
[The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins]
[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?]
Coronary Disease
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin.
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury.
Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.
Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study.
Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease.
RNA-seq Reveals Novel Transcriptome of Genes and Their Isoforms in Human Pulmonary Microvascular Endothelial Cells Treated with Thrombin.
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.
Short heparin thrombin clotting time, increased fibrinogen and platelet aggregates count in coronary disease: a probable hypercoagulable state.
The effect of exercise on thrombin and plasmin generation in middle-aged men.
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.
Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty.
Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
Thrombin generation's role in predicting coronary disease severity.
Thrombogenic potential of human coronary atherosclerotic plaques.
Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels.
[Clinical significance of endothelial dysfunction: studies of human coronary circulation in vivo]
[Evaluation of the hemostatic potential at coronary artery bypass surgery during long-term aspirin therapy].
[Intervening effect of naoxintong on anti-platelet treatment with aspirin]
[New medical anticoagulants]
[Relationship between anti-coagulation system changes of coronary heart disease patients and different syndrome-type in TCM]
[Thrombocyte activity in dilatative cardiomyopathy and latent cardiomyopathy compared to coronary heart disease]
Coronary Occlusion
Heparin resistance in acute coronary occlusion measured by the plasma heparin thrombin time.
Heparin resistance, measured by the plasma heparin thrombin time, in patients on long-term anticoagulatn therapy with phenylindanedione following coronary occlusion.
Increased plasma concentration of fibrin monomer in acute myocardial infarction with early reperfusion.
Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty.
Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction.
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Coronary Stenosis
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Fibrinolysis in Platelet Thrombi.
Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Platelet-dependent thrombin generation in patients with unstable angina pectoris.
Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction.
Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty.
Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators.
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease]
Coronary Thrombosis
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Increased lysophosphatidylcholine content induced by thrombin receptor stimulation in adult rabbit cardiac ventricular myocytes.
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury.
Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death.
Platelet-dependent and procoagulant mechanisms in arterial thrombosis.
Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism.
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis.
Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Role of heparin in coronary thrombolysis.
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Thrombin and antithrombotics.
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
[Direct thrombin antagonists]
[Unstable angina pectoris: coagulation disorder and its therapy]
Coronary Vasospasm
Coronary vascular reactivity after acute myocardial ischemia.
Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus.
COVID-19
Cardiovascular risk in COVID-19 infection.
Coagulation Dysfunction.
Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
Coagulation Panel in Patients with SARS-CoV2 Infection (COVID-19).
Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: A thromboelastographic study.
Coronavirus-induced coagulopathy during the course of disease.
Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46.
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
COVID-19 patients exhibit reduced procoagulant platelet responses.
Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome.
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis.
Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection.
Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19.
Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.
Extracorporeal Membrane Oxygenation Induces Early Alterations in Coagulation and Fibrinolysis Profiles in COVID-19 Patients with Acute Respiratory Distress Syndrome.
Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors.
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19.
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory.
Persistent endotheliopathy in the pathogenesis of long COVID syndrome.
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19.
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19.
Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients.
Protease-activated receptor 1 as a potential therapeutic target for COVID-19.
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.
Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater.
SARS-CoV-2 and Plasma Hypercoagulability.
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype.
Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant.
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
The values of coagulation function in COVID-19 patients.
Thrombin Generation in Patients with Coronavirus Disease 2019.
Thrombin generation in patients with COVID-19 with and without thromboprophylaxis.
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019.
Craniocerebral Trauma
Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury.
Effects of alpha-thrombin on superoxide dismutase levels in human cerebral microvascular endothelial cells.
Procoagulant activity in patients with isolated severe head trauma.
Role of coagulopathy in patients with head trauma.
The incidence and significance of hemostatic abnormalities in patients with head injuries.
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Thrombin: is it on a par with seizures and epilepsy?
Creutzfeldt-Jakob Syndrome
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Crohn Disease
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease.
Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.
Thrombin generation in pediatric patients with Crohn's disease.
Crush Syndrome
[Coagulation and fibrinolytic activity of lymph in various pathological conditions (review of own and literature data)].
Cushing Syndrome
Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease.
Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?
Cystadenocarcinoma
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Cystitis
Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis.
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
[New hemostatic therapy of bleeding of bladder by technique of drip-irrigation using a thrombin solution]
Cystitis, Interstitial
Prostacyclin production in tryptase and thrombin stimulated human bladder endothelial cells: effect of pretreatment with phospholipase A2 and cyclooxygenase inhibitors.
Cysts
Bioplast fibrin coagulum in large cystic defects of the jaw.
Complete Excision of a Simple Dacryops Using Fibrin Sealant and Trypan Blue Mixture.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Leptomeningeal cyst due to vacuum extraction delivery in a twin infant.
Cytochrome-c Oxidase Deficiency
Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency.
Death, Sudden, Cardiac
Morning sudden cardiac death.
Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction.
Decompression Sickness
Effects of aspirin and dipyridamole on platelet function, hematology, and blood chemistry of saturation divers.
Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.
Dehydration
Hypobaric Hypoxia Causes Elevated Thrombin Generation Mediated by FVIII that is Balanced by Decreased Platelet Activation.
Neonatal thromboembolism.
NFAT5-sensitive Orai1 expression and store-operated Ca(2+) entry in megakaryocytes.
Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer.
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.
Content of autoantibodies to bradykinin and beta-amyloid(1-42) as a criterion for biochemical differences between Alzheimer's dementias.
Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation.
Reservations against new oral anticoagulants after stroke and cerebral bleeding.
Targeting thrombin: an inflammatory neurotoxin in Alzheimer's disease.
Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Dementia, Vascular
Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes.
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect.
Thrombin and antithrombin in Binswanger's disease.
Demyelinating Diseases
Early detection of thrombin activity in neuroinflammatory disease.
Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Thrombin regulates the ability of Schwann cells to support neuritogenesis and to maintain the integrity of the nodes of Ranvier.
Dengue
A propeptide-independent protease from Tannerella sp.6_1_58FAA_CT1 displays trypsin-like specificity.
Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection.
Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities.
Elevated levels of soluble ST2 protein in dengue virus infected patients.
Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis.
Multivariate time-series analysis of biomarkers from a dengue cohort offers new approaches for diagnosis and prognosis.
Novel interactions of domain III from the envelope glycoprotein of dengue 2 virus with human plasma proteins.
Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case--control study comparing dengue fever patients with and without bleeding manifestations.
Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease.
Dermatitis
PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses.
Dermatitis Herpetiformis
Levels of F(1+2) prothrombin fragments and thrombin - antithrombin III (TAT) complexes in patients with dermatitis herpetiformis.
Dermatitis, Atopic
Platelet aggregation in atopic dermatitis.
Diabetes Mellitus
Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.
Clot properties and cardiovascular disease.
Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Dissociation of thrombin generation and platelet secretion in diabetes mellitus.
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Endothelial HNF4? potentiates angiogenic dysfunction via enhancement of vascular endothelial growth factor resistance in T2DM.
Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans.
Generation of thrombin activity in relation to factor VIII:C concentrations and vascular complications in type 1 (insulin-dependent) diabetes mellitus.
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Intracellular and extracellular pH dynamics in the human placenta from diabetes mellitus.
Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study.
Plasma thrombin clotting time and plasma fibrinogen in diabetes mellitus and atherosclerosis.
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.
Primary platelet activation in recent-onset type 1 diabetes mellitus.
Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes.
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus.
The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.
The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial.
Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control.
Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus.
Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients.
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
[Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy]
[Evaluation of platelet intracellular calcium ion concentrations with flow cytometry]
[Mobilization of intracellular Ca2+ by ADP and thrombin in platelets of patients with diabetes mellitus with vascular complications]
[Platelet abnormalities in type 2 diabetes mellitus]
Diabetes Mellitus, Type 1
Acute changes in blood glucose concentration do not promote thrombin generation or fibrin breakdown in type 1 diabetes.
Altered platelet membrane dynamic properties in type 1 diabetes.
Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM.
Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM.
Do determinants of platelet function co-segregate with genetic markers of type 1 diabetes mellitus?
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
Increased intracellular calcium and altered phorbol dibutyrate binding to intact platelets in young subjects with insulin-dependent and non-insulin-dependent diabetes mellitus.
Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children.
Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus.
Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study.
Primary platelet activation in recent-onset type 1 diabetes mellitus.
Reduced guanine nucleotide-stimulated polyphosphoinositide specific phospholipase C in platelet hyperaggregation in IDDM.
Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes.
Thrombin generation and factor VIII:C levels in patients with type 1 diabetes complicated by nephropathy.
[Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy]
Diabetes Mellitus, Type 2
Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.
Antifibrin action of phenformin.
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides.
Carbonylation of platelet proteins occurs as consequence of oxidative stress and thrombin activation, and is stimulated by ageing and type 2 diabetes.
Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.
Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose.
Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM.
Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes.
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
Increased intracellular calcium and altered phorbol dibutyrate binding to intact platelets in young subjects with insulin-dependent and non-insulin-dependent diabetes mellitus.
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.
Only minor changes in thrombin generation of children and adolescents with type 1 diabetes mellitus - A case-control study.
Platelet free cytosolic calcium concentration during ageing of type 2 diabetic patients.
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.
Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes.
Secreted modular calcium-binding protein 1 binds and activates thrombin to account for platelet hyperreactivity in diabetes.
Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in Type 2 diabetes mellitus.
The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease.
The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes.
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease.
Thrombin Receptor-Activating Protein (TRAP)-Activated Akt Is Involved in the Release of Phosphorylated-HSP27 (HSPB1) from Platelets in DM Patients.
Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes.
Diabetes, Gestational
Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM.
Diabetic Angiopathies
Increased intraglomerular thrombin formation in diabetic microangiopathy.
Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells.
Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics.
Diabetic Foot
Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study.
Diabetic Nephropathies
Podocyte Integrin-?3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy.
Protease-activated receptors in kidney disease progression.
Thrombin and diabetic nephropathy.
Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease.
Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis.
Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes.
[Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC]
[Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy]
Diabetic Neuropathies
The role of thrombin in the pathogenesis of diabetic neuropathy.
Diabetic Retinopathy
High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment.
Intermittent intraocular thrombin as an adjunct to vitrectomy.
Plasma soluble fibrin monomer complexes in the development of diabetic retinopathy.
Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes.
The use of intravitreal thrombin to control hemorrhage during vitrectomy.
Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.
Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.
Disseminated Intravascular Coagulation
A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
A prothrombin activator (Lopap) modulating inflammation, coagulation and cell survival mechanisms.
Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.
Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria.
Active but inoperable thrombin is accumulated in a plasma protein layer surrounding Streptococcus pyogenes.
Acute generalized, widespread bleeding. Diagnosis and management.
Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy.
An unusual case of an ulcerative colitis flare resulting in disseminated intravascular coagulopathy and a bladder hematoma: a case report.
Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation.
Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases.
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.
Appropriate use of D-dimer in hospital patients.
Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.
Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation.
Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay.
Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release.
Cardiovascular risk in COVID-19 infection.
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Coagulation Activation by Lipopolysaccharides.
Coagulation disorders in severely and critically injured patients.
Coagulation studies.
Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
Comparative effects of proteinase inhibitors, plasminogen antiactivators, heparin and acetylsalicylic acid on the experimental disseminated intravascular coagulation induced by thormbin.
Crocetin administration ameliorates endotoxin-induced disseminated intravascular coagulation in rabbits.
Crosstalk between coagulation and inflammation in mastitis and metritis in dairy cows.
Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation.
Decreased thrombomodulin mRNA expression on peripheral monocytes in disseminated intravascular coagulation patients relates to poor outcomes: The ex vivo effects of lipopolysaccharide and thrombin on monocyte thrombomodulin and CD14 mRNA.
Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies.
Dielectric Blood Coagulometry for the Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Prospective Observational Study.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Disseminated intravascular coagulation and bacterial infections in the elderly.
Disseminated intravascular coagulation and its immune mechanisms.
Disseminated intravascular coagulation associated with aortic dissecting aneurysm.
Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor.
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome.
Disseminated intravascular coagulation.
Disseminated intravascular coagulation. Approach to treatment.
Disseminated intravascular coagulation: clinical and laboratory aspects.
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT).
Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits.
Effect of beta-adrenergic blockade by propranolol upon intravascular coagulation in the rat kidney.
Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model.
Effect of platelet on protein degradation in rat skeletal muscle.
Effects of alpha and beta receptor stimulating and blocking agents on experimental disseminated intravascular coagulation.
Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban.
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Effects of prolonged poisoning by Russell's viper venom on blood coagulation, platelets and fibrinolysis.
Elevated plasma levels of hepatocyte growth factor in rats experimentally envenomated with Bothrops jararaca venom: Role of snake venom metalloproteases.
Enhanced thrombin generation in patients receiving intensive care.
Ex vivo thrombin generation patterns in septic patients with and without disseminated intravascular coagulation.
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Fibrinogen proteolysis by thrombin, plasmin and platelet release in relation to disseminated intravascular coagulation.
Fibrinogen survival and fibrinopeptide A in acute leukemia.
Fibrinolysis in disseminated intravascular coagulation.
Fibronectin, platelet factor 4 and beta-thromboglobulin in endemic hepatosplenic schistosomiasis: relation to acute hematemesis.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Hematological parameters and visceral lesions relationships in rabbit viral hemorrhagic disease.
Hemodynamics of disseminated intravascular coagulation. Effects of intra-aortic thrombin infusions on renal and mesenteric blood flow in the dog.
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery-Results of a Randomized Controlled Trial.
Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon.
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
High-dose antithrombin III treatment of severely injured patients: results of a prospective study.
Hirudin in disseminated intravascular coagulation.
Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure.
Inhibition of thrombin in plasma by heparin or arginine.
Lack of fibrin formation in exercise-induced activation of coagulation.
Lepirudin blunts endotoxin-induced coagulation activation.
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.
Lipopolysaccharide-Induced Hemolysis Is Abolished by Inhibition of Thrombin Generation but Not Inhibition of Platelet Aggregation.
Localization of tissue plasminogen activator on experimental thrombi in rats.
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Microvascular alterations in thrombin-induced experimental disseminated intravascular coagulation in the dog.
Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: In vitro effect of thrombin on monocyte CD163 shedding.
New approaches for the detection of early activation products in thrombotic states.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock.
Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation.
Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome.
Pathways of coagulation/fibrinolysis activation in malignancy.
Phospholipase D1 regulation of TNF-alpha protects against responses to LPS.
Plasma thrombin assay using a chromogenic substrate in disseminated intravascular coagulation due to snake bite envenomation.
Plasmatic parameters of coagulation activation in thrombotic microangiopathy.
Platelet function in sepsis.
Poor prognosis of hypocoagulability assessed by thrombin generation assay in disseminated intravascular coagulation.
Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Protein Z efficiently depletes thrombin generation in disseminated intravascular coagulation with poor prognosis.
Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation.
Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma.
Rat liver macrophages will not phagocytose fibrin during disseminated intravascular coagulation.
Role of DIC in multiple organ failure.
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation.
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Studies in experimental animals on disseminated intravascular coagulation (DIC).
Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function.
The appearance of schistocytes in the peripheral blood in correlation to the degree of disseminated intravascular coagulation. An experimental study in rats.
The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis.
The incidence and significance of hemostatic abnormalities in patients with head injuries.
The influence of durgs on disseminated intravascular coagulation (DIC). II. Effects of naturally occurring and synthetic thrombin inhibitors.
The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
The pathogenesis and management of disseminated intravascular coagulation.
The role of Kupffer's cells in disseminated intravascular coagulation. A morphologic study in thrombin-infused rabbits.
The sepsis-coagulant axis: a review.
Thrombin does not alter vascular hyporeactivity in models of endotoxin-induced septic shock in rats.
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation.
Thrombin generation in acute promyelocytic leukemia.
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin.
Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.
Thrombin-induced disseminated intravascular coagulation in the dog. I: Demonstration of microthrombi in lung.
Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation.
Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients.
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Treatment of Disseminated Intravascular Coagulation.
Vascular and dendritic cell coagulation signaling in sepsis progression.
[Activation of the blood kallikrein-kinin system in disseminated intravascular coagulation in rats. The significance of the pulmonary component and an attempt at correction with aspirin]
[Disseminated intravascular coagulation in the early stage after severe burn: the role of excessive thrombin generation]
[Effect of 4-amidinophenylpyruvic acid on the generalized Sanarelli-Shwartzman phenomenon]
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
[Effect of MD-805, a synthetic thrombin inhibitor, on disseminated intravascular coagulation developing in hematological disorders]
[Evaluation of thrombin in urine as a real-time indicator of clotting activation in glomerulonephritis]
[Experimental studies on disseminated intravascular coagulation (author's transl)]
[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.]
[Mathematical assessment of the blood prothrombinase-thrombin activity by the autocoagulation test]
[Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma]
[Relationship between thrombinemia and free radical processes in the blood]
[Role of the innate immune response in sepsis]
[State of homeostasis under administration of bear fat in rats with exogenous and endogenous thrombinemia].
[The influence of a synthetic thrombin inhibitor on the disseminated intravascular coagulation in the rabbit (author's transl)]
[Thrombocytopenia and disseminated intravascular coagulation in low-dose heparin prophylaxis]
[Use of partial thromboplastin time and thrombin time in the diagnosis of disseminated intravascular coagulation]
Down Syndrome
Acquired coagulation inhibitor delaying fibrinopeptide release.
Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium.
Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis.
Drug Resistant Epilepsy
Thrombin decreases expression of the glutamate transporter GLAST and inhibits glutamate uptake in primary cortical astrocytes via the Rho kinase pathway.
Drug-Related Side Effects and Adverse Reactions
Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.
Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.
Duodenal Ulcer
Endoscopic local injection of ethanolamine oleate and thrombin as an effective treatment for bleeding duodenal ulcer: a controlled trial.
[Evaluation of using fibrin tissue adhesive (Beriplast) and preparations of thrombin and adrenalin in injection hemostasis methods for gastric and duodenal ulcer hemorrhage. Randomized, prospective clinical trial]
Dyslipidemias
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Dyspnea
Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease.
Ecchymosis
Comparison of curative effect between different anticoagulation regimens in continuous renal replacement therapy after cardiac valve replacement.
Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation.
Eclampsia
Blood coagulation profile in Indian patients with pre-eclampsia and eclampsia.
Platelets from eclampsia patients have reduced membrane microviscosity and lower activities of the signalling enzymes.
Edema, Cardiac
Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease.
Ehrlichiosis
Platelet dysfunction associated with experimental acute canine ehrlichiosis.
Eisenmenger Complex
Dual endothelin-1 receptor antagonism attenuates platelet-mediated derangements of blood coagulation in Eisenmenger syndrome.
Embolic Stroke
Alterations of haemostatic markers in various subtypes and phases of stroke.
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source?- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Embolic Stroke Model with Magnetic Nanoparticles.
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Individualized antithrombotic therapy.
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Thrombin Generation in Acute Ischaemic Stroke.
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.
[Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].
Embolism
A case of dabigatran-associated acute renal failure.
A Comparison of Methods for Estimating Glomerular Filtration Rate for a Population in Hawai'i with Non-Valvular Atrial Fibrillation.
A Rare Case Report Of Dabigatran Induced Oral Ulcers.
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.
Acute myocardial infarction after switching from warfarin to dabigatran.
An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique.
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation.
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Dabigatran for stroke prevention in atrial fibrillation.
Dabigatran Use in the Real World A Multihospital System Experience.
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Dabigatran: patient management in specific clinical settings.
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Granulocytes mediate the increase in pulmonary vascular permeability after thrombin embolism.
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Indices of fibrinogen proteolysis and platelet activation during the resolution of pulmonary embolism.
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Intraoperative embolus formation during cardiopulmonary bypass affects the release of S100B.
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report.
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
New anticoagulants in atrial fibrillation.
New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG.
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
Novel oral anticoagulant management issues for the stroke clinician.
Oral anticoagulants for Asian patients with atrial fibrillation.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Pradaxa-induced esophageal ulcer.
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels.
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration.
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms.
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants.
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation.
The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine.
The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation.
The Pharmacology and Therapeutic Use of Dabigatran Etexilate.
The pharmacology and therapeutic use of dabigatran etexilate.
The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Transitions of care in anticoagulated patients.
Unmasking of thrombin vasoconstriction in isolated perfused dog hearts after intracoronary infusion of air embolus.
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
[Pharmacology of the new oral anticoagulants].
[Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Embolism, Fat
Coagulation disorders in severely and critically injured patients.
Encephalitis
Antithrombin activity of an algal polysaccharide.
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor.
The effects of trypsin on rat brain astrocyte activation.
Thrombin Inhibition Reduces the Expression of Brain Inflammation Markers upon Systemic LPS Treatment.
Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.
Encephalomyelitis
Early detection of thrombin activity in neuroinflammatory disease.
Increased thrombin inhibition in experimental autoimmune encephalomyelitis.
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.
Thrombin generation and activity in multiple sclerosis.
Thrombin in inflammatory brain diseases.
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis.
Early detection of thrombin activity in neuroinflammatory disease.
Increased thrombin inhibition in experimental autoimmune encephalomyelitis.
Thrombin Cleavage of Osteopontin Modulates Its Activities in Human Cells In Vitro and Mouse Experimental Autoimmune Encephalomyelitis In Vivo.
Thrombin generation and activity in multiple sclerosis.
Thrombin in inflammatory brain diseases.
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Encephalopathy, Bovine Spongiform
Antithrombin activity of an algal polysaccharide.
Endemic Diseases
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
Endocarditis
The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events.
Endoleak
A case of hybrid repair of ruptured abdominal aortic aneurysm with use of thrombin for acute treatment of type II endoleak.
AneuRx stent-graft failure four years after TAA exclusion.
Colonic necrosis subsequent to catheter-directed thrombin embolization of the inferior mesenteric artery via the superior mesenteric artery: a complication in the management of a type II endoleak.
Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion.
CT-Guided thrombin injection into aneurysm sac in a patient with endoleak after endovascular abdominal aortic aneurysm repair.
Direct thrombin injection into aneurysmal sac in a patient with a type II endoleak.
EVAR: critical applied aortic morphology relevant to type-II endoleaks following device enhancement in patients with abdominal aortic aneurysms.
Inexplicable late type Ia endoleak associated with the low-profile Ovation endograft in a patient with favorable neck anatomy: treatment with transcaval coil embolization.
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair.
Ischemic colitis following translumbar thrombin injection for treatment of endoleak.
Laser-assisted transprosthesial coil embolization combined with thrombin injection for treatment of an endoleak type II after endovascular aneurysm repair.
Percutaneous direct thrombin injection with hydrodissection to manage type II endoleak after endovascular abdominal aortic aneurysm repair.
Percutaneous ultrasound-guided thrombin injection for endoleaks: an alternative.
Percutaneous ultrasound-guided thrombin injection of endoleaks.
Strategies to Reduce the Rate of Type II Endoleaks: Routine Intraoperative Embolization of the Inferior Mesenteric Artery and Thrombin Injection Into the Aneurysm Sac.
Successful treatment of a type-II endoleak with percutaneous CT-guided thrombin injection in a patient after endovascular abdominal aortic aneurysm repair.
The use of direct thrombin injection to treat a type II endoleak following endovascular repair of abdominal aortic aneurysm.
Transcaval embolization as the preferred approach.
Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: translumbar puncture and injection of thrombin into the aneurysm sac.
Type II endoleak: a problem to be solved.
[Endovascular treatment of abdominal aortic aneurysms: 6 years of experience at a single centre.]
[Transarterial occlusion of type 1 endoleak of the aortic arch by coil embolization and thrombin injection after endovascular therapy of retrograde Stanford A dissection]
Endometrial Neoplasms
Application of thrombin gel matrix for the prevention of lymphocele in patients with endometrial cancer: A prospective randomized trial.
Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Transient increase in thrombin generation during radiotherapy of uterine carcinoma: A preliminary study using thrombin-antithrombin III complex measurements.
Endometriosis
Assessment of Coagulation Parameters in Women Affected by Endometriosis: Validation Study and Systematic Review of the Literature.
Chemical pleurodesis with autologous blood and freeze-dried concentrated human thrombin improved spontaneous pneumothorax and thoracic endometriosis: The first case involving a pregnant woman.
Coagulation Status in Women With Endometriosis.
Endometrial epithelial-mesenchymal transition (EMT) by menstruation-related inflammatory factors during hypoxia.
Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation.
Noninvasive evaluation of ovarian endometriosis: a single-center experience.
Novel therapeutic strategies for endometriosis: a pathophysiological perspective.
Possible involvement of thrombin/protease-activated receptor 1 system in the pathogenesis of endometriosis.
The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding.
Endophthalmitis
Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery.
Endotoxemia
A novel fibrinogenase from Agkistrodon acutus venom protects against LPS-induced endotoxemia via regulating NF-?B pathway.
An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia.
Bacterial endotoxin as inhibitor of the enzymatic activity of human thrombin.
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.
Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia.
Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model.
Human models of endotoxemia and recombinant human activated protein C.
Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs.
Inflammation and thrombin generation cause increased thrombin activatable fibrinolysis inhibitor levels in experimental human endotoxemia.
Low-grade endotoxemia and clotting activation in the early phase of pneumonia.
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats.
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia.
Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.
Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans.
Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets.
The influence of hypoxia on platelet function and plasmatic coagulation during systemic inflammation in humans in vivo.
The many faces of tissue factor.
Thrombin and leukocyte recruitment in endotoxemia.
Tissue factor expression in blood cells.
Enterocolitis, Necrotizing
Neonatal thromboembolism.
Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis.
Eosinophilia
Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Epilepsy
An electrochemical aptasensor based on TiO2/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin.
Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic.
Extracellular proteases in epilepsy.
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Lack of association between the prothrombin rs1799963 polymorphism and juvenile myoclonic epilepsy.
New developments in the treatment of neurological diseases.
Role of Thrombin in Central Nervous System Injury and Disease.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Thrombin and its precursor in human cerebrospinal fluid.
Treating seizures and epilepsy with anticoagulants?
Epilepsy, Temporal Lobe
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Epiretinal Membrane
High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment.
The use of intravitreal thrombin to control hemorrhage during vitrectomy.
Thrombin in the management of full thickness macular holes.
Epistaxis
A novel mutation in the FGB: c.1105C>T turns the codon for amino acid B? Q339 into a stop codon causing hypofibrinogenemia.
Risk factors for epistaxis in patients followed in general practices in Germany.
Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation.
[Injury of internal carotid with uncontrollable epistaxis, cured by intra-arterial thrombin injection; with an experimental contribution.]
[The determination of activated partial thromboplastin time, coagulate time and thrombin time in patients with epistaxis of indeterminate cause]
Erythema
Thrombin generation as a predictor of radiotherapy induced skin erythema.
Erythromelalgia
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
Esophageal and Gastric Varices
Absence of disseminated intravascular coagulation with endoscopic sclerosis of esophageal varices.
Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.
Endoscopic treatments for portal hypertension.
Endoscopic use of human thrombin in bleeding gastric varices.
Injection sclerotherapy of esophageal varices using ethanolamine oleate.
Outcomes of endoscopic human thrombin injection in the management of gastric varices.
Pathophysiology of shock and DIC complicating endoscopic embolization with thrombin for esophageal varices.
Preservation of thrombin generation in cirrhosis despite abnormal results of international normalized ratio: implications for invasive procedures.
Recent advances in the endoscopic management of variceal bleeding.
Review article: the management of acute variceal bleeding.
Role and safety of human thrombin injection for the treatment of bleeding gastric varices.
Safety and Efficacy of Thrombin for Bleeding Gastric Varices: A Systematic Review and Meta-Analysis.
Sclerotherapy of esophageal varices by consecutive injection of anhydrous ethanol: 1% polydocanol and thrombin.
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
The management of variceal bleeding.
The use of thrombin injections in the management of bleeding gastric varices: a single-center experience.
Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience.
Thrombin is effective in arresting bleeding from gastric variceal hemorrhage.
Thrombin--an effective treatment for gastric variceal haemorrhage.
[Clinical study on coagulation, fibrinolysis, and complement systems after endoscopic injection sclerotherapy of esophageal varices with human thrombin]
[Clinical usefulness of the measurement of plasma D-dimer levels]
[Diagnosis and therapy of gastrointestinal hemorrhage]
[Pathology and treatment of shock and DIC which complicate endoscopic embolization of esophageal varices with thrombin]
[Pathology of shock accompanying endoscopic embolization of esophageal varices using thrombin]
Esophageal Perforation
Treatment of Esophageal Perforation with Primary Closure and Reinforcement Using TachoSil.
Esophageal Squamous Cell Carcinoma
Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection.
Effect of thrombin receptor expression on microvessel endothelial cells, and survival by coagulation state in oesophageal squamous cell carcinoma.
Essential Hypertension
Basal and stimulated cytosolic platelet calcium in essential hypertension.
Effect of antihypertensive treatment on intracellular calcium concentration and intracellular pH in essential hypertension.
Increased indexes of thrombin activation in advanced stages of hypertension.
Inhibition of platelet aggregability by losartan in essential hypertension.
Platelet phospholipase C activity in salt-dependent hypertension.
Platelets in human essential hypertension: in vitro hyperreactivity to thrombin.
Prothrombin activation fragment 1 + 2 and thrombin-antithrombin-III complexes in plasma of patients with essential arterial hypertension.
[Phospholipase C hypersensitivity in hypertensive rats results from innate and acquired factors]
Eye Diseases
PKC isoenzymes differentially modulate the effect of thrombin on MAPK-dependent RPE proliferation.
Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation.
Thrombin stimulates stress fiber assembly in RPE cells by PKC/CPI-17-mediated MLCP inactivation.
Thrombin-activated PAR1 membrane expression is regulated by Rab11a-RCP complex dissociation.
Eye Hemorrhage
[Results of the surgical treatment of eye injuries complicated by hemophthalmos, using thrombin]
[Use of thrombin in the prevention and arrest of intraocular hemorrhage during vitrectomy in traumatic hemophthalmos]
Eye Injuries
[Results of the surgical treatment of eye injuries complicated by hemophthalmos, using thrombin]
Factor V Deficiency
Acquired factor V deficiency associated with exposure to bovine thrombin in a burn patient.
Acquired factor V inhibitors.
Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma.
Refractory Epistaxis due to Severe Factor V Deficiency with Inhibitor.
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.
Thrombin generation assay is a useful pre-operative tool to predict non-bleeding risk in a patient with mild factor V deficiency.
Factor VII Deficiency
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII: mechanisms of action and current indications.
Factor X Deficiency
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Factor XI Deficiency
Anesthetic management using peripheral nerve block in patients with factor XI deficiency: a case report.
Blood coagulation in hemophilia A and hemophilia C.
Factor XI deficiency in Kerry Blue Terriers.
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency.
Thrombin generation in patients with factor XI deficiency and clinical bleeding risk.
[Thrombocyte dysfunction in children with albinism]
Factor XII Deficiency
Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins.
Factor XIII Deficiency
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Familial Primary Pulmonary Hypertension
Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension.
Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension.
Plasma coagulation profiles in patients with severe primary pulmonary hypertension.
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.
Fatty Liver
Comparison of the coagulation profile of fatty liver haemorrhagic syndrome-susceptible laying hens and normal laying hens.
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Thrombin promotes diet-induced obesity through fibrin-driven inflammation.
Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.
Febrile Neutropenia
Thrombin generation in children with febrile neutropenia.
Fetal Death
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications.
Fetal Growth Retardation
Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins.
Placental syndecan expression is altered in human idiopathic fetal growth restriction.
The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications.
Thrombin activation of endometrial endothelial cells: a possible role in intrauterine growth restriction.
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Fibroma
Fibrin foam and thrombin as used in the surgical removal of a large fibromyxoma of the mandible.
Fibrosarcoma
Generation and role of angiostatin in human platelets.
Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Regulation of prostaglandin synthesis mediated by thrombin and B2 bradykinin receptors in a fibrosarcoma cell line.
Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin.
The interaction between fibrinogen and 3H-arginine labelled proteins derived from fibrosarcoma in the presence of thrombin.
The interaction between fibrinogen and 3H-L-arginine cationic peptides derived from fibrosarcoma in the presence of thrombin.
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Folic Acid Deficiency
Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats.
Foot Ulcer
Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study.
Fournier Gangrene
Low thrombin tissue sealant ARTISS (Baxter), in complex primary closure after Fournier's gangrene.
Gastritis
Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis.
Gastrointestinal Hemorrhage
Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage.
Gelfoam and thrombin in treatment of massive upper gastrointestinal hemorrhage.
Thrombin in the control of upper gastrointestinal hemorrhage; report of three cases.
Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran.
Gastroparesis
Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control.
Genetic Diseases, Inborn
Glycoprotein IIb-IIIa and the translocation of Rap2B to the platelet cytoskeleton.
Hypercoagulability in sickle cell disease: a curious paradox.
Two successful cases of DIEP flaps for breast reconstruction in patients with Factor V Leiden.
Genital Diseases, Female
Wound hematoma: prophylaxis with topical thrombin.
Glioblastoma
A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma.
A novel PAR-1-type thrombin receptor signaling pathway: cyclic AMP-independent activation of PKA in SNB-19 glioblastoma cells.
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells.
Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma.
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Meizothrombin, an intermediate of prothrombin activation, stimulates human glioblastoma cells by interaction with PAR-1-type thrombin receptors.
Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation.
Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling.
PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells.
The involvement of thrombin in the pathogenesis of glioblastoma.
The Ras-related protein, Rap1A, mediates thrombin-stimulated, integrin-dependent glioblastoma cell proliferation and tumor growth.
The role of thrombin in gliomas.
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid beta-protein precursor.
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.
Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells.
Glioma
A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model.
Activity of protein kinase C is necessary for sustained thrombin-induced [Ca2+]i oscillations in rat glioma cells.
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Investigation of PAR-1-type thrombin receptors in rat glioma C6 cells with a novel monoclonal anti-PAR-1 antibody (Mab COR7-6H9).
Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model.
More on: The role of thrombin in gliomas.
More on: the role of thrombin in gliomas.
On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells.
Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling.
Protease activated receptor-1 and brain edema formation in glioma models.
Protease nexin 1 is expressed in the human placenta.
Reply to more on: the role of thrombin in gliomas.
Signaling effects of alpha-thrombin and SFLLRN in rat glioma C6 cells.
Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat glioma models.
The role of thrombin in gliomas.
The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor.
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro.
Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells.
Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells.
Thrombin enhances glioma growth.
Thrombin has a bimodal effect on glioma cell growth.
Thrombin reverts the beta-adrenergic agonist-induced morphological response in rat glioma C6 cells.
Thrombin up-regulates vascular endothelial growth factor in experimental gliomas.
Thrombin-induced cell proliferation and platelet-derived growth factor-AB release from A172 human glioblastoma cells.
Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells.
Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.
Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression.
[Ca2+]i oscillations in single rat glioma cells induced by thrombin through activation of cell surface receptors.
Glomerulonephritis
Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay.
Coagulation factors in nephrotic syndrome.
Constitutive expression and modulation of the functional thrombin receptor in the human kidney.
Cultured rat glomerular epithelial cells show gene expression and production of transforming growth factor-beta: expression is enhanced by thrombin.
Endothelin-1 in children with acute poststreptococcal glomerulonephritis and hypertension.
Nanostructured bioluminescent sensor for rapidly detecting thrombin.
Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Protease-activated receptors in kidney disease progression.
Role of thrombin in mesangial proliferative glomerulonephritis.
Thrombin increases proliferation and decreases fibrinolytic activity of kidney glomerular epithelial cells.
Thrombin regulates components of the fibrinolytic system in human mesangial cells.
Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.
Urinary thrombin: a novel marker of glomerular inflammation for the diagnosis of crescentic glomerulonephritis (prospective observational study).
[Affinity sorbents with tripeptide morpholine ligands for isolation of proteases]
[Evaluation of thrombin in urine as a real-time indicator of clotting activation in glomerulonephritis]
[Extracapillary glomerulonephritis with fibrin deposits. Role of thrombin]
[Role of thrombin and its receptor in the pathogenesis of severe forms of human glomerulonephritis with fibrin deposits]
Glucose Intolerance
[The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance]
Goiter
[The use of the new biological adhesive preparation fibrin polymer in thyroid surgery]
Granuloma
Collagen, fibrinogen and thrombin biological addesive is effective in treating experimental liver injuries.
Fibrin deposition and clearance in chronic granulomatous inflammation: correlation with T-cell function and proteinase inhibitor activity in tissue.
PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses.
The collagen, fibrinogen and thrombin biological adhesive is effective in treating experimental liver injuries.
Granulomatosis with Polyangiitis
Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Gray Platelet Syndrome
Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives.
Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin.
Immunocytochemical localization of fibrinogen during thrombin-induced aggregation of washed human platelets.
Guillain-Barre Syndrome
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Hantavirus Infections
Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection.
Head Injuries, Closed
Coagulopathy in acute head injury--a study of its role as a prognostic indicator.
Hearing Loss, Sensorineural
Thrombin generation in patients with idiopathic sudden sensorineural hearing loss.
Hearing Loss, Sudden
[The correlation analysis of coagulation detection and blood routine parameters of sudden hearing loss].
Heart Arrest
Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European Study.
Disseminated intravascular coagulation in cardiac arrest and resuscitation.
Heart Defects, Congenital
Calibrated automated thrombogram values in infants with cardiac surgery before and after cardiopulmonary bypass.
Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease.
Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography.
Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Thrombin generation determined by calibrated automated thrombography (CAT) in pediatric patients with congenital heart disease.
Thrombin generation in paediatric patients with congenital heart disease. Determination by calibrated automated thrombography.
Thrombin regulation in congenital heart disease after cardiopulmonary bypass operations.
Heart Diseases
Coagulation parameters may predict clinical outcomes in patients with septic acute kidney injury.
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Design, Synthesis and Characterization of Cyclic NU172 Analogues: A Biophysical and Biological Insight.
Direct thrombin inhibitors in cardiac disease.
Effect of anabolic steroids on plasma antithrombin III. alpha2 macroglobulin and alpha1 antitrypsin levels.
Fibrinopeptide A levels in patients with acute ischaemic heart disease.
Low Molecular Weight Heparin and Coronary Intervention.
Neonatal thromboembolism.
New therapeutic option for thromboembolism--dabigatran etexilate.
The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death.
Thrombin generation and activation of the thrombomodulin protein C system in open heart surgery depend on the underlying cardiac disease.
Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy.
Heart Failure
A Prothrombotic State in Patients With a History of Left Ventricular Thrombus.
Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy.
American Heart Association scientific sessions.
Anemic comorbidity reduces capacity of endogenous thrombin generation and is associated with consumptive coagulopathy in patients with heart failure.
Bivalirudin for treatment of LVAD thrombosis: a case series.
Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice.
Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.
Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
High-intensity interval training recuperates capacity of endogenous thrombin generation in heart failure patients with reduced ejection fraction.
Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy.
Platelet function, thrombin and fibrinolytic activity in patients with heart failure.
Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Successful COMPASS, disappointing COMMANDER HF, what have we learned from these two trials?
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Thrombin inhibition during PCI in heart failure patients.
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
[Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.]
Heart Rupture
Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.
Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture.
HELLP Syndrome
Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth.
[Change and significance of coagulation function and von Willebrand factor antigen level in HELLP syndrome].
Hemangioma
Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells.
Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.
[Expression and significance of the proteins in TSP-1 and NF-?B signal pathways of infantile capillary hemangioma].
Hemangioma, Cavernous
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Hemangiosarcoma
Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.
Use of dressing with human fibrin and thrombin during resection of a right atrial angiosarcoma.
Hemarthrosis
Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
Hematologic Diseases
An ultrasensitive chemiluminescence aptasensor for thrombin detection based on iron porphyrin catalyzing luminescence desorbed from chitosan modified magnetic oxide graphene composite.
Dissecting the contribution of thrombin exosite I in the recognition of thrombin binding aptamer.
Hematologic Neoplasms
Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Diagnostic and Prognostic Value of Plasma Factor V Activity and Parameters in Thrombin Generation for Disseminated Intravascular Coagulation in Patients with Hematological Malignancies.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Thrombin Generation among Sudanese Patients with Hematological Malignancies.
Use of intrapulmonary administration of thrombin in hematological malignancy patients with alveolar haemorrhage: A case series.
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
Hematoma, Subdural
Thrombin contributes to the injury development and neurological deficit after acute subdural hemorrhage in rats only in collaboration with additional blood-derived factors.
[The use of Idarucizumab in intracerebral bleeding - a case report].
Hematoma, Subdural, Acute
Acute subdural hematoma: new model delineation and effects of coagulation inhibitors.
Hematoma, Subdural, Chronic
Irrigation with thrombin solution reduces recurrence of chronic subdural hematoma in high risk patients. - Preliminary report -
Hematuria
Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response.
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
Percutaneous Cyanoacrylate Glue Injection into the Renal Pseudoaneurysm to Control Intractable Hematuria After Percutaneous Nephrolithotomy.
Postpyelolithotomy renal artery pseudoaneurysm management with percutaneous thrombin injection: a case report.
Thrombin in treatment of hematuria of renal origin.
[Effect of thrombin on hematuria after operation for benign prostatic hyperplasia]
Hemochromatosis
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
The adaptability of red blood cells.
Hemoglobinuria
Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria.
Highly purified thrombin, esterase thrombin, and the paroxysmal nocturnal hemoglobinuria hemolytic system.
Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria. Mechanism of the enhancement of hemolysis by bovine thrombin.
Paroxysmal nocturnal hemoglobinuria: the role of properdin in the diagnostic thrombin test.
Paroxysmal nocturnal hemoglobinuria; a specific test for the disease based on the ability of thrombin to activate the hemolytic factor.
The mechanism of action of preparations of thrombin on hemolysis of red cells from patients with paroxysmal nocturnal hemoglobinuria.
Thrombin generation and clot retraction studies in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Detection of complement components on unlysed erythrocytes from acid hemolysis and thrombin test reactions in paroxysmal nocturnal hemoglobinuria.
Highly purified thrombin, esterase thrombin, and the paroxysmal nocturnal hemoglobinuria hemolytic system.
Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria. Mechanism of the enhancement of hemolysis by bovine thrombin.
Paroxysmal nocturnal hemoglobinuria: the role of properdin in the diagnostic thrombin test.
Paroxysmal nocturnal hemoglobinuria; a specific test for the disease based on the ability of thrombin to activate the hemolytic factor.
The mechanism of action of preparations of thrombin on hemolysis of red cells from patients with paroxysmal nocturnal hemoglobinuria.
Thrombin generation and clot retraction studies in paroxysmal nocturnal hemoglobinuria.
[Role of thrombin in the mechanism of hemolysis and nocturnal paroxysmal hemoglobinuria.]
Hemolytic-Uremic Syndrome
Cardiac ischemia during hemolytic uremic syndrome.
Neonatal thromboembolism.
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
[Markers of thrombin generation in kidney failure of children with epidemic hemolytic uremic syndrome]
Hemoperitoneum
Ultrasound-guided percutaneous periarterial thrombin injection for paracentesis-related hemoperitoneum.
Hemophilia A
A bispecific antibody demonstrates limited measurability in routine coagulation assays.
A cell-based model of coagulation and the role of factor VIIa.
A Heparin based dual ratiometric sensor for Thrombin.
A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.
A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.
A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
A new parameter in the thrombin generation assay, mean velocity to peak thrombin, reflects factor VIII activity in patients with haemophilia A.
A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia.
A thrombin generation test; the application in haemophilia and thrombocytopenia.
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA.
Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect.
Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.
Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness.
An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.
An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN).
An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency.
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Antithrombin inhibition using nanobodies to correct bleeding in hemophilia.
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma.
Binding of human thrombin to human factor VIII:RAg.
Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation.
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation.
Blood coagulation in hemophilia A and hemophilia C.
Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A.
Can the diagnostic reliability of the thrombin generation test as a global haemostasis assay be improved? The impact of calcium chloride concentration.
Cardiovascular risk in patients with hemophilia.
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experience.
Characteristics and thrombogenicity of factor IX concentrate.
Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.
Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay.
Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study.
Commentary on "Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms".
Comparing Thrombin Generation in Patients with Hemophilia A and Patients on Vitamin K Antagonists.
Comparison of two laboratory assays in monitoring the efficacy of different prophylaxis regimens for severe haemophilia.
Computationally Driven Discovery in Coagulation.
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
Congenital Factor XI Deficiency: An Update.
Correlation of thromboelastographic patterns with clinical presentation and rationale for use of antifibrinolytics in severe haemophilia patients.
Correlation to FVIII:C in Two Thrombin Generation Tests: TGA-CAT and INNOVANCE ETP.
CRM+ haemophilia A due to a missense mutation (372----Cys) at the internal heavy chain thrombin cleavage site.
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis.
Current and emerging biologics for the treatment of hemophilia.
Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Detection by denaturing gradient gel electrophoresis of an Arg1689Cys mutation in a Chinese patient with mild hemophilia A.
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Effect of factor VIII deficiency on generation of thrombin: a biomechanical approach.
Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.
Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
Evaluation of Thrombin Generation Assay in Patients With Hemophilia.
Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
Expression and release of platelet protein disulphide isomerase in patients with haemophilia A.
Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Factor VIII and thrombin generation assays: relevance to pharmacokinetic studies in haemophilia A.
Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
Factor XIa-triggered thrombin generation in severe haemophilia A.
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
Feasibility of Using Thrombin Generation Assay (TGA) for Monitoring Bypassing Agent Therapy in Patients With Hemophilia Having Inhibitors.
First 20 years with recombinant FVIIa (NovoSeven).
Flow and delta-P dictate where thrombin, fibrin, and von Willebrand Factor will be found.
From principle to practice: bridging the gap in patient profiling.
From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation.
FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
FXIII: mechanisms of action in the treatment of hemophilia A.
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.
Global coagulation assays in hemophilia A: A comparison to conventional assays.
Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX.
Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.
Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
Haemophilia patients exhibit prolonged coagulation time but normal lag time of thrombin generation test: are these results really discordant?
Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
Hemophilia A in cardiac operations: a model of reduced thrombin generation.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand.
In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Increased thrombin inactivation in a case of sporadic haemophilia.
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A.
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics.
Joint health scores in a haemophilia A cohort from Pakistan with minimal or no access to factor VIII concentrate: correlation with thrombin generation and underlying mutation.
Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients.
Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma.
LPS-induced expression and release of monocyte tissue factor in patients with haemophilia.
Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
Management of bleeding disorders: basic science.
Management of traumatic hyphema.
Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
Mechanism of action, development and clinical experience of recombinant FVIIa.
Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
Mechanisms and monitoring of bypassing agent therapy.
Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia.
Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
Models of blood coagulation.
Monitoring the bioavailability of FEIBA with a thrombin generation assay.
New approaches for measuring coagulation.
New assays for monitoring haemophilia treatment.
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate).
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine.
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation.
Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.
Plasma and cellular contributions to fibrin network formation, structure and stability.
Platelet activation and aggregation: the importance of thrombin activity. A laboratory model.
Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
Platelets and hemophilia: A review of the literature.
Platelets as modifiers of clinical phenotype in hemophilia.
Platelets significantly modify procoagulant activities in haemophilia A.
Potential role of recombinant factor VIIa as a hemostatic agent.
Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.
Problems in the detection of carriers of hemophilia A: the influence of stress and thrombin.
Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management.
Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.
Pseudoaneurysm in a patient with haemophilia A: thrombin injection plugs the hole.
Pseudoaneurysm in association with a knee endoprothesis operation in an inhibitor-positive haemophilia A patient - treatment with local thrombin.
Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A.
Purification and characterization of factor VIII 372-Cys: a hypofunctional cofactor from a patient with moderately severe hemophilia A.
Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII: 30 years of research and innovation.
Recombinant activated factor VII: mechanisms of action and current indications.
Recombinant factor VIIa: its background, development and clinical use.
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report.
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A.
Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.
Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor.
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results.
Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A.
TAFI made stickier.
Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation.
Targeting anticoagulant protein S to improve hemostasis in hemophilia.
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.
Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
The Art and Science of Building a Computational Model to Understand Hemostasis.
The central role of thrombin in bleeding disorders.
The coagulation defect in hemophilia with particular reference to the conversion of prothrombin to thrombin and the evolution of the prothrombin conversion accelerator.
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
The influence of prophylactic factor VIII in severe haemophilia A.
The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
The nature of the stable blood clot procoagulant activities.
The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A.
The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease.
Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
Thrombin generation and bleeding in haemophilia A.
Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombin generation and phenotypic correlation in haemophilia A.
Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.
Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Thrombin generation assay and other universal tests for monitoring haemophilia therapy.
Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors.
Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.
Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations.
Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia.
Thrombin generation in a patient with an acquired high-titre factor V inhibitor.
Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Thrombin generation in patients with acquired haemophilia and clinical bleeding risk.
Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma.
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective.
Thrombin generation testing in haemophilia comprehensive care centres.
Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A.
Tissue factor in thrombosis and hemorrhage.
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
Treatment of rare factor deficiencies in 2016.
Turoctocog alfa for the treatment of hemophilia A.
Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A.
Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody.
Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
von Willebrand's disease and hemophilia are associated with diminished thromboxane A2 (TXA2) formation in clotting whole blood.
Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?
[Clinical analysis and laboratory findings in a patient with acquired hemophilia a.]
[Hemophilia B in a mixed breed male dog: treatment of a hemorrhagic crisis with fresh frozen plasma]
[Prophylaxis in patients with haemophilia complicated by inhibitors].
[Thrombin generation assays and their clinical application].
[Thrombin generation test].
Hemophilia B
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
Aminoglycoside suppression of nonsense mutations in severe hemophilia.
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B.
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
Haemophilia B caused by mutation of a potential thrombin cleavage site in factor IX.
How factor VIIa works in hemophilia.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia.
Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.
Recalcitrant peroneal artery pseudoaneurysm in a patient with Hemophilia B.
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.
The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
The thrombin generation test in the diagnosis of classical hemophilia and Christmas disease.
Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma.
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
Hemoptysis
Novel Bronchoscopic Management of Airway Bleeding With Absorbable Gelatin and Thrombin Slurry.
Treatment of hemoptysis patients by thrombin and fibrinogen-thrombin infusion therapy using a fiberoptic bronchoscope.
Treatment of massive hemoptysis with intraarterial thrombin injection of a bronchial artery.
[Hemoptysis and thrombase aerosols.]
[Local treatment of tuberculous hemoptysis by thrombase.]
[Thrombin instillation therapy through the fiberoptic bronchoscope in cases of hemoptysis (author's transl)]
Hemorrhagic Disorders
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate.
Multiple myeloma with polyneuropathy and coagulopathy. A case report of the polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin change (POEMS) syndrome.
Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
[DISTURBANCES IN THE CHAIN-REACTION OF THROMBIN FORMATION AS A CAUSE OF HEMORRHAGIC DIATHESIS.]
[DISTURBANCES IN THE CHAIN-REACTION OF THROMBIN FORMATION CAUSING HEMORRHAGIC DIATHESIS.]
[The use of thrombin in hemorrhagic diathesis.]
[Uremic coagulopathy. Role of thrombin]
Hemorrhagic Fever with Renal Syndrome
Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis.
Hemorrhagic Stroke
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis.
Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).
Imaging of Hemorrhagic Stroke.
Prevention of cardioembolic stroke in patients with atrial fibrillation.
Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
Hemostatic Disorders
Empirical and theoretical phenotypic discrimination.
Liver damage induced in rats by malathion impurities.
Monitoring unfractionated heparin therapy in dogs by measuring thrombin generation.
Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs.
Standardization and clinical utility of thrombin-generation assays.
Supramolecular Aptamers on Graphene Oxide for Efficient Inhibition of Thrombin Activity.
Hepatic Encephalopathy
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
Hepatic Insufficiency
The coagulation cascade in cirrhosis.
The relationship of liver insufficiency to fibrinolytic hemorrhage as demonstrated by the serial thrombin time.
Hepatitis
A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin.
Acquired factor VIII inhibitors in nonhemophilic patients.
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Epidemic of homologous serum hepatitis apparently caused by human thrombin.
Human thrombin as vehicle of infection in homologous serum hepatitis.
Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity.
Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases.
Peliosis hepatis mimicking hepatic malignancy: A case report.
Thrombin Generation in Chronic Liver Diseases-A Pilot Study.
Transmission of serum hepatitis. 1970.
[Hfgl2/fibroleukin expression in liver and peripheral blood mononuclear cells (PBMC) and its correlation with disease severity]
[The behavior of Owren's thrombin time in the course of MHV-3 mouse hepatitis]
Hepatitis A
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Platelet and fibrinogen survival with 75Se selenomethionine in acute infectious hepatitis.
Hepatitis B
A cohort study of hepatectomy-related complications and prediction model for postoperative liver failure after major liver resection in 1,441 patients without obstructive jaundice.
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer.
Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease.
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Peliosis hepatis mimicking hepatic malignancy: A case report.
Hepatitis C
Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Modular Combination of Proteolysis-Responsive Transcription and Spherical Nucleic Acids for Smartphone-Based Colorimetric Detection of Protease Biomarkers.
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Hepatitis C, Chronic
Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis.
Hepatitis E
Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing.
Hepatorenal Syndrome
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
Hermanski-Pudlak Syndrome
Enhanced increases in cytosolic Ca2+ in ADP-stimulated platelets from patients with delta-storage pool deficiency--a possible indicator of interactions between granule-bound ADP and the membrane ADP receptor.
Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome.
Herpes Simplex
A fast method for obtaining highly pure recombinant herpes simplex virus type 1 thymidine kinase.
Coagulation initiated on herpesviruses.
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.
Mammalian cell transient expression of tissue factor for the production of antigen.
Peptidomimetic design.
Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Herpes Zoster
A specific thrombin inhibitor, argatroban, alleviates herpes zoster-associated pain.
Angiopoietin-1 Regulates Brain Endothelial Permeability through PTPN-2 Mediated Tyrosine Dephosphorylation of Occludin.
HIV Infections
Coagulation and morbidity in treated HIV infection.
Comparative neurovirulence in lentiviral infections: The roles of viral molecular diversity and select proteases.
HIV infection is associated with decreased thrombin generation.
Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion.
Homozygous Familial Hypercholesterolemia
Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling.
Hydrocephalus
Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin.
Effects of Aerobic Capacity on Thrombin-Induced Hydrocephalus and White Matter Injury.
Hydrocephalus after intraventricular hemorrhage: the role of thrombin.
Impact of sex differences on thrombin-induced hydrocephalus and white matter injury: the role of neutrophils.
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Role of red blood cell lysis and iron in hydrocephalus after intraventricular hemorrhage.
Thrombin and TGF-beta promote human leptomeningeal cell proliferation in vitro.
Thrombin disrupts vascular endothelial-cadherin and leads to hydrocephalus via protease-activated receptors-1 pathway.
Thrombin-induced TGF-?1 pathway: a cause of communicating hydrocephalus post subarachnoid hemorrhage.
Hydrocephalus, Normal Pressure
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Hyperalgesia
Intrathecal protease-activated receptor stimulation produces thermal hyperalgesia through spinal cyclooxygenase activity.
Protease-activated receptor-1 and platelet-derived growth factor in spinal cord neurons are implicated in neuropathic pain after nerve injury.
Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli.
Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants.
Role of Thrombin in Soluble Thrombomodulin-Induced Suppression of Peripheral HMGB1-Mediated Allodynia in Mice.
Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC.
The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats.
The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury.
The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury.
Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
Hypercholesterolemia
Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin.
Antithrombotic actions of statins.
Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates.
CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia.
Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Dyslipidemias and fibrinolysis.
Effects of chronic administration of ethanol on platelets from rabbits with diet-induced hypercholesterolemia. Unchanged characteristics and responses to ADP but reduction of enhanced thrombin-induced, TxA2-independent platelet responses.
Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin.
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis.
Long-term cholesterol feeding alters the reactivity of primate coronary microvessels to platelet products.
Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.
Pathophysiology and initial management of the acute coronary syndromes.
Platelet function in Watanabe heritable hyperlipidemic rabbits. Decreased sensitivity to thromboxane A2.
Platelet-dependent thrombin generation in patients with hyperlipidemia.
Statins decrease thrombin generation in patients with hypercholesterolemia.
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Thrombin-induced inositol phosphate production by platelets from rats with diet-induced or genetically determined hypercholesterolemia.
Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia.
[Effect of surgical menopause on the development of cardiovascular diseases]
Hyperemia
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
[Multivariate analysis for the understanding of typical diabetic hemostasis criteria. 1: Plasma markers]
Hyperglycemia
A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications.
Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependent actin cytoskeleton organization.
Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus.
Anti inflammatory effect of natural honey on bovine thrombin-induced oxidative burst in phagocytes.
Assessment of acute moderate hyperglycemia on traditional and thromboelastometry coagulation parameters in healthy adult horses.
Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation.
Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes.
Hindbrain astrocytes and glucose counter-regulation.
Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.
Hyperglycemia may determine fibrinopeptide A plasma level increase in humans.
Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress.
MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expression.
Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon.
Regulation of mitochondrial function as a promising target in platelet activation-related diseases.
Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes.
Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus.
Hyperhomocysteinemia
Effect of hyperhomocysteinemia on protein C activation and activity.
Hyperhomocysteinemia, antithrombin consumption, and early venous graft closure in surgical coronary revascularization.
Some considerations about the hypercoagulable states and their treatments.
The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential.
Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation.
[Genetic conditioned changes in activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) and recurrent miscarriages]
Hyperinsulinism
Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject.
Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation.
Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity.
The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima.
Thrombin stimulates insulin secretion via protease-activated receptor-3.
Hyperkalemia
Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane.
Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.
Hyperlipidemias
Heparin and atherosclerosis. A review of old and recent findings.
In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway.
Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis.
Normal levels of fibrinopeptide A in patients with primary hyperlipidemia.
Platelet functions in relation to dietary fats in farmers from two regions of France.
Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients.
Platelet-dependent thrombin generation in patients with hyperlipidemia.
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
VIIaAT complexes, procoagulant phospholipids, and thrombin generation during postprandial lipemia.
[Effect of alimentary lipemia on thrombin generation in the plasma of healthy persons and in arteriosclerosis]
[Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy]
[Evaluation of thrombin generation and clot bound thrombin in plasma of hyperlipidemic patients treated with statins]
Hyperlipoproteinemia Type II
Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation?
The effect of human plasma on platelet function in familial hypercholesterolemia.
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hyperlipoproteinemia Type V
Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function.
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hyperlipoproteinemias
Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function.
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Hypersensitivity
A Possible Allergic Reaction Case to Thrombin Injected into Pseudoaneurysm After Radiofrequency Ablation.
An innate host response to the neoplastic cell: syngeneic rat tumor cells can elicit a rapid de novo lymphoid procoagulant response.
Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention.
Asthma is associated with enhanced thrombin formation and impaired fibrinolysis.
Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins.
Enzymatic investigation for delayed-type hypersensitivity reaction. Assay for thrombin and plasmin activities in tuberculin reaction sites.
Fc?RIIa ligation induces platelet hypersensitivity to thrombotic stimuli.
Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.
Hypersensitivity of phospholipase C in platelets of spontaneously hypertensive rats.
Hypersensitivity of platelets to thrombin: formation of stable thrombin-receptor complexes and the role of shape change.
Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs.
Iatrogenic pseudoaneurysm of femoral artery: case report and literature review.
Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits.
Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects.
New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
Platelets from diabetic pigs exhibit hypersensitivity to thrombin.
Progressive relaxation of Go-arrest controls and altered responsiveness to insulin, EGF and thrombin in CCL39 lung fibroblasts over-expressing myc and ras oncogenes.
Protocol for Obtaining Platelet-Rich Plasma (PRP), Platelet-Poor Plasma (PPP), and Thrombin for Autologous Use.
Pseudoaneurysms.
Reduced membrane fluidity in platelets from diabetic patients.
Severe allergic reaction: A rare complication of ultrasound-guided injection of thrombin in a femoral pseudoaneurysm.
The effect of dietary saturated fat and cholesterol on platelet function, platelet survival and response to continuous aortic injury in rats.
The hypersensitivity to thrombin of platelets from diabetic rats is not due to increased thrombin binding.
The role of spinal thrombin through protease-activated receptor 1 in hyperalgesia after neural injury.
Thrombin binding to platelets from hypercholesterolaemic rats.
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
[Hypersensitivity accidents to thrombin following the use of biological glues]
Hypersensitivity, Delayed
Role of thrombin and plasmin in development of delayed hypersensitivity reaction in guinea pig skin.
Hypertension
American Heart Association scientific sessions.
Association of aortic valve sclerosis with thrombin generation in hypertensive patients.
Blood platelets in human essential hypertension.
Cardiology.
Cell calcium handling and intracellular pH regulation in hereditary hypertriglyceridemic rats: reduced platelet response to thrombin stimulation.
Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia.
Cytosolic pH and calcium in Dahl salt-sensitive and salt-resistant rats: the relationship to plasma lipids.
Effect of hypertension on anticoagulated patients with atrial fibrillation.
Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension.
Enhanced thrombin generation in patients with arterial hypertension.
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death.
Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.
Hemostasis imbalance in experimental hypertension.
Hypertension: Thrombin amplification loop in hypertension.
Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats.
Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation - The Hoorn Study.
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Increased indexes of thrombin activation in advanced stages of hypertension.
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.
Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation.
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.
Normal thrombin binding leads to greater fibrinogen binding and increased platelet aggregation in spontaneously hypertensive rats.
Perioperative Hidden Blood Loss in Elderly Cervical Spondylosis Patients With Anterior Cervical Discectomy Fusion and Influencing Factors.
Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension.
Platelet-derived miR-142-3p induces apoptosis of endothelial cells in hypertension.
The dynamics of thrombin formation in patients with pulmonary arterial hypertension.
Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice.
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Ultrasound-guided thrombin injection versus ultrasound-guided compression repair in the treatment of post-catheterization femoral artery pseudoaneurysm: King Saud University Medical Center Experience.
Vascular thrombin receptor regulation in hypertensive rats.
[Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension]
[Effects of taurine and enalapril on blood pressure, platelet aggregation and the regression of left ventricular hypertrophy in two-kidney-one-clip renovascular hypertensive rats]
[Intervening effect of naoxintong on anti-platelet treatment with aspirin]
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients]
[Pre- and postpartum hemostatic characteristics in pregnancy-related hypertension and pre-eclampsia in comparison with normotensive pregnancies]
[Preeclampsia and thrombin generation test].
[Thrombin activity in the blood of patients with coronary insufficiency and hypertension]
Hypertension, Portal
Portal hypertension and gastric lesions in the rat.
Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience.
Hypertension, Pregnancy-Induced
[Pre- and postpartum hemostatic characteristics in pregnancy-related hypertension and pre-eclampsia in comparison with normotensive pregnancies]
Hypertension, Pulmonary
Antithrombin III deficiency in neonatal respiratory distress syndrome.
Chronic Exposure to Fibrin and Fibrinogen Differentially Regulates Intracellular Ca2+ in Human Pulmonary Arterial Smooth Muscle and Endothelial Cells.
Chronic hypoxic pulmonary hypertension. Is thrombin involved?
Effects of antiplatelet drugs on pulmonary responses to thrombin in anesthetized rabbits.
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells.
Role of hemodynamics and vagus nerves in development of fibrin-induced pulmonary edema.
The role of thrombosis in severe pulmonary hypertension.
Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression.
Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.
Thrombin receptor activation peptide induces pulmonary vasoconstriction.
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension.
Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome.
Treatment Algorithms in Systemic Lupus Erythematosus.
Hyperthyroidism
Contact system activation and high thrombin generation in hyperthyroidism.
Hypothyroidism Exacerbates Thrombophilia in Female Rats Fed with a High Fat Diet.
Hypertriglyceridemia
Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma.
Platelet-dependent thrombin generation in patients with hyperlipidemia.
Hypertrophy, Left Ventricular
Acute myocardial infarction with diminutive right coronary artery and obstructive hypertrophic cardiomyopathy without significant coronary stenoses.
Hyphema
Management of traumatic hyphema.
[Retinal neovascularization in a traumatic microhyphema]
Hypoalbuminemia
Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.
Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia.
Hypoglycemia
Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics.
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
Thrombin action on astrocytes in the hindbrain of the rat disrupts glycemic and respiratory control.
Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults.
Hypospadias
Homozygous alpha-thalassemia associated with hypospadias in three survivors.
Hypotension
A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis.
Different hypotensive responses to intravenous bovine and human thrombin preparations in swine.
Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit.
Effect of reticuloendothelial blockade on the development of hypotension after trauma, sepsis, and intravascular coagulation.
Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.
Induction of hypotension in rhesus monkeys and rabbits by intravenous thrombin infusion.
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.
Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
Renal involvement in sepsis: a prospective single-center study of 136 cases.
The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents--lack of relationship to pretreatment streptokinase resistance.
Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
Hypothyroidism
Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy.
Thrombin -Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism.
Hypoxia-Ischemia, Brain
Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy.
Idiopathic Pulmonary Fibrosis
Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression.
Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.
Role of thrombin in pulmonary fibrosis.
[Protein C system in patients with idiopathic pulmonary fibrosis - preliminary report.]
Ileus
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Iliac Aneurysm
The occlusion of an internal iliac aneurysm by the trans-catheter injection of thrombin.
Immunoglobulin Light-chain Amyloidosis
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Infarction, Middle Cerebral Artery
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.
A novel histochemical method for the visualization of thrombin activity in the nervous system.
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice.
Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
EMBOLIC MIDDLE CEREBRAL ARTERY OCCLUSION MODEL USING THROMBIN AND FIBRINOGEN COMPOSED CLOTS IN RAT.
Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus.
Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection.
Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model.
The effects of thrombin preconditioning on focal cerebral ischemia in rats.
Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
Infections
A bacterially produced virus enhancing factor from an entomopoxvirus enhances nucleopolyhedrovirus infection in armyworm larvae.
A Bail Out Solution for an Urgent Situation: Endovascular Exclusion and Embolization of an Infected Femoral Pseudoaneurysm.
A host basal transcription factor is a key component for infection of rice by TALE-carrying bacteria.
A novel medical device coating prevents Staphylococcus aureus biofilm formation on medical device surfaces.
A Predictive Model for Assessing Surgery-Related Acute Kidney Injury Risk in Hypertensive Patients: A Retrospective Cohort Study.
Analysis of the relationship between serum amyloid protein A, procalcitonin, C-reactive protein, and peripherally inserted central catheter infection in patients with malignant tumor.
Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation.
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates.
Concentration- and pH-Dependent Oligomerization of the Thrombin-Derived C-Terminal Peptide TCP-25.
Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia.
DIAGNOSING DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE INFECTION : CAN WE DO WITHOUT FDP & D-DIMER.
Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection.
Disseminated intravascular coagulation in infectious disease.
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Effect of Puumala hantavirus infection on human umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue factor expression and fibrinolysis regulator release.
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.
Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.
Evaluation of hemostaseological status of pigs experimentally infected with African swine fever virus.
Femoral pseudoaneurysms post-cardiac catheterization surgically treated: evolution and prognosis.
Fibrin deposition and clearance in chronic granulomatous inflammation: correlation with T-cell function and proteinase inhibitor activity in tissue.
Herpes simplex virus and atherosclerosis.
Herpesviruses enhance fibrin clot lysis.
Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid.
Human cytomegalovirus infection and atherothrombosis.
Human thrombin as vehicle of infection in homologous serum hepatitis.
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis.
Increasing endothelial cell permeability improves the efficiency of myocyte adenoviral vector infection.
Liver stiffness and thrombin generation in compensated cirrhosis.
Looking at the proteases from a simple perspective.
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Markers for neural degeneration and regeneration: novel highly sensitive methods for the measurement of thrombin and activated protein C in human cerebrospinal fluid.
Measurement of intracellular calcium concentration in intact monolayers of human endothelial cells.
New insights into pathways that determine the link between infection and thrombosis.
Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
Platelet dysfunction associated with experimental acute canine ehrlichiosis.
Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice.
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium.
Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections.
Protein C in critical illness.
Recombinant human activated protein C in severe sepsis.
Reservations against new oral anticoagulants after stroke and cerebral bleeding.
Role of a thrombin generation assay in the prediction of infection severity.
Role of CaM kinase II and ERK activation in thrombin-induced endothelial cell barrier dysfunction.
Salvage of autogenous dialysis access with balloon-assisted thrombin injection.
SARS-CoV-2 and Plasma Hypercoagulability.
Self-Assembling Peptide Solution Accelerates Hemostasis.
Short-term prognosis and influencing factors of patients with acute kidney injury treated with prolonged intermittent renal replacement therapy.
Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs.
Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy.
The coagulation profile in hepatosplenic schistosomiasis.
The frequency of bleeding complications after invasive dental treatment in patients receiving single and dual antiplatelet therapy.
The host basal transcription factor IIA subunits coordinate for facilitating infection of TALEs-carrying bacterial pathogens in rice.
The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.
The procoagulant envelope virus surface: contribution to enhanced infection.
The repertoire of family A-peptide GPCRs in archaic hominins.
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidual cells: implications for preterm labor.
Thrombin and Interleukin-1{beta} Decrease HOX Gene Expression in Human First Trimester Decidual Cells: Implications for Pregnancy Loss.
Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.
Thrombin generation in children with febrile neutropenia.
Thrombin Injection Failure with Subsequent Successful Stent-Graft Placement for the Treatment of an Extracranial Internal Carotid Pseudoaneurysm in a 5-Year-Old Child.
Thrombocytopenia in the experimental leptospirosis of guinea pig is not related to disseminated intravascular coagulation.
Thromboembolic complications in pediatric hematologic malignancies.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Topical thrombins: benefits and risks.
Vacuolating cytotoxin A is associated with increased thrombin generation in gastric mucosa.
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
[Thrombin inhibitors which display antibacterial activity]
Inflammatory Bowel Diseases
A role for proteinase-activated receptor-1 in inflammatory bowel diseases.
Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease.
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease.
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
D-dimer tests detect both plasmin and neutrophil elastase derived split products.
Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease.
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
Increased procoagulant function of microparticles in pediatric inflammatory bowel disease: role in increased thrombin generation.
Increased thrombin generation in inflammatory bowel diseases.
Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.
Thrombin generation and microparticles in inflammatory bowel diseases.
Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease.
Inflammatory Breast Neoplasms
Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway.
Influenza in Birds
A label-free light-up fluorescent sensing platform based upon hybridization chain reaction amplification and DNA triplex assembly.
Influenza, Human
Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.
Critical role of oxidized LDL receptor-1 in intravascular thrombosis in a severe influenza mouse model.
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Extraction of catalytically active neuraminidase of H5N1 influenza virus using thrombin proteolytic cleavage.
Influenza virus H1N1 activates platelets through Fc?RIIA signaling and thrombin generation.
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
Insulin Coma
[Blood fibrinogenase in insulin shock, in electroshock, and in epileptic seizure.]
Insulin Resistance
Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women.
Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes.
Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation.
Heparin-binding EGF-like growth factor (HB-EGF) mediates 5-HT-induced insulin resistance through activation of EGF receptor-ERK1/2-mTOR pathway.
Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice.
The Role of Heparin Cofactor ? in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice.
Thrombin stimulates insulin secretion via protease-activated receptor-3.
Insulinoma
Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines.
Intermittent Claudication
Platelet activation increases with the severity of peripheral arterial disease: implications for clinical management.
Intestinal Diseases
Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(-) secretion in human intestinal epithelial cells.
Intestinal Neoplasms
[Clinical study of hemostatic molecular markers expression in patients with cancer.]
Intestinal Obstruction
The Diagnostic Value of Coagulation Indicators and Inflammatory Markers in Distinguishing Between Strangulated and Simple Intestinal Obstruction.
Intracranial Aneurysm
Lyophilizing thrombin powder-based treatment for hemostasis during coil embolization of ruptured cerebral aneurysm: Two case reports.
Intracranial Hemorrhages
Anticoagulation therapy for atrial fibrillation.
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation.
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Effect of minimally invasive surgery for cerebral hematoma evacuation in different stages on motor evoked potential and thrombin in dog model of intracranial hemorrhage.
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage : A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic.
Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis.
New antithrombotics for secondary prevention of acute coronary syndrome.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Novel oral anticoagulant management issues for the stroke clinician.
Thrombin-Induced Cerebral Hemorrhage: Role of Protease-Activated Receptor-1.
Thromboelastographic profiles of the premature infants with and without intracranial hemorrhage at birth: a pilot study.
Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes.
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Intracranial Hypertension
Steps to consider in the approach and management of critically ill patient with spontaneous intracerebral hemorrhage.
Treatment of intractable arterial hemorrhage during stereotactic brain biopsy with thrombin. Report of three patients.
Intracranial Thrombosis
Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
Development of argatroban as an anticoagulant and antithrombin agent in Japan.
Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis.
Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization.
Iron Overload
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Ischemic Attack, Transient
Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia.
High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
Impact of dabigatran on platelet function and fibrinolysis.
Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab.
Platelet function and thrombin activity in patients with recent cerebral transient ischemic attacks.
Thrombin generation is associated with ischemic stroke at a young age.
Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies.
Ischemic Stroke
?-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-? in stroke.
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
Acidosis, magnesium and acetylsalicylic acid: effects on thrombin.
Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA.
Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study.
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Antithrombin gamma attenuates macrophage/microglial activation and brain damage after transient focal cerebral ischemia in mice.
Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke.
Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.
Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Chronic hyper-reactivity of platelets resulting in enhanced monocyte recruitment in patients after ischaemic stroke.
Coated-platelet levels are elevated in patients with transient ischemic attack.
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation.
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Dabigatran: Experience in standard clinical practice.
Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke.
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression.
Hemostatic markers in acute stroke.
Hemostatic markers in ischemic stroke of undetermined etiology.
High Thrombin Generation after Acute Ischemic Stroke or Transient Ischemic Attack Is Associated with a Reduced Risk of Recurrence: An Observational Cohort Study.
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke.
Increase of aquaporin 9 expression in astrocytes participates in astrogliosis.
Increased procoagulant platelet levels are predictive of death in COVID-19.
Increased thrombin activity following reperfusion after ischemic stroke alters synaptic transmission in the hippocampus.
Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study.
Independent ischemic stroke risk factors in older Americans: a systematic review.
Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation.
Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume.
LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Looking for Our Ten Years Results for Coronary Heart Disease and Ischemic Stroke Group for the Standpoint of Haemostasis.
Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis.
Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA.
Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition.
Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection.
New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke.
Novel oral anticoagulant management issues for the stroke clinician.
Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan.
Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation.
Platelet Reactivity in Patients With Stroke and Hyperlipidemia, GPIb? Assessment.
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).
Prevention of cardioembolic stroke.
Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke.
Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model.
Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke.
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75?mg twice daily administration.
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.
Stroke prevention in atrial fibrillation: atrial appendage closure.
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
The effects of heatwaves and cold spells on patients admitted with acute ischemic stroke.
The influence of immunoglobulin class G from blood plasma of patients with stroke on the activity of some parameters of hemostasis system.
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
The role of thrombin in central nervous system activity and stroke.
The use of a desktop scanning electron microscope as a diagnostic tool in studying fibrin networks of thrombo-embolic ischemic stroke.
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Thrombin Generation in Acute Ischaemic Stroke.
Thrombin generation is associated with ischemic stroke at a young age.
Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke.
Thrombin inhibition in the acute phase of ischaemic stroke using argatroban.
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Thrombin preconditioning upregulates transferrin and transferrin receptor and reduces brain edema induced by lysed red blood cells.
Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2.
Treatment for Patients with Acute Ischemic Stroke Presenting beyond Six Hours of Ischemic Symptom Onset : Effectiveness of Intravenous Direct Thrombin Inhibitor, Argatroban.
Treatment of acute ischemic stroke: recent progress.
Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata.
[Effect of surgical menopause on the development of cardiovascular diseases]
[Strategy for circulatory disturbance]
Joint Diseases
Anticoagulant properties of three mucopolysaccharides used in rheumatology.
Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue.
[1st studies on the problem of rectal resorption of MPS in the treatment of arthroses]
[Hemophilic arthropathies; good results of lavage with thrombin solutions.]
[Successful results of intra-articular injections of thrombin solutions, after irrigation of the joint in the treatment of hemophilic joint diseases.]
Kasabach-Merritt Syndrome
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Kidney Calculi
Coagulum pyelolithotomy: impact on unrecognized stones.
Kidney Cortex Necrosis
Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits.
Kidney Diseases
Impact of fibrinogen carbamylation on fibrin clot formation and stability.
Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells.
Kidney Failure, Chronic
A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.
Atrial fibrillation in dialysis patients: time to abandon warfarin?
Contact Activation Inhibitor, AB023, in Heparin-Free Hemodialysis: Results of a Randomized Phase 2 Clinical Trial.
Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients.
Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
Increased thrombin and plasmin generation in chronic renal failure.
Increased thrombin generation in patients with chronic renal failure.
Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure.
Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients.
Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient.
Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.
Vitamin k antagonists: beyond bleeding.
[Local microviscosity of platelet membranes from patients with chronic renal failure on hemodialysis]
[Uremic coagulopathy. Role of thrombin]
Kidney Neoplasms
Does renal carcinoma affect the expression of P-selectin on platelets?
The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer.
von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
Klinefelter Syndrome
Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry.
Testosterone treatment and association with thrombin generation and coagulation inhibition in Klinefelter syndrome: A cross-sectional study.
Laryngeal Neoplasms
Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
Lecithin Cholesterol Acyltransferase Deficiency
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Leiomyoma
Topical thrombin-related corneal calcification.
Leiomyosarcoma
[Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis]
Leishmaniasis
Evaluation of secondary haemostasis in canine leishmaniasis.
Leprosy
Markers of platelet, endothelial cell and blood coagulation activation in leprosy patients with antiphospholipid antibodies.
Leptospirosis
Coagulation studies in leptospirosis.
Evaluating the moonlight role of supramolecule ErpY-like lipoprotein of Leptospira in thrombin-catalyzed fibrin clot inhibition, binding to complement factors H & -I, and its diagnostic potential.
Leukemia
alpha-Thrombin inhibits signal transducers and activators of transcription 3 signaling by interleukin-6, leukemia inhibitory factor, and ciliary neurotrophic factor in CCL39 cells.
Analysis of a Ca2+-activated K+ channel that mediates hyperpolarization via the thrombin receptor pathway.
Antithrombin activity of some constituents from Origanum vulgare.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion.
Fibrinogen survival and fibrinopeptide A in acute leukemia.
High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration.
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Interleukins and colony stimulating factors in human myeloid leukemia cell lines.
Laboratory characterization of leukemic cell procoagulants.
Management of traumatic hyphema.
Molecular cloning of the rat vascular smooth muscle thrombin receptor. Evidence for in vitro regulation by basic fibroblast growth factor.
Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.
Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules.
Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML).
Successful treatment of spontaneous rupture of the internal carotid artery in an acute promyelocytic leukemia patient using ultrasound-guided thrombin injection.
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia.
The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis?
The effect of cytosine arabinoside on platelet aggregation.
Thrombin generation in acute myeloblastic leukemia.
Thrombin generation in acute promyelocytic leukemia.
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Thrombin generation in children with febrile neutropenia.
Thrombin Maybe Plays an Important Role in MK Differentiation into Platelets.
Thrombin, but not thromboxane, stimulates megakaryocytic differentiation in human megakaryoblastic leukemia cells.
Thrombin-induced calcium oscillation in human platelets and MEG-01, a megakaryoblastic leukemia cell line.
Thromboembolic complications in pediatric hematologic malignancies.
Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants.
[Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance].
[Coagulation and formation of malignant effusions]
[Study of fibrinolysis inhibitors in 117 acute leukemia patients]
Leukemia, Erythroblastic, Acute
Analysis of receptor-G protein interactions in permeabilized cells.
Antisense-mediated loss of calcium homoeostasis endoplasmic reticulum protein (CHERP; ERPROT213-21) impairs Ca2+ mobilization, nuclear factor of activated T-cells (NFAT) activation and cell proliferation in Jurkat T-lymphocytes.
Effect of protein kinase A on inositide metabolism and rap 1 G-protein in human erythroleukemia cells.
Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis.
Internalization and recycling of activated thrombin receptors.
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Thrombin stimulates the production of phosphatidylinositol 3,4-bisphosphate in human erythroleukemia cells.
Leukemia, Megakaryoblastic, Acute
Thrombin receptors activate potassium and chloride channels.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Commonly used drugs in hematologic disorders.
Leukemia, Myeloid
Interleukins and colony stimulating factors in human myeloid leukemia cell lines.
Leukemia, Myeloid, Acute
Hemostatic function on hyper-fibrinolytic disseminated intravascular coagulation.
Identification and characterization of human hemopoietic mast cell colonies.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML).
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Thrombin generation in acute myeloblastic leukemia.
Thrombin generation in acute promyelocytic leukemia.
[Blood coagulation changes in children with acute myelogenous leukemia: thrombin effect or proteolysis]
Leukemia, Promyelocytic, Acute
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblastic leukemia (AML).
Successful treatment of spontaneous rupture of the internal carotid artery in an acute promyelocytic leukemia patient using ultrasound-guided thrombin injection.
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia.
Thrombin generation in acute promyelocytic leukemia.
Leukocytosis
Multi-cellular activation in vivo by endotoxin in humans--limited protection by adenosine infusion.
Pleocytosis and elevation of prostaglandins F2a and E2 in cerebrospinal fluid following intracisternal injection of thrombin.
Leukopenia
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Pulmonary hemodynamic effects of antisheep serum-induced leukopenia.
Leukostasis
Experimental studies on the adult respiratory distress syndrome: effects of induced DIC; granulocytes and elastase in mini pigs.
Livedo Reticularis
Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata.
Liver Cirrhosis
A role for thrombin in liver fibrosis.
Acquired thrombin inhibitor in a patient with liver cirrhosis.
Bile Acids Do Not Contribute to the Altered Calcium Homeostasis of Platelets from Rats with Biliary Cirrhosis.
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage.
Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association?
Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.
Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis.
Disseminated intravascular coagulation in liver cirrhosis.
Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis.
Evaluation of fibrinolysis in hepatic cirrhosis. Relation of serial thrombin time and euglobulin lysis time.
Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event.
Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.
Progressive antithrombin activity and the concentration of three thrombin inhibitors in liver cirrhosis.
Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis.
Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors.
Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis.
The Coagulation System Contributes to {alpha}V{beta}6 Integrin Expression and Liver Fibrosis Induced by Cholestasis.
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Thrombin and factor Xa link the coagulation system with liver fibrosis.
Thrombin clotting time and fibrin polymerization in liver cirrhosis.
Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis.
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
[The characteristics of clinical course of chronic hepatitis B and liver cirrhosis pathology of child patient]
Liver Diseases
Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.
Acquired dysfibrinogenaemia in acute and chronic liver disease.
AGA Clinical Practice Update: Coagulation in Cirrhosis.
Alterations in Fibrin Structure in Patients with Liver Diseases.
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study.
Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure.
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease.
Clinical utility of viscoelastic tests of coagulation in patients with liver disease.
Coagulation abnormalities in 22 cats with naturally occurring liver disease.
Coagulation and fibrosis in chronic liver disease.
Coagulation Profile and its Correlation with Severity of Liver Dysfunction and Gastrointestinal Bleed in Alcoholic Liver Disease Patients.
Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyser.
Effect of liver damage on the level of coagulation factor II, X and VII in human and bovine plasma.
Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia.
Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation.
Fibrinolysis and fibrinogenolysis in liver disease.
Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis.
In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation.
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis.
Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage.
Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin.
Platelet aggregation in portal cirrhosis.
Prolonged thrombin clotting times in liver disease.
Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease.
Quantification of thrombelastographic changes after blood component transfusion in patients with liver disease in the intensive care unit.
Relation of simple clotting tests to clotting factor levels in liver disease.
Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association?
The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.
The multiple coagulopathies of biliary atresia.
The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Thrombin activation and increased fibrinolysis in patients with chronic liver disease.
Thrombin and plasmin generation in patients with liver disease.
Thrombin dynamics in children with liver disease or extrahepatic portal vein obstruction or shunt.
Thrombin Generation in Chronic Liver Diseases-A Pilot Study.
Thrombin generation in patients with non-cirrhotic vascular liver diseases treated or not treated with vitamin K antagonist.
Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease.
Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis.
Thrombin generation test in children and adolescents with chronic liver disease.
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Thrombin promotes diet-induced obesity through fibrin-driven inflammation.
Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury.
[Hemostatic studies on acquired abnormal fibrinogenemia in severe liver diseases and umbilical cord blood]
[INFLUENCE OF THE "COTHROMBIN PLASMATIC FACTOR" IN THE INCREASE OF THROMBIN TIME IN LIVER DISEASE PATIENTS.]
[Thrombin time in liver diseases.]
Liver Failure
Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes.
Hyperfibrinogenemia as a cause of prolonged thrombin clotting time.
Pitfalls in the Use of Anticoagulants.
[Substitution of antithrombin III by synthetic thrombin inhibitors]
Liver Failure, Acute
Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation.
Hemostasis in patients with acute kidney injury secondary to acute liver failure.
Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure.
[Increased thrombin synthesis in patients with fulminant hepatic failure and its treatment with antithrombin III evaluated by plasma levels of thrombin-antithrombin III complex]
Liver Neoplasms
The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
Lung Diseases
Antithrombin III deficiency in neonatal respiratory distress syndrome.
Effects of inhaled thrombin receptor agonists in mice.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
PKCdelta mediates thrombin-augmented fibroblast-mediated collagen gel contraction.
Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells.
Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.
Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury.
Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant.
Thrombin Increases Lung Fibroblast Survival While Promoting Alveolar Epithelial Cell Apoptosis via the ER Stress Marker CHOP.
Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation.
Thrombin induces collagen gel contraction partially through PAR1 activation and PKC-epsilon.
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
[Evaluation of serum thrombomodulin in patients with interstitial pneumonia]
Lung Diseases, Interstitial
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Associations of D-dimer with CT Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study.
Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings.
Fibrinopeptide A reactive peptides and procoagulant activity in bronchoalveolar lavage: relationship to rheumatoid interstitial lung disease.
Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.
Significance of thrombin in bleomycin-induced pulmonary fibrosis.
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.
Thrombin Increases Lung Fibroblast Survival While Promoting Alveolar Epithelial Cell Apoptosis via the ER Stress Marker CHOP.
[The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder]
Lung Injury
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis.
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Anticoagulant therapy in acute lung injury.
Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury.
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Early coagulation events induce acute lung injury in a rat model of blunt traumatic brain injury.
Haemostatic changes in the pulmonary blood during cardiopulmonary bypass.
Hematopoietic protease nexin-1 protects against lung injury by preventing thrombin signaling in mice.
PAR2-Mediated cAMP Generation Suppresses TRPV4-Dependent Ca2+ Signaling in Alveolar Macrophages to Resolve TLR4-Induced Inflammation.
Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice.
Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury.
Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats.
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
The coagulation system and pulmonary endothelial function in acute lung injury.
The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.
The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome.
Thrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Akt-dependent NF-?B/p300 activation.
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-?B and activator protein-1.
Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice.
[Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung]
Lung Neoplasms
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Abnormal haemostasis in small cell lung cancer.
Air-leak management after upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a pilot trial comparing sealant and standard treatment.
Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.
Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Cooperation of protease-activated receptor 1 and integrin ???5 in thrombin-mediated lung cancer cell invasion.
Glycosaminoglycans and activated contact system in cancer patient plasmas.
Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA.
PTEN plays an important role in thrombin-mediated lung cancer cell functions.
Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines.
TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.
The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin.
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
[Analysis of the Incidence of Lower Extremity Venous Thrombosis and Its Related Risk Factors in Admitted Patients with Lung Cancer].
[Selected parameters of coagulation, fibrinolysis and antibodies to fibrinogen in lung cancer]
Lupus Erythematosus, Systemic
Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus.
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Characterization of the thrombin generation profile in systemic lupus erythematosus.
Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus.
Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state.
Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus.
Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE).
Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation.
Osteopontin: another piece in the systemic lupus erythematosus immunopathology puzzle.
Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin.
The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
[Hemorrhagic syndrome due to a heparin-like anticoagulant in a patient with systemic lupus erythematosus].
Lupus Nephritis
Calorie restriction decreases platelet-derived growth factor (PDGF)-A and thrombin receptor mRNA expression in autoimmune murine lupus nephritis.
Treatment Algorithms in Systemic Lupus Erythematosus.
Lymphocele
Application of thrombin gel matrix for the prevention of lymphocele in patients with endometrial cancer: A prospective randomized trial.
[Fibrinogen and thrombin coated patch use on collagen support for lymphocele prevention after lumbar-aortic lymphadenectomy in gynecological neoplasms].
Lymphoma
Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets.
Procoagulant activity of T lymphoblastoid cells in extrinsic and intrinsic coagulation systems.
Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa.
Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants.
[Relationship between coagulation function and international prognostic index in lymphoma patients].
Lymphoma, B-Cell
Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets.
Thrombin Maybe Plays an Important Role in MK Differentiation into Platelets.
Lymphoma, Non-Hodgkin
Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non-Hodgkin's lymphomas and acute leukemias.
Macular Degeneration
Different Effects of Thrombin on VEGF Secretion, Proliferation, and Permeability in Polarized and Non-polarized Retinal Pigment Epithelial Cells.
Macular Edema
Animal Models of Retinal Vein Occlusion.
Malaria
Alterations of blood coagulation in controlled human malaria infection.
Coagulation Status and Platelet Functions in Children with Severe Falciparum Malaria and their Correlation of Outcome.
Functional analyses yield detailed insight into the mechanism of thrombin inhibition by the antihemostatic salivary protein cE5 from Anopheles gambiae.
Monocyte tissue factor expression induced by Plasmodium falciparum-infected erythrocytes.
Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases.
Possible involvement of platelets in Plasmodium yoelii nigeriensis malaria infection in mice.
Unique thrombin inhibition mechanism by anophelin, an anticoagulant from the malaria vector.
Malaria, Cerebral
Testing the effect of PAR1 inhibitors on Plasmodium falciparum-induced loss of endothelial cell barrier function.
Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence.
Marfan Syndrome
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Mastitis
Crosstalk between coagulation and inflammation in mastitis and metritis in dairy cows.
Mastocytoma
Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells.
Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells.
Involvement of protein kinase C in thrombin-induced translocation of Gi2 alpha from the membrane to the cytosol in mouse mastocytoma P-815 cells.
Melanoma
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.
Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation.
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Fibrin serves as a divalent ligand that regulates neutrophil-mediated melanoma cells adhesion to endothelium under shear conditions.
Gene regulation in melanoma progression by the AP-2 transcription factor.
Heparanase and Thrombin: Common Signalling Pathways in Melanoma Cells?
Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets.
Identification of a synthetic nonapeptide sequence that inhibits motility in culture of a melanoma subclone that possesses a high metastatic potential.
Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.
Management of traumatic hyphema.
Microcarrier culture of bowes melanoma cells in serum-free medium with Human plasma fraction IV-4+ V.
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.
miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells.
Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown.
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation.
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.
Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF.
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes.
Prothrombin and its derivatives stimulate motility of melanoma cells.
Regulation of gene expression in melanoma: new approaches for treatment.
Regulatory Effect of Cell Density on the Platelet-aggregating Activity of Human Melanoma Cell Line.
Role and regulation of the thrombin receptor (PAR-1) in human melanoma.
Sequential binding of ?V?3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils.
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target.
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy.
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA.
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.
Thrombin-mediated impairment of fibroblast growth factor-2 activity.
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment.
Transcriptional regulation of metastasis-related genes in human melanoma.
Transient resistance to B16F10 melanoma growth and metastasis in CD43-/- mice.
Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1.
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth.
Melanoma, Amelanotic
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.
Melanoma, Experimental
Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Effects of thrombin/thrombosis in angiogenesis and tumour progression.
Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
MELAS Syndrome
Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
Melioidosis
Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis.
Production and purification of Burkholderia pseudomallei BipD protein.
Memory Disorders
Impaired adult hippocampal neurogenesis and cognitive ability in a mouse model of intrastriatal hemorrhage.
Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin.
Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice.
Meningioma
PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells.
Menorrhagia
Defective fibrinogen polymerization associated with a novel gamma279Ala-->Asp mutation.
High prevalence of reduced thrombin generation and/or decreased platelet response in women with unexplained heavy menstrual bleeding.
Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization.
Successful use of recombinant factor VIIa for management of severe menorrhagia in an adolescent with an acquired inhibitor of human thrombin.
Mesenteric Ischemia
Prothrombin Arg541Trp Mutation Leads to Defective PC (Protein C) Pathway Activation and Constitutes a Novel Genetic Risk Factor for Venous Thrombosis.
Mesothelioma
Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth.
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth.
Metabolic Diseases
Clot properties and cardiovascular disease.
Metabolic Syndrome
Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).
Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation.
Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels.
Increased RhoA/Rho-Kinase Activity and Markers of Endothelial Dysfunction in Young Adult Subjects with Metabolic Syndrome.
Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.
The intestinal microbiome potentially affects thrombin generation in human subjects.
The top 12 advances in vascular medicine.
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?
Metrorrhagia
Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment.
Migraine Disorders
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
The elusive role of thrombin in migraine.
MINOCA
Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA).
Mirizzi Syndrome
EUS-guided thrombin injection of cystic artery pseudoaneurysm leading to Mirizzi's syndrome and hemobilia.
Mitral Valve Insufficiency
Platelet and blood clotting activation in patients with mitral valve prolapse.
Mitral Valve Prolapse
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Mitral Valve Stenosis
Changes in Platelet, Coagulation, and Fibrinolytic Activities in Mitral Stenosis After Percutaneous Mitral Valvotomy: Role of Hemodynamic Changes and Systemic Inflammation.
Coagulation activity is increased in the left atrium of patients with mitral stenosis.
Effect of mitral valvuloplasty in mitral stenosis on coagulation activity.
Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin fragment 1+2 in mitral stenosis.
Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Increased left atrial thrombin generation in mitral stenosis is not reflected in arterial prothrombin fragment 1+2 levels.
Monoclonal Gammopathy of Undetermined Significance
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Mononeuropathies
Treatment Algorithms in Systemic Lupus Erythematosus.
Mucopolysaccharidoses
Heparin Cofactor II Thrombin Complex as a Biomarker for Mucopolysaccharidosis: Indian Experience.
Multiple Myeloma
A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.
Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin.
Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Bleeding diathesis in multiple myeloma.
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients.
Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Gamma globulin inhibition of fibrin clot formation.
Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma.
Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications.
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography.
Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway.
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test.
Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients.
Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study.
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma.
[Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma]
[Increased thrombin time in a patient with multiple myeloma]
Multiple Sclerosis
Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis.
Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic.
The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review.
The involvement of thrombin in the pathogenesis of glioblastoma.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Thrombin generation and activity in multiple sclerosis.
Thrombin generation correlates with disease duration in multiple sclerosis (MS): Novel insights into the MS-associated prothrombotic state.
Thrombin in inflammatory brain diseases.
Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.
Muscular Diseases
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Muscular Dystrophies
Expression of trypsin-like proteases and protease nexin-1 in mdx mouse muscles.
Myelodysplastic Syndromes
Elevated extracellular trap formation and contact system activation in acute leukemia.
Hemorrhagic risk due to platelet dysfunction in myelodysplastic patients, correlations with anemia severity and iron overload.
Myeloproliferative Disorders
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.
Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation.
[Abnormalities of thrombocyte function in myeloproliferative disorders. I. Defective thrombocyte aggregation by ADP, collagen, noradrenaline and thrombin]
Myocardial Infarction
A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators.
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.
A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study.
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease.
Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction.
Advances in antithrombin therapy for ST-elevation myocardial infarction.
Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Interim results.
Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates.
Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation.
Association of a common polymorphism in the factor XIII gene with myocardial infarction.
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Association of recurrent myocardial infarction with hemostatic factors: a prospective study.
Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction.
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction.
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
Cardiology.
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Coagulation activation and long-term outcome in acute coronary syndromes.
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction.
Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential.
Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.
Cost effectiveness of anticoagulation in acute coronary syndromes.
Course of indicators of thrombin activity in the early phase of acute myocardial infarction: effect of fibrinolytic therapy and acute percutaneous coronary angioplasty.
Desirudin: a review of its use in the management of thrombotic disorders.
Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.
Development and evaluation of a new canine myocardial infarction model using a closed-chest injection of thrombogenic material.
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy).
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy).
Direct thrombin inhibitors - a survey of recent developments.
Direct thrombin inhibitors as adjuncts to thrombolytic therapy.
Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists' Collaborative Group.
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial.
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction.
Effects of thrombin and thrombin receptor activation on cardiac function after acute myocardial infarction.
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.
Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
Failure of thrombin generation markers to triage patients presenting with chest pain.
Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.
Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction.
Functional and antigenic antithrombin III in angina pectoris and acute myocardial infarction patients.
G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone.
Haemostatic function in coronary artery disease (CAD).
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
In the Bivalirudin Era, are we still Looking for a Potent Antiplatelet Agent?
Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.
Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay.
Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood.
Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.
Influence of aromatic and aliphatic moieties on thrombin inhibitors potency.
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Intima-Media Thickness of Common Carotid and Brachial Arteries and Prothrombin Fragment 1 + 2 Are Associated with Left Ventricular Diastolic Dysfunction in Patients with Myocardial Infarction.
Intra-pericardial thrombin injection for post-infarction left ventricular free wall rupture.
Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications.
Intramyocardial thrombin promotes angiogenesis and improves cardiac function in an experimental rabbit model of acute myocardial infarction.
Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?
Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.
Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Long-term anticoagulation in patients with coronary disease, and future developments.
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Low molecular weight heparin in acute stroke.
Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction.
Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction.
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.
Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors.
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.
Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials.
Morning sudden cardiac death.
Newer antithrombin agents in acute coronary syndromes.
Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Oral antiplatelet agents in cardiovascular disease.
Oral antiplatelet therapy in acute coronary syndromes: recent developments.
Oral direct thrombin inhibition: a double-edged sword?
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.
Persistent generation of thrombin after acute myocardial infarction.
Plaque herniation after stenting the culprit lesion with myocardial bridging in ST elevation myocardial infarction: A case report.
Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction.
Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets.
Plasmin-mediated activation of contact system in response to pharmacological thrombolysis.
Platelet hyperreactivity to thrombin in patients with myocardial infarction and normal or slightly abnormal coronary arteries.
Prevention of cardiovascular events after acute coronary syndrome.
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
Procedural outcomes with use of the flash ostial system in aorto-coronary ostial lesions.
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Prostaglandin E1 (PGE1): effect on the human fibrinolytic system.
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction.
Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets.
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction.
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
Serum immunoglobulin E and sudden cardiac arrest during myocardial infarction.
Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction.
Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction.
Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
Targeting thrombin--rational drug design from natural mechanisms.
The -5061/D polymorphism of the thrombin receptor (PAR-1) gene is not related to myocardial infarction in the ECTIM study. The Etude Cas-Temoins de l'Infarctus du Myocarde. MONICA Members Group.
The clinical effects of IABP pumps combined with tirofiban in the treatment of acute myocardial infarction and on patients' serum levels.
The dynamics of thrombin formation.
The ECG as decision support in STEMI.
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.
The Narrow Therapeutic Index of Thrombin Inhibition: Implications for Newer Antithrombotic Therapies.
The thrombolytic paradox.
The TIMI 9b and GUSTO IIb Trials and the "Thrombin Hypothesis"
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial.
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thrombin and its receptor enhance ST segment elevation in acute myocardial infarction by activating the K(ATP) channel.
Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest.
Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury.
Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction.
Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
Thrombin generation and myocardial infarction during infusion of tissue-plasminogen activator.
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Thrombin generation in patients with a first acute myocardial infarction.
Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023).
Thrombin generation in the Glasgow Myocardial Infarction Study.
Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Thrombin induced platelet-fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction.
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Thrombin inhibitors as anticoagulant agents.
Thrombin inhibitors in acute myocardial infarction.
Thrombin receptor and ventricular arrhythmias after acute myocardial infarction.
Thrombinogenesis and its pharmacological modulation in atherosclerosis.
Thrombocytopenia induced by dabigatran: two case reports.
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.
Thromboxane A2 synthesizing activity of platelets in coronary artery diseases.
Tissue factor-induced Thrombin Generation in the Fasting and Postprandial State among Elderly Survivors of Myocardial Infarction.
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction.
Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction?
[Assessment of hemostasis in patients with myocardial infarction complicated by deep venous thrombosis]
[Blood coagulation and fibrinolysis in arteriosclerosis]
[Comparative analysis of thrombin and anti-thrombin antibody levels in donors and myocardial infarction patients]
[Contributory changes in variables of coagulation and fibrinolysis to the patency of coronary arteries in patients with acute myocardial infarction]
[Effect of surgical menopause on the development of cardiovascular diseases]
[Effects of exercise on markers of hemostatic activation in young survivors of myocardial infarction]
[Pathophysiology of acute coronary syndromes]
[Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.]
[Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction]
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins]
[Thrombin and anti-thrombin antibody levels in the blood of patients with acute myocardial infarction]
[Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status]
Myocardial Ischemia
Activation of thrombin receptor increases intracellular Na+ during myocardial ischemia.
Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling.
Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
Bivalirudin: a new promising direct antithrombin.
Calcium-independent phospholipase A2-catalyzed plasmalogen hydrolysis in hypoxic human coronary artery endothelial cells.
Cardiovascular actions of thrombin receptor activation in vivo.
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy).
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy).
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine.
Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease.
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Effects of exercise test on plasma markers of an activation of coagulation and/or fibrinolysis in patients with symptomatic or silent myocardial ischemia.
Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.
Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion.
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Inhibition of thrombin-induced endothelium-dependent relaxation after coronary ischemia in the dog: possible role of the coagulation cascade.
Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.
Mediation of cardiac ischemia by thromboxanes released from human platelets.
Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury.
Successful treatment of an iatrogenic giant femoral artery pseudoaneurysm with percutaneous thrombin injection.
Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs.
The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
Thrombin generation's role in predicting coronary disease severity.
Thrombin in myocardial ischemia-reperfusion during cardiac surgery.
Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart.
Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease.
Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study Group.
[Contents of natural antibodies to thrombin and alpha-2-macroglobulins in the blood of donors and patients with ischemic heart disease]
[Effect of surgical menopause on the development of cardiovascular diseases]
[Signs of thrombin formation in venous occlusion in patients with ischemic heart disease and the role of the protein C activation system in its utilization]
[The advantage of test on thrombin generation for evaluation of hemostasis potential under implementation of coronary bypass surgery in patients with ischemic heart disease.]
[The effect of an antiatherosclerotic diet including omega-3 polyunsaturated fatty acids of marine and plant origins on the indices of cellular and humoral immunity in patients with ischemic heart disease and a disordered carbohydrate tolerance]
[THE TEST OF GENERATION OF THROMBIN IN DYNAMICS IN PATIENTS AFTER TRANSCUTANEOUS CORONARY INTERVENTION].
Myocarditis
Coagulation, protease-activated receptors, and viral myocarditis.
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction.
The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications.
[Total index of thrombocyte aggregation in patients with an acute viral myocarditis]
Myoma
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Myotonic Dystrophy
Management of traumatic hyphema.
Normal platelet aggregation in myotonic dystrophy.
Myotoxicity
New immunization protocol to produce crotalic antivenom combining Crotalus durissus terrificus venom and its PLA2.
Nasal Polyps
Chronic Rhinosinusitis and the Coagulation System.
Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors.
Nasopharyngeal Carcinoma
Routine coagulation molecules predict nasopharyngeal carcinoma and associated metastases.
Neonatal Sepsis
Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis.
Neoplasm Metastasis
A KLK4 proteinase substrate capture approach to antagonize PAR1.
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma.
Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma.
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Cancer and thromboembolism: from biology to clinics.
Cancer and thrombosis in women - molecular mechanisms.
Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation.
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro.
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung.
Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues.
Does haemophilia influence cancer-related mortality in HIV-negative patients?
Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation.
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Effects of thrombin/thrombosis in angiogenesis and tumour progression.
Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?
Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis.
Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice.
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease.
Experimental metastasis and primary tumor growth in mice with hemophilia A.
Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function.
Glycosaminoglycans and activated contact system in cancer patient plasmas.
Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.
Hemostatic factors, innate immunity and malignancy.
Heparin enhances serpin inhibition of the cysteine protease cathepsin L.
Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway.
Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis.
Looking at the proteases from a simple perspective.
Mechanism of thrombin-induced angiogenesis.
Mechanisms coupling thrombin to metastasis and tumorigenesis.
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.
Mechanistic insights into thrombin's switch between "slow" and "fast" forms.
Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.
Molecular regulation of blood clotting in tumor biology.
Nanochannels for diagnostic of thrombin-related diseases in human blood.
Oral thrombostatin FM19 inhibits prostate cancer.
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity.
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.
PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts.
Protease-activated receptor 1: a role in prostate cancer metastasis.
Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer.
Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Protease-activated receptors in cancer: A systematic review.
Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.
Role of platelet integrin GPIIb-GPIIIa, fibronectin, von Willebrand factor, and thrombin in platelet-tumor interaction in vitro and metastasis in vivo.
Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.
Role of thrombin as a tumor growth factor.
Role of thrombin in angiogenesis and tumor progression.
Role of thrombin in tumor angiogenesis, implantation, and metastasis.
Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas.
Special pharmacokinetics of dipetarudin suggests a potential antitumor activity of this thrombin inhibitor.
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Targeting hemostasis-related moieties for tumor treatment.
The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor.
The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis - a Possible Therapeutic Target.
The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells.
The involvement of thrombin in the pathogenesis of glioblastoma.
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
The pivotal role of thrombin in cancer biology and tumorigenesis.
The role of thrombin in tumor cell metastasis.
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Three label-free thrombin aptasensors based on aptamers and [Ru(bpy)2(o-mopip)]2.
Thrombin and antithrombotics.
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Thrombin Generation and Cancer: Contributors and Consequences.
Thrombin generation and the pathogenesis of cancer.
Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells.
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Thrombin Inhibition and Cyclophosphamide Synergistically Block Tumor Progression and Metastasis.
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma.
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases.
Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling.
Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.
Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.
Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis.
Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis.
Thrombin: implications for intratumor therapy against metastasis.
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Thrombosis in children with malignancy.
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment.
Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors.
Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Twist is required for thrombin-induced tumor angiogenesis and growth.
Use of dabigatran etexilate to reduce breast cancer progression.
[Construction and application of a new prokaryotic expression vector derivative of pBV220]
[The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma]
[Thrombin and angiogenesis of cancer - review.]
[Thrombin and tumor metastasis - review]
Neoplasm Micrometastasis
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.
Neoplasms
'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia.
(S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
A 24-h work shift in intensive care personnel: biological pathways between work stress and ill health.
A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells.
A Differential Role for Endocytosis in Receptor-mediated Activation of Nox1.
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo.
A factor X-activating cysteine protease from malignant tissue.
A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer.
A KLK4 proteinase substrate capture approach to antagonize PAR1.
A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability.
A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases.
A New Paradigm for the Treatment of Alzheimer's Disease: Targeting Vascular Activation.
A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma.
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
A novel recombinant snake venom metalloproteinase from Agkistrodon acutus protects against taurocholate-induced severe acute pancreatitis in rats.
A paradoxical pro-apoptotic effect of thrombin on smooth muscle cells.
A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.
A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma.
A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression.
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.
A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model.
Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase.
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Acquired Factor V Inhibitor After Antibiotic Therapy: A Clinical Case Report and Review of the Literature.
Actions of heparin that may affect the malignant process.
Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients.
Activation of the coagulation system in cancerogenesis and metastasation.
Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro.
Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.
Agonist-stimulated release of von Willebrand factor and procoagulant factor VIII in rats with and without risk factors for stroke.
Alkylation of phosphorothioated thrombin binding aptamers improves the selectivity of inhibition of tumor cell proliferation upon anticoagulation.
Altered adhesive properties of cord blood endothelial outgrowth cells expressing IL-1ra.
Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy.
Altered plasma fibrin clot properties in patients with digestive tract cancers: Links with the increased thrombin generation.
Amidolytic assay for procoagulant activity of lymphoid and tumor cells.
An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients.
An intracisternal A-particle DNA sequence is closely linked to the thrombomodulin gene in some strains of laboratory mice.
Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma.
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Anticancer Activities of Tumor-killing Nanorobots.
Anticancer and antithrombin activity of Russian plants.
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Antithrombin activity of some constituents from Origanum vulgare.
Antithrombin III and Factor VIII in patients with neoplasms.
Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation.
Aquaporin 4 is increased in association with human immunodeficiency virus dementia: implications for disease pathogenesis.
Arsenic May Act as a Pro-Metastatic Carcinogen Through Promoting Tumor Cell-Induced Platelet Aggregation.
Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.
Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity.
Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells.
Bi-cell surface plasmon resonance detection of aptamer mediated thrombin capture in serum.
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia.
Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.
Blood coagulation and thrombosis in patients with ovarian malignancy.
Bombesin, calcium homeostasis and tumour growth.
Bradykinin and thrombin synergistically potentiate interleukin 1 and tumour necrosis factor induced prostanoid biosynthesis in human dental pulp fibroblasts.
Brain Tumors Enhance Plasmatic Coagulation: The Role of Hemeoxygenase-1.
Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion.
Bryostatins mimic the effects of phorbol esters in intact human platelets.
c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia.
Caffeine induces endothelial tissue factor expression via phosphatidylinositol 3-kinase inhibition.
Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP.
Cancer and thromboembolism: from biology to clinics.
Cancer and thrombosis in women - molecular mechanisms.
Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression.
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms.
Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer.
Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.
Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics.
Cellular localization of activated factor X by Xa-specific probes.
Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding.
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Characteristic biological features of human megakaryoblastic leukaemia cell lines.
Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2).
Characterization of platelet activity in neuroblastoma.
Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography.
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation.
Chronological expression of PAR isoforms in acute liver injury and its amelioration by PAR2 blockade in a rat model of sepsis.
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Clinical trials with anticoagulant and antiplatelet therapies.
Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop.
Clotting factors in tumour tissue: implications for cancer therapy.
Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk.
Coagulation and fibrinolysis in chronic venous insufficiency.
Coagulation and fibrinolysis in gastric cancer.
Coagulation and metastasis: what does the experimental literature tell us?
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.
Coagulation-related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer.
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Coincidental acquisition of growth autonomy and metastatic potential during the malignant transformation of factor-dependent CCL39 lung fibroblasts.
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.
Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles.
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
Comparison of blood activation in the wound, active vent, and cardiopulmonary bypass circuit.
Comparison of some antineoplastic drugs on inhibiting thrombin catalizing fibrinogen clotting in vitro.
Comparison of stimulated tissue factor expression by brain microvascular endothelial cells from normotensive (WKY) and hypertensive (SHR) rats.
Concentration dependent anti-inflammatory effects thrombin on polyphosphate-mediated inflammatory responses in vitro and in vivo.
Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.
Contribution of thrombin-reactive brain pericytes to blood-brain barrier dysfunction in an in vivo mouse model of obesity-associated diabetes and an in vitro rat model.
Controllable gelation of artificial extracellular matrix for altering mass transport and improving cancer therapies.
Cooperation of protease-activated receptor 1 and integrin ???5 in thrombin-mediated lung cancer cell invasion.
Correlates of thrombin generation in patients with advanced prostate cancer.
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Crosslinked duplex DNA nanogels that target specified proteins.
Cytosolic phospholipase A2 and the distinct transcriptional programs of astrocytoma cells.
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia.
Decrease in platelet serotonin level in uterine cervix cancer patients.
Defective Arachidonate Release and PGE2 Production in Gialpha2-Deficient Intestinal and Colonic Subepithelial Myofibroblasts.
Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction.
Development of a sandwich ELISA for the thrombin light chain identified by serum proteome analysis.
Development of an Image-Based HCS-Compatible Method for Endothelial Barrier Function Assessment.
Development of aptamer-conjugated magnetic graphene/gold nanoparticle hybrid nanocomposites for specific enrichment and rapid analysis of thrombin by MALDI-TOF MS.
Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells.
Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues.
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes.
Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents.
Distinct mechanisms for N-acetylcysteine inhibition of cytokine-induced E-selectin and VCAM-1 expression.
Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.
Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption.
Diverse roles of tissue factor-expressing cell subsets in tumor progression.
Does haemophilia influence cancer-related mortality in HIV-negative patients?
Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis.
DP-1904, a specific inhibitor of thromboxane A2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells.
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study.
Effect of ascorbate on plasminogen activator inhibitor-1 expression and release from platelets and endothelial cells in an in-vitro model of sepsis.
Effect of autologous transplant of peripheral blood mononuclear cells in combination with proangiogenic factors during experimental revascularization of lower limb ischemia.
Effect of ceramide on interleukin-6 synthesis in osteoblast-like cells.
Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth.
Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation.
Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.
Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.
Effects of cancer on platelets.
Effects of inhaled thrombin receptor agonists in mice.
Effects of lopap on human endothelial cells and platelets.
Effects of Lower Concentration Thrombin on High-Mobility Group Box 1 Protein-Mediated Inflammatory Responses.
Effects of thrombin/thrombosis in angiogenesis and tumour progression.
Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?
EL-4 tumor cell-induced human and rabbit platelet aggregations.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Emergence of hamster fibroblast tumors in nude mice--evidence for in vivo selection leading to loss of growth factor requirement.
Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis.
Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-?B inactivation.
Endoscopic use of human thrombin in bleeding gastric varices.
Endothelial cell monolayers as a model system to investigate dengue shock syndrome.
Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice.
Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion.
Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.
Endothelial dysfunction in experimental hyperhomocysteinemia.
Endothelin-1 secretion from cultured rabbit gastric epithelial cells.
Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas.
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Epigenetic regulation of tissue factor inducibility in endothelial cell senescence.
Evaluation of the Activity of Heparin Injected into the Fully Implantable Catheter for Chemotherapy (Portocath) between Two Moments of Use.
Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay.
Evidence for actin cytoskeleton-dependent and -independent pathways for RelA/p65 nuclear translocation in endothelial cells.
Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease.
Experimental and clinical studies on liver regeneration following transcatheter portal embolization.
Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin.
Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer.
Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation.
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains.
Factor V deficiency: a concise review.
Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.
Fibrin monomer increases platelet adherence to tumor cells in a flowing system: a possible role in metastasis?
Fibrinogen and tumor cell metastasis.
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Fibrinogen-coated droplets of olive oil for delivery of docetaxel to a fibrin(ogen)-rich ascites form of a murine mammary tumor.
Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Fibrinolytic abnormalities associated with progression of pediatric solid tumors.
Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors.
Fibronectin Matrix Formation is a Prerequisite for Colonization of Kidney Tumor Cells in Fibrin.
Flamethrowers: blood cells and cancer thrombosis risk.
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability.
Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis.
Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells.
GAS6 inhibits granulocyte adhesion to endothelial cells.
Genetic determinants of cancer coagulopathy, angiogenesis and disease progression.
Glycosaminoglycans and activated contact system in cancer patient plasmas.
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection.
Growth regulation of vessel wall cells and of tumor cells by thrombin, factor XIII and fibronectin.
Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.
Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies.
Hemostatic alterations in cancer patients.
Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?
Hemostatic factors, innate immunity and malignancy.
Heparanase activity in cultured endothelial cells.
Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels.
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.
Heparin modulates chemokines in human endometrial stromal cells by interaction with tumor necrosis factor ? and thrombin.
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester.
Highly purified human alpha-thrombin promotes morphological transformation of BALB/c 3T3 cells.
Highly stable surface-enhanced Raman spectroscopy assay on abnormal thrombin levels in the blood plasma of cancer patients.
Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure.
Histamine differentially interacts with tumor necrosis factor-alpha and thrombin in endothelial tissue factor induction: the role of c-Jun NH2-terminal kinase.
Human alpha-thrombin stimulates proliferation of interferon-gamma differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1.
Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties.
Human cultured endothelial cells do secrete endothelin-1.
Human tumor cells cultured "in vitro" activate platelet function by producing ADP or thrombin.
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells.
Identification of a thrombin sequence with growth factor activity on macrophages.
Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis.
Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.
Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.
Immunohistochemical Evaluation of Hemostatic Changes in Glioblastoma Multiforme and Low-Grade Astrocytoma.
Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal).
In an in-vitro model using human fetal membranes, 17-? hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
In an in-vitro model using human fetal membranes, ?-lipoic acid inhibits inflammation induced fetal membrane weakening.
In vitro antitumor and anti-angiogenic activities of a shrimp chondroitin sulfate.
Incidence of thromboembolic events after use of gelatin-thrombin-based hemostatic matrix during intracranial tumor surgery.
Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma.
Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma.
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway.
Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis.
Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent.
Influence of endothelial cell protein C receptor on breast cancer development.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1.
Inhibition of coagulation proteases Xa and IIa decreases ischemia-reperfusion injuries in a preclinical renal transplantation model.
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.
Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Injured tissues favor cancer cell implantation via fibrin deposits on scar zones.
Insoluble fibrinogen particles for harvesting and expanding attachment-dependent cells and for trapping suspended cancer cells in the presence of blood.
Interaction of human tumor cells with human platelets and the coagulation system.
Interplay of Plasmodium falciparum and thrombin in brain endothelial barrier disruption.
Intra-arterial infusion of thrombin: Animal experiments.
Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1.
JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro.
Label-free visualization and quantification of single cell signaling activity using metal-clad waveguide (MCWG)-based microscopy.
Laparoscopic partial nephrectomy for selected central tumours: omitting the bolster.
Large femoral aneurysm as a late complication after vessel closure device application.
Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities.
Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression.
Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients.
Light Chain Mutation Effects on the Dynamics of Thrombin.
Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model.
Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway.
Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.
Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis.
Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
Looking at the proteases from a simple perspective.
Markers of coagulation activation after hepatic resection for cancer: evidence of sustained upregulation of coagulation.
Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2.
Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.
Matrix metalloproteinases target protease-activated receptors on the tumor cell surface.
Measurement of heparin in plasma: influence of inter-subject and circadian variability in heparin sensitivity according to method.
Mechanism of thrombin-induced angiogenesis.
Mechanisms involved in the early interaction between HeLa cells, platelets and endothelial cells in vitro under the influence of thrombin. Effects of acetylsalicylic acid and Na-salicylate.
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination.
Mechanisms of cancer-induced thrombosis in cancer.
Mechanisms of cell death in primary cortical neurons and PC12 cells.
Mechanisms of hepatocyte growth factor activation in cancer tissues.
Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma.
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium.
Minocycline reduces intracerebral hemorrhage-induced brain injury.
Modeling and simulation of procoagulant circulating tumor cells in flow.
Modulation of human uterine smooth muscle cell collagen contractility by thrombin, Y-27632, TNF alpha and indomethacin.
Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells.
Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators.
Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.
Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells.
Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages.
Molecular regulation of blood clotting in tumor biology.
Mononuclear cell-conditioned medium enhances thrombin-stimulated PGI2 production by human umbilical vein endothelial cells in culture.
Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown.
Mutation analysis of the non-muscle myosin light chain kinase (MLCK) deletion constructs on CV1 fibroblast contractile activity and proliferation.
Myosin Light Chain Kinase Signaling in Endothelial Barrier Dysfunction.
Nanomechanics of the endothelial glycocalyx in experimental sepsis.
New and old anticoagulants in cancer.
New antithrombotic drugs: potential for use in oncology.
New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
Noninvasive evaluation of ovarian endometriosis: a single-center experience.
Obesity, Thrombotic Risk, and Inflammation in Cancer.
Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation.
OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation.
On the mechanism(s) of thrombin induced angiogenesis.
Oncogenic regulation of tissue factor and thrombosis in cancer.
Oral thrombostatin FM19 inhibits prostate cancer.
Organ-selective regulation of vascular adhesion protein-1 expression in man.
Osteogenic Peptides in Bone Regeneration.
Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling.
P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2).
p38 MAPK controls prothrombin expression by regulated RNA 3' end processing.
p53 controls hPar1 function and expression.
PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress.
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
PAR 1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells.
PAR-3 Knockdown Enhances Adhesion Rate of PANC-1 Cells via Increased Expression of Integrin?v and E-Cadherin.
PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism.
Pathogenesis, clinical and laboratory aspects of thrombosis in cancer.
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.
Pathways of coagulation/fibrinolysis activation in malignancy.
Peliosis hepatis mimicking hepatic malignancy: A case report.
Phelligridimer A, a highly oxygenated and unsaturated 26-membered macrocyclic metabolite with antioxidant activity from the fungus Phellinus igniarius.
Phosphatidylcholine synthesis in platelets is stimulated by diacylglycerol but not by phorbol ester.
Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Plasma composition distribution in cancer: Discrimination by thrombin and factor Xa generation.
Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer - Relationship with Clinical Outcome.
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation.
Platelet enhancement of tumor cell adhesion to subendothelial matrix: role of platelet cytoskeleton and platelet membrane.
Platelet-activating factor produced by endothelial cells. A molecule with autocrine and paracrine properties.
Platelet-aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms.
Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells.
Platelet-aggregating activities of metastasizing tumor cells. IV. Effects of cell surface modification on thrombin generation, platelet aggregation and subsequent lung colonization.
Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity.
Platelet-derived microparticles and coagulation activation in breast cancer patients.
Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro.
Platelet-mimicry of cancer cells: epiphenomenon with clinical significance.
Platelets and cancer: implications for antiangiogenic therapy.
Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
PMA inhibits the growth of human fibroblasts after the induction of immediate-early genes.
PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation.
PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?
PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion.
PO-24 - Determinants of thrombin generation in gynaecological malignancies.
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma.
PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer.
Preconditioning of primary human endothelial cells with inflammatory mediators alters the "set point" of the cell.
Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study.
Preeclampsia-associated homeostasis changes in pregnant woman after ART.
PreproEndothelin-1 expression in human mesangial cells: evidence for a p38 mitogen-activated protein kinase/protein kinases-C-dependent mechanism.
Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation.
Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188.
Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate.
Pro-Coagulant and Pro-Thrombotic Effects of Paclitaxel Mediated by Red Blood Cells.
Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.
Procoagulant properties of human MV3 melanoma cells.
Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury.
Progestin and thrombin regulate tissue factor expression in human term decidual cells.
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung.
Proinflammatory signaling functions of thrombin in cancer.
Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2).
Promotion of lung tumor colonization in mice by the synthetic thrombin inhibitor (no. 805) and its reversal by leech salivary gland extracts.
Promotion of transendothelial neutrophil passage by human thrombin.
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.
Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor. Comparison with umbilical vein endothelial cells.
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.
Protease-activated receptor 1: a role in prostate cancer metastasis.
Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure.
Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer.
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Protease-activated receptors in cancer: A systematic review.
Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin.
Protein kinase C is differentially regulated by thrombin, insulin, and epidermal growth factor in human mammary tumor cells.
Protein kinase C modulates pulmonary endothelial permeability: a paradigm for acute lung injury.
Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions.
Proteinase-activated receptors.
Prothrombin 3'end Gene Variants in Patients With Sporadic Colon Adenocarcinoma.
Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF?, in Peripheral Blood.
Pseudotumors after renal parenchymal sparing surgery.
Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.
Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay.
Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase.
Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-alpha.
Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells.
Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1.
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report.
Redundant signaling of tissue factor and thrombin in cancer progression?
Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer.
Regulation of P-selectin expression by inflammatory mediators in canine jugular endothelial cells.
Regulation of tissue factor pathway inhibitor expression in smooth muscle cells.
Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample.
Reservations against new oral anticoagulants after stroke and cerebral bleeding.
Rhamnan sulfate extracted from Monostroma nitidum attenuates blood coagulation and inflammation of vascular endothelial cells.
Rho GTPases and the regulation of endothelial permeability.
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells.
Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study.
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
RNA-seq Reveals Novel Transcriptome of Genes and Their Isoforms in Human Pulmonary Microvascular Endothelial Cells Treated with Thrombin.
Role and regulation of the thrombin receptor (PAR-1) in human melanoma.
Role of E- and P-selectin in migration of monocytes and polymorphonuclear leucocytes to cytokine and chemoattractant-induced cutaneous inflammation in the rat.
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.
Role of endothelin in human hypertension.
Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells.
Role of Hypercoagulable State for Predictive Ovarian Malignancy in Women with a Pelvic Mass.
Role of NADPH oxidases in the control of vascular gene expression.
Role of plasma, platelets, and endothelial cells in tumor metastasis.
Role of platelet membrane in enhancement of tumor cell adhesion to endothelial cell extracellular matrix.
Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo.
Role of Protease-Activated Receptor-1 in Glioma Growth.
Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis.
Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice.
Role of thrombin as a tumor growth factor.
Role of thrombin in angiogenesis and tumor progression.
Role of Thrombin in Central Nervous System Injury and Disease.
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Role of thrombin in the proliferative response of T-47D mammary tumor cells. Mitogenic action and pleiotropic modifications induced together with epidermal growth factor and insulin.
Role of thrombin in tumor angiogenesis, implantation, and metastasis.
Role of tissue factor expression in thrombin generation by canine tumor cells.
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Scoring ligand similarity in structure-based virtual screening.
Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells.
Selective recognition of co-assembled thrombin aptamer and docetaxel on mesoporous silica nanoparticles against tumor cell proliferation.
Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy.
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Sex differences in the expression of cell adhesion molecules on microvesicles derived from cultured human brain microvascular endothelial cells treated with inflammatory and thrombotic stimuli.
Signaling mechanism in the induction of apoptosis by thrombin in human tumor cells.
Significance of plasma fibrinopeptide A (fpA) in patients with malignancy.
Single gold nanoparticles counter: an ultrasensitive detection platform for one-step homogeneous immunoassays and DNA hybridization assays.
Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.
Smart Nanotherapeutic Targeting of Tumor Vasculature.
Solid tumor cells express functional "tethered ligand" thrombin receptor.
Soluble CD40 ligand plasma levels in lung cancer.
Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis.
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Special pharmacokinetics of dipetarudin suggests a potential antitumor activity of this thrombin inhibitor.
Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Stauffer's syndrome in renal cell carcinoma evidence for intravascular coagulation.
Stiff Substrates Increase Inflammation-Induced Endothelial Monolayer Tension and Permeability.
Stimulation of proteinase activated receptor-2 causes endothelial cells to promote blood coagulation in vitro.
Stimulus-dependent release of tissue-regenerating factors by equine platelets.
Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines.
Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine.
Successful Enucleation of a Large Pancreatic Head Schwannoma.
Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy.
Survival After Solid Cancers in Antithrombotic Trials.
Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability.
Synergistic interactions of bradykinin, thrombin, interleukin 1 and tumor necrosis factor on prostanoid biosynthesis in human periodontal-ligament cells.
Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile.
Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation.
Targeting hemostasis-related moieties for tumor treatment.
Targeting nucleolin to obstruct vasculature feeding with an intelligent DNA nanorobot.
Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice.
Targeting Tumor Vasculature With an Oncolytic Virus.
TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.
TGF? upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.
The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines.
The activation of platelet aggregation by human cholangiocarcinoma cells is mediated through thrombin receptor.
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread.
The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.
The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development.
The chemotherapy of C3H mice bearing Gardner lymphosarcoma with bovine fibrinogen-methotrexate derivative.
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.
The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial.
The effects of thrombin and cytokines upon the biomechanics and remodeling of isolated amnion membrane, in vitro.
The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
The hemostatic system and angiogenesis in malignancy.
The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions.
The involvement of thrombin in the pathogenesis of glioblastoma.
The involvement of thrombin RGD in metastasis: characterization of a cryptic adhesive site.
The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology.
The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer.
The pivotal role of thrombin in cancer biology and tumorigenesis.
The role of coagulation and platelets in colon cancer-associated thrombosis.
The role of fibrin in tumor metastasis.
The role of thrombin in tumor cell metastasis.
The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression.
The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer.
The synergistic effect of Au-COF nanosheets and artificial peroxidase Au@ZIF-8(NiPd) rhombic dodecahedra for signal amplification for biomarker detection.
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca(2+)](i) mobilization in human astrocytoma cells.
Therapeutic Roles of Heparin Anticoagulants in Cancer and Related Disorders.
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Three-dimensional porous microarray of gold modified electrode for ultrasensitive and simultaneous assay of various cancer biomarkers.
Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?
Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms.
Thrombin and antithrombotics.
Thrombin and cancer: from molecular basis to therapeutic implications.
Thrombin and its precursor in human cerebrospinal fluid.
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells.
Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Thrombin and TGF-beta promote human leptomeningeal cell proliferation in vitro.
Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun.
Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro.
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Thrombin biology in the 21st century: implications in hemostasis, inflammation, coagulopathies, and cancer. Proceedings of a seminar. September, 2005.
Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products.
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?.
Thrombin drives tumorigenesis in colitis-associated colon cancer.
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration.
Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.
Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase.
Thrombin enhances glioma growth.
Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms.
Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin.
Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface.
Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Thrombin Generation and Cancer: Contributors and Consequences.
Thrombin generation and the pathogenesis of cancer.
Thrombin generation as a predictor of radiotherapy induced skin erythema.
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Thrombin generation in children with febrile neutropenia.
Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients.
Thrombin increases the metastatic potential of tumor cells.
Thrombin induces apoptosis in human tumor cells.
Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1? translational pathway in colorectal cancer cells.
Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes.
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.
Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma.
Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222.
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Thrombin Inhibition and Cyclophosphamide Synergistically Block Tumor Progression and Metastasis.
Thrombin inhibition by malignant and normal cells: a cell-bound antithrombin effect.
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C.
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.
Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism.
Thrombin physiology and pathophysiology.
Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes.
Thrombin Promotes Macrophage Polarization into M1-Like Phenotype to Induce Inflammatory Responses.
Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: role of platelet glycoproteins P-selectin and GPIIb-IIIA.
Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells.
Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation.
Thrombin receptor overexpression in malignant and physiological invasion processes.
Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.
Thrombin stimulates arachidonate metabolism in murine tumor cells.
Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.
Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.
Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway.
Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Thrombin-induced activation of cultured rodent microglia.
Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium.
Thrombin-induced Migration and Matrix Metalloproteinase-9 Expression Are Regulated by MAPK and PI3K Pathways in C6 Glioma Cells.
Thrombin-induced, TNFR-dependent miR-181c downregulation promotes MLL1 and NF-?B target gene expression in human microglia.
Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling.
Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Thrombin-mediated impairment of fibroblast growth factor-2 activity.
Thrombin-specific sites of fibrinogen in small cell carcinoma of the lung.
Thrombin-unique coagulation system protein with multifaceted impacts on cancer and metastasis.
Thrombin: A Pivotal Player in Hemostasis and Beyond.
Thrombin: implications for intratumor therapy against metastasis.
Thrombomodulin enhances the invasive activity of mouse mammary tumor cells.
Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma.
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.
Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Thrombosis and cancer.
Thrombosis in brain tumors.
Thrombosis in children with malignancy.
Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.
Tissue factor and fibrin in tumor angiogenesis.
Tissue Factor and PAR2 Signaling in the Tumor Microenvironment.
Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp.
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy.
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Tissue factor, thrombin, and cancer.
Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation.
Tissue factor: A potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells.
TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation.
Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression.
Transcriptional control of melanoma metastasis: The importance of the tumor microenvironment.
Translational inhibition of E-selectin expression stimulates P-selectin-dependent neutrophil recruitment.
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.
Treatment of venous thrombosis in the cancer patient.
Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors.
Trousseau's syndrome: cancer-associated thrombosis.
Tumor angiogenesis: thrombin and metalloproteinases in focus.
Tumor cell generation of thrombin via functional prothrombinase assembly.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Tumor cell prothrombotic properties.
Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin.
Tumor cells induce platelet aggregation and intraplatelet calcium ion movements.
Tumor metastasis has a significant relationship with the development of acute ischemic stroke in Chinese cancer patients: a retrospective study.
Tumor necrosis factor causes amplification of arachidonic acid metabolism in response to interleukin 1, bradykinin, and other agonists.
Tumor necrosis factor decreases thrombin receptor expression in endothelial cells.
Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression.
Tumor Necrosis Factor-alpha Increases in the Brain after Intracerebral Hemorrhage and Thrombin Stimulation.
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
Tumour infarction after pre-operative embolisation of renal carcinoma.
Twist is required for thrombin-induced tumor angiogenesis and growth.
Ultrasensitive Ambient Mass Spectrometry Immunoassays: Multiplexed Detection of Proteins in Serum and on Cell Surfaces.
Universal surface-enhanced Raman scattering amplification detector for ultrasensitive detection of multiple target analytes.
Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations.
Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.
Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.
US-triggered ultra-sensitive "thrombus constructor" for precise tumor therapy.
Use of dabigatran etexilate to reduce breast cancer progression.
Use of gelatin matrix thrombin tissue sealant as an effective hemostatic agent during laparoscopic partial nephrectomy.
Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells.
Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor.
Venous Thromboembolism in Gynecological Malignancy.
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Verapamil inhibits to different extents agonist-induced Ca2+ transients in human tumor cells and in vitro tumor cell growth.
Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling.
von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
[A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin]
[Acquired factor V deficiency: A rare bleeding disorder with variable clinical presentations.]
[Advances on mechanisms of coagulation with non-small cell lung cancer].
[Biochemistry of tumor cell thrombosis: thrombin as growth hormone]
[Biological effects of thrombin]
[Biomolecular markers in cancer-associated thromboembolism].
[Changes of prethrombotic state indexes in patients with malignant cancer]
[Coagulation and formation of malignant effusions]
[Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model.]
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]
[Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors]
[Evaluation of hypercoagulable state in patients with malignancies by using prothrombin fragment F1 + 2]
[Expression evaluation of in loco coagulation system in colorectal cancer]
[Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.]
[Fibrin glue injection therapy with diluted thrombin for complicated postoperative fistulas following digestive surgery].
[Future potential indications for an oral thrombin inhibitor]
[Improvement of hemostasis in laparoscopic and open partial nephrectomy with gelatin thrombin matrix (FloSeal)]
[Occlusion of the renal artery by intra-arterial injection of thrombin in a case of inoperable renal tumour (author's transl)]
[Reactions of derivatives of beta-lactam antibiotics with non-antibacterial biological activity]
[Role of CD47 in hematologic malignancies].
[Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis]
[Studies on platelet aggregation induced by human cultured carcinoma cell lines]
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
[Thrombin and angiogenesis of cancer - review.]
[Thrombin and tumor metastasis - review]
[Thrombin induced tumour growth - pharmacological control]
[Thrombin preconditioning reduces brain injury caused by intracerebral infusion of high dose thrombin]
[Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells]
[Thrombocytopenia induced by lipopolysaccharide may be not related to coagulation and inflammatory response].
[Thrombosis and coronary disease: neutrophils, nitric oxide and aspirin]
[Ultrasound diagnosis of venous tumor thrombi in kidney cancer. A prospective study]
Neoplastic Cells, Circulating
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Modeling and simulation of procoagulant circulating tumor cells in flow.
Nephritis
Current perspective on antithrombin drugs.
Nephrosis
In vivo measurements of fibrin formation and degradation in nephrotic patients.
Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.
Nephrotic Syndrome
A study of impaired fibrin polymerization in patients with the nephrotic syndrome.
Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome.
Concentration of three thrombin inhibitors in the nephrotic syndrome in adults.
Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
Hemostatic molecular markers in nephrotic syndrome.
Human alpha2-macroglobulin and its antitrypsic and antithrombin activities in serum and plasma.
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Mechanisms of the development of acquired antithrombin III deficiency in the experimental nephrotic syndromes.
Molecular markers of hemostasis activation in nephrotic syndrome.
Neonatal thromboembolism.
Nephrotic syndrome: a platelet hyperaggregability state.
Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia.
Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
The assesment of prothrombotic potential using thrombin generation assay in pediatric patients with nephrotic syndrome: preliminary study.
The prolonged thrombin time of nephrotic syndrome.
Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
[Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome]
[Howie's antithrombin activity and thrombin inhibitors in the nephrotic syndrome]
[Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome]
Nervous System Diseases
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Neurilemmoma
Local Regulation of Thrombin Activity by Factor Xa in Peripheral Nerve Schwann Cells.
Thrombin and protein C pathway in peripheral nerve Schwann cells.
Neuritis
Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Neuritis, Autoimmune, Experimental
Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
Neuroblastoma
Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombins.
Addition of protease inhibitors to culture medium of neuroblastoma cells induces both neurite outgrowth and phosphorylation of microtubule-associated protein MAP-1B.
Binding of human thrombin to cultured human endothelial cells.
Characterization of platelet activity in neuroblastoma.
Characterization of the prothrombin gene expression during nerve differentiation.
Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells.
Exogenous thrombin inhibits neuritogenesis in cultured neuroblastoma cells but not in rat hippocampal neurons.
Functional sites of glia-derived nexin (GDN): importance of the site reacting with the protease.
Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation.
Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor.
Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban.
Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
Modulation of morphological differentiation of human neuroepithelial cells by serine proteases: independence from blood coagulation.
Modulation of neurite outgrowth in neuroblastoma cells by protein kinase C and platelet-activating factor.
Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase.
Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition.
Plasticity-related serine proteases in the brain (review).
Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line.
Proteolytic regulation of neurite outgrowth from neuroblastoma cells by thrombin and protease nexin-1.
Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro.
Thrombin binding and stimulation of cyclic guanosine monophosphate formation in neuroblastoma cells.
Thrombin binding to human brain and spinal cord.
Thrombin causes neurite retraction in neuronal cells through activation of cell surface receptors.
Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons.
Thrombin is the major serum factor stimulating phosphoinositide turnover, but not DNA synthesis in human neuroblastoma SH-EP cells.
Thrombin modulates and reverses neuroblastoma neurite outgrowth.
Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation.
Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses.
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Thrombin stimulation of guanosine 3',5'-monophosphate formation in murine neuroblastoma cells (clone N1E-115).
Transient neuritogenesis in NB2a/d1 neuroblastoma cells induced by glial-derived protease inhibitors.
Veno-occlusive Disease in Pediatric Patients After Hematopoietic Stem Cell Transplantation: Relevance of Activated Coagulation and Fibrinolysis Markers and Natural Anticoagulants.
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Neurodegenerative Diseases
Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease.
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection.
Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1.
Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis.
Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases.
Quantitative reverse transcriptase PCR to gauge increased protease-activated receptor 1 (PAR-1) mRNA copy numbers in the Wobbler mutant mouse.
Role of Thrombin in Central Nervous System Injury and Disease.
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Specific fibrinogen and thrombin concentrations promote neuronal rather than glial growth when primary neural cells are seeded within plasma-derived fibrin gels.
Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile.
Thrombin and its precursor in human cerebrospinal fluid.
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain.
Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders.
Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities.
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase.
Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase.
Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders.
Neuroectodermal Tumors, Primitive
[Study on the mechanisms of thrombin to inhibit neurite outgrowth]
Neurogenic Inflammation
Cerebrovascular inflammation following subarachnoid hemorrhage.
Neuroinflammatory Diseases
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes.
Deficiency of tPA Exacerbates White Matter Damage, Neuroinflammation, Glymphatic Dysfunction and Cognitive Dysfunction in Aging Mice.
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor.
Early detection of thrombin activity in neuroinflammatory disease.
Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes.
Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-?B Phosphorylation.
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.
Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease.
Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1.
Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
[Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?]
Neurologic Manifestations
Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population.
The role of thrombin in gliomas.
Neutropenia
Thrombin generation in children with febrile neutropenia.
Non-alcoholic Fatty Liver Disease
Coagulation-driven hepatic fibrosis requires protease activated receptor-1 (PAR-1) in a mouse model of TCDD-elicited steatohepatitis.
Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Non-ST Elevated Myocardial Infarction
Anticoagulation during and after acute coronary syndrome.
Contemporary use of glycoprotein IIb/IIIa inhibitors.
Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory.
Role of thrombin generation assays in the diagnosis of acute myocarditis and non-ST myocardial infarction.
Noonan Syndrome
Hematological findings in Noonan syndrome.
Nose Diseases
Role of thrombin in chronic rhinosinusitis-associated tissue remodeling.
Obesity
alpha-Thrombin upregulates G alpha i3 in human vascular endothelial cells.
Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy.
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation.
Maternal thrombin generation and D-dimer levels in obesity and pregnancy: results from the maternal thrombin generation in obesity and pregnancy (MaTOPs) study.
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Obesity and thrombin-generation profiles in women with venous thromboembolism.
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity.
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
The repertoire of family A-peptide GPCRs in archaic hominins.
Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease.
Thrombin generation in cardiovascular disease and mortality - results from the Gutenberg Health Study.
Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro.
Thrombin promotes diet-induced obesity through fibrin-driven inflammation.
Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation.
Obesity, Morbid
Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity.
Staple-Line Reinforcement with a Thrombin Matrix During Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Case Series.
Thrombin generation in morbid obesity: significant reduction after weight loss.
Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity.
Obstetric Labor, Premature
Activation of coagulation system in preterm labor and preterm premature rupture of membranes.
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: Evidence of an increased thrombin generation.
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.
Early second trimester maternal plasma levels of thrombin-inhibitor complexes and subsequent spontaneous preterm delivery.
Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor.
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications.
The role of thrombin in preterm parturition.
Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidual cells: implications for preterm labor.
[Hemostaseologic studies of maternal blood in intrauterine retardation and threatened premature labor]
Oliguria
Renal involvement in sepsis: a prospective single-center study of 136 cases.
Optic Nerve Diseases
Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child.
Oral Submucous Fibrosis
Regulation of protease-activated receptor-1 expression in human buccal fibroblasts stimulated with arecoline.
Oral Ulcer
[Thrombin therapy of severe mouth ulcers.]
Osteitis
Management of chronic osteitis and osteomyelitis with a coagulum of autogenous blood + penicillin + thrombin; (on the base of 56 cases results).
Osteoarthritis
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation.
Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis.
Relationship between cathepsin B and thrombin in rheumatoid arthritis.
Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor.
Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue.
Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis.
Osteoma, Osteoid
Percutaneous thrombin injection treatment of a gluteal pseudoaneurysm following radiofrequency ablation of a hip osteoid osteoma in a 6-year-old boy.
Osteomyelitis
Management of chronic osteitis and osteomyelitis with a coagulum of autogenous blood + penicillin + thrombin; (on the base of 56 cases results).
The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis.
Osteonecrosis
Preventive effects of the anti-vasospasm agent via the regulation of the Rho-kinase pathway on the development of steroid-induced osteonecrosis in rabbits.
Osteoporosis
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.
The safety of heparins in end-stage renal disease.
[Biological effects of vitamin K and concentration of vitamin K in Norwegian food]
Osteosarcoma
A novel phospholipase C inhibitor and phorbol esters reveal selective regulation of thrombin- and parathyroid hormone-stimulated signaling pathways in rat osteosarcoma cells.
Endothelin-1 modulates calcium signaling by epidermal growth factor, alpha-thrombin, and prostaglandin E1 in UMR-106 osteoblastic cells.
Platelet-Derived TGF-? Induces Tissue Factor Expression via the Smad3 Pathway in Osteosarcoma Cells.
Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line.
Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin.
The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity.
The zymogen prothrombin stimulates cell locomotion and calcium influx in murine osteosarcoma cells by different mechanism from thrombin.
Thrombin and parathyroid hormone mobilize intracellular calcium in rat osteosarcoma cells by distinct pathways.
Thrombin effects on osteoblastic cells. II. Structure-function relationships.
Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma.
Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.
Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases.
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Thrombin's effects on osteoblastic cells. I. Cytosolic calcium and phosphoinositides.
Ovarian Neoplasms
A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.
Blood coagulation and thrombosis in patients with ovarian malignancy.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
PO-24 - Determinants of thrombin generation in gynaecological malignancies.
Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome.
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells.
Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition.
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
[Expression of the cell surface receptor for thrombin, thrombomodulin, in human ovarian cancer cells]
Overweight
Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Effects of 6 Months of Active Commuting and Leisure-Time Exercise on Fibrin Turnover in Sedentary Individuals with Overweight and Obesity: A Randomised Controlled Trial.
Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels.
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events.
Normalization of haemostatic alterations in overweight children with weight loss due to lifestyle intervention.
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men.
Pancreatic Diseases
Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis.
Pancreatic Neoplasms
A Combined Activity of Thrombin and P-Selectin Is Essential for Platelet Activation by Pancreatic Cancer Cells.
Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PACA-2).
Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.
Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice.
Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Effect of Low Molecular Weight Heparins and Fondaparinux upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3.
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients.
PO-27 - Thrombin generation in pancreatic cancer and multiple myeloma with use of calibrated automated thrombography.
The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls.
Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.
Thrombin stimulates integrin ?1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-activated receptor (PAR)-1.
[A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin]
Pancreatic Pseudocyst
Endoscopic use of oxidized regenerated cellulose and topical thrombin: a novel approach for control of bleeding pancreatic pseudocyst wall after endoscopic cystgastrostomy.
Pancreatitis
Acute pancreatitis in Soweto, South Africa: relationship between trypsinogen load, trypsinogen activation, and fibrinolysis.
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Endoscopic ultrasound guided thrombin injection of angiographically occult pancreatitis associated visceral artery pseudoaneurysms: Case series.
Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man.
Percutaneous ultrasound-guided thrombin injection as first-line treatment of pancreatic pseudoaneurysm.
The relationship of coagulation factors to clinical complications of acute pancreatitis.
Thrombin Generation in vitro and in vivo, and Disturbed Tissue Factor Regulation in Patients with Acute Pancreatitis.
Treatment of a splenic artery pseudoaneurysm by endoscopic ultrasound-guided thrombin injection.
Ultrasonic-guided percutaneous injection of pancreatic pseudoaneurysm with thrombin.
[Role of increase in permeability and circulatory failure in the development of organ dysfunction in severe acute pancreatitis]
Pancreatitis, Chronic
Endoscopic ultrasound-guided thrombin injection in a large splenic artery aneurysm: first report in a patient with tropical chronic pancreatitis.
Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection.
Percutaneous thrombin injection for the treatment of a post-pancreatitis pseudoaneurysm.
Ultrasound guided thrombin injection to treat a pseudoaneurysm secondary to chronic pancreatitis.
Paraproteinemias
Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to rituximab.
Hyperfibrinogenemia as a cause of prolonged thrombin clotting time.
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
[Increased thrombin time in a patient with multiple myeloma]
Paratuberculosis
Cloning and expression in Escherichia coli of DNA encoding a 60 kDa stress protein of Mycobacterium paratuberculosis, the causative agent of Johne's disease.
Paresthesia
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Parkinson Disease
Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease.
Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Role of thrombin-PAR1-PKC?/? axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro.
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.
Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase.
Pelvic Floor Disorders
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Pemphigoid, Bullous
Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases.
Penile Induration
Multicenter Prospective Study of Grafting With Collagen Fleece TachoSil in Patients With Peyronie's Disease.
Peptic Ulcer
A randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer.
Adding heat probe treatment to adrenaline injection for spurting haemorrhage of peptic ulcers. Injection of adrenaline and human thrombin is best option.
Discussion on a randomized trial comparing heater probe plus thrombin with heater probe plus placebo for bleeding peptic ulcer.
Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin.
Endoscopic management of acute peptic ulcer bleeding.
Experimental studies of injection therapy for ulcer haemorrhage in rabbits.
Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Injection therapy of bleeding peptic ulcer. A prospective, randomized trial using epinephrine and thrombin.
Spontaneous antithrombin in a patient with benign paraprotein.
[Endoscopic hemostasis against hemorrhage from the upper gastrointestinal tract: its indication and limitation]
[Endoscopic hemostasis in hemorrhagic peptic ulcer. A review and pilot study of local thrombin injection combined with systemic fibrinolysis inhibition (with tranexamic acid)]
[Somatostatin in severe peptic ulcer hemorrhage]
Peptic Ulcer Hemorrhage
Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin.
Pericarditis
Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population.
Treatment Algorithms in Systemic Lupus Erythematosus.
Periodontal Diseases
Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro.
Expression and activity of thrombomodulin in human gingival epithelium: in vivo and in vitro studies.
Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts.
Periodontitis
Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis.
Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis.
Activation of human prothrombin by arginine-specific cysteine proteinases (Gingipains R) from porphyromonas gingivalis.
Expression and activity of thrombomodulin in human gingival epithelium: in vivo and in vitro studies.
Thrombin and bradykinin enhance prostaglandin production in human peripheral blood monocytes.
Peripheral Arterial Disease
Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
Altered coagulation profile in peripheral artery disease patients.
Antithrombotic Agents.
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case-Control Study.
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease.
Use of Bivalirudin as the Foundation Anticoagulant during Percutaneous Peripheral Interventions.
Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Vorapaxar and optimal aspirin dose: The FDA outlook.
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.
Peripheral Nerve Injuries
Neural thrombin and protease nexin I kinetics after murine peripheral nerve injury.
Peripheral Nervous System Diseases
A novel histochemical method for the visualization of thrombin activity in the nervous system.
Thrombin and its precursor in human cerebrospinal fluid.
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
Peripheral Vascular Diseases
A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Exercise in claudicants is accompanied by excessive thrombin generation.
Hypercoagulability in patients with peripheral vascular disease.
Peritonitis
Effect of activated protein C on secretory activity of rat peritoneal mast cells.
Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.
Human Neutrophils Support Thrombin Generation in Peritonitis.
[The role of PAR family receptors in activation of mast cells in the norm and in acute inflammation in rats]
Peroneal Neuropathies
Calf compartment syndrome and lumbar plexopathy following topical bovine thrombin-induced coagulopathy.
Persistent Infection
Arterio-biliary fistulas: What to choose as endovascular treatment?
Pilonidal Sinus
Novel Approach of Treatment of Pilonidal Sinus Disease With Thrombin Gelatin Matrix as a Sealant.
Treatment of pilonidal sinus disease with thrombin gelatin matrix - a video vignette.
Pituitary ACTH Hypersecretion
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.
Placental Insufficiency
Placental insufficiency is characterized by platelet activation in the fetus.
Plague
Structure-function analysis of Yersinia pestis YopM's interaction with alpha-thrombin to rule on its significance in systemic plague and to model YopM's mechanism of binding host proteins.
plasma kallikrein deficiency
Antithrombotic potential of the contact activation pathway.
plasmin deficiency
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis: Successful treatment with direct thrombin inhibitor and fresh plasma.
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency.
Platelet Storage Pool Deficiency
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Thrombin and ionophore A23187-induced dense granule secretion in storage pool deficient platelets: evidence for impaired nucleotide storage as the primary dense granule defect.
Pleural Effusion
Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
The contribution of factor V to the coagulant property of pleural fluid.
Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.
Pleurisy
Release of endothelins and platelet-activating factor by a rat pleural mesothelial cell line.
[Action of thrombin on the serofibrinous pleurisies of substitution of therapeutic pneumothorax.]
Pneumonia
A case of delayed death after accidental intravenous injection of thrombin.
Anticoagulant therapy for acute lung injury or pneumonia.
Asef controls vascular endothelial permeability and barrier recovery in the lung.
Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.
Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice.
Enhanced thrombin generation and depressed anticoagulant function in children with pneumonia.
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19.
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.
Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.
Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling.
Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells.
p300 and C/EBP?-regulated IKK? expression are involved in thrombin-induced IL-8/CXCL8 expression in human lung epithelial cells.
Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection.
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity.
Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury.
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis.
Thrombin-induced CCAAT/enhancer-binding protein ? activation and IL-8/CXCL8 expression via MEKK1, ERK, and p90 ribosomal S6 kinase 1 in lung epithelial cells.
Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-?B pathways in human lung epithelial cells.
Thrombin-induced NF-?B activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells.
[Coagulopathy correlates with outcomes in patients with community- acquired pneumonia].
[Peculiarities of thrombin generation and prognosis of unfavourable outcome in patients with severe pneumonia and pneumogenic sepsis].
[The DNA binding activity of nuclear factor-?B in patients with severe pneumonia and the intervention effects of Xuebijing injection.]
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Pneumonia, Bacterial
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Pneumoperitoneum
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Pneumothorax
Chemical pleurodesis with autologous blood and freeze-dried concentrated human thrombin improved spontaneous pneumothorax and thoracic endometriosis: The first case involving a pregnant woman.
Comparative studies using a rigid thoracoscope and fiberoptic bronchoscope to treat spontaneous pneumothorax.
Intrabronchial Infusion of Autologous Blood Plus Thrombin for Intractable Pneumothorax After Bronchial Occlusion Using Silicon Spigots: A Case Series of 9 Patients With Emphysema.
[Action of thrombin on the serofibrinous pleurisies of substitution of therapeutic pneumothorax.]
[Chemical pleurodesis induced with fibrin glue in the treatment of inoperable spontaneous pneumothorax]
[Efficacy and safety of position selection combined with intra-pleural thrombin injection in the treatment of postoperative persistent air leakage in bullous pulmonary-pleural diseases].
[Intramuscular injections of thrombase can absorb the sero-fibrinous effusions of therapeutic pneumothorax.]
Polyarteritis Nodosa
WIDELY DISTRIBUTED NECROTIZING ARTERITIS INDUCED IN RABBITS BY EXPERIMENTAL RENAL ALTERATIONS. IV. DEMONSTRATION OF DECREASED AMOUNT OF THROMBIN CLOTTABLE PLASMA PROTEIN DURING DEVELOPMENT OF THE ARTERIAL LESIONS.
Polycystic Ovary Syndrome
Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation.
Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Polycythemia
Neonatal thromboembolism.
Use of clinical pathology in evaluation of horses with colic.
Polycythemia Vera
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Budd-Chiari syndrome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment.
Identification and treatment of arterial thrombophilia.
Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombotic disease in the myeloproliferative neoplasms.
[Inhibition of thrombin in the plasma of patients with polycythemia vera]
Polyneuropathies
An electrochemical aptasensor based on TiO2/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin.
Enhancement of aptamer immobilization using egg shell-derived nano-sized spherical hydroxyapatite for thrombin detection in neuroclinic.
Postpartum Hemorrhage
Hematome peridural chez une parturiente au decours d'un choc hemorragique: [Epidural hematoma after hemorrhagic shock in a parturient].
Pelvic arterial pseudoaneurysm-a rare complication of Cesarean section: diagnosis and novel treatment.
Postthrombotic Syndrome
Current treatment of acute lower extremity deep venous thrombosis.
Pre-Eclampsia
A prospective study investigating the mechanism of thrombocytopenia in preeclampsia.
A suggestion about the cause of inflammation in acute atherosis complicating poor placentation in preeclampsia.
Activation of PAR-1/NADPH oxidase/ROS signaling pathways is crucial for the thrombin-induced sFlt-1 production in extravillous trophoblasts: possible involvement in the pathogenesis of preeclampsia.
Alterations of profibrinolytic receptor annexin A2 in pre-eclampsia: A possible role in placental thrombin formation.
Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth.
Analysis of perinatal coagulation function in preeclampsia.
Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins.
Blood coagulation profile in Indian patients with pre-eclampsia and eclampsia.
Coagulation and fibrinolysis in preeclampsia and neonates.
Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia.
Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis.
Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women.
Effects of serum from preeclamptic women on prostacyclin production by human endothelial cells.
Effects of thrombin, PAR-1 activating peptide and a PAR-1 antagonist on umbilical artery resistance in vitro.
Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia.
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia.
Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia.
Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy.
Hemostatic abnormalities may predict chronic hypertension after preeclampsia.
Identification of unexplored substrates of the serine protease, thrombin, using N-terminomics strategy.
Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia.
Increased thrombin generation in women with a history of preeclampsia.
Inhibiting trophoblast PAR-1 overexpression suppresses sFlt-1-induced anti-angiogenesis and abnormal vascular remodeling: a possible therapeutic approach for preeclampsia.
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation.
Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension.
Platelet activation and endogenous thrombin potential in pre-eclampsia.
Possibility of Coagulation System Activation Determination with Tissue Factor in Pregnancy Complications.
Pre-eclampsia part 1: current understanding of its pathophysiology.
Preeclampsia-eclampsia syndrome and coagulation.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia.
The procoagulant activity of red blood cells from patients with severe preeclampsia.
The role of coagulation and fibrinolysis in preeclampsia.
Thrombin enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts; possible involvement in the pathogenesis of preeclampsia.
Thrombin impairs the angiogenic activity of extravillous trophoblast cells via monocyte chemotactic protein-1 (MCP-1): A possible link with preeclampsia.
Thrombin regulates monocyte chemoattractant protein-1 expression in human first trimester and term decidual cells.
Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.
Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.
[Endothelial damage and blood coagulation activation in preeclampsia]
[Preeclampsia and thrombin generation test].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes.
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups.
Thrombin generation in children with febrile neutropenia.
Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy.
von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts.
Pregnancy Complications
Possibility of Coagulation System Activation Determination with Tissue Factor in Pregnancy Complications.
Premature Birth
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: Evidence of an increased thrombin generation.
Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.
Early second trimester maternal plasma levels of thrombin-inhibitor complexes and subsequent spontaneous preterm delivery.
Effect of Thrombin on Human Amnion Mesenchymal Cells, Mouse Fetal Membranes, and Preterm Birth.
Nrf2 Activation Inhibits Effects of Thrombin in Human Amnion Cells and Thrombin-induced Preterm Birth in Mice.
Phospholipid Scramblase Expression in the Pregnant Mouse Uterus in LPS-Induced Preterm Delivery.
Prospective investigation of second-trimester thrombin activation and preterm birth.
Thrombin Augments LPS-Induced Human Endometrial Endothelial Cell Inflammation via PAR1 Activation.
Priapism
Treatment of posttraumatic high-flow priapism in 8-year-old boy with percutaneous ultrasound-guided thrombin injection.
[Strategies for the treatment and prevention of priapism in children].
Primary Myelofibrosis
Thrombin Generation Testing in Patients with Myelofibrosis.
Prion Diseases
Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.
Prolactinoma
Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.
Prostatic Hyperplasia
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Transurethral resection versus holmium laser enucleation of the prostate: A prospective randomized trial comparing perioperative thrombin generation and fibrinolysis.
[Effect of thrombin on hematuria after operation for benign prostatic hyperplasia]
Prostatic Neoplasms
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines.
A SERS-LFA biosensor combined with aptamer recognition for simultaneous detection of thrombin and PDGF-BB in prostate cancer plasma.
Coagulation monitoring with thrombin generation test during endoscopic extraperitoneal radical prostatectomy for prostate cancer in a patient with severe haemophilia B.
Correlates of thrombin generation in patients with advanced prostate cancer.
Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells.
Effect of thrombin tube on PSA determination, a clue for false negative in screening for prostate cancer.
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Expression of functional protease-activated receptor 1 in human prostate cancer cell lines.
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability.
Mechanism of thrombin-induced angiogenesis.
Oral thrombostatin FM19 inhibits prostate cancer.
PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
Rational design and applications of a Rac GTPase-specific small molecule inhibitor.
Role of thrombin as a tumor growth factor.
Role of thrombin in angiogenesis and tumor progression.
The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies.
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells.
Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222.
Thrombin receptor expression is upregulated in prostate cancer.
Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells.
Protein C Deficiency
Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association?
Heparin-induced thrombocytopenia: a ten-year retrospective.
Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
Protein C deficiency screening using a thrombin generation assay - an upgrade.
Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis.
The protein C pathway.
The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation.
The use of direct oral anticoagulants in inherited thrombophilia.
Protein S Deficiency
A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma.
Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus.
Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels.
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Regulation of coagulation by protein S.
Sequential multiple retinal vein occlusions and transient ischemic attack in MTHFR polymorphism and protein S deficiency.
The use of direct oral anticoagulants in inherited thrombophilia.
Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.
Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency.
Protein-Energy Malnutrition
[Prolonged thrombin time observed in protein-energy malnutrition]
protein-glutamine gamma-glutamyltransferase deficiency
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Proteinuria
Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs.
Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.
Favorable Maternal and Fetal Effects of Danshensu in an Experimental Mice Model of Preeclampsia.
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
Mechanisms of the development of acquired antithrombin III deficiency in the experimental nephrotic syndromes.
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy.
The assesment of prothrombotic potential using thrombin generation assay in pediatric patients with nephrotic syndrome: preliminary study.
Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.
Urinary Thrombin as a Marker of Glomerular Inflammation Associated with Renal Injury in Type 2 Diabetes.
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
Psoriasis
[Relationship between syndrome pattern of psoriasis and platelet thrombin sensitive protein and CD36 molecular expression]
Pulmonary Arterial Hypertension
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
The dynamics of thrombin formation in patients with pulmonary arterial hypertension.
Pulmonary Atresia
[Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue]
Pulmonary Disease, Chronic Obstructive
Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.
Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation.
Air-leak management after upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a pilot trial comparing sealant and standard treatment.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease.
Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease.
Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.
In vivo thrombin generation and platelet hyperactivity in patients with chronic obstructive pulmonary disease.
Increased Platelet-Monocyte Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity.
Mammalian target of rapamycin and p70S6K mediate thrombin-induced nuclear factor-?B activation and IL-8/CXCL8 release in human lung epithelial cells.
Thrombin generation in chronic obstructive pulmonary disease: Dependence on plasma factor composition.
Ultrasensitive electrochemical aptasensor for the detection of thrombin based on dual signal amplification strategy of Au@GS and DNA-CoPd NPs conjugates.
Pulmonary Edema
Alpha-thrombin-induced pulmonary vasoconstriction.
Beneficial effects of a leukotriene receptor antagonist on thrombin-induced pulmonary edema in the rat.
Blockade of histamine receptors and thrombin-induced microembolic pulmonary edema in the rat.
Capsaicin-sensitive nerves exert an inhibitory effect on the development of fibrin-induced pulmonary edema in rats.
Effect of ibuprofen on thrombin-induced pulmonary edema in the rat.
Effects of vasodilators on fibrin-induced pulmonary edema, so-called neurogenic pulmonary edema, in the rat.
Ezrin/radixin/moesin proteins differentially regulate endothelial hyperpermeability after thrombin.
Factors influencing fibrin-induced pulmonary edema.
Opposing effects of isoflurane and sevoflurane on neurogenic pulmonary edema development in an animal model.
Presence and quantification of neuropeptide Y in pulmonary edema fluids in rats.
Role of central nervous system nitric oxide in the development of neurogenic pulmonary edema in rats.
Role of hemodynamics and vagus nerves in development of fibrin-induced pulmonary edema.
Pulmonary Embolism
14-3-3? regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function.
Anticoagulant Decapeptide Interacts with Thrombin at the Active Site and Exosite-I.
Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site.
Anticoagulation in the prevention and treatment of pulmonary embolism.
Anticoagulation: the present and future.
Bothrojaracin, a Bothrops jararaca snake venom-derived (pro)thrombin inhibitor, as an anti-thrombotic molecule.
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies.
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Development and Characterization of an Inducible Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
Direct oral anticoagulants in rare venous thrombosis.
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension.
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Low molecular weight heparin in acute stroke.
Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Molecular Imaging of Activated Platelets Allows the Detection of Pulmonary Embolism with Magnetic Resonance Imaging.
Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography.
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Oral antithrombotic effects of acylhydrazone derivatives.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Persistent generation of thrombin after acute myocardial infarction.
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism.
Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice.
Pulmonary embolism: current treatment options.
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Retrieval of "Recovery IVC Filter" after 383 days.
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-111-labeled platelets.
The dynamics of thrombin formation.
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.
Transitions of care in anticoagulated patients.
Treatment of accidental perianal injection of topical thrombin with intravenous antithrombin.
Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice.
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
[Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma]
[Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin]
[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].
Pulmonary Fibrosis
ADAM17/EGFR-dependent ERK activation mediates thrombin-induced CTGF expression in human lung fibroblasts.
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease.
Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.
Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis.
Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.
Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis.
Role of thrombin in pulmonary fibrosis.
Roles of high-mobility group box 1 and thrombin in murine pulmonary fibrosis and the therapeutic potential of thrombomodulin.
Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.
Significance of thrombin in bleomycin-induced pulmonary fibrosis.
Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice.
Thrombin contributes to bronchoalveolar lavage fluid mitogenicity in lung disease of the premature infant.
Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis.
Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation.
Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells.
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
Thrombin.
Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-?B and activator protein-1.
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
[The role of thrombin on lung fibroblast growth and fibrosis in bleomycin-induced lung disorder]
Purpura, Thrombocytopenic, Idiopathic
Anaesthetic management of a patient with thrombocytopenia.
Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin.
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Purpura, Thrombotic Thrombocytopenic
Identification and treatment of arterial thrombophilia.
Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Thrombin generation in thrombotic thrombocytopenic purpura.
Quadriplegia
Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study.
Radiation Pneumonitis
Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis.
Radiculopathy
The potential for salmon fibrin and thrombin to mitigate pain subsequent to cervical nerve root injury.
Renal Insufficiency
A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure.
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Anticoagulation in acute cardiac care in patients with chronic kidney disease.
Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin.
Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure.
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Hirudin in renal insufficiency.
Protective effect of angiotensin II inhibition on acute renal failure after intravascular coagulation in the rat.
Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy.
[Anticoagulation in patients with chronic renal failure]
[Markers of thrombin generation in kidney failure of children with epidemic hemolytic uremic syndrome]
[Novel oral anticoagulants and their use in the perioperative setting].
Renal Insufficiency, Chronic
Evaluation of a heparin assay method using a fluorogenic synthetic peptide substrate for thrombin.
Evaluation of hemostasis in patients with end-stage renal disease.
Systemic anticoagulation considerations in chronic kidney disease.
Reperfusion Injury
Antithrombin and ischemia/reperfusion.
Antithrombin III prevents deleterious effects of remote ischemia-reperfusion injury on healing of colonic anastomoses.
Crosstalk between thrombosis and inflammation in lung reperfusion injury.
Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine.
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
Hydroxysafflor Yellow A suppresses thrombin generation and inflammatory responses following focal cerebral ischemia-reperfusion in rats.
Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass.
Local and systemic coagulation marker response to musculocutaneous flap ischemia-reperfusion injury and remote ischemic conditioning: An experimental study in a porcine model.
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury.
Potential non-glycoprotein IIb/IIIa effects of abciximab.
Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy.
Recovery of endothelium-dependent relaxations four weeks after ischemia and progressive reperfusion in canine coronary arteries.
Sodium/hydrogen exchange inhibition with cariporide reduces leukocyte adhesion via P-selectin suppression during inflammation.
Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition.
The Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in Hypercholesterolemic Pigs.
Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury.
Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage.
Thrombin in myocardial ischemia-reperfusion during cardiac surgery.
Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury.
[Specific inhibition of thrombin activity during cardiopulmonary bypass reduces ischemia-reperfusion injury of the lung]
Respiratory Distress Syndrome
Adult respiratory distress syndrome (ARDS): experimental models with elastase and thrombin infusion in pigs.
Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters.
Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
Critical role of non-muscle myosin light chain kinase in thrombin-induced endothelial cell inflammation and lung PMN infiltration.
Fibrinolytic activity, thrombin inhibitor and kinetics of clot formation in premature infants with respiratory distress syndrome.
Fresh frozen plasma/red blood cell resuscitation regimen that restores procoagulants without causing adult respiratory distress syndrome.
Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.
Neonatal thromboembolism.
Protease-activated receptor 1 as a potential therapeutic target for COVID-19.
Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2.
Respiratory Distress Syndrome, Newborn
A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome.
Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome.
Respiratory Insufficiency
Effect of reptilase on respiratory insufficiency induced by intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog.
Experimental studies on the adult respiratory distress syndrome: effects of induced DIC; granulocytes and elastase in mini pigs.
Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.
Retinal Detachment
Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment.
Use of fibrin glue in ocular surgery.
[Thrombin-antithrombin III complexes in plasma and subretinal fluid in patients with perforated retinal detachment]
Retinal Diseases
Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation.
Thrombin regulates chemokine induction during human retinal pigment epithelial cell/monocyte interaction.
Retinal Hemorrhage
[Experimental retinal vein obstruction induced by transadventitial administration of thrombin in the rabbit]
Retinal Perforations
Broad internal limiting membrane peeling with adjunctive plasma-thrombin for repair of large macular holes: A retrospective case series.
High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment.
Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery.
Thrombin in the management of full thickness macular holes.
Retinal Vein Occlusion
In retinal vein occlusion platelet response to thrombin is increased.
Intravitreal thrombin activity is elevated in retinal vein occlusion.
Retinopathy of Prematurity
Thrombin infusion to control bleeding during vitrectomy for stage V retinopathy of prematurity.
Rhabdomyolysis
New considerations on pathways involved in acute traumatic coagulopathy: the thrombin generation paradox.
Rhabdomyosarcoma
Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.
Thrombin Regulates the Metastatic Potential of Human Rhabdomyosarcoma Cells: Distinct Role of PAR1 and PAR3 Signaling.
Thrombin: implications for intratumor therapy against metastasis.
Rheumatic Diseases
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Rhinitis, Allergic
Role of the coagulation system in allergic inflammation in the upper airways.
Rhinitis, Allergic, Seasonal
Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma.
Sagittal Sinus Thrombosis
A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection.
Sarcoidosis
Role of thrombin in pulmonary fibrosis.
Sarcoma
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
[Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells]
Sarcoma, Avian
Binding and internalization of thrombin by normal and transformed chick cells.
Plasminogen-independent fibrinolysis by proteases produced by transformed chick embryo fibroblasts.
Schistosomiasis
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni.
Scleroderma, Systemic
Anti-inflammatory and anti-fibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Role of thrombin in pulmonary fibrosis.
Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers.
Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through endothelin-1 receptor A up-regulation.
Scoliosis
Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients.
Gelatine matrix with human thrombin decreases blood loss in adolescents undergoing posterior spinal fusion for idiopathic scoliosis: a multicentre, randomised clinical trial.
Seizures
Blood coagulation and fibrinolysis in eclamptic patients and their correlation with the clinical signs.
Minimal Traumatic Brain Injury in Mice: Protease-Activated Receptor 1 and Thrombin-Related Changes.
Platelet-derived growth factor B-chain homodimer suppressing a convulsion of epilepsy model mouse El.
Potentiation of NMDA receptor function by the serine protease thrombin.
Prolonged Localized Mild Hypothermia Does Not Affect Seizure Activity After Intracerebral Hemorrhage in Rats.
Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage.
Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus.
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?
Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus.
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Thrombin facilitates seizures through activation of persistent sodium current.
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Thrombin injection for repair of pseudoaneurysms: a case for caution.
Thrombin regulation of synaptic transmission: implications for seizure onset.
Thrombin: is it on a par with seizures and epilepsy?
Treating seizures and epilepsy with anticoagulants?
[Blood fibrinogenase in insulin shock, in electroshock, and in epileptic seizure.]
Seizures, Febrile
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
Sepsis
A case of disseminated intravascular coagulation caused by Brucella melitensis.
A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis.
A Double-Chambered Protein Nanocage Loaded with Thrombin Receptor Agonist Peptide (TRAP) and ?-Carboxyglutamic Acid of Protein C (PC-Gla) for Sepsis Treatment.
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells.
Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin.
Activation of endothelial cell protease activated receptor 1 by the protein C pathway.
Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria.
Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.
Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.
Anticoagulant modulation of inflammation in severe sepsis.
Antimicrobial and Anticoagulant Activity of N-chlorotaurine (NCT), N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-monochloro-2,2-dimethyltaurine (NVC-612) in Human Blood.
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.
Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.
Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters.
Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase.
Characteristics of thrombin generation in a fulminant porcine sepsis model.
Coagulation and inflammation.
Coagulation disorders in patients with cirrhosis and severe sepsis.
Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis.
Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure.
COVID-19 and cardiovascular problems in elderly patients: Food for thought.
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity.
Critical role of autophagy regulator Beclin1 in endothelial cell inflammation and barrier disruption.
Crosstalk between inflammation and thrombosis.
Current clinical practice. DIC 2002: a review of disseminated intravascular coagulation.
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.
Dielectric Blood Coagulometry for the Early Detection of Sepsis-Induced Disseminated Intravascular Coagulation: A Prospective Observational Study.
Drotrecogin alfa.
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Dynamic changes in thrombin generation in abdominal sepsis in mice.
Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Endogenous thrombin potential as marker of procoagulant response that can be useful in early stage of sepsis.
Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients.
Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-?B and AP-1.
Fibrinolysis in disseminated intravascular coagulation.
Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls.
Hemostatic changes in neonates with anoxia and sepsis.
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Heparin-induced thrombocytopenia in the cardiac patient: 10 points to help the physician.
Histones as mediators of host defense, inflammation and thrombosis.
Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis.
Impairment of thrombin generation in the early phases of the host response of sepsis.
Inflammation and coagulation. An overview.
Lepirudin blunts endotoxin-induced coagulation activation.
Lipopolysaccharide-Induced Hemolysis Is Abolished by Inhibition of Thrombin Generation but Not Inhibition of Platelet Aggregation.
Macrophage Migration Inhibitory Factor-Induced Autophagy Contributes to Thrombin-Triggered Endothelial Hyperpermeability in Sepsis.
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.
Modulators of coagulation. A critical appraisal of their role in sepsis.
Neonatal thromboembolism.
Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms.
Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome.
Pathophysiology, staging and therapy of severe sepsis in baboon models.
Platelet aggregation as a sign of septicemia in thermal injury. A prospective study.
Platelet-derived microparticles regulates thrombin generation via phophatidylserine in abdominal sepsis.
Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice.
Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood.
Rac1 regulates sepsis-induced formation of platelet-derived microparticles and thrombin generation.
Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-alpha.
Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Regulation of endothelial cell inflammation and lung polymorphonuclear lymphocyte infiltration by transglutaminase 2.
Regulation of RelA/p65 and Endothelial Cell Inflammation by Proline-Rich Tyrosine Kinase 2.
Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
Review of cellular and molecular pathways linking thrombosis and innate immune system during sepsis.
Role of a thrombin generation assay in the prediction of infection severity.
Role of thrombin in the pathogenesis of central nervous system inflammatory diseases.
Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets.
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation.
Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
Synergistic effects of tumor necrosis factor-alpha and thrombin in increasing endothelial permeability.
The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis.
The many faces of tissue factor.
The pathogenesis of sepsis.
The protein C pathway and sepsis.
The protein C pathway.
The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome.
Thrombin and leukocyte recruitment in endotoxemia.
Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun.
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms.
Thrombin generation and mortality during Staphylococcus aureus sepsis.
Thrombin generation in abdominal sepsis is Rho-kinase-dependent.
Thrombin generation in severe sepsis.
Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin.
Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation.
Thrombin physiology and pathophysiology.
Thrombin-cleaved syndecan-3/-4 ectodomain fragments mediate endothelial barrier dysfunction.
Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation.
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Tissue Factor Pathway Inhibitor and P-Selectin as Markers of Sepsis-Induced Non-overt Disseminated Intravascular Coagulopathy.
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
Unlike thrombin, protein C and activated protein C do not affect vascular tone.
Vascular and dendritic cell coagulation signaling in sepsis progression.
[Activated proteine C]
[Approbation of a new test system determining the activity of a plasmin inhibitor in patients with sepsis]
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
[Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults]
[Predictive value of complement and coagulation indicators in sepsis related acute kidney injury].
[Protein C and coagulation in sepsis]
[Role of the innate immune response in sepsis]
[Thrombin generation in critical illnesses].
[Use of thrombin generation assay for the evaluation of coagulation and anticoagulant activity of hemostasis system in patients with abdominal sepsis].
Shock, Septic
A purified antithrombin III--heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock.
Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells.
Characterization of circulating thrombin in patients with septic shock: a prospective observational study.
Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography.
Effects of dexamethasone on endotoxin shock in the anesthetized pony: hematologic, blood gas, and coagulation changes.
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs.
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Immunohaemostasis: a new view on haemostasis during sepsis.
Influence of antithrombin III on coagulation and inflammation in porcine septic shock.
Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Neutrophil elastase, thrombin and plasmin in septic shock.
Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation.
Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction.
Porins from Salmonella typhimurium accelerate human blood coagulation in vitro by selective stimulation of thrombin activity: implications in septic shock DIC pathogenesis.
Recombinant antitrypsin Pittsburgh undergoes proteolytic cleavage during E. coli sepsis and fails to prevent the associated coagulopathy in a primate model.
The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution.
The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic shock.
Thrombin does not alter vascular hyporeactivity in models of endotoxin-induced septic shock in rats.
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study.
Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management.
Shoulder Dislocation
A Rare Case of Axillary Artery Pseudoaneurysm Due to Shoulder Dislocation Treated With Percutaneous Thrombin Injection.
Shwartzman Phenomenon
Failure to provoke the local Shwartzman reaction with thrombin.
PRODUCTION OF THE GENERALIZED SHWARTZMAN REACTION IN PREGNANT RATS BY INTRAVENOUS INFUSION OF THROMBIN.
Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits.
The effects of infusion of thrombin or endotoxin in rabbits treated with cortisone.
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Sinus Thrombosis, Intracranial
A rabbit model of cerebral venous sinus thrombosis established by ferric chloride and thrombin injection.
Photothrombosis combined with thrombin injection establishes a rat model of cerebral venous sinus thrombosis.
Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis.
Skin Diseases
Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1.
Skin Ulcer
Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban.
Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series.
Sleep Apnea Syndromes
Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing.
Sleep Apnea, Central
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Sleep Apnea, Obstructive
Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing.
Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: Effect on hypercoagulability.
Sleep Deprivation
Chronic sleep deprivation markedly reduces coagulation factor VII expression.
Small Cell Lung Carcinoma
Abnormal haemostasis in small cell lung cancer.
Spasm
Endothelium and asymmetrical responses of the coronary arterial wall.
Fibrinopeptide A is released into the coronary circulation after coronary spasm.
Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina.
Plasmin and thrombin inhibitors in essentially untreated patients with coronary artery spasm.
Pleocytosis and elevation of prostaglandins F2a and E2 in cerebrospinal fluid following intracisternal injection of thrombin.
[Blood coagulation and fibrinolysis in ischemic heart disease]
Spinal Cord Injuries
Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats.
Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling.
Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury.
The thrombin receptor links brain derived neurotrophic factor to neuron cholesterol production, resiliency and repair after spinal cord injury.
The thrombin receptor modulates astroglia-neuron trophic coupling and neural repair after spinal cord injury.
Thrombin enhances NGF-mediated neurite extension via increased and sustained activation of p44/42 MAPK and p38 MAPK.
Spondylitis, Ankylosing
Thrombin generation in ankylosing spondylitis.
ST Elevation Myocardial Infarction
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Anticoagulation during and after acute coronary syndrome.
Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction.
Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition.
Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
Emergency Percutaneous Coronary Interven-tion (PCI) for the care of patients with ST-Elevation Myocardial Infarction (STEMI).
Enoxaparin in patients with primary percutaneous coronary intervention for acute ST segment elevation myocardial infarction.
Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction.
New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications.
Plaque herniation after stenting the culprit lesion with myocardial bridging in ST elevation myocardial infarction: A case report.
Platelet dysfunction after Out of Hospital Cardiac Arrest. Results from POHCAR: A prospective observational, cohort study.
Platelet Reactivity and Intramyocardial Hemorrhage in Patients With ST-Segment Elevation Myocardial Infarction.
Practical Strategies for the Management of Anticoagulation Therapy: Unsolved Issues in the Cardiac Catheterization Laboratory.
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients.
[Prehospital Care of Patients with Acute ST Elevation Myocardial Infarction.]
Starvation
EGF and insulin action in fibroblasts. Evidence that phosphoinositide hydrolysis is not an essential mitogenic signalling pathway.
Status Epilepticus
Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.
Inhibition of protease-activated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus.
Systemic thrombin inhibition ameliorates seizures in a mouse model of pilocarpine-induced status epilepticus.
Thrombin and the Protease-Activated Receptor-1 in Organophosphate-Induced Status Epilepticus.
Thrombin as Key Mediator of Seizure Development Following Traumatic Brain Injury.
Stomach Neoplasms
Alteration of haemostasis in non-metastatic gastric cancer.
Coagulation and fibrinolysis in gastric cancer.
Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis.
Thrombin conducts epithelial?mesenchymal transition via protease?activated receptor?1 in human gastric cancer.
Stomach Ulcer
A prospective, randomized trial of thrombin versus cyanoacrylate injection in the control of acute gastric variceal hemorrhage.
Control of upper gastrointestinal hemorrhage by endoscopic spraying of clotting factors.
Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Hemostatic effects of powdered gelfoam thrombin solution and blood transfusions in an instance of recurring massive hemorrhage from a large chronic gastric ulcer: report of a case.
Thrombin receptor agonist Peptide immobilized in microspheres stimulates reparative processes in rats with gastric ulcer.
Strabismus
Use of fibrin glue in ocular surgery.
Streptococcal Infections
Reduced thrombin generation increases host susceptibility to group A streptococcal infection.
Stroke
?T -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke.
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.
A murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment.
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
A plasmatic factor may cause platelet activation in acute ischemic stroke.
A Rare Case Report Of Dabigatran Induced Oral Ulcers.
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.
Acute myocardial infarction after switching from warfarin to dabigatran.
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
American Heart Association scientific sessions.
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.
Analysis of the influence of dabigatran on coagulation factors and inhibitors.
Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.
Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Another oral thrombin inhibitor for stroke preventionin atrial fibrillation?
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Anticoagulation for atrial fibrillation in the elderly.
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
Anticoagulation therapy for atrial fibrillation.
Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia.
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Antithrombotic medication for cardioembolic stroke prevention.
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Antithrombotics in atrial fibrillation and coronary disease.
Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study.
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.
Aptamers act as activators for the thrombin mediated-hydrolysis of peptide substrates.
Argatroban in thrombotic stroke.
Argatroban tPA stroke study: study design and results in the first treated cohort.
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Atrial fibrillation: modern concepts and management.
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Benefit-Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation.
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Blood coagulation and fibrinolysis in haemorrhagic stroke.
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms.
Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran.
Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy.
Changing the guard in long-term anticoagulation: clinical and economic implications.
Characterization of a New Model of Thromboembolic Stroke in C57 black/6J mice.
Chemical shift sodium imaging in a mouse model of thromboembolic stroke at 9.4 T.
Clinical and laboratory predictors of deep vein thrombosis after acute stroke.
Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: a Case Series.
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Clopidogrel hydrogen sulphate for atrial fibrillation.
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different.
Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease.
Coated-platelets predict stroke at 30 days following TIA.
Comparative effectiveness of oral anticoagulants in everyday practice.
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.
Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential.
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.
Ctnnb1 transcriptional upregulation compensates for Mdm2/p53-mediated ?-catenin degradation in neutrophils following cardioembolic stroke.
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Current Perspective on Use of NOAC in Clinical Practice in India.
Cutting through the statistical fog: understanding and evaluating non-inferiority trials.
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation.
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Dabigatran for stroke prevention in atrial fibrillation.
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.
Dabigatran in clinical practice.
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Dabigatran Use in the Real World A Multihospital System Experience.
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source?- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
Dabigatran, a Cause of Hematologic Emergency.
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.
Dabigatran-induced chronic progressive immune hemolytic anemia: A case report.
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Dabigatran: patient management in specific clinical settings.
Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Differences in fibrin fiber diameters in healthy individuals and thromboembolic ischemic stroke patients.
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities.
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Direct thrombin inhibition to prevent stroke in atrial fibrillation.
Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation.
Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models.
Direct thrombin inhibitors: stroke prevention in atrial fibrillation and potential anti-inflammatory properties.
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
DYSREGULATION OF Ca(2+) MOVEMENT IN PLATELETS FROM PATIENTS WITH ACUTE ISCHAEMIC STROKE.
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.
Effect of hypertension on anticoagulated patients with atrial fibrillation.
Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.
Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Efficacy And Safety of Dabigatran Etexilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial Fibrillation.
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis.
Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering.
Embolic Stroke Model with Magnetic Nanoparticles.
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Enhancing the anticoagulant profile of meizothrombin.
Evaluating and assessing dabigatran drug interactions.
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.
Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome.
Functional Occurrence of the Interaction of Tissue Plasminogen Activator With the NR1 Subunit of N-Methyl-D-Aspartate Receptors During Stroke.
G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents.
Gastrointestinal disorders and dabigatran.
Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection.
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Impact of dabigatran on platelet function and fibrinolysis.
Impaired Na+-dependent glutamate uptake in platelets during depolarization of their plasma membrane.
Impaired renal function and bleeding in elderly treated with dabigatran.
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
In-thrombus thrombin secretion: a new diagnostic marker of atrial fibrillation in cryptogenic stroke.
Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment.
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Increase of aquaporin 9 expression in astrocytes participates in astrogliosis.
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Increased thrombin generation potential in symptomatic versus asymptomatic moderate or severe carotid stenosis and relationship with cerebral microemboli.
Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran.
Intracerebral hirudin injection attenuates ischemic damage and neurologic deficits without altering local cerebral blood flow.
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic.
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect.
Left atrial appendage thrombus on full-dose dabigatran treatment: a case report.
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Management of Dabigatran-associated Intracerebral and Intraventricular Hemorrhage: A Case Report.
Management of dabigatran-induced bleeding with continuous venovenous hemodialysis.
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
Mechanisms of modulation of brain microvascular endothelial cells function by thrombin.
Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1.
Mild hypothermia enhances the neuroprotective effects of a selective thrombin inhibitor following transient focal ischemia in rats.
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis.
Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage.
New anticoagulant treatments to protect against stroke in atrial fibrillation.
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
New anticoagulants.
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG.
New developments in the treatment of neurological diseases.
New options for stroke prevention in atrial fibrillation.
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
New oral anticoagulants: will they replace warfarin?
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.
No Association between Thrombin Generation and Intra-Plaque Haemorrhage in Symptomatic Carotid Atherosclerotic Plaques: The Plaque at RISK (PARISK) Study.
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Novel anticoagulant therapy: principle and practice.
Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Novel therapies for the prevention of stroke.
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Oral anticoagulants for Asian patients with atrial fibrillation.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations.
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan.
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events.
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk.
Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1).
Positive Outcome After Intentional Overdose of Dabigatran.
Post Stroke Seizures and Epilepsy: From Proteases to Maladaptive Plasticity.
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Pradaxa-induced esophageal ulcer.
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Preventing stroke in atrial fibrillation: the SPORTIF programme.
Preventing stroke in patients with atrial fibrillation: current treatments and new concepts.
Prevention of stroke in patients with atrial fibrillation.
Prevention of Stroke in Patients With Atrial Fibrillation.
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke.
Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.
Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1.
Protective effects of beta-blockers in cerebrovascular disease.
Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels.
Quantitative Detection of Thrombin Activity in an Ischemic Stroke Model.
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Reducing cardiac events after acute coronary syndromes.
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials).
Removal of dabigatran by hemodialysis.
Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage.
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Role of Thrombin in Central Nervous System Injury and Disease.
S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Smoking and coagulation: the sticky fibrin phenomenon.
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.
Spontaneous reperfusion after in situ thromboembolic stroke in mice.
SPORTIF III and SPORTIF V: Stroke Prevention Using the Direct Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation.
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack.
Statins and the risk of bleeding in patients taking dabigatran.
Stratification of venous thromboembolism risk in stroke patients by Caprini score.
Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
Stroke management.
Stroke prevention and treatment.
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants.
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.
Stroke prevention using an oral thrombin inhibitor in atrial fibrillation.
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. Pooled Analysis from the SPORTIF III and V Studies.
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices.
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Stroke prevention: managing modifiable risk factors.
Stroke thrombolysis in patients taking dabigatran.
Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
Targeting thrombin--rational drug design from natural mechanisms.
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
The current and future role of the novel oral anticoagulants--indications beyond atrial fibrillation.
The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIb?-Mediated Platelet Aggregation.
The dynamics of thrombin formation.
The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing.
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation.
The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke.
The Pharmacology and Therapeutic Use of Dabigatran Etexilate.
The pharmacology and therapeutic use of dabigatran etexilate.
The pharmacology of novel oral anticoagulants.
The role of aspirin for stroke prevention in atrial fibrillation.
The role of leukocytes in acute ischemic stroke-related thrombosis: a notable but neglected topic.
The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
The role of thrombin in central nervous system activity and stroke.
The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran.
The use of dabigatran in elderly patients.
The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients.
Thrombi of different pathologies: implications for diagnosis and treatment.
Thrombin and antithrombotics.
Thrombin antithrombin complex and IL-18 serum levels in stroke patients.
Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke.
Thrombin Generation in Acute Ischaemic Stroke.
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke.
Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults.
Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron.
Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model.
Thrombin preferentially induces autophagy in glia cells in the rat central nervous system.
Thrombin-induced hyperactivity of platelets of young stroke patients: involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation.
Thrombin: is it on a par with seizures and epilepsy?
Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
Thrombus formation in left atrium on dabigatran therapy.
Tissue factor/factor VIIa pathway mediates coagulation activation in induced-heat stroke in the baboon.
Transitions of care in anticoagulated patients.
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
Treating arrhythmias: an expert opinion.
Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.
Ulinastatin as an Adjuvant Therapy to Restricting Volumes of Resuscitation Fluid Strategy for Patients with Septic Shock after Initial Management.
Update on anti-coagulation in atrial fibrillation.
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Validation of a stroke model in rat compatible with rt-PA-induced thrombolysis: new hope for successful translation to the clinic.
Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies.
Vitamin K antagonists. Ready to be replaced?
Warfarin versus new agents: interpreting the data.
What did we learn from new oral anticoagulant treatment?
What's new in stroke? The top 10 studies of 2009-2011: part II.
Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Will oral antithrombin agents replace warfarin?
Ximelagatran (AstraZeneca).
Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Ximelagatran for stroke prevention in atrial fibrillation.
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Ximelagatran--recent comparisons with warfarin.
Ximelagatran.
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
[Characteristics of circulation and microcirculation in healthy people of Han nationality at different altitudes].
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
[Dabigatran: a new therapeutic alternative in the prevention of stroke].
[Direct oral thrombin inhibitor, "dabigatran"].
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
[Evidence of novel oral anticoagulants (NOAC)].
[Inflammatory mechanisms, arteriosclerosis and ischemic stroke: clinical data and perspectives]
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
[Monitoring of Oral Thrombin Inhibitor].
[New antithrombotics for atrial fibrillation.]
[New oral anticoagulants : Better than vitamin K antagonists?]
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
[New treatments for stroke and thromboembolism prevention in atrial fibrillation].
[Novel oral anticoagulants (NOAC)].
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
[Perioperative management and therapy of bleeding complications].
[Pharmacology of the new oral anticoagulants].
[Strategy for circulatory disturbance]
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
[Waiting for the new oral anticoagulants: questions and answers about dabigatran].
Stroke, Lacunar
Chronic Systemic Immune Dysfunction in African-Americans with Small Vessel-Type Ischemic Stroke.
Hematologic abnormalities occur in both cortical and lacunar infarction.
[Coagulation and fibrinolytic activation in lacunar infarct patients]
Stupor
[Narcosis, platelet aggregation and arousing drugs]
Subarachnoid Hemorrhage
Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin.
Basic and translational research on proteinase-activated receptors: the role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage.
Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB.
Cerebral arterial contractions induced by human and bovine thrombin.
Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid hemorrhage.
Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage.
Effect of thrombin injection on cerebral vascular in rats with subarachnoid hemorrhage.
Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model.
Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage.
Impairment of endothelium-dependent relaxation in human basilar artery after subarachnoid hemorrhage.
Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin.
Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage.
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
Role of SCH79797 in Maintaining Vascular Integrity in Rat Model of Subarachnoid Hemorrhage.
Thrombin activity in cerebrospinal fluid after subarachnoid hemorrhage.
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Thrombin inhibition in subarachnoid hemorrhage.
Thrombin reduces cerebral arterial contractions caused by cerebrospinal fluid from patients with subarachnoid hemorrhage.
Surgical Wound Infection
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Management of Iatrogenic Pseudoaneurysms in Patients Undergoing Coronary Artery Bypass Grafting.
Syphilis
Analysis of the N-terminal region of the 47-kilodalton integral membrane lipoprotein of Treponema pallidum.
[Study the safty and effectivity of human thrombin after tonsillectomy]
Systemic Vasculitis
Thromboembolic disease in systemic vasculitis is associated with enhanced microparticle-mediated thrombin generation.
Tangier Disease
Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia.
Tauopathies
Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling.
Telangiectasia, Hereditary Hemorrhagic
Hereditary hemorrhagic telangiectasia with intestinal bleeding; case report and therapy with tropical thrombin.
Telangiectasis
Hereditary hemorrhagic telangiectasia with intestinal bleeding; case report and therapy with tropical thrombin.
Tetanus
Effects of tetanus toxin, Salmonella typhimurium porin, and bacterial lipopolysaccharide on platelet aggregation.
The anticoagulant activated protein C (aPC) promotes metaplasticity in the hippocampus through an EPCR-PAR1-S1P1 receptors dependent mechanism.
Thalassemia
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.
Thrombasthenia
Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP.
Antibodies against platelet membrane glycoproteins. II. Influence on ADP- and collagen-induced platelet aggregation, crossed immunoelectrophoresis studies and relevance to Glanzmann's thrombasthenia.
Association of Factor V Secretion with Protein Kinase B Signaling in Platelets from Horses with Atypical Equine Thrombasthenia.
Impaired platelet procoagulant mechanisms in patients with bleeding disorders.
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma.
Involvement of GPIIb-IIIa on human platelets in phosphotyrosine-specific dephosphorylation.
Involvement of platelet glycoprotein IIb-IIIa (alpha IIb-beta 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3',4'-bisphosphate.
Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients.
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII: 30 years of research and innovation.
Recombinant activated factor VII: mechanisms of action and current indications.
Redistribution of activated pp60c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets.
The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
[Analysis of platelet surface conformation in thrombin-induced aggregation]
thrombin deficiency
A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer.
Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling.
The central role of thrombin in bleeding disorders.
Warfarin pretreatment reduces cell death and mmp-9 activity in experimental intracerebral hemorrhage.
Thrombocythemia, Essential
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Cytoskeleton protein composition upon platelet stimulation with thrombin in essential thrombocythemia.
Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.
Lactate production by thrombin-activated platelets of patients with primary thrombocythemia.
Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.
Thrombotic disease in the myeloproliferative neoplasms.
Thrombocytopenia
5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
A case series describing the use of argatroban in patients on extracorporeal circulation.
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience.
A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis.
A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation.
A Predictive Model for the Anticoagulant Bivalirudin Administered to Cardiac Surgical Patients.
A prospective study investigating the mechanism of thrombocytopenia in preeclampsia.
A synopsis of the clinical uses of argatroban.
A thrombin generation test; the application in haemophilia and thrombocytopenia.
Abnormal coagulation and fibrinolysis in eclampsia. A clinical and laboratory correlation study.
Acquired thrombotic risk factors in the critical care setting.
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Adaptive control of bivalirudin in the cardiac intensive care unit.
Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
An overview of the heparin-induced thrombocytopenia syndrome.
Anaesthetic management of a patient with thrombocytopenia.
Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Anticoagulation for continuous renal replacement therapy.
Anticoagulation in CRRT: agents and strategies in Australian ICUs.
Anticoagulation options for intermittent haemodialysis.
Anticoagulation options for pediatric hemodialysis.
Anticoagulation with a selective thrombin inhibitor in a woman with heparin-induced thrombocytopenia.
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.
Antiplatelet and Anticoagulant Drugs in Interventional Radiology.
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Antithrombotic Management during Percutaneous Mitral Valve Repair with the Mitraclip System in a Patient with Heparin-Induced Thrombocytopenia.
Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.
Application of Piezo-Based Measuring System for Evaluation of Nucleic Acid-Based Drugs Influencing the Coagulation.
Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.
Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
Argatroban anticoagulation in pediatric patients: a literature analysis.
Argatroban anticoagulation in renal dysfunction: a literature analysis.
Argatroban for anticoagulation in continuous renal replacement therapy.
Argatroban in adult extracorporeal membrane oxygenation.
Argatroban in extracorporeal membrane oxygenation.
Argatroban is stable in citrated whole blood for 24 hours.
Argatroban therapy in heparin-induced thrombocytopenia.
Argatroban Therapy in Patients with Coronary Artery Disease and Heparin-Induced Thrombocytopenia.
Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia.
Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Bivalirudin Anticoagulation for a Pediatric Patient with Heparin-Induced Thrombocytopenia and Thrombosis Requiring Cardiopulmonary Bypass for Ventricular Assist Device Placement.
Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review.
Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.
Bivalirudin use during radiofrequency catheter ablation procedures in two patients with a history of heparin-induced thrombocytopenia.
Bivalirudin use in an infant with persistent clotting on unfractionated heparin.
Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected].
Bleeding risk factors associated with argatroban therapy in the critically ill.
Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong.
Bothrops jararaca envenomation: Pathogenesis of hemostatic disturbances and intravascular hemolysis.
Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation.
Characterization and quantitation by flow cytometry of membranous microparticles formed during activation of platelet suspensions with ionophore or thrombin.
Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
Clinical picture and laboratorial evaluation in human loxoscelism.
Coagulation changes in eclampsia: their frequency and pathogenesis.
Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: a case report.
Coagulation studies of viral hepatitis occurring during pregnancy.
Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair.
Coagulopathy management in liver transplantation.
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Concentration of D-dimers in healthy cats and sick cats with and without disseminated intravascular coagulation (DIC).
Correction to the article "Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection", Published on Acta Med Port 2021 Jan;34(1):35-46.
Crystallographic, Spectroscopic, and Theoretical Investigation of the Efficiently Separated 21R and 21S-Diastereoisomers of Argatroban.
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia.
Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.
Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Direct Thrombin Inhibitor Resistance and Possible Mechanisms.
Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes.
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Direct thrombin inhibitors in heparin-induced thrombocytopenia.
Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia.
Direct Thrombin Inhibitors.
Disseminated intravascular clotting in kwashiorkor.
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated intravascular coagulation: a clinical/laboratory study of 48 patients.
Diverging signaling events control the pathway of GPVI down-regulation in vivo.
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
Early Identification of Argatroban Resistance and the Consideration of Factor VIII.
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.
Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit.
Effect of renal function on the pharmacodynamics of argatroban.
Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis.
Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin - induced thrombocytopenia.
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.
Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection.
Epoprostenol Therapy for a Pediatric Patient With Subacute Heparin-Induced Thrombocytopenia and a Ventricular Assist Device Undergoing Heart Transplant: A Case Report.
Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia.
Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.
Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.
Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit.
Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients.
Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia.
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia.
Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.
Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
Hematologic changes in brucellosis.
Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.
Hemostatic and thrombotic issues in cardiac surgery.
Heparin induced thrombocytopenia management with bivalirudin.
Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality.
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.
Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis.
Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors.
Heparin-induced thrombocytopenia: clinical manifestations and management strategies.
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents.
Hirudin in renal insufficiency.
Histones as mediators of host defense, inflammation and thrombosis.
Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin-fibrinogen interactions.
Hypercoagulability progresses to hypocoagulability during evolution of acetaminophen-induced acute liver injury in pigs.
Identification and treatment of arterial thrombophilia.
Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia.
Impact of renal function on argatroban therapy during percutaneous coronary intervention.
Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro.
In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes.
In vitro study of r-hirudin permeability through membranes of different haemodialysers.
Incidence of Thrombocytopenia among Patients Receiving Heparin Venous Thromboembolism Prophylaxis.
Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis.
Induction of endogenous fibrinolysis inhibition in the dog. Effect of intravascular coagulation and release of free fatty acids.
Infectious canine hepatitis: animal model for viral-induced disseminated intravascular coagulation.
Inhibition by adenosine diphosphate of the thrombocytopenia induced in rabbits by collagen or thrombin.
Interference of thrombin in immunological assays for hirudin specific antibodies.
Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Laboratory tests for heparin-induced thrombocytopenia: a multicenter study.
Lepirudin dosing in dialysis-dependent renal failure.
Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy.
Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.
Low-Molecular-Weight Heparins : Mechanisms, Trials, and Role in Contemporary Interventional Medicine.
Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke.
Mammary gland carcinoma in a dog with peripheral blood and bone marrow involvement associated with disseminated intravascular coagulation.
Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review.
Management of heparin-induced thrombocytopenia.
Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
Massive pulmonary embolism presenting as disseminated intravascular coagulation.
Massive transfusion coagulopathy.
Modeling the effects of bivalirudin in cardiac surgical patients.
Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex.
Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Monitoring of hirudin therapy with the Thrombelastograph.
Natural language processor as a tool to assess heparin induced thrombocytopenia awareness.
Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.
New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.
New anticoagulant agents: direct thrombin inhibitors.
New anticoagulants.
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
New treatment options for heparin-induced thrombocytopenia.
Newer antithrombin agents in acute coronary syndromes.
Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation.
Novel oral anticoagulants for heparin-induced thrombocytopenia.
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Pharmacology of argatroban.
Pharmacotherapy of acute coronary syndrome: the ACUITY trial.
Plasma exchange for heparin-induced thrombocytopenia in patients on extracorporeal circuits: A challenging case and a survey of the field.
Platelet aggregation in portal cirrhosis.
Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.
Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia.
Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.
Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and thrombosis.
Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.
Predicting and Evaluating the Effect of Bivalirudin in Cardiac Surgical Patients.
Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition.
Procoagulant activity of the MC28 fibrosarcoma cell line in vitro and in vivo.
Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model.
Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia.
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis.
Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.
Reversible crystallization of argatroban after subcutaneous application in pigs.
Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.
Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia.
Roles of protease-activated receptors in a mouse model of endotoxemia.
SARS-CoV-2 and pulmonary embolism: who stole the platelets?
Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.
Simultaneous Pancreas-Kidney Transplantation in a Patient with Heparin-Induced Thrombocytopenia on Dabigatran Therapy.
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation.
Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs.
Successful recovery after an overdose of argatroban.
Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature.
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.
Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis.
Systemic lupus erythematosus presenting with haemorrhagic manifestation.
TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia.
The coagulation profile in hepatosplenic schistosomiasis.
The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment.
The paradox of heparin-induced thrombocytopenia: future anticoagulation.
The pathogenesis of leptospirosis I. Hemorrhages in experimental leptospirosis in guinea pigs.
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
The proof for new oral anticoagulants: clinical trial evidence.
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
The safety of heparins in end-stage renal disease.
The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia.
Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions.
Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions.
Thrombin generation and heparin-induced thrombocytopenia.
Thrombin generation in patients with cirrhosis: the role of platelets.
Thrombin-induced leukopenia and thrombocytopenia are attenuated by PAF antagonist WEB 2086.
Thrombocytopenia and release of platelet amines induced by thrombin and bacterial lipopolysaccharide. Observations after infusion of low molecular weight dextran.
Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia.
Thrombocytopenia following heparin flush.
Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation.
Thrombocytopenia in cardiovascular patients: diagnosis and management.
Thrombocytopenia in preeclampsia and eclampsia.
Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation.
Thrombocytopenia induced by dabigatran: two case reports.
Thromboelastometry analysis of thrombocytopenic dengue patients: a cross-sectional study.
Titration of Bivalirudin Infusion in the Pediatric Cardiac Catheterization Laboratory: A Case Report.
To general haemostasis--the evidence-based route.
Transfusion medicine service policies for recombinant factor VIIa administration.
Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program.
Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor.
Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
Unfractionated heparin for hemodialysis: still the best option.
Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.
Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.
Use of direct thrombin inhibitors in acute coronary syndrome.
Usefulness of pretest clinical score (4Ts) combined with immunoassay for the diagnosis of heparin-induced thrombocytopenia.
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia.
Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis.
Warfarin-induced limb gangrene in the setting of lung adenocarcinoma.
Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome.
What are the anticoagulation options for intermittent hemodialysis?
Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
[Acute coronary syndrome: peri-interventional antithrombotic therapy]
[Anesthetic management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor]
[Anticoagulation and chronic hemodialysis.]
[Anticoagulation in patients with chronic renal failure]
[Autoimmune thrombocytopenia in chronic liver disease]
[Calcium heparin-induced immunologic thrombocytopenia complicated with venous gangrene of the legs. Report of a clinical case]
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
[Fondaparinux treatment in heparin induced thrombocytopenia:a case report].
[Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report]
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.]
[Heparin-induced thrombocytopenia]
[Indications for anticoagulants]
[Intraoperative management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor]
[Modern anticoagulation. Problems of the proven, hope for the new]
[News on antithrombotic therapy and pregnancy].
[Optimal dose of bivalirudin in dialysis patients at high risk of heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case report].
[Point-of-Care Testing in Trauma Patients - Methods and Evidence].
[Recurring pulmonary artery embolisms and disseminated intravascular coagulation in right atrial myxoma]
[Two surgical case reports showing atypical heparin-induced thrombocytopenia]
Thrombocytopenia, Neonatal Alloimmune
Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.
Thrombocytosis
Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis.
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.
Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism.
Exercise-induced platelet and leucocyte activation is not enhanced in well-controlled Type 1 diabetes, despite increased activity at rest.
Identification and treatment of arterial thrombophilia.
Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E.
Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.
Thrombin Generation Testing in Patients with Myelofibrosis.
Thromboembolism
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses.
A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice.
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Acute management of bleeding in patients on novel oral anticoagulants.
Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.
Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.
Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice.
Antithrombotic therapy for stroke prevention in atrial fibrillation.
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature.
Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.
ART-123 Asahi Kasei.
Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture.
Case Report Series of Left Atrial Thrombus Formation in Patients on Dabigatran Therapy.
Changes in Markers of Thrombin Generation and Interleukin-6 During Unicondylar Knee and Total Knee Arthroplasty.
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period. Comparison with chronic atrial fibrillation.
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Comparison between ultrasound-guided compression and para-aneurysmal saline injection in the treatment of postcatheterization femoral artery pseudoaneurysms.
Continuous thrombin infusion leads to a bleeding phenotype in sheep.
Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene.
Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Further simplification of cryoprecipitate coagulum pyelolithotomy without thrombin.
Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran.
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
Hemorrhagic complications associated with dabigatran use.
Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients.
Increased fibrinopeptide A after prothrombin complex concentrates.
Individualized antithrombotic therapy.
Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216.
Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
Laboratory measurement of the direct oral anticoagulants.
Left atrial thrombus under dabigatran in a patient with nonvalvular atrial fibrillation.
Mechanism of thrombin-induced angiogenesis.
Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.
Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials.
Mouse models of focal arterial and venous thrombosis.
New Anticoagulants for the Prevention of Thromboembolism.
New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation.
Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.
Perioperative Management of Anticoagulation-Review of Latest Evidence.
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.
Pharmacophore Design, Virtual Screening, Molecular Docking and Optimization Approaches to Discover Potent Thrombin Inhibitors.
Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats.
Pseudoaneurysms.
Reversal of novel oral anticoagulants in patients with major bleeding.
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment.
Salvage of autogenous dialysis access with balloon-assisted thrombin injection.
Sequential multiple retinal vein occlusions and transient ischemic attack in MTHFR polymorphism and protein S deficiency.
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.
Should all patients with non-valvular atrial fibrillation be anticoagulated?
Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
The Antithrombotic Activity of EP224283, a Neutralizable Dual Factor Xa Inhibitor/Glycoprotein IIbIIIa Antagonist, Exceeds That of the Coadministered Parent Compounds.
The association of direct thrombin inhibitor anticoagulants with cardiac thromboses.
The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits.
The effect of major surgery, low doses of heparin and thromboembolism on plasma antithrombin. Comparison of immediate thrombin inhibiting capacity and the antithrombin III content.
The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI.
The thrombin inhibitors hirudin and Refludan® activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
Thrombin activity resides on LVAD Dacron inflow and outflow grafts.
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
Thrombin-mediated impairment of fibroblast growth factor-2 activity.
Thrombocytopenia induced by dabigatran: two case reports.
Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis.
Thrombus formation in left atrium on dabigatran therapy.
Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation.
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Use of Direct Thrombin Inhibitor for Treatment of Cerebral Venous Thrombosis.
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor.
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.
What can ongoing clinical trials of anticoagulants demonstrate?
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Ximelagatran: an oral direct thrombin inhibitor.
[Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives]
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?]
[Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature]
[Concentration of thrombin antithrombin III complex and plasmin alpha 2-plasmin inhibitor complex in nephrotic syndrome]
[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
[Focus on managing AF and preventing stroke].
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
[New antithrombotics for atrial fibrillation.]
[Therapeutic evaluation of recombinant thrombomodulin]
[Update on the prevention of thromboembolic phenomena in atrial fibrillation]
Thromboinflammation
COVID-19 patients exhibit reduced procoagulant platelet responses.
Histones link inflammation and thrombosis through the induction of Weibel-Palade Body exocytosis.
Inflammation and thrombosis in COVID-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.
Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Tissue Factor-Enriched Neutrophil Extracellular Traps Promote Immunothrombosis and Disease Progression in Sepsis-Induced Lung Injury.
TMEM16F-Mediated Platelet Membrane Phospholipid Scrambling Is Critical for Hemostasis and Thrombosis but not Thromboinflammation in Mice.
Thrombophilia
A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure.
A genetic risk factor for thrombophilia in a Han Chinese family.
A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
A novel approach for detecting hypercoagulability utilizing thromboelastography.
Abnormalities in hemostasis in acute promyelocytic leukemia.
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Activated protein C resistance: from phenotype to genotype and clinical practice.
Activity levels of natural anticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment.
Age-Based Difference in Activation Markers of Coagulation and Fibrinolysis in Extracorporeal Membrane Oxygenation.
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Assessment of the procoagulant potential after laparoscopic sleeve gastrectomy: a potential role for extended thromboprophylaxis.
Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study.
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.
Blood coagulation and platelet profiles in persistent post-splenectomy thrombocytosis. The relationship to thromboembolism.
Blood hemostasis in exercise and training.
c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype.
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
Calibrated Automated Thrombogram During Pregnancy in Unexplained Recurrent Miscarriages: A Pilot Study.
Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension.
Cardiopulmonary bypass pumps and thrombin generation: what goes around comes around.
Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer.
Characteristics of thrombin generation in a fulminant porcine sepsis model.
Chronic idiopathic non-cirrhotic portal vein thrombosis treated with a mesocaval shunt procedure and anticoagulation.
Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism.
Clinical and biological factors that contribute to thrombin generation in prothrombin G20210A carriers: a case-control study in a single Thrombophilia Center.
Coagulation Dysfunction.
Coagulation phenotypes in septic shock as evaluated by calibrated automated thrombography.
Coagulation profile during induction chemotherapy in childhood acute lymphoblastic leukemia.
Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay.
Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies.
Computational analysis of intersubject variability and thrombin generation in dilutional coagulopathy.
D-Dimers, Thrombin-Antithrombin Complexes, and Risk Factors for Thromboembolism in Hospitalized Patients.
Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis.
Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia.
Differentiation of enzymatic from platelet hypercoagulability using the novel thrombelastography parameter delta (delta).
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users.
Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes.
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus.
Enhanced thrombin generation after cardiopulmonary bypass surgery.
Establishment of Methods for Performing Thrombelastography and Calibrated Automated Thrombography in Rats.
Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model.
Evaluation of Hypercoagulability in Obese Children With Thrombin Generation Test and Microparticle Release: Effect of Metabolic Parameters.
Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test.
Evidence for activation of the coagulation system in migraine with aura.
Factor Xa or thrombin: is factor Xa a better target?
Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis.
Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia.
Fibrinogen plasma levels as a marker of thrombin activation in diabetes.
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability.
Genetic Determinants of Thrombin Generation and Their Relation to Venous Thrombosis: Results from the GAIT-2 Project.
Grave's disease with transverse and sigmoid sinus thrombosis needing surgical intervention.
Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin.
Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia.
Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation.
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Hypercoagulability following major partial liver resection - detected by thrombomodulin-modified thrombin generation testing.
Hypercoagulability in cats with cardiomyopathy.
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events.
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.
Hypercoagulability in patients with peripheral vascular disease.
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.
Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.
Hypercoagulability is most prevalent early after injury and in female patients.
Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery.
Hypercoagulable state in Cushing's syndrome: a systematic review.
Idiopathic pulmonary fibrosis associated with pulmonary vein thrombosis: a case report.
Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.
Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus.
Increased activity of procoagulant factors in patients with small cell lung cancer.
Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis.
Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report.
Increased thrombin generation in women with a history of preeclampsia.
Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting.
Inherited thrombophilia and venous thromboembolism.
Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
Iron-Deficiency and Estrogen Are Associated With Ischemic Stroke by Up-Regulating Transferrin to Induce Hypercoagulability.
Light Chain Mutation Effects on the Dynamics of Thrombin.
Management of thrombophilia.
Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism.
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG).
Microparticles: a link to increased thrombin generation.
Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry.
Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells.
Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr.
Monitoring platelet dependent thrombin generation in mice.
Onset of Thrombin Generation Occurs More Rapidly in Pediatric Patients With Celiac Disease.
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Panax notoginseng saponins reduce high-risk factors for thrombosis through peroxisome proliferator-activated receptor -? pathway.
Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay.
Perioperative thromboprophylaxis in liver transplant patients.
Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis.
Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation.
PLASMA RESUSCITATION PROMOTES COAGULATION HOMEOSTASIS FOLLOWING SHOCK-INDUCED HYPERCOAGULABILITY.
Plasma soluble fibrin monomer complexes in nephrotic syndrome--with reference to hypoalbuminemia.
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
Presence of nucleosomes in plasma and increased thrombin generation in dogs with acute and chronic gastroenteropathies.
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation.
Prominent protein Z-induced thrombin inhibition in cirrhosis: A new functional assay for hypercoagulability assessment.
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Reactivation of the coagulation system: rationale for long-term antithrombotic treatment.
Recombinant factor VIIa does not induce hypercoagulability in vitro.
Red blood cells and thrombin generation in sickle cell disease.
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals.
Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA).
Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia.
Screening for thrombophilia: a laboratory perspective.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Short-term venous stasis induces fibrinolytic activation but not thrombin formation.
Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions.
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
The APC-PCI concentration as an early marker of activation of blood coagulation A study of women on combined oral contraceptives.
The approach to heparin-induced thrombocytopenia.
The coagulation profile in hepatosplenic schistosomiasis.
The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy.
The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
The haemostatic system in acromegaly: a single-centre case-control study.
The Northwick Park Heart Study: Evidence from the Laboratory.
The plasma hemostatic proteome: thrombin generation in healthy individuals.
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states.
The role of thrombin in the pathogenesis of diabetic neuropathy.
The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability.
Think of HIT.
Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets: a potential correlation with caspase activation.
Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability.
Thrombin generation and atherosclerosis.
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
Thrombin generation and international normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy.
Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia.
Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism.
Thrombin Generation Assay Detects Moderate-Intensity Statin-Induced Reduction of Hypercoagulability in Diabetes.
Thrombin Generation in Acute Ischaemic Stroke.
Thrombin generation in ankylosing spondylitis.
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Thrombin generation in clinical conditions.
Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Thrombin generation in patients with severe thermal injury.
Thrombin generation in pediatric patients with Crohn's disease.
Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
Thrombin generation profiles in deep venous thrombosis.
Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients.
Thrombin inhibitors in women on oral contraceptives.
Thrombin regulates monocyte chemoattractant protein-1 expression in human first trimester and term decidual cells.
Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia.
Thrombin stimulates insulin secretion via protease-activated receptor-3.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma.
Thrombophilic variables do not increase the generation or procoagulant activity of thrombin during cardiopulmonary bypass.
Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood.
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Using the laboratory to predict recurrent venous thrombosis.
Value of prothrombin fragment 1.2 (F 1.2) in the diagnosis of stroke in young patients with antiphospholipid antibodies.
Visceral Adiposity Is an Independent Determinant of Hypercoagulability as Measured by Thrombin Generation in Morbid Obesity.
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
[Changes in the blood clotting system of patients with atherosclerotic and senile dementias]
[Effects of the synthetic proteinase inhibitor, FOY, on hypercoagulability after surgery for esophageal carcinoma]
[Thrombin generation test].
[Usefulness of a modified thrombin generation test in the diagnosis of chronometric hypercoagulability]
Thrombophlebitis
[Morphologic changes in the thrombus and venous wall in experimental phleobothrombosis and thrombophlebitis]
Thrombosis
"Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure.
111In-labeled platelet scintigraphy and two-dimensional echocardiography for detection of left atrial appendage thrombi. Studies in a new canine model.
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
1982 George Simon Memorial Fellowship Award. Experimental studies with 111indium-labeled platelets in pulmonary embolism.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
4-thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growth on subendothelial matrix.
99mTc-NC100668, an agent for imaging venous thromboembolism: The effect of anticoagulant or thrombolytic therapy on the uptake and retention of radioactivity in blood clots in vivo.
A biologically active surface enzyme assembly that attenuates thrombus formation.
A canine model of controlled thrombotic vascular occlusion.
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
A closed-chest porcine model of coronary dissection and thrombosis.
A collaborative study to establish an international standard for alpha-thrombin.
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity.
A Critical Role of Thrombin/PAR-1 in ADP-induced Platelet Secretion and the Second Wave of Aggregation.
A dedicated animal model for mechanical thrombectomy in acute stroke.
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo.
A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis.
A dual thrombin receptor system for platelet activation.
A few immobilized thrombins are sufficient for platelet spreading.
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model.
A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells.
A fusion protein with improved thrombolytic effect and low bleeding risk.
A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis.
A guide to drug use during percutaneous coronary intervention.
A Heparin based dual ratiometric sensor for Thrombin.
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
A mechanism of thrombosis requiring neither platelets nor thrombin.
A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides.
A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.
A model of thrombin inactivation in heparinized and nonheparinized tubes with consequences for thrombus formation.
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
A multiscale model of venous thrombus formation with surface-mediated control of blood coagulation cascade.
A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition.
A new rat model of thrombotic focal cerebral ischemia.
A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity.
A novel approach to thrombin inhibition.
A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
A novel class of small functional peptides that bind and inhibit human alpha-thrombin isolated by mRNA display.
A novel di-peptide Met-Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq-mediated signaling.
A novel fibrinogenase from Agkistrodon acutus venom protects against DIC via direct degradation of thrombosis and activation of protein C.
A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
A novel near-infrared fluorescence sensor for detection of thrombin activation in blood.
A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation.
A novel serine protease with anticoagulant and fibrinolytic activities from the fruiting bodies of mushroom Agrocybe aegerita.
A peptide analogue of thrombin receptor-activating peptide inhibits thrombin and thrombin-receptor-activating peptide-induced vascular smooth muscle cell proliferation.
A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass.
A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.
A porcine deep vein thrombosis model for magnetic resonance-guided monitoring of different thrombectomy procedures.
A Preclinical Porcine Model of Portal Vein Thrombosis in Liver Cirrhosis.
A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication.
A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty.
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells.
A simple, cost-effective, and rapid separation process for the isolation of anticoagulant active fraction from the fruit extract of Momordica charantia: Characterization of bioactive components and anticoagulant mechanism of active fraction in a mouse model.
A systems approach to hemostasis: 2. Computational analysis of molecular transport in the thrombus microenvironment.
A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity.
A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly.
A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V.
A Thrombin-Responsive Nanoprobe for In Vivo Visualization of Thrombus Formation through Three-Dimensional Optical/Computed Tomography Hybrid Imaging.
A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters.
Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets.
Absence of distal emboli during in vivo laser recanalization.
Absence of platelet-dependent fibrin formation in a patient with Scott syndrome.
Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase.
Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation.
Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond.
Action of gold sodium thiomalate on experimental thrombosis in vivo.
Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis.
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases.
Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation.
Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces.
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Activation of coagulation and fibrinolysis in microsurgical reconstructions in the lower extremities.
Activation of coagulation during treatment with haemodialysis.
Activation of coagulation system in dilated cardiomyopathy: comparison of patients with and without left ventricular thrombus.
Activation of platelet function through G protein-coupled receptors.
Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.
Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis.
Activity of coagulation and fibrinolytic system components in the vein thrombus.
Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma.
Acute and persistent platelet and coagulant activities in atherothrombosis.
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck.
Acute Myocardial Infarction and the Role of Aspirin, Heparin, and Warfarin.
Acute thrombogenic effects of fibrin sealant on microvascular anastomoses in a rat model.
ADAMTS13 exerts a thrombolytic effect in microcirculation.
Adamts18 deficiency increases arterial thrombus formation associated with vascular defects in mice.
Adhesion and aggregation of thrombin prestimulated human platelets: evaluation of surface-bound fibrinogen and surface-bound albumin.
Advances in antithrombotic therapy: novel agents.
Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents.
African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation.
Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT).
Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
Age-related changes in factor VII proteolysis in vivo.
Agkihpin, a novel SVTLE from Gloydius halys Pallas, promotes platelet aggregation in vitro and inhibits thrombus formation in vivo in murine models of thrombosis.
Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor.
alpha-thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood.
alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis.
alpha-Thrombin upregulates G alpha i3 in human vascular endothelial cells.
Alpha-thrombin-catalyzed hydrolysis of fibrin I. Alternative binding modes and the accessibility of the active site in fibrin I-bound alpha-thrombin.
Alterations in endothelial thrombomodulin expression in zymosan-induced lung injury.
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway.
Amplified electrochemical aptasensor taking AuNPs based sandwich sensing platform as a model.
An addition was made to the abstract: the association of direct thrombin inhibitor anticoagulants with cardiac thromboses.
An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey.
An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells, and protein C activation.
An evaluation of global coagulation assays in myeloproliferative neoplasm.
Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.
Animal model of acute deep vein thrombosis.
Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
Anti-hypertensive effect of the Dongchunghacho, Isaria sinclairii, in the spontaneously hypertensive rats.
Anti-thormbin III and heparin clotting times in thrombosis and atherosclerosis.
Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H. Wright.
Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome.
Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis.
Antibodies to topical bovine thrombin correlate with access thrombosis.
Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate.
Anticoagulant and antithrombotic properties of a gamma-carboxyglutamic acid-rich peptide derived from the light chain of blood coagulation factor X.
Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site.
Anticoagulant drugs: an update.
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
Anticoagulation of patients with heparin-induced thrombocytopenia in cardiac surgery.
Anticoagulation options for intermittent haemodialysis.
Anticoagulation: the present and future.
Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty.
Antiplatelet and anticoagulant use after myocardial infarction.
Antiplatelet and antithrombin therapies in the acute coronary syndromes.
Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin.
Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A.
Antithrombin activity of an algal polysaccharide.
Antithrombin and ischemia/reperfusion.
Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis.
Antithrombin deficiency: A pediatric disorder.
Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis.
Antithrombin III modulates the effect of thrombin on the metabolism of glycosaminoglycans in cultured endothelial cells.
Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Antithrombin III. Key factor in extracorporeal circulation.
Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.
Antithrombin-heparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention.
Antithrombins and the importance of good control.
Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin.
Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation.
Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.
Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor.
Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
Antithrombotic Agents.
Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Antithrombotic effect in vivo of thrombotic substances adsorbed on a platinum surface.
Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model.
Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.
Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
Antithrombotic effects of hirulog in a rat carotid endarterectomy model.
Antithrombotic effects of odorless garlic powder both in vitro and in vivo.
Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis.
Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury.
Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin.
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
Antithrombotic potential of the contact activation pathway.
Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction.
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
Apoptosis in atherosclerosis: beneficial or detrimental?
Application of enzyme immunoassays to coagulation testing.
Approaches to selective peptidic inhibitors of factor Xa.
Aqueous extracts of Ocimum basilicum L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio--venous shunt thrombosis in vivo.
Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation.
Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat.
Argatroban administration as therapy for thrombosis in patients with continuous-flow ventricular assist devices.
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
Argatroban anticoagulation in pediatric patients: a literature analysis.
Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits.
Argatroban as novel therapy for suspected thrombosis in patients with continuous flow left ventricle assist device and hemolysis.
Argatroban in the management of heparin-induced thrombocytopenia.
Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture.
Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Argatroban: a review of its use in the management of heparin-induced thrombocytopenia.
Arginase activity is increased by thrombin: a mechanism for endothelial dysfunction in arterial thrombosis.
Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
Arterial thrombosis associated with immune thrombocytopenia: presence of a platelet aggregating IgG synergistic with thrombin and adrenalin.
Arterial thrombosis: relevance of a model with two levels of severity assessed by histological, ultrastructural and functional characterization.
Arteriosclerosis obliterans in a rabbit model.
Artificial microvascular graft thrombosis: the consequences of platelet membrane glycoprotein Ib inhibition and thrombin inhibition.
Aspirin in the treatment of cardiovascular disease: a review.
Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation.
Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation.
Assessment and management of coagulopathy in critically-ill patients with liver failure.
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Assessment of Coagulation and Hemostasis Biomarkers in a Subset of Patients With Chronic Cardiovascular Disease.
Assessment of raloxifene, estradiol-17?, dl-ormeloxifene and levormeloxifene on thrombin activity.
Assessment of thrombin generation: useful or hype?
Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Association of aortic valve sclerosis with thrombin generation in hypertensive patients.
Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions.
Autologous thrombin for treatment of pseudoaneurysms.
Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm.
Balloon assisted, ultrasound guided percutaneous thrombin injection of a large radial artery pseudoaneurysm using a trans-venous approach via an Ipsilateral Arteriovenous Fistula.
Balloon-Assisted Ultrasound-Guided Percutaneous Thrombin Injection of Iatrogenic Femoral Artery Pseudoaneurysms: A Case Report and Description of the Technique.
Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position.
Biflavones from Ginkgo biloba as inhibitors of human thrombin.
Binding-Induced 3D-Bipedal DNA Walker for Cascade Signal Amplification Detection of Thrombin Combined with Catalytic Hairpin Assembly Strategy.
Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future.
Bioengineered surfaces to improve the blood compatibility of biomaterials through direct thrombin inactivation.
Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization.
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Biomolecular surface engineering of pancreatic islets with thrombomodulin.
Biorheology of platelet activation in the bloodstream distal to thrombus formation.
Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.
Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis.
Bivalirudin for anticoagulation in children.
Bivalirudin for left ventricular assist device thrombosis.
Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.
Bivalirudin for treatment of LVAD thrombosis: a case series.
Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
Bivalirudin, thrombin and platelets: clinical implications and future directions.
Bivalirudin: a new generation antithrombotic drug.
Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
Bleeding disorders: characterization, dental considerations and management.
Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Blood coagulation and thrombosis in patients with ovarian malignancy.
Blood coagulation: hemostasis and thrombin regulation.
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture.
Bovine thrombin: history, use, and risk in the surgical patient.
Brachial pseudoaneurysm of the neonate with partial response to thrombin injections and late spontaneous thrombosis and regression during expectant management.
By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin.
C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates and protects against carotid artery occlusion and cerebral stroke.
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.
Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival.
Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Cardiac-Specific Overexpression of Oxytocin Receptor Leads to Cardiomyopathy in Mice.
Cardioprotection and thrombolysis by anistreplase in anesthetized dogs.
Cardiovascular actions of thrombin receptor activation in vivo.
Cardiovascular chemotherapy: anticoagulants.
Cartilage oligomeric matrix protein is a natural inhibitor of thrombin.
Catalytic microgelators for decoupled control of gelation rate and rigidity of the biological gels.
Catheter-directed endovascular application of thrombin: Report of 3 cases and review of the literature.
Cellular folding pathway of a metastable serpin.
Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface.
Cerebral hemodynamics following internal maxillary artery ligation in the goat.
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Characteristics of a cheese-like food produced by fermentation of the mushroom Schizophyllum commune.
Characteristics of Fibrin Formation and Clot Stability in Individuals with Congenital Type IIb Protein C Deficiency.
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits.
Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.
Chemically modified thrombin and anhydrothrombin that differentiate macromolecular substrates of thrombin.
Chemokines in the pathogenesis of vascular disease.
Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity.
Clinical and Experimental Analysis of Platelet Micro Particles Inducing Thrombosis after Coronary Stenting.
Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update.
Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Clinical potential of antithrombotic drugs in coronary syndromes.
Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene.
Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation.
Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.
Clot properties and cardiovascular disease.
Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk.
Coagulation and fibrinolysis in gastric cancer.
Coagulation and inflammation.
Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation.
Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow.
Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.
Coil embolization of inferior epigastric artery pseudoaneurysm after percutaneous thrombin injection failure: a case report.
Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction.
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Comparative aspects of blood coagulation.
Comparative effects o ADP and thrombin in producing stasis thrombosis.
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Comparison of Effects of Anti-thrombin Aptamers HD1 and HD22 on Aggregation of Human Platelets, Thrombin Generation, Fibrin Formation, and Thrombus Formation Under Flow Conditions.
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Comparison of in vitro and in vivo properties of rhirudin (HBW 023) and a synthetic analogous peptide.
Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.
Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors.
Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Compression repair versus low-dose thrombin injection for the treatment of iatrogenic femoral pseudoaneurysm: a retrospective case-control study.
Compressive mechanical properties of the intraluminal thrombus in abdominal aortic aneurysms and fibrin-based thrombus mimics.
Computational modelling of inhibitor binding to human thrombin.
Computational Study of Thrombus Formation and Clotting Factor Effects under Venous Flow Conditions.
Congenital structural and functional fibrinogen disorders: a primer for internists.
Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction.
Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models.
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Constitutive Dimerization of Glycoprotein VI (GPVI) in Resting Platelets Is Essential for Binding to Collagen and Activation in Flowing Blood.
Contained rupture of a celiac artery aneurysm treated with aortic endograft deployment and assisting percutaneous coil and thrombin infusion.
Contrast-enhanced ultrasound-guided thrombin injection in the management of iatrogenic pseudoaneurysm (PSA): A case report and review of literatures.
Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin.
Core and shell platelets of a thrombus: A new microfluidic assay to study mechanics and biochemistry.
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo.
Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters.
Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study.
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity.
Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface.
COVID-19-associated coagulopathy: An exploration of mechanisms.
Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement.
Critical role of FcR gamma-chain, LAT, PLCgamma2 and thrombin in arteriolar thrombus formation upon mild, laser-induced endothelial injury in vivo.
Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association?
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis.
Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors.
Crystal structure of wild-type human thrombin in the Na+-free state.
Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism.
Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with ?-thrombin.
Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk.
Current perspective on antithrombin drugs.
Current role of antithrombotic agents in the treatment of acute coronary syndromes.
CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
Cystic artery pseudoaneurysm presenting as a complication of laparoscopic cholecystectomy treated with percutaneous thrombin injection.
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis.
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium.
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm.
Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Design and synthesis of para-fluorophenylalanine amide derivatives as thrombin receptor antagonists.
Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Desirudin reduces the rate of microvenous thrombosis in a rat model.
Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.
Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay.
Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation.
Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
Development of a new model of transvenous thrombosis in the pig superior sagittal sinus using thrombin injection and balloon occlusion.
Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Deviations in coagulation activation due to treatment with different haemodialysis membranes.
Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Dilutional control of prothrombin activation at physiologically relevant shear rates.
Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look.
Direct thrombin inhibitors - a survey of recent developments.
Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions.
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct thrombin inhibitors in cardiovascular medicine.
Direct thrombin inhibitors.
Direct Thrombin Inhibitors.
Direct thrombin inhibitors: current status and future prospects.
Direct thrombin inhibitors: Patents 2002-2012 (Review).
Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice.
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Disseminated intravascular coagulation.
Disseminated Intravascular Coagulation.
Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Dissolution of peripheral arterial thrombi by ultrasound.
Distribution of sac pressure in an experimental aneurysm model after endovascular repair: the effect of endoleak types I and II.
DNA Aptamers to Thrombin Exosite I. Structure-Function Relationships and Antithrombotic Effects.
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Domains specifying thrombin-receptor interaction.
Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial.
Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood.
Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.
Dual P2Y 12 receptor signaling in thrombin-stimulated platelets--involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity.
Dual role of collagen in factor XII-dependent thrombus formation.
Dual role of platelet protein kinase C in thrombus formation: stimulation of pro-aggregatory and suppression of procoagulant activity in platelets.
Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms.
Dynamic Nature of Thrombin Generation, Fibrin Formation, and Platelet Activation in Unstable Angina and Non-Q-Wave Myocardial Infarction.
Dynamics of thrombin generation and flux from clots during whole human blood flow over collagen/tissue factor surfaces.
Early Identification of Argatroban Resistance and the Consideration of Factor VIII.
Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure.
Early myocardial reperfusion: an assessment of current strategies in acute myocardial infarction.
Early thrombolysis by recombinant tissue-plasminogen activator is beneficial to the ischemic myocardium.
Edema from intracerebral hemorrhage: the role of thrombin.
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.
Effect of a potent thrombin inhibitor, No. 407, on novel experimental thrombosis generated by acetic acid.
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Effect of anticoagulants and antiplatelet agents on platelet-mediated thrombin generation.
Effect of argatroban on the formation of artificial thrombus on dogs.
Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo.
Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters.
Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface.
Effect of blood loss during caesarean section on coagulation parameters.
Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat.
Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina.
Effect of monomethylmethacrylate on procoagulant activities of human monocytes and umbilical vein endothelial cells in vitro.
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin.
Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery.
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
Effects of alpha(2)-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma.
Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis.
Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin fragment 1+2 in mitral stenosis.
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo.
Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Effects of FEIBA on platelet and leucocyte activation in severe haemophilia patients with inhibitors.
Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats.
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Effects of intraarterial thrombin in the swine model.
Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.
Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Effects of plasmin on rabbit platelets.
Effects of polysulfonate derivative (GL 522-Y-1) on coagulation in vitro and thrombosis in vivo.
Effects of radiographic contrast agents on thrombin formation and activity.
Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma.
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats.
Effects of shear rate on propagation of blood clotting determined using microfluidics and numerical simulations.
Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Effects of thermal exposure on binding of heparin in vitro to the arterial wall and to clot and on the chronic angiographic luminal response to local application of a heparin film during angioplasty in an in vivo rabbit model.
Effects of thrombin on interactions between beta3-integrins and extracellular matrix in platelets and vascular cells.
Effects of tirofiban on haemostatic activation in vitro.
Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis.
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
Efficacy and safety of a coagulated thrombus injection for peripheral artery perforation: The coagulated thrombus hemostasis method.
Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.
Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts.
Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases.
Elevated plasma factor VIII enhances venous thrombus formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor.
Embolization of a subclavian artery aneurysm with steel coils and thrombin.
Embolization of hepatic artery pseudo-aneurysm facilitated by selective injection of thrombin and thrombin-soaked coils.
Emerging anticoagulant strategies.
Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Empirical and theoretical phenotypic discrimination.
Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis.
Encryption and decryption of tissue factor.
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy.
Endothelial dysfunction and inhibition of converting enzyme.
Endothelial injury induced by thrombin or thrombi.
Endothelium and asymmetrical responses of the coronary arterial wall.
Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen.
Endovascular treatment of a massive retroperitoneal bleeding: successful balloon-catheter delivery of intra-arterial thrombin.
Endovascular treatment of an iatrogenic perforation of the internal iliac vein.
Endovascular treatment of refractory iatrogenic femoral artery pseudoaneurysm using Amplatzer vascular plugs following unsuccessful retrograde Angio-Seal deployment.
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.
Enhancement of blood coagulation by soluble fibrin complexes.
Enhancement of thrombolysis by ultrasound.
Enoxaparin does not ameliorate limb ischemia-reperfusion injury.
Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS).
Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome.
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Epidemiological characteristics of platelet aggregability.
Equid herpesvirus type 1 activates platelets.
Erythrocyte compression index is impaired in patients with residual vein obstruction.
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
Establishing the Transient Mass Balance of Thrombosis: From Tissue Factor to Thrombin to Fibrin Under Venous Flow.
Etiopathophysiology of disseminated intravascular coagulation.
Evaluating blood clot progression using magnetic particle spectroscopy.
Evaluation of a commercial kit for the radioimmunoassay of fibrinopeptide A.
Evaluation of a post-operative thrombin inhibitor replacement protocol to reduce haemorrhagic and thrombotic complications after paediatric liver transplantation.
Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model.
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents.
Evaluation of Morphological and Clinical Factors Related to Failure of Percutaneous Treatment with Thrombin Injection of Femoral Pseudoaneurysms from Cardiac Catheterization.
Evaluation of plaque stability of advanced atherosclerotic lesions in apo e-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban.
Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Evaluation of the effects of esophageal varicosclerosants on local vascular occlusion and systemic blood coagulation.
Evaluation of the in vitro detection of the hypercoagulable state using the thrombin generation test and plasma clot impedance test.
Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography.
Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Evidence for Activation of Tissue Factor by an Allosteric Disulfide Bond.
Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression.
Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation.
Expect the unexpected: acute and subacute coronary stent thrombosis following percutaneous thrombin injection for treatment of femoral pseudoaneurysm.
Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Experimental production of superior sagittal sinus thrombosis in the dog.
Experimental studies of injection agents for peptic ulcer bleeding endoscopic control.
Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Experimental treatment of thrombotic vascular occlusion.
Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.
Exploring potential anticoagulant drug formulations using thrombin generation test.
Expression of the thrombin receptor in developing bone and associated tissues.
Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.
Expression of thrombin receptors in endothelial cells and neutrophils from normal and preeclamptic pregnancies.
Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood.
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Facilitating roles of murine platelet glycoprotein Ib and alphaIIbbeta3 in phosphatidylserine exposure during vWF-collagen-induced thrombus formation.
Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.
Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions.
Factor VLeiden inhibits fibrinolysis in vivo.
Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Factor XI and contact activation as targets for antithrombotic therapy.
Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.
Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.
Factor XII (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke.
Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.
Factor XII in Hemostasis and Thrombosis: Active Player or (Innocent) Bystander?
Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.
Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog.
Failure of thrombin-antithrombin III complexes in the diagnosis of deep vein thrombosis.
Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.
Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis.
Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V.
Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia.
Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm.
Femoral artery thrombosis following percutaneous treatment with thrombin injection of a femoral artery pseudoaneurysm: a case report.
Femoral pseudoaneurysm thrombinjection.
Fibrin films: overlooked hemostatic barriers against microbial infiltration.
Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
Fibrin networks regulate protein transport during thrombus development.
Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo.
Fibrinogen anomalies and disease. A clinical update.
Fibrinogen Bbeta14 Arg-->Cys: further evidence for a role in thrombosis.
Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway.
Fibrinogen.
Fibrinolysis in Platelet Thrombi.
Fibrinolytic and Thrombolytic Effects of an Enzyme Purified from the Fruiting Bodies of Boletus pseudocalopus (Agaricomycetes) from Korea.
Fibrinopeptide A is released into the coronary circulation after coronary spasm.
Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment.
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
First trimester maternal concentrations of thrombin-inhibitor complexes and the presence of histologic placental lesions at delivery.
Flow and delta-P dictate where thrombin, fibrin, and von Willebrand Factor will be found.
Flow and thrombosis at orifices simulating mechanical heart valve leakage regions.
Flow mediated fibrin thrombus formation in an endothelium-lined model of arterial branching.
Flow-related platelet deposition on subendothelium.
Fondaparinux: use in thromboprophylaxis of acute medical patients.
Food-derived antithrombotic peptides: Preparation, identification, and interactions with thrombin.
Forced Unfolding of Coiled-Coils in Fibrinogen by Single-Molecule AFM.
Formulation and Characterization of Antithrombin Perfluorocarbon Nanoparticles.
Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages.
Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin.
From principle to practice: bridging the gap in patient profiling.
Functional cyclophilin D moderates platelet adhesion, but enhances the lytic resistance of fibrin.
Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom.
Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits.
FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834.
Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.
Generation and phenotypic analysis of protein S-deficient mice.
Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists.
Genome sequencing, purification, and biochemical characterization of a strongly fibrinolytic enzyme from Bacillus amyloliquefaciens Jxnuwx-1 isolated from Chinese traditional douchi.
Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin.
Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction.
Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome.
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.
Glycosaminoglycans and activated contact system in cancer patient plasmas.
GPV is a marker of in vivo platelet activation--study in a rat thrombosis model.
Growth regulation of fibroblasts by thrombin, factor XIII and fibronectin.
Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation.
Hemocompatibility and anti-fouling behavior of multilayer biopolymers immobilized on gold-thiolized drug-eluting cardiovascular stents.
Hemostasis and anti-necrotic activity of wound-healing dressing containing chitosan nanoparticles.
Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hemostatic alterations in cancer patients.
Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction.
Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus.
Heparin cofactor II inhibits thrombus formation in a rat thrombosis model.
Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.
Heparin, heparin plus ASA and dipyridamole, and arteriovenous fistula as adjuvant methods to prevent rethrombosis after venous thrombectomy. Experimental study in rabbits.
Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.
Heparin-induced thrombocytopenia type II: a serious hazard in preemptive renal transplantation: a case report.
Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis.
Heparin-induced thrombocytopenia.
Heparin-induced thrombocytopenia: a ten-year retrospective.
Heparin-induced thrombocytopenia: diagnosis and management.
Heparin-induced thrombocytopenia: natural history, diagnosis, and management.
Heparin-Like Chitosan Hydrogels with Tunable Swelling Behavior, Prolonged Clotting Times, and Prevented Contact Activation and Complement Activation.
High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.
High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains.
Hirudin and hirudin analogues as new anticoagulant agents.
Hirudin and other thrombin inhibitors experimental results and potential clinical applications.
Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries.
Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
Hirudin: clinical potential of a thrombin inhibitor.
HIT paradigms and paradoxes.
Homocysteine and thrombosis: from basic science to clinical evidence.
Homology model of human prothrombinase based on the crystal structure of Pseutarin C.
How does association process affect fibrinogen hydrolysis by thrombin?
How Na(+) activates thrombin - a review of the functional and structural data.
How Na+ activates thrombin--a review of the functional and structural data.
Human endometrial endothelial cells: isolation, characterization, and inflammatory-mediated expression of tissue factor and type 1 plasminogen activator inhibitor.
Human fibrinogen.
Human lesion studies.
Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion.
Human thrombi contain an abundance of active thrombin.
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.
Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass.
Hypercoagulability in the left atrium: Part II: Coagulation factors.
Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity.
Hypercoagulable states.
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.
Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect.
Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes.
Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI.
Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth.
Identification of a thrombin sequence with growth factor activity on macrophages.
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2).
Identification of the functional food ingredients with antithrombotic properties via virtual screen and experimental studies.
Impact of aerobic exercise on haemostatic indices in pediatric patients with haemophilia.
Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots.
Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis.
Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets.
Importance of antithrombin therapy during coronary angioplasty.
Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.
Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
In prothrombin G20210A carriers the genetic mutation and the history of Venous Thrombosis contribute both to thrombin generation independently of factor II plasma levels.
In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIb?.
In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach.
In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization.
In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe.
In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi.
In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy.
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
In vivo thrombus formation.
Inactivation of alpha- and beta- thrombin by antithrombin-III and heparin.
Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.
Incomplete dabigatran reversal with idarucizumab.
Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina.
Increased platelet, but unaltered fibrinogen, accumulation in experimental thrombi in alloxan-induced diabetic rabbits.
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Increased thrombin generation in splanchnic vein thrombosis is related to the presence of liver cirrhosis and not to the thrombotic event.
Increased thrombogenesis and embolus formation in mice lacking glycoprotein V.
Independent ischemic stroke risk factors in older Americans: a systematic review.
Indium-111 platelet scintigraphy and two-dimensional echocardiography for detection of left ventricular thrombus: influence of clot size and age.
Influence of aromatic and aliphatic moieties on thrombin inhibitors potency.
Infrarenal Abdominal Aortic Pseudoaneurysm: Is It a Real Emergency?
Inherited thrombophilia and venous thromboembolism.
Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis.
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.
Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor.
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.
Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis.
Inhibition of factor XIa as a new approach to anticoagulation.
Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy.
Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
Inhibition of neointimal hyperplasia by a specific thrombin inhibitor.
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Inhibition of platelets and thrombin: implications for treatment of coronary artery thrombosis.
Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Inhibition of thrombin-induced neuronal cell death by recombinant thrombomodulin and E5510, a synthetic thrombin receptor signaling inhibitor.
Inhibition of tissue factor limits the growth of venous thrombus in the rabbit.
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.
Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Initial clinical use of a novel mechanical thrombectomy device, XCOILTM, in hemodialysis graft and fistula declot procedures.
Injection therapy for endoscopic haemostasis.
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Insights into platelet-based control of coagulation.
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Integrating platelet and coagulation activation in fibrin clot formation.
Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex.
Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in haemostasis.
Intercostal artery pseudoaneurysm after ultrasound-guided liver biopsy: a case report and review of the literature.
Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism.
Interindividual Variability and Normal Ranges of Whole Blood and Plasma Thrombin Generation.
Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice.
Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis.
Internal iliac artery aneurysm embolization with direct percutaneous puncture and thrombin injection.
Internal iliac artery pseudoaneurysm following renal transplant biopsy successfully treated with endovascular stenting and thrombosis: a case report.
Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
Interventional therapy for stenosis and aneurysm in renal graft artery: report of 9 cases.
Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury.
Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab.
Intracardiac thrombus in a patient with mitral bioprosthesis and atrial fibrillation treated with direct oral anticoaugulant: A case report.
Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation.
Intraoperative thrombolytic therapy as a treatment of small vessel thrombosis: an experimental study.
Intraprocedural and postprocedural perigraft arterial sac embolization (PASE) for endoleak treatment.
Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in precapillary pulmonary arterioles.
Intravascular thrombosis: definitive detection by quantitative tissue characterization in vitro.
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Intrinsic pathway of coagulation and arterial thrombosis.
Introducing the pro-coagulant contact system in the numerical assessment of device-related thrombosis.
Introduction of a thrombin sensor based on its interaction with dabigatran as an oral direct thrombin inhibitor.
Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3).
Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
Investigation of Interactions between Thrombin and Ten Phenolic Compounds by Affinity Capillary Electrophoresis and Molecular Docking.
Investigation of the anticoagulant and antithrombotic effects of chlorogenic acid.
Investigation of the selectivity of thrombin-binding aptamers for thrombin titration in murine plasma.
Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days.
Ipsilateral femoral vein compression: a contraindication to thrombin injection of femoral pseudoaneurysms.
Iron modulates the alpha chain of fibrinogen.
Is Increased Thrombin Activation in Patients With Abdominal Aortic Aneurysms Dependent on Area or Volume of Aneurysm Thrombus Mass?
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Is thrombin generation at the time of an acute thromboembolic episode a predictor of recurrence? The LInköping Study on Thrombosis (LIST)--a 7-year follow-up.
Isolation and characterization of a new chemokine receptor gene, the putative chicken CXCR1.
Kaempferol inhibits thrombosis and platelet activation.
Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition.
Kinetics of pulmonary platelet deposition and clearance during thrombin-induced microembolism in rabbits.
Kinetics of the coagulation cascade including the contact activation system: sensitivity analysis and model reduction.
Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling.
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.
Label-free aptamer biosensor for thrombin detection based on functionalized graphene nanocomposites.
Laboratory assessment of antithrombotic therapy: what tests and if so why?
Laboratory tests for heparin-induced thrombocytopenia: a multicenter study.
Lack of fibrin formation in exercise-induced activation of coagulation.
Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons.
LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in rats and dogs.
Leaf-Inspired Authentically Complex Microvascular Networks for Deciphering Biological Transport Process.
Leeches to hirulogs and other thrombin-directed antithrombotics.
Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
Left atrial thrombus formation after brief interruption of rivaroxaban.
Lepirudin blunts endotoxin-induced coagulation activation.
Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism.
Links between inflammation and thrombogenicity in atherosclerosis.
Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis.
Local delivery of an antithrombin inhibits platelet-dependent thrombosis.
Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock.
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen in heparinized blood.
Long-term estrogen treatment of mice with a prothrombotic phenotype induces sustained increases in thrombin generation without affecting tissue fibrin deposition.
Looking at the proteases from a simple perspective.
Low molecular weight heparin in acute stroke.
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Low-dose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms.
Low-molecular-weight heparin-induced thrombocytopenia in a child.
Low-molecular-weight heparins and unstable angina--current perspectives.
Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm.
Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells.
Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients.
Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow.
M-AAA-Thrombin: Potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1.
Management of a spontaneous renal capsule hematoma following cardiac catheterization involving use of a platelet glycoprotein IIb/IIIa inhibitor: a case report.
Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction.
Maternal fibrinogen is necessary for embryonic development.
Maternal thrombophilia and neonatal thrombosis.
Mathematical analysis of mural thrombogenesis. Concentration profiles of platelet-activating agents and effects of viscous shear flow.
Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
Measurement of hematological, clinical chemistry, and infection parameters from hirudinized blood collected in universal blood sampling tubes.
Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations.
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).
Mechanical and Biochemical Role of Fibrin Within a Venous Thrombus.
Mechanical thrombectomy and intravascular imaging for cerebral venous sinus thrombosis: a preclinical model.
Mechanical Thrombectomy of Iliac Vein Thrombosis in a Pig Model Using the Rotarex and Aspirex Catheters.
Mechanism and inhibition kinetics of peptide P13 as thrombin inhibitor.
Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
Mechanisms for the anticoagulant effects of synthetic antithrombins.
Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S.
Mechanisms of hydroxyethyl starch induced dilutional coagulopathy.
Mechanisms of platelet activation by thrombin: A short history.
Mechanisms of thromboembolism at arterial plaques.
Mechano-rheological properties of the murine thrombus determined via nanoindentation and finite element modeling.
Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice.
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.
MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10.
Microvascular responses to cardiopulmonary bypass.
Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages.
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Modality-Specific Occult Intrarenal Pseudoaneurysm in a Renal Allograft and the Legacy of Catheter Angiography.
Modeling thrombin generation: plasma composition based approach.
Modeling Thrombus Shell: Linking Adhesion Receptor Properties and Macroscopic Dynamics.
Modes and consequences of thrombin's interaction with fibrin.
Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha.
Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1.
Molecular abnormalities responsible for thrombosis. Genetic aspects.
Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A.
Molecular basis of fibrin clot elasticity.
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Molecular biology: insight into the causes and prevention of restenosis after arterial intervention.
Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.
Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.
Monitoring Compound-Related Effects on Coagulability in Rats and Cynomolgus and Rhesus Monkeys by Thrombin Generation Kinetic Measurement.
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary Intervention.
Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
Multifunctional Thrombin-Activatable Polymer Capsules for Specific Targeting to Activated Platelets.
Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis.
Multiscale model of fibrin accumulation on the blood clot surface and platelet dynamics.
Multiscale simulation of thrombus growth and vessel occlusion triggered by collagen/tissue factor using a data-driven model of combinatorial platelet signalling.
Multivessel coronary thrombosis resulting from heparin induced thrombocytopenia.
NADPH oxidase 1 is a novel pharmacological target for the development of an antiplatelet drug without bleeding side effects.
NADPH Oxidases Are Required for Full Platelet Activation In Vitro and Thrombosis In Vivo but Dispensable for Plasma Coagulation and Hemostasis.
Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis.
Nanostructured bioluminescent sensor for rapidly detecting thrombin.
Natural inhibitors of thrombin.
Near-Patient Thrombin Generation in Patients Undergoing Elective Cardiac Surgery.
Necrotic platelets provide a procoagulant surface during thrombosis.
Neonatal thromboembolism.
Nephrotic syndrome: a platelet hyperaggregability state.
Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation.
New acrylic microspheres for arterial embolization: combining radiopacity for precise localization with immobilized thrombin to trigger local blood coagulation.
New anticoagulants.
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
New antithrombotic strategies for resistant thrombotic processes.
New approaches to treatment of myocardial infarction.
New frontiers in the management of unstable coronary artery disease.
New insights into modulation of thrombin formation.
New insights into the role of erythrocytes in thrombus formation.
New targets for antithrombotic drugs.
New therapeutic option for thromboembolism--dabigatran etexilate.
New thrombin inhibitors in cardiovascular disease.
New treatment options for heparin-induced thrombocytopenia.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
NLRP3 regulates platelet integrin ?IIb?3 outside-in signaling, hemostasis and arterial thrombosis.
NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation.
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Normal pregnancy is associated with an increase in thrombin generation from the very early stages of the first trimester.
Novel anti-platelet activity of protocatechuic acid through inhibition of high shear stress-induced platelet aggregation.
Novel Anticoagulant Peptide from Lactoferrin Binding Thrombin at the Active Site and Exosite-I.
Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.
Novel approaches to the treatment of thrombosis.
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Novel inhibitors of factor X for use in cardiovascular diseases.
Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia.
Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation.
Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression.
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Novel single nucleotide mutations in exon-10 of human coagulation Factor V gene in patients with pulmonary thromboembolism.
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.
Obesity and thrombin-generation profiles in women with venous thromboembolism.
On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences.
Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation.
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.
Oral Antithrombins and the Future of Antithrombotic Therapy.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog.
Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.
Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems.
Orthodontics and dentistry for the hemophilic patient.
Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.
Overview of heparin-induced thrombocytopenia.
Overwiew of the Coagulation System and laboratory tests for its study.
P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation.
Pancreatic tail pseudoaneurysm: percutaneous treatment by thrombin injection.
PAR3 is a cofactor for PAR4 activation by thrombin.
PAR4 activation involves extracellular loop-3 and transmembrane residue Thr153.
Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.
PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Pathogenesis of thrombosis in unstable angina.
Pathogenesis of vascular disease in hyperhomocysteinaemia.
Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.
Pathological haemostasis and "prothrombotic state" in Behçet's disease.
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond.
Pathophysiology of coronary thrombosis.
Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization.
Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression.
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Percutaneous repair of abdominal aortic pseudoaneurysm by catheter-based delivery of thrombin.
Percutaneous thrombin injection in an infant to treat hepatic artery pseudoaneurysm after failed embolization.
Percutaneous thrombin injection of a pulmonary artery pseudoaneurysm refractory to coil embolization.
Percutaneous thrombin injection of carotid artery pseudoaneurysm.
Percutaneous ultrasonographically guided thrombin injection of iatrogenic pseudoaneurysms in unusual sites.
Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms.
Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis.
Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin.
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis.
Pharmacological Profile of JNJ-64179375: A Novel, Long Acting Exosite-1 Thrombin Inhibitor.
Pharmacological survey of recombinant hirudin.
Pharmacology of argatroban.
Pharmacology of selective thrombin inhibitors.
Pharmacophore Design, Virtual Screening, Molecular Docking and Optimization Approaches to Discover Potent Thrombin Inhibitors.
Phenolic-amine chemistry mediated synergistic modification with polyphenols and thrombin inhibitor for combating the thrombosis and inflammation of cardiovascular stents.
Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions.
Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties.
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia.
Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis.
Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI.
Plaque rupture, thrombosis, and therapeutic implications.
Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis.
Plasma level changes of fibrinopeptide A after uncomplicated coronary angioplasty.
Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets.
Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII.
Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.
Platelet adhesion to human brain microvascular endothelial cells in vitro. Observation with video-enhanced contrast microscopy.
Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists.
Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin.
Platelet and leukocyte activation in salvaged blood and the effect of its reinfusion on the circulating blood.
Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow.
Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Platelet full length TFPI-? in healthy volunteers is not affected by sex or hormonal use.
Platelet function assays.
Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects.
Platelet inhibitor therapy. Agents and clinical implications.
Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion.
Platelet polymorphisms in thrombotic disorders.
Platelet populations and priming in hematological diseases.
Platelet protease-activated receptor antagonism in cardiovascular medicine.
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Platelet receptor polymorphisms and thrombotic risk.
Platelet receptors and signaling in the dynamics of thrombus formation.
Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS.
Platelet regulation of thrombin generation in cardiovascular disease.
Platelet response heterogeneity in thrombus formation.
Platelet thrombin receptor antagonism and atherothrombosis.
Platelet thromboembolism.
Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.
Platelet-derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice.
Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study.
Platelet-derived microparticles associate with fibrin during thrombosis.
Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis.
Platelet-targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse.
Platelets and anti-platelet therapy.
Platelets and coagulation in thrombus formation: aberrations in the Scott syndrome.
Platelets loaded with thrombin-encapsulated liposomes have increased coagulability.
Platelets, endothelium, and vessel injury.
Platelets, leukocytes, and coagulation.
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?
Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
Possibility of Using Mesenchymal Stromal Cells to Restore Lymph Flow in Experimental Phlebothrombosis.
Post-sternotomy intercostal artery pseudoaneurysm. Sonographic diagnosis and thrombosis by ultrasound-guided percutaneous thrombin injection.
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Postpartum coronary artery dissection complicated by heparin-induced thrombocytopenia and thrombosis.
Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
Potent Trivalent Inhibitors of Thrombin through Hybridization of Salivary Sulfopeptides from Hematophagous Arthropods.
Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition.
Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes.
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice.
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method.
Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology.
Predicting the pharmacology of thrombin inhibitors.
Prediction of enzyme binding: human thrombin inhibition study by quantum chemical and artificial intelligence methods based on X-ray structures.
Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study.
Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition.
Prekallikrein deficiency in a 15-year-old boy with Ménière's disease: a case report.
Preparation of anhydrothrombin and characterization of its interaction with natural thrombin substrates.
Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis.
Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin.
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II.
Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats.
Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy.
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Principles underlying the use of conjunctive agents with plasminogen activators.
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Procoagulant Adaptation of a Blood Coagulation Prothrombinase-like Enzyme Complex in Australian Elapid Venom.
Procoagulant platelets and the pathways leading to cell death.
Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli.
Production of thrombi on intact endothelium by use of antiheparin agents in vivo.
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Progress in the design of low molecular weight thrombin inhibitors.
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245.
Prolonged activation of prothrombin on the vascular wall after arterial injury.
Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
Prolonged expression of procoagulant activity of human platelets degranulated by thrombin.
Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries.
Pros and cons of new oral anticoagulants.
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.
Prospective randomized study comparing ultrasound-guided thrombin injection to compression in the treatment of femoral pseudoaneurysms.
Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.
Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Protease-activated receptors in cardiovascular diseases.
Protection against thrombosis in mice lacking PAR3.
Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism.
Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice.
Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions.
Proteomic Signature of Thrombin-Activated Platelets After In Vivo Nitric Oxide-Donor Treatment: Coordinated Inhibition of Signaling (Phosphatidylinositol 3-Kinase-{gamma}, 14-3-3{zeta}, and Growth Factor Receptor-Bound Protein 2) and Cytoskeleton Protein Translocation.
Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.
Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease.
Prothrombotic effects of high uric acid in mice via activation of MEF2C-dependent NF-?B pathway by upregulating let-7c.
Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va.
Prothrombotic state in Churg-Strauss syndrome: a case report.
Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Prototype percutaneous thrombolytic device: preclinical testing in subacute inferior vena caval thrombosis in a pig model.
Protraction of whole blood and plasma clot lysis in patients with high levels of an inhibitor of tissue-type plasminogen activator.
Pseudoaneurysm in children: diagnosis and interventional management.
Pseudoaneurysm of the radial artery diagnosed by bedside ultrasound.
Pseudoaneurysm of ulnar artery after endoscopic carpal tunnel release.
Purification and Biochemical Characterization of a Novel Fibrinolytic Enzyme from Culture Supernatant of Cordyceps militaris.
Purification, compositional analysis, and anticoagulant capacity of chondroitin sulfate/dermatan sulfate from bone of corb (Sciaena umbra).
Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic adenosine monophosphate-dependent signaling in endothelial exocytosis.
QSAR studies of N(1)-(5-chloro-2-pyridyl)-2-{[4-(alkyl methyl)benzoyl]amino}-5-chlorobenzamide analogs.
Quantification of device adherent, circulating, and organ pool of thrombin and fibrinogen after cardiopulmonary bypass in a pig model.
Quantifying Platelet Margination in Diabetic Blood Flow.
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase.
Rate-limiting roles of tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes.
Reactive oxygen metabolites and arterial thrombosis.
Recent Advances in Argatroban-Warfarin Transition in Patients With Heparin-induced Thrombocytopenia.
Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.
Recognition and treatment of unstable angina.
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo.
Recombinant human activated protein C (Xigris).
Recombinant human activated protein C: current insights into its mechanism of action.
Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model.
Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.
Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin.
Recombinant thrombomodulin inhibits thrombin-induced vascular endothelial growth factor production in neuronal cells.
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Reduced model to predict thrombin and fibrin during thrombosis on collagen/tissue factor under venous flow: Roles of ?'-fibrin and factor XIa.
Reduced thrombus formation in native blood of homozygous factor VII-deficient patients at high arterial wall shear rate.
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice.
Regulation of mitochondrial function as a promising target in platelet activation-related diseases.
Regulation of thrombin generation at cell surfaces.
Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina.
Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
Relationship between thrombin generation and carotid intima-media thickness.
Relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs.
Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs.
Resistance to activated protein C caused by a factor V gene mutation.
Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report.
Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser.
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
Retrieval of "Recovery IVC Filter" after 383 days.
Reversal of target-specific oral anticoagulants.
Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment.
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis.
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Role of coagulation factors in cerebral venous sinus and cerebral microvascular thrombosis.
Role of platelet activation and fibrin formation in thrombogenesis.
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Role of the coagulation system in the pathogenesis of sickle cell disease.
Role of the thrombin receptor in development and evidence for a second receptor.
Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Role of thrombin in arterial thrombosis: implications for therapy.
Role of thrombin signalling in platelets in haemostasis and thrombosis.
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis.
Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation.
Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model.
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice.
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Safety evaluation of percutaneous ultrasound-guided thrombin injection into pseudoaneurysms.
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction.
Salvage of autogenous dialysis access with balloon-assisted thrombin injection.
Scanning electron microscopy of experimental thrombus formation in canine lateral saphena vein.
Scintigraphic assessment of arterial embolism at mixed thrombin and technetium 99m injection therapy for femoral pseudoaneurysms.
Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation.
Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.
Selective Thrombosis of Tumor for Enhanced Hypoxia-Activated Prodrug Therapy.
Self-regulated hirudin delivery for anticoagulant therapy.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing.
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury.
Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation.
Shear dependence of the fibrin coagulation kinetics in vitro.
Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A.
Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II.
Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation.
Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover.
Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions.
Site-specific thromboembolism: a novel animal model for stroke.
Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation.
Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa.
Smart Nanotherapeutic Targeting of Tumor Vasculature.
Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation.
Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo.
Solidification mechanisms of chitosan-glycerol phosphate/blood implant for articular cartilage repair.
Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke.
Some antiphospholipid antibodies inhibit phospholipase A2 activity.
Spatial aspects of blood coagulation: Two decades of research on the self-sustained traveling wave of thrombin.
Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear.
Spontaneous pseudo-aneurysm of the deep femoral artery treated by a covered stent.
Standard for human thrombin.
Standardization of a well-controlled in vivo mouse model of thrombus formation induced by mechanical injury.
Statin drugs and dietary isoprenoids as antithrombotic agents.
Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.
Stent-assisted recanalisation of acute occlusive arteries in patients with acute limb ischaemia.
Strategies and progress towards the ideal orally active thrombin inhibitor.
Strategies for inhibiting the effects of thrombin.
Stroke prevention in atrial fibrillation: atrial appendage closure.
Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.
Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.
Structural stability of human alpha-thrombin studied by disulfide reduction and scrambling.
Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19.
STUDIES ON BLOOD COAGULATION : IV. THE NATURE OF THE CLOTTING DEFICIENCY IN HEMOPHILIA.
Studies on the pathogenesis of the generalized Shwartzman reaction. Production of glomerular thrombosis and renal cortical necrosis by intraaortic thrombin infusion in normal and leucopenic rabbits.
Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-111-labeled platelets.
Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor.
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.
Sulfated modification and anticoagulant activity of pumpkin (Cucurbita pepo, Lady Godiva) polysaccharide.
Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets.
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain.
Suppression of thrombolysis in a canine model of pulmonary embolism.
Supramaximal calcium signaling triggers procoagulant platelet formation.
Surface characterization and platelet adhesion studies on polyethylene surface with hirudin immobilization.
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
Surgery versus non-surgical treatment for femoral pseudoaneurysms.
Susceptibility to thrombosis in normal young, aging, cortisone-treated, heparinized and x-irradiated hamsters as tested by topical application of thrombin.
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
Sustained-release synthetic biomarkers for monitoring thrombosis and inflammation using point-of-care compatible readouts.
Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation.
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin.
Synergy between thrombin and serotonin in inducing vascular smooth muscle cell proliferation.
Synthetic and recombinant antithrombin drugs.
Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin?
Systems Analysis of Thrombus Formation.
t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
TAFI gene polymorphisms in patients with cerebral venous thrombosis.
Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation.
Targeted antithrombotic protein micelles.
Targeting Factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Targeting of externalized ?B-crystallin on irradiated endothelial cells with pro-thrombotic vascular targeting agents: Potential applications for brain arteriovenous malformations.
Targeting platelet GPIb? reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis.
Targeting platelet thrombin receptor signaling to prevent thrombosis.
Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.
Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy.
Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges.
Targeting thrombin--rational drug design from natural mechanisms.
Targeting Tumor Vasculature With an Oncolytic Virus.
The 29-kDa proteins phosphorylated in thrombin-activated human platelets are forms of the estrogen receptor-related 27-kDa heat shock protein.
The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits.
The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays.
The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
The approach to heparin-induced thrombocytopenia.
The Art and Science of Building a Computational Model to Understand Hemostasis.
The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis.
The association of direct thrombin inhibitor anticoagulants with cardiac thromboses.
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
The biology of thrombin in acute coronary syndromes.
The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences.
The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function.
The class I phosphoinositide 3-kinases ? and ? control antiphospholipid antibodies-induced platelet activation.
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro.
The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding.
The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
The contribution of TFPI? to the hemostatic response to injury in mice.
The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment.
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
The discovery and characterization of a novel nucleotide-based thrombin inhibitor.
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats.
The dynamic changes of LDH isoenzyme 3 and D-dimer following pulmonary thromboembolism in canine.
The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study.
The effect of cigarette smoke extract on thrombomodulin-thrombin binding: an atomic force microscopy study.
The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models.
The effect of high-density-lipoprotein on thrombus formation on and endothelial cell attachement to biomaterial surfaces.
The effect of red blood cells on thrombin generation.
The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
The effect of thrombin inhibition in a rat arterial thrombosis model.
The effect of thrombin on low-density lipoprotein permeability and uptake by an arterial endothelial smooth muscle cell bilayer.
The effect of tirofiban on microvascular thrombosis: crush model.
The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI.
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
The factor VII zymogen structure reveals reregistration of beta strands during activation.
The hemolytic-uremic syndrome--toxin, thrombin, and thrombosis.
The history of phenotypic testing in thrombosis and hemostasis.
The hypercoagulable profile of patients with stent thrombosis.
The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test.
The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction.
The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury.
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
The Importance of Tissue Factor Expression by Porcine NICC in Triggering IBMIR in the Xenograft Setting.
The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin.
The Influence of Flow on the Concentration of Platelet Active Substances in the Vicinity of Mural Microthrombi.
The Influence of Hindered Transport on the Development of Platelet Thrombi Under Flow.
The influence of platelet-smooth muscle cell interaction on the oxidative modification of low-density lipoprotein.
The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity.
The levels of five markers of hemostasis and endothelial status at different stages of normotensive pregnancy.
The mechanism of action of thrombin inhibitors.
The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.
The new anticoagulants.
The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner.
The pathogenesis and management of disseminated intravascular coagulation.
The plasma hemostatic proteome: thrombin generation in healthy individuals.
The possible role of endothelin-1 in the pathogenesis of coronary vasospasm.
The red blood cell death receptor and thrombosis.
The relation among vessel injury, thrombus formation, and platelet survival in rabbits.
The relationship between aortic aneurysm sac thrombus volume on coagulation, fibrinolysis and platelet activity.
The relationship between thrombin and platelets: linking vessel injury to thrombosis and inflammation.
The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
The release of B beta 1-42 from fibrinogen and fibrin by plasmin.
The Research Progress of Direct Thrombin Inhibitors.
The response of smooth muscle cells to alpha-thrombin depends on its arterial origin: comparison among different species.
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
The role of apoptosis in vascular disease.
The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
The role of intravascular coagulation in pregnancy related acute renal failure.
The role of leukocytes in acute ischemic stroke-related thrombosis: a notable but neglected topic.
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
The role of the contact pathway in thrombus propagation.
The role of the red cell membrane in thrombin generation.
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke.
The role of thrombin in coronary artery thrombosis.
The role of thrombin inhibition during percutaneous coronary intervention.
The scientific basis for selection of measures of thrombogenicity.
The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer.
The thrombin inhibitors hirudin and Refludan® activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets.
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo.
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
The trimeric autotransporter DsrA is a major mediator of fibrinogen binding in Haemophilus ducreyi.
The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.
The Way to Select a Suitable Patient Population for Thrombin Receptor Antagonist from the Large Clinical Trial Database of the TRA-2P-TIMI50 Trial.
Therapeutic inhibition of thrombin activities, receptors, and production.
Therapeutic potential of protease-activated receptor-1 antagonists.
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Thrombin activates MAPKAP2 kinase in vascular smooth muscle.
Thrombin activity associated with indwelling central venous catheters.
Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
Thrombin adsorption and possible relations to thrombus formation.
Thrombin and fibrin-induced growth of fibroblasts: role in wound repair and thrombus organization.
Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process.
Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells.
Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.
Thrombin augments vascular cell-dependent migration of human mast cells: role of MGF.
Thrombin binding to GPIbalpha induces integrin alphaIIbbeta3 dependent platelet adhesion to fibrin in ex vivo flowing whole blood.
Thrombin binding to platelets and their activation in plasma.
Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells.
Thrombin bound to a fibrin clot confers angiogenic and hemostatic properties on endothelial progenitor cells.
Thrombin contraction of vascular smooth muscle: implications for vasospasm.
Thrombin domains: structure, function and interaction with platelet receptors.
Thrombin elaboration in endotoxin-induced intravascular fibrin deposition. A leukocyte dependent process distinct from systemic hypercoagulability.
Thrombin Exosite 1 Inhibition with JNJ-64179375 Inhibits Thrombus Formation in a Human Translational Model of Thrombosis.
Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow.
Thrombin formation.
Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Thrombin Generation and Cancer: Contributors and Consequences.
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Thrombin generation and fibrin clot structure.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombin generation and venous thromboembolism.
Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics.
Thrombin generation assays for optimizing low molecular weight heparin dosing in pregnant women at risk of thrombosis.
Thrombin generation by intimal tissue factor contributes to thrombus formation on macrophage-rich neointima but not normal intima of hyperlipidemic rabbits.
Thrombin Generation Following Severe Trauma: Mechanisms, Modulators, and Implications For Hemostasis And Thrombosis.
Thrombin generation in ankylosing spondylitis.
Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM.
Thrombin generation in clinical conditions.
Thrombin generation in plasma: its assessment via the endogenous thrombin potential.
Thrombin generation in subjects with lupus anticoagulant without prior thrombosis or gestational morbidities.
Thrombin generation in two families with MYH9-related platelet disorder.
Thrombin generation profile in non-thrombotic factor V Leiden carriers.
Thrombin generation profiles in deep venous thrombosis.
Thrombin generation test as a marker for high risk venous thrombosis pregnancies.
Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals.
Thrombin Generation Testing in Patients with Myelofibrosis.
Thrombin generation's role in predicting coronary disease severity.
Thrombin generation, fibrin clot formation and hemostasis.
Thrombin generation.
Thrombin generation: What have we learned?
Thrombin hypothesis of thrombus generation and vascular lesion formation.
Thrombin in arterial thrombosis.
Thrombin induces apoptosis in human tumor cells.
Thrombin induces endothelial arginase through AP-1 activation.
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.
Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells.
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism.
Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
Thrombin inhibition by the serpins.
Thrombin inhibition compared with other antithrombotic drugs in rats.
Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection.
Thrombin inhibition is impaired in plasma of sick neonates.
Thrombin Inhibition: Preliminary Assessment of the Anticoagulant Potential of Turnera subulata (Passifloraceae).
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Thrombin inhibitors A new generation of antithrombotics.
Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway.
Thrombin injection for treatment of false aneurysms after failed compression therapy in patients on full-dose antiplatelet and heparin therapy.
Thrombin injection versus compression of femoral artery pseudoaneurysms.
Thrombin interaction with platelet membrane glycoprotein Ib alpha.
Thrombin interactions with cells of the megakaryocytic lineage.
Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.
Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency.
Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation.
Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood.
Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes.
Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell.
Thrombin rapidly induces protein kinase D phosphorylation, and protein kinase C delta mediates the activation.
Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents.
Thrombin receptor antagonists as novel therapeutic targets.
Thrombin regulation by physiological inhibitors: the role of vitronectin.
Thrombin regulation in children differs from adults in the absence and presence of heparin.
Thrombin regulation in mother and fetus during pregnancy.
Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation.
Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and -independent pathways.
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification.
Thrombin stimulated platelet accumulation on protein coated glass capillaries: role of adhesive platelet alpha-granule proteins.
Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Thrombin-cofactor interactions: structural insights into regulatory mechanisms.
Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro.
Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-?B pathways in human lung epithelial cells.
Thrombin-induced NF-?B activation and IL-8/CXCL8 release is mediated by c-Src-dependent Shc, Raf-1, and ERK pathways in lung epithelial cells.
Thrombin-loaded alginate-calcium microspheres: A novel hemostatic embolic material for transcatheter arterial embolization.
Thrombin-sensitive expression of the store operated Ca(2+) channel Orai1 in platelets.
Thrombin-soaked coils: estimation of thrombin dose.
Thrombin-Targeted Liposomes Establish A Sustained Localized Anticlotting Barrier Against Acute Thrombosis.
Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.
Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis.
Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.
Thrombogenicity of small-diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa.
Thrombogenicity of the injured vessel wall--role of antithrombin and heparin.
Thrombolysis by rotational thrombectomy followed by tissue plasminogen activator: evaluation by angioscopy.
Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism.
Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis.
Thrombomodulin is associated with increased mortality and organ failure in mechanically ventilated children with acute respiratory failure: biomarker analysis from a multicenter randomized controlled trial.
Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis.
Thrombomodulin, an endothelial anticoagulant; its structure, function and expression.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Thromboplastic activity of human arterial walls and its interaction with the plasmatic coagulation system.
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.
Thrombosis and hormone replacement therapy in postmenopausal women.
Thrombosis of a proximal aortic false aneurysm following AAA repair by endovascular thrombin injection.
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins.
Thrombus formation by the application of thrombin to the outer surface of mouse mesenteric vein: comparison with the application of ADP.
Thrombus formation on apex of arterial stenoses: the need for a fluid high shear stenosis diagnostic device.
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi.
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?
Thrombus weight as a measure of hypercoagulability induced by drugs.
Thrombus-induced endothelial dysfunction: Hemoglobin and fibrin decrease nitric oxide bioactivity without altering eNOS.
Thrombus-targeted nanoparticles for thrombin-triggered thrombolysis and local inflammatory microenvironment regulation.
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.
Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange.
Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model.
Tissue factor expressed by adherent cells contributes to hemodialysis-membrane thrombogenicity.
Tissue factor expression by monocytes: regulation and pathophysiological roles.
Tissue factor in thrombosis and hemorrhage.
Tissue factor pathway vs. collagen pathway for in vivo platelet activation.
Tissue plasminogen activator production by monocytes in venous thrombolysis.
Titania gel reduces thrombin generation.
Titration of Bivalirudin Infusion in the Pediatric Cardiac Catheterization Laboratory: A Case Report.
Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey.
Transcatheter thrombin embolization of a giant visceral artery aneurysm.
Transient intermittent lymphocyte activation is responsible for the instability of angina.
Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure.
Transitions of care in anticoagulated patients.
Translational regulation of the serum- and glucocorticoid-inducible kinase-1 (SGK1) in platelets.
Transport-Reaction Model of Mural Thrombogenesis: Comparisons of Mathematical Model Predictions and Results from Baboon Models.
Traumatic Pseudoaneurysm of Anterior Tibial Artery Treated by Thrombin Injection.
Treatment for femoral pseudoaneurysms.
Treatment of accidental perianal injection of topical thrombin with intravenous antithrombin.
Treatment of Dabigatran-Associated Bleeding: Case Report and Review of the Literature.
Treatment of femoral artery pseudoaneurysms using ultrasound-guided thrombin injection.
Treatment of heparin-induced thrombocytopenia: a critical review.
Treatment of heparin-induced thrombocytopenia: a practical argatroban dosing protocol for nurses.
Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair.
Treatment of iatrogenic femoral artery false aneurysms with ultrasound-guided thrombin injection.
Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection.
Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin.
Treatment of iatrogenic pseudoaneurysm of brachial artery with percutaneous ultrasonographically guided thrombin injection (PUGTI): a case report and a literature review.
Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Tripeptide SQL Inhibits Platelet Aggregation and Thrombus Formation by Affecting PI3K/Akt Signaling.
Trousseau's syndrome: multiple definitions and multiple mechanisms.
Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
Two novel mutations in the fibrinogen ? nodule.
Ultrasonography-guided percutaneous thrombin injection of postcatheterization pseudoaneurysms.
Ultrasound enhancement of rabbit femoral artery thrombolysis.
Ultrasound guided human thrombin injection. A new modality in the management of femoral artery pseudo-aneurysms.
Ultrasound Guided Percutaneous Injection of Thrombin: Effective Technique for Treatment of Iatrogenic Femoral Pseudoaneurysms.
Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention.
Ultrasound-Guided Fibrin Glue Injection for Treatment of Iatrogenic Femoral Pseudoaneurysms.
Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery.
Ultrasound-guided thrombin injection for treatment of superficial traumatic pseudoaneurysms and associated expanding hematomas: experience in five patients.
Ultrasound-guided thrombin injection is the treatment of choice for femoral pseudoaneurysms.
Ultrasound-guided thrombin injection versus ultrasound-guided compression therapy of iatrogenic femoral false aneurysms: Single center experience.
Ultrasound-guided thrombin injections for arterial pseudoaneurysms: a 14-year study conducted at King Khalid University Hospital Vascular Lab.
Ultrasound-guided thrombin-gelatin injection is effective for the treatment of iatrogenic femoral artery pseudoaneurysms: Initial results.
Unchecked thrombin is bad news for troubled arteries.
Understanding thrombin and hemostasis.
Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation.
Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib.
Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators.
Up-regulation of fibrinogen-like protein 2 in porcine endothelial cells by xenogeneic CD40 signal.
Update on antithrombin I (fibrin).
Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II.
Uptake and inactivation of thrombin on aortic endothelium and neo-intima.
Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.
Usefulness of Platelet Function Tests to Predict Bleeding with Antithrombotic Medications.
Using the laboratory to predict recurrent venous thrombosis.
Validation and application of an automated 96 -well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of SCH 201781 in human plasma.
VAMP3 is associated with endothelial Weibel-Palade bodies and participates in their Ca(2+)-dependent exocytosis.
Vascular endothelial cell activation and permeability responses to thrombin.
Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Vasoactive agents and production of thrombosis during intravascular coagulation. 2. alpha-Adrenergic stimulation: effects and mechanisms.
VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.
Vena cava superior syndrome developing in a dialysis patient with antithrombin III deficiency following temporary catheterization.
Venous infarction of the adrenal glands.
Venous puncture wound hemostasis results in a vaulted thrombus structured by locally nucleated platelet aggregates.
Venous thromboembolism in heparin-induced thrombocytopenia.
Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
Vessel wall-related risk factors in acute vascular events.
Vorapaxar.
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.
Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation.
Ximelagatran--recent comparisons with warfarin.
[A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)]
[A novel photochemical model of the middle cerebral artery for thrombosis research and evaluation of anti-thrombotic agents]
[Activated proteine C]
[ACTIVATION OF PROTEIN C IN THE IN VITRO THROMBOLYSIS].
[Acute femoral artery thrombosis after thrombin injection of a pseudoaneurysm]
[An experimental study of arterial graft implantation--the effects of an anti-thrombin agent, argatroban, and an anti-platelet agent, clopidogrel (SR 25990 C) on the inner capsule]
[Antiphospholipid antibodies and thrombosis: the putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody]
[Antithrombin therapy in acute coronary syndromes]
[Application of a monoclonal antibody SZ-51 specific for activated human platelets in canine thrombosis imaging]
[Artificial arterial thrombosis using solutions of fibrinogen and thrombin (preliminary report)]
[Besides fibrinogen, are haemostatic, coagulation and/or fibrinolytic parameters predictors or markers of the risk of cardiovascular events?]
[Biochemistry of tumor cell thrombosis: thrombin as growth hormone]
[Blood coagulation and fibrinolysis in ischemic heart disease]
[Coagulation and fibrinolytic activity of lymph in various pathological conditions (review of own and literature data)].
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
[Complex supraclavicular false aneurysm. Case report.]
[Coronary thrombosis--pathogenic basis of acute coronary syndromes]
[Determination of biological activity of extract from hirudo by N-benzoyl-L-arginine ethyl ester]
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].
[Discovery and prospects of a novel thrombophilia: antithrombin resistance].
[Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome]
[Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report]
[Effects of tetrandrine on platelet aggregation, platelet adhesion and coagulation]
[Establishment of rat model of venous thromboembolism]
[Experimental model of early chronic pelvic vein thrombosis with occlusion spirals and thrombin]
[Experimental retinal vein obstruction induced by transadventitial administration of thrombin in the rabbit]
[Formation of streptokinase-heparin complexes and their properties]
[Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma--a case report]
[Heparin-induced thrombocytopenia type II with thrombosis in an intensive care patient : Therapy management using the direct thrombin inhibitor argatroban.]
[Heterozygous prothrombin gene mutation G20210A and associated diseases]
[Hirudin: the relative failure of a very promising molecule]
[Hypercoagulable state in Duchenne muscular dystrophy]
[Influence of suture material on the development of postoperative complications in vascular surgery and their prevention].
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
[Measuring thrombin formation].
[Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies]
[Mechanisms of re-stenosis after angioplasty]
[MORPHOLOGICAL CHANGES AFTER THE USE OF MULTIPOTENT STROMAL CELLS OF BONE MARROW ORIGIN TO RESTORE THE LYMPH FLOW IN THE REGION OF THROMBOSED VEIN].
[Morphological composition and functions of the human blood coagulating and anticoagulating systems in prolonged exposure to low ammonia concentrations in a sealed environment]
[Morphological results of stromal stem cells of bone marrow origin into the thrombosed vein in experiment].
[New aspects in the treatment of hemangioma]
[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)]
[New medical anticoagulants]
[New pharmaceuticals in cardiology : Heart failure, anticoagulation, dyslipidemia].
[Novel oral anticoagulants--issues in clinical practice].
[Peptides as inhibitors of thrombin coagulation activity and of thrombocyte aggregation]
[Platelet abnormalities in type 2 diabetes mellitus]
[Platelet--vessel wall interactions]
[Platelets and arterial thrombosis]
[Preliminary study on epidemiology of deep venous thrombosis of lower extremity in patients with high risk]
[Programmed cellular death and atherogenesis: from molecular mechanisms to clinical aspects]
[Progression from a routine examination to a study. Having come this far, what should be done from now? A thrombosis risk factor study]
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]
[Protein C congenital deficiency. A case report]
[Relation of the formation of the fibrin network of a blood clot to the amount of thrombin in complexes with endogenous heparin]
[Relation of Thromboelastography with Coagulation Function and Plt Count in Different Coagulation States].
[Replacement of the thoracic aorta by sealed dacron prostheses (author's transl)]
[Research progress in hirudin fusion protein--review]
[Role of platelets in atherosclerosis and arterial thrombosis]
[Significance of coronary thrombosis for chronic myocardial ischemia]
[Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin]
[Strategies to improve reperfusion with fibrinolytic therapy in ST-T elevation myocardial infarction]
[Stroke Associated with Atrial Fibrillation and Novel Oral Anticoagulants (NOACs)].
[Study on antithrombotic activities and structure-activity relationships of Veratrum nigrum Alkaloids].
[Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].
[The effect of thymoptin on enzymatic fibrinolysis]
[The formation of paradoxical thrombin and emboli by an interauricular shunt. Comments on F. Wilh, Zahn's articles: Thrombus formation, current status of this problem. Thrombosis of several branches of the inferior vena cava with consecutive emboli in the pulmonary, splenic, renal and right iliac arteries]
[The hemostatic system in the acute coronary syndromes: physiopathological and therapeutic implications]
[The importance of the plasmatic blood clotting system in the early stages of arterial thrombogenesis (author's transl)]
[The numerous properties of the anticoagulant protein C]
[Therapeutic evaluation of recombinant thrombomodulin]
[Thrombin and its pharmacologic regulation]
[Thrombin generation assays and their clinical application].
[Thrombin receptor in thrombosis]
[Thrombin, enzyme of hemostasis and thrombosis: a model of enzymatic autoregulation]
[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?]
[Thrombin: antithrombotic properties and pharmacological consequences]
[Thrombocytes, thrombin, thrombosis and heart infarct]
[Thrombosis and thrombin]
[Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)]
[Treatment of iatrogenic femoral pseudoaneurysms by ultrasound-guided percutaneous thrombin injection: effectiveness and complications]
[Treatment of pseudoaneurysms with injection of thrombin]
[Ultrasonographic contrast injection enhances safety of thrombin - induced obliteration of femoral artery pseudoaneurysm.]
[Ultrasound guided percutaneous thrombin injection for treatment of a pseudoaneurysm after inguinal or brachial catheterization; good results in 14 patients]
[Unstable atherosclerotic plaque and acute coronary syndromes]
[Uremic coagulopathy. Role of thrombin]
[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].
[Use of thrombin generation assay for the evaluation of coagulation and anticoagulant activity of hemostasis system in patients with abdominal sepsis].
[Usefulness of sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms]
Thrombotic Microangiopathies
Cardiovascular risk in COVID-19 infection.
Constitutive expression and modulation of the functional thrombin receptor in the human kidney.
Thrombotic Stroke
Activation of coagulation and fibrinolytic systems following stroke.
Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi.
Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation.
Torsades de Pointes
Computer prediction of cardiovascular and hematological agents by statistical learning methods.
Toxemia
Fibrinopeptide A and intravascular coagulation in normotensive and hypertensive pregnancy and parturition.
[Platelet function during pregnancy, labor, early puerperium, and in preeclampsia]
Toxic Optic Neuropathy
Intraocular hemocoagulase in human vitrectomy.
Trauma, Nervous System
A novel aspect of thrombin in the tissue reaction following central nervous system injury.
Role of Thrombin in Central Nervous System Injury and Disease.
Thrombin may contribute to the pathophysiology of central nervous system injury.
Tricuspid Valve Prolapse
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Trypanosomiasis, African
Isolation and characterization of the tsetse thrombin inhibitor: a potent antithrombotic peptide from the saliva of Glossina morsitans morsitans.
Tuberculosis
Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.
[Blood coagulation function in pulmonary tuberculosis patients at the stages of surgical treatment]
Tuberculosis, Pulmonary
[The use of a concentrate of antithrombin III and disaggregants in the preoperative preparation of patients with pulmonary tuberculosis]
Tuberous Sclerosis
Pseudoaneurysm after spontaneous rupture of renal angiomyolipoma in tuberous sclerosis: successful treatment with percutaneous thrombin injection.
Univentricular Heart
[Acquired thrombin inhibitor in a 9-year-old child after total correction of univentricular heart with pulmonary atresia and administration of fibrin glue]
Uremia
Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure. A possible link to increased cardiovascular mortality?
Mechanisms of platelet aggregation disturbances and their relation to treatment in patients with chronic uremia.
Modulation of the cationic amino acid transport system y+L by surface potential, ouabain and thrombin in human platelets: effects of uremia.
Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release.
[Thrombin formation before and after kidney transplantation in uremia]
Urinary Bladder Neoplasms
Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity.
Urinary Incontinence
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Urogenital Neoplasms
Role of the Coagulation System in Genitourinary Cancers: Review.
Urolithiasis
[The role of immunologic factors in the pathogenesis of urolithiasis]
Urticaria
Activation of the Blood Coagulation System in Patients with Chronic Spontaneous Urticaria.
Chronic urticaria: A disease at a crossroad between autoimmunity and coagulation.
Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria.
Increase of coagulation potential in chronic spontaneous urticaria.
Increased Mean Platelet Volume and C-Reactive Protein Levels in Patients With Chronic Urticaria With a Positive Autologous Serum Skin Test.
Increased thrombin generation potential in patients with chronic spontaneous urticaria.
Inflammation and Coagulation in Urticaria and Angioedema.
Mast cells are critical for the limitation of thrombin-induced skin inflammation.
Uterine Cervical Neoplasms
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
Uterine Hemorrhage
Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding.
Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells.
The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states.
Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding.
Transvaginal ultrasound-guided direct thrombin injection for the treatment of intramyometrial pseudoaneurysm in a young female with uterine hemorrhage after failed uterine artery embolization.
Vaginal bleeding in early pregnancy and circulating markers of thrombin generation.
Uterine Prolapse
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Varicocele
[Embolotherapy: principles and indications.]
Varicose Veins
A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.
Endoscopic treatments for portal hypertension.
EUS-guided thrombin injection for management of gastric fundal varices.
Human thrombin for the treatment of gastric and ectopic varices.
Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices: a prospective randomized trial.
Injection sclerotherapy of esophageal varices using ethanolamine oleate.
Manifestations of temporary symptoms during endoscopic variceal sclerotherapy using thrombin as a sclerosant.
Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices.
Superficial thrombophlebitis of the lower limbs in patients with varicose veins.
Thrombin and ethanolamine injection therapy in arresting uncontrolled bleeding from duodenal varices.
Thrombin injection for bleeding duodenal varices.
Thrombin Is an Effective and Safe Therapy in the Management of Bleeding Gastric Varices. A Real-World Experience.
[Sclerosing of bleeding oesophageal varices (author's transl)]
Vascular Diseases
A steady-state competition model describes the modulating effects of thrombomodulin on thrombin inhibition by plasminogen activator inhibitor-1 in the absence and presence of vitronectin.
A Thrombin-Responsive Nanoprobe for In Vivo Visualization of Thrombus Formation through Three-Dimensional Optical/Computed Tomography Hybrid Imaging.
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice.
Fibrinopeptide A excretion in urine in patients with atherosclerotic artery disease.
Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin (PAR1) Receptor Antagonist.
Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases.
Inflammatory cell participation in coagulation.
New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology.
Novel and emerging therapies in cardiology and haematology.
PKC-delta/c-Src-mediated EGF receptor transactivation regulates thrombin-induced COX-2 expression and PGE(2) production in rat vascular smooth muscle cells.
Placental insufficiency is characterized by platelet activation in the fetus.
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Role of protease-activated receptors in the vascular system.
Shear stress reduces protease activated receptor-1 expression in human endothelial cells.
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation.
Thrombin-antithrombin III complexes in type II diabetes mellitus.
Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation.
Vascular System Injuries
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
A novel biologic activity of thrombin: stimulation of monocyte chemotactic protein production.
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.
A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity.
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.
Activation of blood coagulation by plaque rupture: mechanisms and prevention.
Active Versus Passive Anchoring Vascular Closure Devices Following Percutaneous Coronary Intervention: A Safety and Efficacy Comparative Analysis.
Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB.
An overview of the structure and function of thrombin.
Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.
Antithrombin: facts and new hypotheses.
Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists.
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.
Bidirectional transmembrane modulation of integrin alphaIIbbeta3 conformations.
Bioinspired artificial platelets: past, present and future.
Biorheology of platelet activation in the bloodstream distal to thrombus formation.
Cardiovascular actions of thrombin receptor activation in vivo.
Cellular mechanisms of atherogenesis.
Characterization of thrombin receptor expression during vascular lesion formation.
Chloride channels are necessary for full platelet phosphatidylserine exposure and procoagulant activity.
Coagulation factor V: a plethora of anticoagulant molecules.
Complement factor C4a does not activate protease-activated receptor 1 (PAR1) or PAR4 on human platelets.
Continuous Detection of Increasing Concentrations of Thrombin Employing a Label-Free Photonic Crystal Aptasensor.
Conversion of thrombin into an anticoagulant by protein engineering.
Coordination of platelet agonist signaling during the hemostatic response in vivo.
Corneal activation of prothrombin to form thrombin, independent of vascular injury.
Critical roles for thrombin in acute and chronic inflammation.
Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation.
CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells.
Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases.
Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development.
Dual P2Y 12 receptor signaling in thrombin-stimulated platelets--involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity.
Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells.
Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation.
Endogenous fibrinolysis facilitates clot retraction in vivo.
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.
Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid.
Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Fibrinogen.
Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Gene targeting in hemostasis. tissue factor.
Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells.
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Homocysteine and thrombosis: from basic science to clinical evidence.
Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.
Human brain pericytes differentially regulate expression of procoagulant enzyme complexes comprising the extrinsic pathway of blood coagulation.
Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.
Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes.
Identification of critical residues on thrombin mediating its interaction with fibrin.
Impairment of the hemostatic potential of platelets during storage as evaluated by flow cytometry, thrombin generation, and thrombelastography under conditions promoting formation of coated platelets.
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery.
Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide.
Inhibition of neointimal hyperplasia by a specific thrombin inhibitor.
Inhibition of thrombin receptor signaling on ?-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury.
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide.
Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling.
Leukocyte repletion reverses protective effect of neutropenia in thrombin-induced increase in lung vascular permeability.
LIM and cysteine-rich domains 1 is required for thrombin-induced smooth muscle cell proliferation and promotes atherogenesis.
Lipoprotein metabolism and thrombosis.
LPS-induced expression and release of monocyte tissue factor in patients with haemophilia.
Lysoplasmenylcholine increases neutrophil adherence to human coronary artery endothelial cells.
Mechanisms Regulating Acquisition of Platelet-Derived Factor V/Va by Megakaryocytes.
Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits.
Multifunctional roles of thrombin.
NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells.
Necrotic platelets provide a procoagulant surface during thrombosis.
New antithrombotic strategies for resistant thrombotic processes.
New insights into the spatiotemporal localization of prothrombinase in vivo.
Pharmacokinetics and pharmacology of hirulog-like peptide.
PKCtheta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion.
Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2.
Platelet functions beyond haemostasis.
Platelet GP Ib/IX/V complex: physiological role.
Platelet receptors and signaling in the dynamics of thrombus formation.
Platelet response heterogeneity in thrombus formation.
Platelets and their membranes in hemostasis: physiology and pathophysiology.
Platelets as modifiers of clinical phenotype in hemophilia.
Platelets, leukocytes, and coagulation.
Potential non-glycoprotein IIb/IIIa effects of abciximab.
Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.
Protease-activated receptor 3 is a second thrombin receptor in humans.
Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.
Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin.
Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation.
Reduction in vascular lesion formation by hirudin secreted from retrovirus-transduced confluent endothelial cells on vascular grafts in baboons.
Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors.
Relative Contribution of STIM1 and CalDAG-GEFI to Calcium-Dependent Platelet Activation and Thrombosis.
Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor.
rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation.
Role of caveolin-1 expression in the pathogenesis of pulmonary edema in ventilator-induced lung injury.
Role of the thrombin receptor in development and evidence for a second receptor.
Role of thrombin in endothelial cell monolayer repair in vitro.
Roles of platelets and factor XI in the initiation of blood coagulation by thrombin.
Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury.
Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinases.
Shear stress reduces protease activated receptor-1 expression in human endothelial cells.
Signaling during platelet adhesion and activation.
Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation.
Stimulation of human smooth muscle cell proliferation by thrombin involves increased synthesis of platelet-derived growth factor.
Structure and function of platelet receptors initiating blood clotting.
Structure and interaction modes of thrombin.
Suboptimal activation of protease-activated receptors enhances {alpha}2{beta}1 integrin-mediated platelet adhesion to collagen.
Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.
Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition.
Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit.
The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice.
The in vitro effect of recombinant factor VIIa on coated platelet formation and clot dynamics of stored platelet concentrates.
The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.
The regulation of clotting factors.
The role of alpha(v)beta3 integrins in vascular healing.
The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty.
The role of secondary growth factor production in thrombin-induced proliferation of vascular smooth muscle cells.
The role of the membrane in the expression of the vitamin K-dependent enzymes.
The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.
The structure of thrombin: a janus-headed proteinase.
Thrombin activates the growth, cell-cycle kinetics, and clustering of human dental pulp cells.
Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression.
Thrombin and platelet activation.
Thrombin and protease-activated receptors (PARs) in atherothrombosis.
Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.
Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species.
Thrombin contraction of vascular smooth muscle: implications for vasospasm.
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process.
Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha.
Thrombin induces cyclooxygenase-2 expression and prostaglandin E(2) release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages.
Thrombin induces rapid PAR1-mediated non-classical FGF1 release.
Thrombin induces thrombomodulin mRNA expression via the proteolytically activated thrombin receptor in cultured bovine smooth muscle cells.
Thrombin mediated migration of osteogenic cells.
Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells.
Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells.
Thrombin promotes aortic endothelial cell spreading and microfilament formation in nonconfluent monolayer cultures.
Thrombin receptor expression in normal and atherosclerotic human arteries.
Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells.
Thrombin receptor function and cardiovascular disease.
Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells.
Thrombin regulates nerve growth factor secretion from vascular, but not bladder smooth muscle cells.
Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells.
Thrombin stimulates platelet-derived growth factor release by alveolar macrophages in rats--significance in bleomycin-induced pulmonary fibrosis.
Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin.
Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism.
Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells.
Thrombin stimulates synthesis of type IV collagen and tissue inhibitor of metalloproteinases-1 by cultured human mesangial cells.
Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4.
Thrombin-induced alterations in endothelial permeability.
Thrombin-induced CCAAT/enhancer-binding protein ? activation and IL-8/CXCL8 expression via MEKK1, ERK, and p90 ribosomal S6 kinase 1 in lung epithelial cells.
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma).
Thromboxane A2 potentiates thrombin-induced proliferation of coronary artery smooth muscle cells.
Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease.
Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells.
Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib.
Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor.
von Willebrand factor and the endothelium.
Zinc is a transmembrane agonist that induces platelet activation in a tyrosine phosphorylation-dependent manner.
Vasculitis
Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis.
Necrotizing vasculitis. Etiologic aspects of immunology and coagulopathy.
Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.
Treatment Algorithms in Systemic Lupus Erythematosus.
Vasculitis, Central Nervous System
Treatment Algorithms in Systemic Lupus Erythematosus.
Vasospasm, Intracranial
Basic and translational research on proteinase-activated receptors: the role of thrombin receptor in cerebral vasospasm in subarachnoid hemorrhage.
Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB.
Cerebral arterial contractions induced by human and bovine thrombin.
Comparison of responses elicited by alpha-thrombin in isolated canine basilar, coronary, mesenteric, and renal arteries.
Comparison of the inhibitory effects of antithrombin III, alpha 2-macroglobulin, and thrombin in human basilar arteries: relevance to cerebral vasospasm.
Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage.
Does thrombin prevent cerebral vasospasm following aneurysmal subarachnoid haemorrhage?
Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model.
Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage.
Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin.
Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.
Venous Thromboembolism
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
A genetic risk factor for thrombophilia in a Han Chinese family.
A mathematical model to quantify the effects of platelet count, shear rate, and injury size on the initiation of blood coagulation under venous flow conditions.
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
A review of global coagulation assays - Is there a role in thrombosis risk prediction?
A review of the clinical uses of ximelagatran in thrombosis syndromes.
Acute management of bleeding in patients on novel oral anticoagulants.
An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients.
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Antithrombotic Agents.
Antithrombotic therapy in atrial fibrillation. -Evaluation and positioning of new oral anticoagulant agents-.
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
Challenges in the prevention of venous thromboembolism in the elderly.
Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients.
Clinical experience with ximelagatran in orthopaedic surgery.
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies.
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies.
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.
Dabigatran - the First Approved DTI for SPAF.
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity.
Dabigatran Etexilate for the Prophylaxis of Venous Thromboembolism After Hip or Knee Replacement: Rationale for Dose Regimen.
Dabigatran etexilate in atrial fibrillation.
Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Dabigatran Etexilate: Pivotal Trials for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty.
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials.
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience.
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Dabigatran: patient management in specific clinical settings.
Dabigatran: ready for prime time?
Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography.
Desirudin Dosing and Monitoring in Moderate Renal Impairment.
Determination of dabigatran in human plasma samples.
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Diagnostic Accuracy in Acute Venous Thromboembolism: Comparing D-Dimer, Thrombin Generation, Overall Hemostatic Potential, and Fibrin Monomers.
Direct antithrombins: new perspectives in cardiovascular medicine.
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population.
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment.
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Direct Thrombin Inhibitors.
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Dual Anticoagulation in Recurrent Thromboembolic Events with Failure of Monotherapy: A Novel Approach.
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study.
Early Identification of Argatroban Resistance and the Consideration of Factor VIII.
Early thrombin formation capacity in trauma patients and association with venous thromboembolism.
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram.
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Ex Vivo Thrombin Generation in Patients With Venous Thromboembolic Disease or Atrial Fibrillation on Long-Term Oral Anticoagulation.
Exploring the utility of a novel point-of-care whole blood thrombin generation assay following trauma: A pilot study.
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.
Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism.
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.
Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.
Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens.
Interference of thrombin in immunological assays for hirudin specific antibodies.
Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.
Lessons From Ximelagatran : Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery.
Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.
Long-term anticoagulation in patients with coronary disease, and future developments.
Management of thrombophilia.
Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism.
Markers of thrombin and plasmin generation in patients with inherited thrombophilia.
Monitoring and reversal strategies for new oral anticoagulants.
More on: high thrombin generation and the risk of recurrent venous thromboembolism.
New Anticoagulants - Promising and Failed Developments.
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
New anticoagulants.
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
New concepts in heparin-induced thrombocytopenia: diagnosis and management.
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
New oral anticoagulants for the treatment of venous thromboembolism.
New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors.
New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients.
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct xa inhibitors.
New therapeutic option for thromboembolism--dabigatran etexilate.
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Old and new anticoagulant drugs: a minireview.
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism.
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
Phased-array intracardiac echocardiographic imaging of acute cardiovascular emergencies: Experimental studies in dogs.
PK evaluation of fondaparinux sodium for the treatment of thrombosis.
PO-24 - Determinants of thrombin generation in gynaecological malignancies.
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer.
Prediction of Venous Thromboembolism in Patients With Cancer By Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study.
Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.
Primary prophylaxis of venous thromboembolism in surgical patients.
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism.
Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Quantification of hypercoagulable state after blunt trauma: Microparticle and thrombin generation are increased relative to injury severity, while standard markers are not.
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.
Stability of Dabigatran Etexilate in Manufacturer's Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack.
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Targeting thrombin--rational drug design from natural mechanisms.
The approach to heparin-induced thrombocytopenia.
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
The direct thrombin inhibitors: their role and use for rational anticoagulation.
The effect of beta-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism.
The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature.
The endogenous thrombin potential and the risk of venous thromboembolism.
The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer.
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.
The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism.
The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism.
The role of ximelagatran in the treatment of venous thromboembolism.
Therapeutic inhibition of thrombin activities, receptors, and production.
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Thrombin generation and procoagulant microparticle profiles after acute trauma: A prospective cohort study.
Thrombin generation and venous thromboembolism.
Thrombin generation as an intermediate phenotype for venous thrombosis.
Thrombin Generation Assay in Hospitalized Nonsurgical Patients: A New Tool to Assess Venous Thromboembolism Risk?
Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
Thrombin generation in patients after acute deep-vein thrombosis.
Thrombin Generation in Patients With Suspected Venous Thromboembolism.
Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study.
Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism.
Thrombocytopenia induced by dabigatran: two case reports.
Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement.
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran.
Treatment of venous thromboembolism with new oral anticoagulants according to patient risk.
Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Treatment of venous thrombosis in the cancer patient.
Trousseau's syndrome: cancer-associated thrombosis.
Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula - a retrospective single centre experience.
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype.
Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
Vitamin K antagonists. Ready to be replaced?
Ximelagatran (AstraZeneca).
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Ximelagatran--recent comparisons with warfarin.
Ximelagatran.
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
[Dabigatran therapy--perioperative management and interpretation of coagulation tests].
[From heparin to synthetic antithrombotic drugs]
[New oral anticoagulants for treatment of venous thromboembolism].
[New oral anticoagulants from the perspective of trauma surgery].
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics]
[Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals]
[Prevention of venous thromboembolism in surgical patients].
[The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement]
[Therapeutic approach to the bleeding in association with "old" and "new" anticoagulants].
[Thrombin generation test].
[What's new on antithrombotics in 2007?]
Venous Thrombosis
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
A novel near-infrared fluorescence sensor for detection of thrombin activation in blood.
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly.
Abdominal Contouring Procedures Increase Activity of the Coagulation Cascade.
Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond.
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Advances in antithrombotic therapy: novel agents.
African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation.
Alternatives to heparin infusion.
An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo.
Antibodies to serine proteases in the antiphospholipid syndrome.
Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls.
Anticoagulation-related intracranial hemorrhages.
Anticoagulation: the present and future.
Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.
Antithrombotic Agents.
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor.
Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Association Analysis of Tissue Factor Pathway Inhibitor Polymorphisms and Haplotypes with Osteonecrosis of the Femoral Head in the Korean Population.
Association of G20210A Prothrombin Gene Mutation and Cerebral Ischemic Stroke in Young Patients.
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Blood coagulation and thrombosis in patients with ovarian malignancy.
Cardiovascular chemotherapy: anticoagulants.
Challenges in the development of orally bioavailable thrombin active site inhibitors.
Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity.
Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment.
Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosis.
Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies.
Critical appraisal of current antithrombotic trials in patients undergoing total hip replacement.
CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury.
D-dimer, thrombin generation, and risk of a first venous thrombosis in the elderly.
D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis.
Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin.
Direct antithrombins: new perspectives in cardiovascular medicine.
Direct oral anticoagulants in rare venous thrombosis.
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation.
Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.
Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat.
Effect of heparin on the activation of factor XI by fibrin-bound thrombin.
Effect of monomethylmethacrylate on procoagulant activities of human monocytes and umbilical vein endothelial cells in vitro.
Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.
Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.
Emerging anticoagulant strategies.
Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis.
Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
Failure of thrombin-antithrombin III complexes in the diagnosis of deep vein thrombosis.
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment.
Genetic Determinants of Thrombin Generation and Their Relation to Venous Thrombosis: Results from the GAIT-2 Project.
Hematology pharmacology: anticoagulant, antiplatelet, and procoagulant agents in practice.
Heparin-induced thrombocytopenia during renal replacement therapy.
Heparin-induced thrombocytopenia: a ten-year retrospective.
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.
HIT paradigms and paradoxes.
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis.
In prothrombin G20210A carriers the genetic mutation and the history of Venous Thrombosis contribute both to thrombin generation independently of factor II plasma levels.
In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis.
Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study.
Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders.
Inhibition of annexin V binding to cardiolipin and thrombin generation in an unselected population with venous thrombosis.
Inhibition of thrombin generation in human plasma by phospholipid transfer protein.
Interleukin-10 promoter polymorphism and venous thrombosis: a case-control study.
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood.
Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition.
Laparoscopic ligation of the infrarenal vena cava in combination with transfemoral thrombin infusion: a new animal model of chronic deep venous thrombosis.
LB30057, an orally effective direct thrombin inhibitor, prevents arterial and venous thrombosis in rats and dogs.
Low molecular weight heparin in acute stroke.
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Mechanisms for the anticoagulant effects of synthetic antithrombins.
Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
New anticoagulants for venous thromboembolic disease.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
NMR solution structure of a novel hirudin variant HM2, N-terminal 1-47 and N64-->V + G mutant.
Novel single nucleotide mutations in exon-10 of human coagulation Factor V gene in patients with pulmonary thromboembolism.
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Novel therapeutic agents in the management of hemorrhage and thrombosis.
Obesity and thrombin-generation profiles in women with venous thromboembolism.
Oral antithrombotic effects of acylhydrazone derivatives.
Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Oral, direct thrombin and factor?Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?
Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay.
Percutaneous injection of thrombin for the treatment of pseudoaneurysms: the German multicentre registry.
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Pharmacological survey of recombinant hirudin.
Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case-Control Study.
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis.
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Prevention of thrombus formation with glyprolines on various models of prethrombotic state and thrombosis in rats.
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Prophylactic use of antithrombin III concentrate following surgery in congenital antithrombin III deficiency.
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Rapid screening and identification of anticoagulation component from carthami flos by two-dimensional thrombin affinity chromatography combined with HPLC-MS/MS.
Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin.
Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation.
Retrieval of "Recovery IVC Filter" after 383 days.
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment.
Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
The activated factor X-antithrombin III reaction rate: a measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits.
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
The dynamics of thrombin formation.
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential.
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.
The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179.
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: comment.
The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: reply.
The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C.
The role of procoagulants and anticoagulants in the development of venous thromboembolism.
The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism.
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease.
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
Thrombin and antithrombotics.
Thrombin and plasmin activity and platelet activation in the development of venous thrombosis.
Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions.
Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
Thrombin generation and venous thromboembolism.
Thrombin generation as an intermediate phenotype for venous thrombosis.
Thrombin generation in clinical conditions.
Thrombin generation in patients after acute deep-vein thrombosis.
Thrombin generation profiles in deep venous thrombosis.
Thrombin generation test as a marker for high risk venous thrombosis pregnancies.
Thrombin generation tests.
Thrombin generation: What have we learned?
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification.
Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?
Transitions of care in anticoagulated patients.
Treatment Algorithms in Systemic Lupus Erythematosus.
Trypsin and thrombin induced venous thrombosis and its prevention with dicumarol, 3,3' methylenebis (4 hydroxycoumarin).
Two symptomatic cases of dysfibrinogenemia in China: one with gamma-chain Arg275Cys mutation and another without detectable mutation in fibrinogen genes.
Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
Use of Direct Thrombin Inhibitor for Treatment of Cerebral Venous Thrombosis.
Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia.
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Venous thrombosis associated with HMG-CoA reductase inhibitors.
Venous thrombosis revisited.
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation.
Ximelagatran--recent comparisons with warfarin.
[Clinical research on Sanmiao powder combined fibrinogenase for injection in treatment of acute deep venous thrombosis of lower limbs].
[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors]
[Continuous heparin therapy in deep venous thrombosis and its monitoring with the Howel and thrombin times. Prospective study]
[Direct Inhibition of Thrombin. A New Strategy for the Treatment of Atrial Fibrillation and Acute Coronary Syndrome?]
[Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis]
[Establishment of rat model of venous thromboembolism]
[Management of major bleeding complications in patients on long-term treatment with oral anticoagulants].
[Morphologic changes in the thrombus and venous wall in experimental phleobothrombosis and thrombophlebitis]
[New medical anticoagulants]
[New oral anticoagulants : Better than vitamin K antagonists?]
[Pharmacology of the new oral anticoagulants].
[Preliminary study on epidemiology of deep venous thrombosis of lower extremity in patients with high risk]
[Progression from a routine examination to a study. Having come this far, what should be done from now? A thrombosis risk factor study]
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs]
[Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin]
[Thrombin generation test].
[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?]
[Use of a thrombin inhibitor for treatment of deep vein thrombosis and pulmonary thromboembolism in patients with thrombophilia].
Ventilator-Induced Lung Injury
Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury.
Lung endothelial barrier protection by iloprost in the 2-hit models of ventilator-induced lung injury (VILI) involves inhibition of Rho signaling.
Measurement of local permeability at subcellular level in cell models of agonist- and ventilator-induced lung injury.
Ventricular Dysfunction, Left
Direct effects of thrombin on myocyte contractile function.
Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model.
Ventricular Fibrillation
Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation.
Ins(1,4,5)P3 and arrhythmogenic responses during myocardial reperfusion: evidence for receptor specificity.
Virus Diseases
A novel surgical glue composed of gelatin and N-hydroxysuccinimide activated poly(L-glutamic acid): Part 1. Synthesis of activated poly(L-glutamic acid) and its gelation with gelatin.
Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.
Soft tissue adhesive composed of modified gelatin and polysaccharides.
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells.
Vitamin D Deficiency
Thrombin generation and fibrin clot structure after vitamin D supplementation.
Vitamin K Deficiency
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Coagulopathy in Zellweger spectrum disorders: a role for vitamin K.
The multiple coagulopathies of biliary atresia.
Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency.
Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.
Vitamin K Deficiency Bleeding
[Prevention of hemorrhagic disease of newborn with oral plasmatic thrombin.]
Vitreoretinopathy, Proliferative
Dabigatran inhibits intravitreal thrombin activity.
Intraocular human thrombin infusion in diabetic vitrectomies.
The role of thrombin in proliferative vitreoretinopathy.
Thrombin Generation in Vitreous and Subretinal Fluid of Patients with Retinal Detachment.
Thrombin induces Slug-mediated E-Cadherin transcriptional repression and the parallel up-regulation of N-cadherin by a transcription-independent mechanism in RPE cells.
Thrombin promotes actin stress fiber formation in RPE through Rho/ROCK-mediated MLC phosphorylation.
Thrombin promotes the expression of Ccnd1 gene in RPE cells through the activation of converging signaling pathways.
Thrombin stimulates RPE cell motility by PKC-zeta- and NF-kappaB-dependent gene expression of MCP-1 and CINC-1/GRO chemokines.
Thrombin stimulates RPE cell proliferation by promoting c-Fos-mediated cyclin D1 expression.
Vitreous and subretinal fluid concentrations of orally administered dabigatran in patients with rhegmatogenous retinal detachment.
Vitreous Hemorrhage
Intraocular human thrombin infusion in diabetic vitrectomies.
The use of intravitreal thrombin to control hemorrhage during vitrectomy.
von Willebrand Disease, Type 1
Key role of glycoprotein Ib-V-IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.
von Willebrand Disease, Type 3
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
von Willebrand Diseases
Effect of thrombin and ADP on a membrane bound cyclic AMP dependent kinase of human platelets. Studies on normal platelets and those from patients with Von Willebrand's disease.
Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
Features of Marfan syndrome not listed in the Ghent nosology - the dark side of the disease.
Key role of glycoprotein Ib-V-IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow.
Management of traumatic hyphema.
Mild Bleeders: Diagnosis is Elusive in Large Number of Patients.
New approaches for measuring coagulation.
Platelets compensate for poor thrombin generation in type 3 von Willebrand disease.
The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.
Thrombin generation during a regular menstrual cycle in women with von Willebrand disease.
Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages.
Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective.
[Thrombinography: towards a globalization of coagulation tests]
Whooping Cough
Activation of phospholipase C by heat shock requires GTP analogs and is resistant to pertussis toxin.
Agonist receptors and G proteins as mediators of platelet activation.
Agonist stimulation of Na+/K+/Cl- cotransport in rat glomerular mesangial cells. Evidence for protein kinase C-dependent and Ca2+/calmodulin-dependent pathways.
Bombesin and thrombin affect discrete pools of intracellular calcium through different G-proteins.
Ca2+ ionophore A23187 and thrombin inhibit the pertussis-toxin-induced ADP-ribosylation of the alpha-subunit of the inhibitory guanine-nucleotide-binding protein and other proteins in human platelets.
Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.
Changes in G protein pattern and in G protein-dependent signaling during erythropoietin- and dimethylsulfoxide-induced differentiation of murine erythroleukemia cells.
Changes of cytosolic calcium ion concentrations in human endothelial cells in response to thrombin, platelet-activating factor, and leukotriene B4.
Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition.
Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells.
Crosstalk between thrombin and adenylyl cyclase-stimulating agonists in proliferating human erythroid progenitor cells.
Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells.
Differences in intracellular calcium signaling after activation of the thrombin receptor by thrombin and agonist peptide in osteoblast-like cells.
Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells.
Differential routes of Ca2+ influx in Swiss 3T3 fibroblasts in response to receptor stimulation.
Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells.
Distinct mechanisms regulate 5-HT2 and thrombin receptor desensitization.
Distinct signaling functions for Shc isoforms in the heart.
Dual effect of thrombin on voltage-dependent Ca2+ channels of portal vein smooth muscle cells.
Effect of pertussis toxin on the phosphodiesteratic cleavage of the polyphosphoinositides by guanosine 5'-O-thiotriphosphate and thrombin in permeabilized human platelets.
Effect of thrombin on calcium homeostasis in chick embryonic heart cells. Receptor-operated calcium entry with inositol trisphosphate and a pertussis toxin-sensitive G protein as second messengers.
Effects of thrombin, phorbol myristate acetate and prostaglandin D2 on 40-41 kDa protein that is ADP ribosylated by pertussis toxin in platelets.
Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment.
Endothelial dysfunction and vascular disease.
Endothelin-induced increases in vascular smooth muscle Ca2+ do not depend on dihydropyridine-sensitive Ca2+ channels.
Evidence of fibrinogen degradation in rat anaphylaxis.
Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation.
Expression of a mutant Gi2 alpha subunit inhibits ATP and thrombin stimulation of cytoplasmic phospholipase A2-mediated arachidonic acid release independent of Ca2+ and mitogen-activated protein kinase regulation.
Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis.
Further evidence for a phospholipase C-coupled G protein in hamster fibroblasts. Induction of inositol phosphate formation by fluoroaluminate and vanadate and inhibition by pertussis toxin.
G proteins and phospholipase C mediate thrombin-induced generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells.
G-proteins and endothelial responses.
Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc.
GTP gamma S increases thrombin-mediated inositol trisphosphate accumulation in permeabilized human endothelial cells.
Guanosine 5'-O-(3-thiotrisphosphate) potentiates both thrombin- and platelet-derived growth factor-induced inositol phosphate release in permeabilized vascular smooth muscle cells. Signaling mechanisms distinguished by sensitivity to pertussis toxin and phorbol esters.
Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets.
Homologous desensitization of HEL cell thrombin receptors. Distinguishable roles for proteolysis and phosphorylation.
Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells.
Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells.
Inhibition of Rho-Kinase Abrogates Migration of Human Transitional Cell Carcinoma Cells: Results of an in vitro Study.
Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin.
Involvement of 5-HT2 receptors in chronic endothelial dysfunction after balloon injury of porcine coronary arteries.
Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells.
Involvement of protein kinase C in thrombin-induced translocation of Gi2 alpha from the membrane to the cytosol in mouse mastocytoma P-815 cells.
Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.
Mast cell tryptase is a mitogen for cultured fibroblasts.
Mechanism of thrombin-induced vasodilation in human coronary arterioles.
Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells.
Mediation of growth factor induced DNA synthesis and calcium mobilization by Gq and Gi2.
Modulation of brain Na+ channels by a G-protein-coupled pathway.
Multiple Signaling Pathways Contribute to the Thrombin-induced Secretory Phenotype in Vascular Smooth Muscle Cells.
Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein.
Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis.
Ni-mediated inhibition of human platelet adenylate cyclase by thrombin.
No direct correlation between Ca2+ mobilization and dissociation of Gi during platelet phospholipase A2 activation.
PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells.
Pertussis toxin inhibits thrombin-induced activation of phosphoinositide hydrolysis and Na+/H+ exchange in hamster fibroblasts.
Pertussis toxin reduces endothelium-dependent and independent responses to alpha-2- adrenergic stimulation in systemic canine arteries and veins.
Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts.
Pertussis toxin-sensitive and -insensitive thrombin stimulation of Shc phosphorylation and mitogenesis are mediated through distinct pathways.
Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets.
Phospholipase C-beta3 mediates the thrombin-induced Ca2+ response in glial cells.
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle.
Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases.
Receptor and G protein-mediated responses to thrombin in HEL cells.
Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and -insensitive pathways.
Regulation of HSP70 by PTH: a model of gene regulation not mediated by changes in cAMP levels.
Regulation of phosphoinositide-3-kinase by G protein beta gamma subunits in a rat osteosarcoma cell line.
Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of G(q/11), Gi and G(12/13) proteins in signalling by alpha1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors.
Regulation of thrombin-induced endothelial cell activation by bacterial toxins.
Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2.
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Role of the third intracellular loop and of the cytoplasmic tail in the mitogenic signaling of the protease-activated receptor 1.
Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein.
Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor.
Sodium fluoride induces phosphoinositide hydrolysis, Ca2+ mobilization, and prostacyclin synthesis in cultured human endothelium: further evidence for regulation by a pertussis toxin-insensitive guanine nucleotide-binding protein.
Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin.
Stimulus-response coupling in a cell-free platelet membrane system. GTP-dependent release of Ca2+ by thrombin, and inhibition by pertussis toxin and a monoclonal antibody that blocks calcium release by IP3.
Strong and persistent activation of inositol lipid breakdown induces early mitogenic events but not Go to S phase progression in hamster fibroblasts. Comparison of thrombin and carbachol action in cells expressing M1 muscarinic acetylcholine receptors.
Suppression of the voltage-gated K+ current of human megakaryocytes by thrombin and prostacyclin.
Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells.
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells.
The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice.
The G-protein G(i) regulates mitosis but not DNA synthesis in growth factor-activated fibroblasts: a role for the nuclear translocation of G(i).
The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain.
The inositol phosphate response to thrombin in rat right atria differs from the response to noradrenaline.
The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein.
Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures.
Thrombin activation of the Na+/H+ exchanger in vascular smooth muscle cells. Evidence for a kinase C-independent pathway which is Ca2+-dependent and pertussis toxin-sensitive.
Thrombin exerts a dual effect on stimulated adenylate cyclase in hamster fibroblasts, an inhibition via a GTP-binding protein and a potentiation via activation of protein kinase C.
Thrombin induces c-fos expression in cultured human endothelial cells by a Ca2(+)-dependent mechanism.
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.
Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.
Thrombin is a novel regulator of hexokinase activity in mesangial cells.
Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart.
Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells.
Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists.
Thrombin receptor agonist peptide induction of mitogenesis in CCL39 cells.
Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses.
Thrombin signal transduction of the fibrinolytic system in human adult venous endothelium in vitro.
Thrombin signalling in U937 human monocytic cells is coupled to inositol phosphate formation but not to thromboxane B2 synthesis nor to inhibition of adenylate cyclase: distinct differences in thrombin signalling between U937 cells and platelets.
Thrombin stimulates inositol phosphate formation, intracellular calcium fluxes and DNA synthesis in cultured fetal human non-pigmented ciliary epithelial cells.
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Thrombin stimulates PDGF production and monocyte adhesion through distinct intracellular pathways in human endothelial cells.
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets.
Thrombin-induced Ca2+ mobilization in vascular smooth muscle utilizes a slowly ribosylating pertussis toxin-sensitive G protein. Evidence for the involvement of a G protein in inositol trisphosphate-dependent Ca2+ release.
Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells.
Thrombin-induced prostacyclin biosynthesis in human endothelium: role of guanine nucleotide regulatory proteins in stimulus/coupling responses.
Thrombin-stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells.
Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells.
Transfected adenosine A1 receptor-mediated modulation of thrombin-stimulated phospholipase C and phospholipase A2 activity in CHO cells.
Treatment of human platelets with trypsin, thrombin, or collagen inhibits the pertussis toxin-induced ADP-ribosylation of a 41-kDa protein.
Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussis toxin-sensitive heterotrimeric G-protein.
[Activation mechanisms by thrombin and vasopressin of fibroblasts in spontaneously hypertensive rats]
Wilms Tumor
Characterization of platelet activity in neuroblastoma.
Xanthogranuloma, Juvenile
Management of traumatic hyphema.